var images_info;if (!images_info) images_info =[]; images_info["97"]={"97002":{"type":"graphic_picture","displayName":"Large local reaction to insect sting","title":"Large local reaction to insect sting","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Large local reaction to insect sting</div><div class=\"cntnt\"><img style=\"width:586px; height:387px;\" src=\"images/ALLRG/97002_Lrglclrctninsctstng.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Gunter Sturm, MD, PhD.</div><div id=\"graphicVersion\">Graphic 97002 Version 2.0</div></div></div>"},"97004":{"type":"graphic_picture","displayName":"Nummular eczema histo","title":"Histologic features of nummular eczema","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Histologic features of nummular eczema</div><div class=\"cntnt\"><img style=\"width:496px; height:170px;\" src=\"images/DERM/97004_Nummular_eczema_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Irregular acanthosis, spongiosis, and superficial perivascular inflammatory infiltrate.<br />(B) Spongiosis is accompanied by exocytosis of inflammatory cells.</div><div class=\"graphic_reference\">​Reproduced with permission from: Wu H, Brandling-Bennett HA, Harrist TJ. Noninfectious vesiculobullous and vesiculopustular diseases. In: Lever's Histopathology of the Skin, 10th ed, Elder DE, Elenitsas R, Johnson B Jr, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 97004 Version 3.0</div></div></div>"},"97006":{"type":"graphic_picture","displayName":"Keloid histo","title":"Histopathologic features of keloids","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of keloids</div><div class=\"cntnt\"><img style=\"width:420px; height:264px;\" src=\"images/DERM/97006_Keloid_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Nodules of spindle cells with abundant collagen are present in the dermis with prominent hyalinization. <br />(B) Glassy eosinophilic and hyalinized collagen ﬁbers are interspersed with swathes of ﬁbroblasts.</div><div class=\"graphic_reference\">Reproduced with permission from: Beer TW, Lam MH, Heenan PJ. Tumors of fibrous tissue involving the skin. In: Lever's Histopathology of the Skin, 10th ed, Elder DE, Elenitsas R, Johnson B Jr, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 97006 Version 3.0</div></div></div>"},"97009":{"type":"graphic_picture","displayName":"Keloid neck","title":"Keloid scar","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Keloid scar</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/97009_Keloidneck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large keloid is present on the neck of this patient.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 97009 Version 2.0</div></div></div>"},"97014":{"type":"graphic_picture","displayName":"Hypertrophic scar 2","title":"Hypertrophic scar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hypertrophic scar</div><div class=\"cntnt\"><img style=\"width:434px; height:712px;\" src=\"images/DERM/97014_Hypertrophicscar2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypertrophic scar at the site of a surgical wound. Multiple telangiectasias are visible on the scar surface.</div><div class=\"graphic_reference\">Reproduced with permission from: Diepgen TL, Yihune G, et al. Dermatology Online Atlas. Published online at: <a href=\"http://www.dermis.net/\" spellcheck=\"true\" target=\"_blank\">www.dermis.net</a>. Copyright &copy; 1996-2015 DermIS. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97014 Version 2.0</div></div></div>"},"97015":{"type":"graphic_picture","displayName":"Headmaster collar","title":"Headmaster collar","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Headmaster collar</div><div class=\"cntnt\"><img style=\"width:406px; height:600px;\" src=\"images/ONC/97015_Headmaster_collar.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2014 Symmetric Designs. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97015 Version 1.0</div></div></div>"},"97016":{"type":"graphic_diagnosticimage","displayName":"MRI brain schistosomiasis","title":"Magnetic resonance imaging of the brain in neuroschistosomiasis","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging of the brain in neuroschistosomiasis</div><div class=\"cntnt\"><img style=\"width:728px; height:280px;\" src=\"images/ID/97016_MRI_brain_schistosomiasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">32-year-old man with cerebral schistosomiasis.<br />(A) Axial contrast-enhanced T1-weighted magnetic resonance image (MRI) shows punctate multinodular enhancement pattern surrounding central linear enhancement.<br />(B) Sagittal contrast-enhanced T1-weighted MRI confirms linear (arrow) and nodular enhancement pattern in different imaging plane.<br />(C) Axial T2-weighted MR image shows hyperintense mass (arrow) with surrounding vasogenic edema involving right parietal lobe.</div><div class=\"graphic_reference\">Reprinted with permission from the American Journal of Roentgenology. Sanelli PC, Lev MH, Gonzalez RG, Schaefer PW. Unique Linear and Nodular MR Enhancement Pattern in Schistosomiasis of the Central Nervous System: Report of Three Patients. AJR Am J Roentgenol 2001; 177:1471. Copyright &copy; 2001 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 97016 Version 2.0</div></div></div>"},"97018":{"type":"graphic_table","displayName":"Causes of mild or moderate increases in AST ALT","title":"Differential diagnosis of mildly and moderately elevated serum aminotransferases (<15 times upper limit of normal)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of mildly and moderately elevated serum aminotransferases (&lt;15 times upper limit of normal)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Hepatic disease</td> <td class=\"subtitle1\">Nonhepatic disease</td> </tr> <tr> <td class=\"subtitle2\">ALT predominant (AST/ALT &#60;1)</td> <td class=\"subtitle2\">AST predominant (AST/ALT &#8805;1)</td> <td class=\"subtitle2\">&nbsp;</td> </tr> <tr> <td>Drug-induced liver injury</td> <td>Alcoholic hepatitis</td> <td>Muscle injury (strenuous exercise, myopathy)</td> </tr> <tr> <td>Chronic viral hepatitis (HBV, HCV)</td> <td>Cirrhosis due to viral hepatitis or NAFLD</td> <td>Adrenal insufficiency</td> </tr> <tr> <td>Occupational, toxin-related hepatocellular damage</td> <td>Wilson disease</td> <td>Myocardial infarction, heart failure</td> </tr> <tr> <td>Autoimmune hepatitis</td> <td>&nbsp;</td> <td>Anorexia nervosa</td> </tr> <tr> <td>NAFLD</td> <td>&nbsp;</td> <td>Thyroid disease</td> </tr> <tr> <td>Genetic disorders <ul class=\"decimal_heading\"> <li>Wilson disease </li> <li>Hemochromatosis </li> <li>Alpha-1 antitrypsin deficiency </li> </ul> </td> <td>&nbsp;</td> <td>Celiac disease</td> </tr> <tr> <td>Congestive hepatopathy</td> <td>&nbsp;</td> <td>&nbsp;Macro AST</td> </tr> <tr> <td>Malignant infiltration of the liver</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALT: alanine aminotransferase; AST: aspartate aminotransferase; HBV: hepatitis B virus; HCV: hepatitis C virus; NAFLD: nonalcoholic fatty liver disease.</div><div id=\"graphicVersion\">Graphic 97018 Version 5.0</div></div></div>"},"97023":{"type":"graphic_picture","displayName":"CLL/SLL Bone marrow biopsy specimens","title":"Chronic lymphocytic leukemia/small lymphocytic lymphoma involving bone marrow biopsy specimens","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Chronic lymphocytic leukemia/small lymphocytic lymphoma involving bone marrow biopsy specimens</div><div class=\"cntnt\"><img style=\"width:229px; height:512px;\" src=\"images/HEME/97023_CLL_SLL_biopsy_specimens.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bone marrow biopsy specimens with hematoxylin and eosin stain demonstrate infiltration with chronic lymphocytic leukemia/small lymphocytic lymphoma in three main patterns:<br />(A) Nodular pattern.<br />(B) Interstitial pattern.<br />(C) Diffuse pattern. In this field, a vague pale area is present, consistent with a pseudofollicle.</div><div class=\"graphic_reference\">Reproduced with permission from: Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Ioachim's Lymph Node Pathology, 4th ed, Ioachim HL, Medeiros LJ (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 97023 Version 3.0</div></div></div>"},"97036":{"type":"graphic_picture","displayName":"Muscle biopsy amyloid myopathy","title":"Muscle biopsy showing amyloid myopathy","html":"<div class=\"graphic\"><div style=\"width: 820px\" class=\"figure\"><div class=\"ttl\">Muscle biopsy showing amyloid myopathy</div><div class=\"cntnt\"><img style=\"width:800px; height:211px;\" src=\"images/NEURO/97036_Musclebiopsyamyloidmyop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frozen sections of the deltoid muscle<br />(A) Trichrome stain shows a necrotic muscle fiber.<br />(B) Congo red stain shows extensive amyloid deposition in a perimysial blood vessel wall that is intensely red when viewed under rhodamine optics (C).</div><div class=\"graphic_reference\">From: Ghosh PS, Thaera GM, Tracy JA. Teaching neuroimages: dyspnea as a presenting manifestation of amyloid myopathy. Neurology 2013; 81:e184. DOI: <A spellcheck=true href=\"http://www.neurology.org/content/81/24/e184.long\" target=_blank>10.1212/01.wnl.0000437300.51312.9e</A>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright © 2013 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 97036 Version 3.0</div></div></div>"},"97037":{"type":"graphic_diagnosticimage","displayName":"Transient elastography liver","title":"Transient elastography of the liver","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transient elastography of the liver</div><div class=\"cntnt\"><img style=\"width:289px; height:215px;\" src=\"images/GAST/97037_Transien_elastography_liver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transient elastography showing the measurement of liver stiffness in kilopascals (kPa) along the left side of the screen. An A-mode image is displayed to assist the operator in selecting the measurement zone. On the right side, the values of 10 measurements are shown with the mean value depicted at the bottom of the screen.</div><div id=\"graphicVersion\">Graphic 97037 Version 1.0</div></div></div>"},"97038":{"type":"graphic_diagnosticimage","displayName":"Point shear wave elastography liver","title":"Point-shear wave elastography of the liver","html":"<div class=\"graphic\"><div style=\"width: 848px\" class=\"figure\"><div class=\"ttl\">Point-shear wave elastography of the liver</div><div class=\"cntnt\"><img style=\"width:828px; height:283px;\" src=\"images/GAST/97038_Pnt_shear_wave_elastog_livr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Point-shear wave elastography using acoustic radiation force impulse in healthy liver parenchyma (A) and complete cirrhosis (B). The shear wave speed and the depth of the region of interest (rectangular box) are shown on the right side of the image.</div><div id=\"graphicVersion\">Graphic 97038 Version 1.0</div></div></div>"},"97040":{"type":"graphic_table","displayName":"Mean shear wave velocities liver","title":"Mean shear wave velocities of the left and right liver lobes on point-shear wave elastography using acoustic radiation force impulse","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mean shear wave velocities of the left and right liver lobes on point-shear wave elastography using acoustic radiation force impulse</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"12%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup><colgroup width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author</td> <td class=\"subtitle1\">N</td> <td class=\"subtitle1\">Subjects</td> <td class=\"subtitle1\">Left lobe (m/s)</td> <td class=\"subtitle1\">Right lobe (m/s)</td> <td class=\"subtitle1\">Ref</td> </tr> <tr> <td>Karlas T, et al</td> <td class=\"centered\">50</td> <td>Healthy individuals</td> <td class=\"centered\">1.28 &#177; 0.19</td> <td class=\"centered\">1.15 &#177; 0.17</td> <td class=\"centered\">[1]</td> </tr> <tr> <td>Karlas T, et al</td> <td class=\"centered\">23</td> <td>Patients with F1 or F2 fibrosis</td> <td class=\"centered\">2.1 &#177; 0.72</td> <td class=\"centered\">1.75 &#177; 0.89</td> <td class=\"centered\">[1]</td> </tr> <tr> <td>Toshima T, et al</td> <td class=\"centered\">103</td> <td>24 healthy volunteers, 79 patients with chronic liver disease</td> <td class=\"centered\">1.90 &#177; 0.68</td> <td class=\"centered\">1.61 &#177; 0.51</td> <td class=\"centered\">[2]</td> </tr> <tr> <td>Piscaglia F, et al</td> <td class=\"centered\">14</td> <td>Healthy individuals</td> <td class=\"centered\">1.29 (1.00 to 1.60)</td> <td class=\"centered\">1.15 (0.80 to 1.74)</td> <td class=\"centered\">[3]</td> </tr> <tr> <td>Piscaglia F, et al</td> <td class=\"centered\">114</td> <td>Patients with chronic liver disease</td> <td class=\"centered\">1.79 (0.80 to 4.00)</td> <td class=\"centered\">1.67 (0.45 to 3.76)</td> <td class=\"centered\">[3]</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Ref: reference; N: number of patients studied.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Karlas T, Pfrepper C, Wiegand J, et al. Acoustic radiation force impulse imaging (ARFI) for non-invasive detection of liver fibrosis: examination standards and evaluation of interlobe differences in healthy subjects and chronic liver disease. Scand J Gastroenterol 2011; 46:1458. </li>&#xD;&#xA;    <li>Toshima T, Shirabe K, Takeishi K, et al. New method for assessing liver fibrosis based on acoustic radiation force impulse: a special reference to the difference between right and left liver. J Gastroenterol 2011; 46:705. </li>&#xD;&#xA;    <li>Piscaglia F, Salvatore V, Di Donato R, et al. Accuracy of VirtualTouch Acoustic Radiation Force Impulse (ARFI) imaging for the diagnosis of cirrhosis during liver ultrasonography. Ultraschall Med 2011; 32:167.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 97040 Version 1.0</div></div></div>"},"97041":{"type":"graphic_diagnosticimage","displayName":"2D-shear wave elastography liver","title":"Two-dimensional shear wave elastography of the liver","html":"<div class=\"graphic\"><div style=\"width: 627px\" class=\"figure\"><div class=\"ttl\">Two-dimensional shear wave elastography of the liver</div><div class=\"cntnt\"><img style=\"width:607px; height:210px;\" src=\"images/GAST/97041_2D_shear_wave_elasto_liver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two-dimensional shear wave elastography in a patient with healthy liver parenchyma (A) and a patient with liver cirrhosis (B). The color indicates the stiffness of the liver: blue means soft, and red means hard. At least one box can be drawn within the area being evaluated; the value of the shear wave speed is shown on the right side of the image either in m/s (top) or in kPa (bottom).</div><div id=\"graphicVersion\">Graphic 97041 Version 1.0</div></div></div>"},"97042":{"type":"graphic_diagnosticimage","displayName":"Strain elastography liver","title":"Strain elastography of the liver","html":"<div class=\"graphic\"><div style=\"width: 633px\" class=\"figure\"><div class=\"ttl\">Strain elastography of the liver</div><div class=\"cntnt\"><img style=\"width:613px; height:190px;\" src=\"images/GAST/97042_Strain_elastography_liver.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Strain elastography showing healthy liver parenchyma (A) and liver cirrhosis (B).</div><div id=\"graphicVersion\">Graphic 97042 Version 1.0</div></div></div>"},"97043":{"type":"graphic_table","displayName":"Methods to evaluate liver fibrosis","title":"Advantages and disadvantages of noninvasive methods to evaluate liver fibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Advantages and disadvantages of noninvasive methods to evaluate liver fibrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Parameters</td> <td class=\"subtitle1\">Transient elastography</td> <td class=\"subtitle1\">pARFI</td> <td class=\"subtitle1\">2D-SWE</td> <td class=\"subtitle1\">MR elastography</td> <td class=\"subtitle1\">Serum biomarkers</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Advantages</strong></td> <td>High accuracy, rapid results</td> <td>High accuracy, rapid results</td> <td>High accuracy, rapid results</td> <td>High accuracy</td> <td>Availability</td> </tr> <tr> <td>Reproducibility</td> <td>Reproducibility</td> <td>Reproducibility</td> <td>Reproducibility</td> <td>Reproducibility</td> </tr> <tr> <td>Very easy to learn</td> <td>Easy to learn</td> <td>Easy to learn, larger measurement area than other ultrasound techniques</td> <td>Examination of the whole liver</td> <td>&nbsp;</td> </tr> <tr> <td>&nbsp;</td> <td>Conventional ultrasound images are also obtained</td> <td>Conventional ultrasound images are also obtained</td> <td>Conventional MR images are also obtained</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>Obesity and ascites are not limiting</td> <td>Ascites is not limiting</td> <td>Obesity and ascites are not limiting</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"6\"><strong>Disadvantages</strong></td> <td>Technical requirements (elastography equipment) </td> <td>Technical requirements (ultrasound equipment)</td> <td>Technical requirements (ultrasound equipment)</td> <td>Technical requirements (MR imaging equipment)</td> <td>Nonspecific (eg, hyperbilirubinemia, hemolysis, inflammation)</td> </tr> <tr> <td>Intermediate cost</td> <td>Intermediate cost</td> <td>Intermediate cost</td> <td>High cost, time-consuming</td> <td>Relatively high cost, limited availability (patent)</td> </tr> <tr> <td>Limited recognition of intermediate stages of fibrosis</td> <td>Limited recognition of intermediate stages of fibrosis</td> <td>Limited recognition of intermediate stages of fibrosis</td> <td>Limited recognition of intermediate stages of fibrosis</td> <td>Limited recognition of intermediate stages of fibrosis</td> </tr> <tr> <td>Blind selection of measurement area</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Not applicable in case of iron deposition</td> <td>Results not immediately available</td> </tr> <tr> <td>Restricted value in obese patients and patients with ascites</td> <td>Narrow range of values, small measurement area</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>False positive values in patients with acute hepatitis, cholestasis, and heart failure</td> <td>Quality criteria not well-defined</td> <td>Quality criteria not well-defined</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">pARFI: point-shear wave elastography using acoustic radiation force impulse; 2D-SWE: two-dimensional shear wave elastography; MR: magnetic resonance.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Cui XW, Friedrich-Rust M, De Molo C, et al. Liver elastography, comments on EFSUMB elastography guidelines 2013. World J Gastroenterol 2013; 19:6329.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 97043 Version 1.0</div></div></div>"},"97044":{"type":"graphic_picture","displayName":"Skin lesions in MCTD","title":"Skin lesions in MCTD","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Skin lesions in MCTD</div><div class=\"cntnt\"><img style=\"width:562px; height:530px;\" src=\"images/RHEUM/97044_SkinlesionsMCTD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema and superficial ulceration, suggestive of vasculitis, affecting the fingers and toes of a patient with MCTD.</div><div class=\"graphic_footnotes\">MCTD: mixed connective tissue disease.</div><div class=\"graphic_reference\">From: Sen S, Sinhamahapatra P, Choudhury S, et al. Cutaneous manifestations of mixed connective tissue disease: Study from a tertiary care hospital in eastern India. Indian&nbsp;J Dermatol 2014; 59:35. DOI: <a href=\"http://www.e-ijd.org/article.asp?issn=0019-5154;year=2014;volume=59;issue=1;spage=35;epage=40;aulast=Sen\" spellcheck=\"true\" target=\"_blank\">10.4103/0019-5154.123491</a>. Reproduced with permission from Wolters Kluwer - MedKnow. Copyright &copy; 2014 Asian Academy of Dermatology and Venereology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 97044 Version 2.0</div></div></div>"},"97045":{"type":"graphic_picture","displayName":"Malar rash in MCTD","title":"Malar rash","html":"<div class=\"graphic\"><div style=\"width: 725px\" class=\"figure\"><div class=\"ttl\">Malar rash</div><div class=\"cntnt\"><img style=\"width:705px; height:530px;\" src=\"images/RHEUM/97045_MalarrashMCTD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Malar rash, in a butterfly distribution, in a patient with MCTD.</div><div class=\"graphic_footnotes\">MCTD: mixed connective tissue disease.</div><div class=\"graphic_reference\">From: Sen S, Sinhamahapatra P, Choudhury S, et al. Cutaneous manifestations of mixed connective tissue disease: Study from a tertiary care hospital in eastern India. Indian J Dermatol 2014; 59:35. DOI: <a href=\"http://www.e-ijd.org/article.asp?issn=0019-5154;year=2014;volume=59;issue=1;spage=35;epage=40;aulast=Sen\" spellcheck=\"true\" target=\"_blank\">10.4103/0019-5154.123491</a>. Reproduced with permission from Wolters Kluwer - MedKnow. Copyright &copy; 2014 Asian Academy of Dermatology and Venereology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 97045 Version 2.0</div></div></div>"},"97046":{"type":"graphic_diagnosticimage","displayName":"Histologic changes in esophageal muscular layer of MCTD patients","title":"Histologic changes in the esophageal muscular layer of MCTD patients","html":"<div class=\"graphic\"><div style=\"width: 825px\" class=\"figure\"><div class=\"ttl\">Histologic changes in the esophageal muscular layer of MCTD patients</div><div class=\"cntnt\"><img style=\"width:805px; height:408px;\" src=\"images/RHEUM/97046_Hstlgi_esph_msclr_MCTD_ptnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histological changes in the esophageal muscle layer of MCTD patients. Muscular changes in the esophagus were particularly marked in the inner circular muscular layer.<br />(A) Slight degeneration of muscular tissue at a very early stage.<br />(B) Atrophy and degeneration at a relatively early stage.<br />(C) Degeneration of muscular tissue with ﬁbrosis.<br />(D) Severe atrophy and degeneration of muscular tissue with ﬁbrosis involving almost the entire muscular layer.<br />Original magniﬁcation: upper, ×20; lower, ×200. Elastica-Masson stain.</div><div class=\"graphic_footnotes\">MCTD: mixed connective tissue disease.</div><div class=\"graphic_reference\">Reproduced from: Uzuki M, Kamataki A, Watanabe M, et al. Histological analysis of esophageal muscular layers from 27 autopsy cases with mixed connective tissue disease (MCTD). Pathol Res Pract 2011; 207:383. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97046 Version 1.0</div></div></div>"},"97052":{"type":"graphic_diagnosticimage","displayName":"Point-shear wave elastography focal liver lesions","title":"Point-shear wave elastography of focal liver lesions","html":"<div class=\"graphic\"><div style=\"width: 651px\" class=\"figure\"><div class=\"ttl\">Point-shear wave elastography of focal liver lesions</div><div class=\"cntnt\"><img style=\"width:631px; height:216px;\" src=\"images/GAST/97052_Pnt_shr_wav_elasto_foc_livr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Point-shear wave elastography for evaluation of focal nodular hyperplasia (A) and focal fatty lesion of liver (B). Almost all focal liver lesions are stiffer than the surrounding hepatic parenchyma except focal fatty sparing.</div><div id=\"graphicVersion\">Graphic 97052 Version 1.0</div></div></div>"},"97053":{"type":"graphic_diagnosticimage","displayName":"2D-shear wave elastography focal liver lesions","title":"Two-dimensional shear wave elastography of focal liver lesions","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">Two-dimensional shear wave elastography of focal liver lesions</div><div class=\"cntnt\"><img style=\"width:605px; height:198px;\" src=\"images/GAST/97053_2D_shr_wav_elst_foc_lvr_les.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two-dimensional shear wave elastography for evaluation of hemangioma (A) and hepatocellular carcinoma (B). Almost all liver neoplasias show higher shear wave velocities compared with the surrounding hepatic parenchyma.</div><div id=\"graphicVersion\">Graphic 97053 Version 1.0</div></div></div>"},"97054":{"type":"graphic_diagnosticimage","displayName":"Strain elastography FNH","title":"Strain elastography of focal nodular hyperplasia","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Strain elastography of focal nodular hyperplasia</div><div class=\"cntnt\"><img style=\"width:585px; height:362px;\" src=\"images/GAST/97054_Strain_elastography_FNH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Strain elastography image of a small focal nodular hyperplasia (blue). Almost all liver neoplasias are stiffer than the surrounding hepatic parenchyma.</div><div id=\"graphicVersion\">Graphic 97054 Version 1.0</div></div></div>"},"97057":{"type":"graphic_figure","displayName":"Thrombin structure","title":"Thrombin structure showing active site","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Thrombin structure showing active site</div><div class=\"cntnt\"><img style=\"width:600px; height:520px;\" src=\"images/HEME/97057_Thrombin_xray_crystallograp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Three-dimensional structure of thrombin based on x-ray crystallography. Thrombin is a serine protease. A deep groove surrounds the active site serine, shown in red. The entrance into the active site is partially occluded by a hydrophobic insertion loop on the top and an autolysis (self-cleavage) loop at the bottom. Thus, physiologic substrates must align with the anion-binding exosite-I (ABE-I) on the right, and sometimes with ABE-II as well, in order to gain entrance into the groove and interact with the active site. The pink stick figure within the groove is a direct thrombin inhibitor (peptide) used during crystallization to prevent thrombin autolysis. The arrow points to glutamic acid at position 229, which, when substituted with lysine (E229K), converts thrombin from a procoagulant enzyme into an anticoagulant enzyme. E229K thrombin no longer cleaves fibrinogen to fibrin monomer or activates platelets; but it is able to bind to thrombomodulin on the endothelial cell surface and activate protein C.<sup>[1,2]</sup></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Gibbs CS, Coutre SE, Tsiang M, et al. Conversion of thrombin into an anticoagulant by protein engineering. Nature 1995; 378:413.</li>&#xD;&#xA;    <li>Tsiang M, Paborsky LR, Li WX, et al. Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo. Biochemistry 1996; 35:16449.</li>&#xD;&#xA;</ol>&#xD;&#xA;Courtesy of Lawrence LK Leung, MD.</div><div id=\"graphicVersion\">Graphic 97057 Version 3.0</div></div></div>"},"97072":{"type":"graphic_diagnosticimage","displayName":"CT scan showing a pericardial metastasis","title":"CT scan showing a large pericardial metastasis from small cell lung carcinoma","html":"<div class=\"graphic\"><div style=\"width: 528px\" class=\"figure\"><div class=\"ttl\">CT scan showing a large pericardial metastasis from small cell lung carcinoma</div><div class=\"cntnt\"><img style=\"width:508px; height:401px;\" src=\"images/RADIOL/97072_CT_-prcr_smll_cll_lng_carc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the heart shows a 4.5 cm lobular metastatic soft mass (arrow) involving the pericardium of the posterolateral aspect of the left ventricle. The primary lesion was a small cell carcinoma of the lung.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 97072 Version 1.0</div></div></div>"},"97073":{"type":"graphic_diagnosticimage","displayName":"CT scan of metastatic disease to the pericardium","title":"CT scan showing metastatic involvement of the pericardium in a patient with melanoma","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">CT scan showing metastatic involvement of the pericardium in a patient with melanoma</div><div class=\"cntnt\"><img style=\"width:490px; height:421px;\" src=\"images/RADIOL/97073_CT_scan_meta_dis_prcrd_mel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the heart shows focal nodularity (arrowhead) and thickening of the pericardium (arrow) from metastatic melanoma. A loculated pleural effusion is present (dashed arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 97073 Version 1.0</div></div></div>"},"97074":{"type":"graphic_diagnosticimage","displayName":"CT scan of pericardial effusion and RV collapse","title":"CT scan showing a pericardial effusion resulting in right ventricular (RV) collapse related to metastatic adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">CT scan showing a pericardial effusion resulting in right ventricular (RV) collapse related to metastatic adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:595px; height:241px;\" src=\"images/RADIOL/97074_CT_scan_peri_tamp_mets_adno.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT through the chest (A) shows a large pericardial effusion (arrow) with a collapsed right ventricle (dashed arrow) indicating tamponade. A subsegmental region of atelectasis is present (arrowhead). Image B is reformatted in the coronal plane and shows a large pericardial effusion (arrow), collapsed right ventricle (dashed arrow), and focal atelectasis (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 97074 Version 1.0</div></div></div>"},"97075":{"type":"graphic_figure","displayName":"Lissamine green staining in keratoconjunctivitis sicca","title":"Lissamine green staining of the bulbar conjunctiva in keratoconjunctivitis sicca","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Lissamine green staining of the bulbar conjunctiva in keratoconjunctivitis sicca</div><div class=\"cntnt\"><img style=\"width:726px; height:485px;\" src=\"images/RHEUM/97075_Lsmn_grn_stn_krtcjnctv_scca.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lissamine green staining of the bulbar conjunctiva in Sj&ouml;gren's-related dry eye disease.<br />(A) Lissamine green background staining of the bulbar conjunctiva. Some pooling of dye is present, but &lt;10 discrete individual green dots are seen in the interpalpebral area. These findings would equate to a score of 0 with the Sj&ouml;gren's International Collaborative Clinical Alliance (SICCA) ocular stain scoring system<sup>[1]</sup>.<br />(B) Lissamine green staining of the bulbar conjunctiva showing discrete individual green dots, numbering &gt;10 and &lt;33, in the interpalpebral area. These findings equate to a SICCA ocular staining score of 1. Staining on the surface of the adjacent pingueculum is considered an artifact and is therefore ignored.<br />(C) Discrete individual green dots, numbering 33 to 100, are seen in the interpalpebral area equating to a SICCA ocular staining score of 2. The two areas of partial confluent staining are each &lt;4 mm<sup>2</sup> and are therefore scored as 33 to 100 dots.<br />(D) More than 100 individual green dots are present in the interpalpebral area and are associated with many areas of confluent staining.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Whitcher JP, Shiboski CH, Shiboski SC, et al. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sjogren's Syndrome International Registry. Am J Ophthalmol 2010; 149:405.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: Whitcher JP, Shiboski CH, Shiboski SC, et al. A simplified quantitative method for assessing keratoconjunctivitis sicca from the Sj&ouml;gren's Syndrome International Registry. Am J Ophthalmol 2010; 149:405. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97075 Version 2.0</div></div></div>"},"97076":{"type":"graphic_diagnosticimage","displayName":"GTN liver metastases PET","title":"Gestational trophoblastic neoplasia: Positron emission tomography of liver metastases","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Gestational trophoblastic neoplasia: Positron emission tomography of liver metastases</div><div class=\"cntnt\"><img style=\"width:582px; height:520px;\" src=\"images/ONC/97076_GTN_liver_metastases_PET.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 97076 Version 1.0</div></div></div>"},"97077":{"type":"graphic_figure","displayName":"Parkland Formula nomogram for adult burns","title":"Parkland Formula nomogram for adult burns","html":"<div class=\"graphic\"><div style=\"width: 1202px\" class=\"figure\"><div class=\"ttl\">Parkland Formula nomogram for adult burns</div><div class=\"cntnt\"><img style=\"width:1182px; height:740px;\" src=\"images/EM/97077_Parkland_Formula_adult_burn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><strong>Instructions</strong> (summary)<strong>:</strong><br /><ol>&#xD;&#xA;    <li>Place a straight edge so that it intersects the correct values for both BWt (kg or stones) and TBSA (%), and read VTBI (L) per period.</li>&#xD;&#xA;    <li>Place a straight edge so that it intersects the correct values for both VTBI (L), and the time remaining in the FIRST PERIOD (h) from time of the burn injury.<br />    Give the VTBI (L) as Hartmann's solution at the rate indicated where the straight edge intersects the RATE (mL/h or drops/min) scale until the end of the First Period.</li>&#xD;&#xA;    <li>Then: Place a straight edge so that it intersects the correct values for both VTBI (L) and the cross marked \"SECOND PERIOD\".<br />    Give the VTBI (L) as Hartmann's solution at the rate indicated where the straight edge intersects the RATE (mL/h or drops/min) scale until the end of the Second Period (16 h).</li>&#xD;&#xA;    <li>If additional resuscitation fluid has been given to the patient prior to admission, subtract this volume from the VTBI (L) in step 2); but VTBI (L) in step 3) remains unchanged.</li>&#xD;&#xA;</ol></div><div class=\"graphic_reference\">Originally published in: Theron A, Bodger O, Williams D. Comparison of three techniques using the Parkland Formula to aid fluid resuscitation in adult burns. Emerg Med J 2014; 31:730. Reproduced with permission. Copyright &copy; 2014 Dr. David Williams, Welsh Centre for Burns.</div><div id=\"graphicVersion\">Graphic 97077 Version 1.0</div></div></div>"},"97078":{"type":"graphic_algorithm","displayName":"Cofactor-responsive neonatal seizures","title":"Diagnostic and treatment algorithm for cofactor-responsive neonatal seizures","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diagnostic and treatment algorithm for cofactor-responsive neonatal seizures</div><div class=\"cntnt\"><img style=\"width:404px; height:603px;\" src=\"images/NEURO/97078_Physexamcorrelneonaseiz.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IV: intravenous; EEG: electroencephalography; PLP: pyridoxal 5'-phosphate; alpha-AASA: alpha-aminoadipic semialdehyde; PNPO: pyridoxamine 5'-phosphase oxidase.<br />* Risk of apnea, particularly when pyridoxine is given IV.<br />&para; Repeated every 5 to 15 minutes with continuous EEG monitoring.<br />&Delta; alpha-AASA is also elevated in molybdenum cofactor/sulfite oxidase deficiency.<br /><span class=\"lozenge\">&loz;</span> If biotinidase deficiency has not been excluded by newborn screen.</div><div id=\"graphicVersion\">Graphic 97078 Version 5.0</div></div></div>"},"97084":{"type":"graphic_diagnosticimage","displayName":"Subtraction ictal SPECT co-registered to MRI (SISCOM)","title":"Subtraction ictal SPECT co-registered to MRI (SISCOM)","html":"<div class=\"graphic\"><div style=\"width: 640px\" class=\"figure\"><div class=\"ttl\">Subtraction ictal SPECT co-registered to MRI (SISCOM)</div><div class=\"cntnt\"><img style=\"width:620px; height:596px;\" src=\"images/NEURO/97084_Sbtr_ict_SPCT_crgs_MRI_SSCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal SISCOM&nbsp;image&nbsp;showing a region of hyperperfusion in the left inferior frontal lobe (arrow). Patient has drug-resistant focal epilepsy of left superior temporal lobe origin. Brain MRI was normal. (Note: The left cerebral hemisphere is on the right side of the figure).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance image; SISCOM: subtraction ictal SPECT co-registered to MRI; SPECT: single photon emission computed tomography.</div><div id=\"graphicVersion\">Graphic 97084 Version 2.0</div></div></div>"},"97086":{"type":"graphic_figure","displayName":"Age of onset in autosomal dominant Alzheimer disease","title":"Age at symptom onset by mutated gene in autosomal dominant Alzheimer disease","html":"<div class=\"graphic\"><div style=\"width: 781px\" class=\"figure\"><div class=\"ttl\">Age at symptom onset by mutated gene in autosomal dominant Alzheimer disease</div><div class=\"cntnt\"><img style=\"width:761px; height:617px;\" src=\"images/NEURO/97086_Agesymptmonstmuttgene.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Age at symptom onset for all affected individuals are shown grouped by the affected gene, with APP mutations having an additional subclass for gene duplications. APP = amyloid precursor protein; PS1 = presenilin 1; PS2 = presenilin 2.</div><div class=\"graphic_reference\">From: Ryman D, Acosta-Baena N, Aisen P, et al. Symptom onset in autosomal dominant Alzheimer disease: A systematic review and meta-analysis. Neurology 2014; 83:253. DOI: <A spellcheck=true href=\"http://www.neurology.org/content/83/3/253.abstract\" target=_blank>10.1212/WNL.0000000000000596</A>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright © 2014 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 97086 Version 3.0</div></div></div>"},"97087":{"type":"graphic_table","displayName":"Causes of angioedema classified by mechanism","title":"Causes of angioedema classified by mechanism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of angioedema classified by mechanism</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Mechanism</td> <td class=\"subtitle1\">Known or presumed&nbsp;pathophysiology&nbsp;</td> <td class=\"subtitle1\">Examples</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" rowspan=\"4\"> <p><strong>Activation of mast cells</strong></p> <p>Clinical characteristics &ndash; Often associated with pruritus and urticarial.</p> <p>May present as part of an allergic reaction or anaphylaxis.</p> </td> <td class=\"indent1\">IgE-mediated mast cell activation (type I hypersensitivity)&nbsp;</td> <td>Allergic reactions to foods, drugs, latex, insect stings, other allergens</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Direct mast cell activation</td> <td>Opioids, radiocontrast agents</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Perturbations in arachidonic acid metabolism</td> <td>Aspirin and other NSAIDs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Immunologic and other non-IgE-mediated mast cell activation<span style=\"color: #ff0000;\">&nbsp;</span></td> <td>Idiopathic histaminergic angioedema, often associated with chronic spontaneous urticaria or inducible urticaria</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" rowspan=\"3\"> <p><strong><strong>Generation of bradykinin</strong></strong></p> <p>Clinical characteristics &ndash;<strong>&nbsp;Not</strong> associated with pruritus or urticaria.</p> <p>May present with abdominal symptoms due to bowel wall edema.</p> </td> <td class=\"indent1\">Inhibition of enzymes involved in degradation of bradykinin&nbsp;</td> <td>ACE inhibitors</td> </tr> <tr> <td class=\"indent1\">Deficiency or dysfunction of complement C1 inhibitor&nbsp;due to mutation</td> <td class=\"divider_bottom\">Hereditary angioedema (also known as hereditary C1 inhibitor deficiency or dysfunction)</td> </tr> <tr> <td class=\"indent1\">Deficiency or dysfunction of complement C1 inhibitor often due to anti-C1 inhibitor antibody or an underlying malignancy</td> <td class=\"divider_bottom\">Acquired C1 inhibitor deficiency</td> </tr> <tr> <td class=\"indent1\" rowspan=\"6\"> <p><strong>Unknown pathophysiology</strong></p> <p>Clinical characteristics &ndash; Variable.</p> <p>Sometimes&nbsp;associated with urticaria.</p> </td> <td class=\"indent1\">&nbsp;</td> <td class=\"divider_bottom\">Idiopathic nonhistaminergic angioedema</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td class=\"divider_bottom\">Infections (especially in children)</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td class=\"divider_bottom\">Drugs &ndash; Calcium channel blockers, fibrinolytic agents, herbal medicines, other hypereosinophilic syndrome</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td class=\"divider_bottom\">Hypereosinophilic syndrome</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td class=\"divider_bottom\">Gleich syndrome</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>Urticarial vasculitis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E; NSAIDs: nonsteroidal anti-inflammatory drugs; ACE inhibitors: angiotensin-converting enzyme inhibitors.</div><div id=\"graphicVersion\">Graphic 97087 Version 7.0</div></div></div>"},"97115":{"type":"graphic_picture","displayName":"Nephrectomy of nonfunctional upper pole of a duplex system","title":"Nephrectomy of nonfunctional upper pole of a duplex system","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Nephrectomy of nonfunctional upper pole of a duplex system</div><div class=\"cntnt\"><img style=\"width:596px; height:240px;\" src=\"images/PEDS/97115_Nephrec_nnfnc_up_ple_dp_sys.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Laparoscopic view of a nonfunctional dysplastic upper pole segment and dilated ureter in a duplex collecting system. This patient had obstruction due to a non-refluxing ureter. (B) Laparoscopic view of the ligature removal of the nonfunctional upper pole segment.</div><div id=\"graphicVersion\">Graphic 97115 Version 1.0</div></div></div>"},"97117":{"type":"graphic_algorithm","displayName":"Algorithm for the treatment of DVT","title":"Algorithm for the treatment of lower extremity deep venous thrombosis (DVT)","html":"<div class=\"graphic\"><div style=\"width: 967px\" class=\"figure\"><div class=\"ttl\">Algorithm for the treatment of lower extremity deep venous thrombosis (DVT)</div><div class=\"cntnt\"><img style=\"width:947px; height:542px;\" src=\"images/PULM/97117_Algorithm_treatment_DVT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm only applies to patients with a <strong>first</strong> episode of DVT.</div><div class=\"graphic_footnotes\">* Please refer to the UpToDate topic on deep venous thrombosis: long-term anticoagulation (three to six months).<br />&para; Patients with an unprovoked distal DVT should receive at least three months of anticoagulation. A small proportion may benefit from indefinite anticoagulation. Please refer to the UpToDate topic on rationale and indications for indefinite anticoagulation in patients with venous thromboembolism.<br />&Delta; Please refer to the UpToDate topic on rationale and indications for indefinite anticoagulation in patients with venous thromboembolism.</div><div id=\"graphicVersion\">Graphic 97117 Version 2.0</div></div></div>"},"97118":{"type":"graphic_table","displayName":"Targeted preconception physical examination","title":"Targeted preconception physical examination for women with diabetes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Targeted preconception physical examination for women with diabetes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Dilated funduscopic examination by an ophthalmologist</td> </tr> <tr> <td>Examination for thyromegaly</td> </tr> <tr> <td>Cardiac auscultation </td> </tr> <tr> <td>Evaluation for carotid bruits and pulses present to the periphery</td> </tr> <tr> <td>Blood pressure measurement in both arms and pulse, lying and standing to check for orthostasis</td> </tr> <tr> <td>Lung auscultation</td> </tr> <tr> <td>Check for succession splash if patient not fasting</td> </tr> <tr> <td>Check sensation and check for tremor, hypo- or hyper-reflexia</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 97118 Version 1.0</div></div></div>"},"97119":{"type":"graphic_table","displayName":"Whole body skeletal evaluation","title":"Whole-body skeletal evaluation in patients with bone metastases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Whole-body skeletal evaluation in patients with bone metastases</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical scenario</td> <td class=\"subtitle1\">Preferred study</td> </tr> <tr> <td>Need for comprehensive whole-body cancer staging</td> <td>Integrated FDG-PET/CT; bone scan if PET not done</td> </tr> <tr> <td>Multiple myeloma (lytic bone disease)</td> <td>Whole-body skeletal plain radiographic survey<br /> or<br /> Low-dose whole-body CT</td> </tr> <tr> <td>Multiple myeloma (sclerotic bone lesions [eg, POEMS syndrome])</td> <td>Nuclear medicine bone scan</td> </tr> <tr> <td>Rapidly progressive metastases associated with minimal reactive bone formation</td> <td>Integrated FDG-PET/CT</td> </tr> <tr> <td>Ewing sarcoma family of tumors with primary lytic tumor</td> <td>Integrated FDG-PET/CT</td> </tr> <tr> <td>All others</td> <td>Nuclear medicine bone scan</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: Computed tomography; POEMS: multiple myeloma with polyneuropathy, organomegaly, endocrinopathy, monoclonal spike, and skin changes; FDG-PET: 18-fluorodeoxyglucose positron emission tomography.</div><div id=\"graphicVersion\">Graphic 97119 Version 2.0</div></div></div>"},"97120":{"type":"graphic_table","displayName":"Medications associated with acute angle-closure glaucoma","title":"Medications associated with acute angle-closure glaucoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications associated with acute angle-closure glaucoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Alpha/beta adrenergic agonists</td> </tr> <tr> <td class=\"indent1\"> <p>Eye drops (topical mydriatics): Phenylephrine*, apraclonidine, dipivefrin</p> <p>Nose drops: Ephedrine*, naphazoline*</p> Systemic: Ephedrine*, epinephrine, phenylephrine*</td> </tr> <tr> <td class=\"subtitle1_single\">Anticholinergic agents</td> </tr> <tr> <td class=\"indent1\"> <p>Eye drops (mydriatics): Atropine, homatropine, cyclopentolate, tropicamide</p> <p>Inhaled: Ipratropium</p> Systemic: Atropine, scopolamine, other medicines with anticholinergic effect</td> </tr> <tr> <td class=\"subtitle1_single\">Anticonvulsant/multipurpose analgesic</td> </tr> <tr> <td class=\"indent1\">Topiramate</td> </tr> <tr> <td class=\"subtitle1_single\">Antihistamines</td> </tr> <tr> <td class=\"indent1\"> <p>H<sub>1</sub> receptor antagonists eg, diphenhydramine, chlorpheniramine, loratadine</p> H<sub>2</sub> receptor antagonists eg, cimetidine, ranitidine</td> </tr> <tr> <td class=\"subtitle1_single\">Beta<sub>2</sub> adrenergic agonists</td> </tr> <tr> <td class=\"indent1\">Inhaled bronchodilators: albuterol (salbutamol), terbutaline</td> </tr> <tr> <td class=\"subtitle1_single\">Diuretics</td> </tr> <tr> <td class=\"indent1\">Acetazolamide, hydrochlorothiazide</td> </tr> <tr> <td class=\"subtitle1_single\">Cholinergic agents</td> </tr> <tr> <td class=\"indent1\">Pilocarpine, acetylcholine, carbachol</td> </tr> <tr> <td class=\"subtitle1_single\">Psychiatric drugs</td> </tr> <tr> <td class=\"indent1\"> <p>Tricyclic antidepressants (TCAs) eg, amitriptyline, imipramine</p> <p>Selective serotonin reuptake inhibitors (SSRIs) eg, citalopram, paroxetine</p> Serotonin norepinephrine reuptake inhibitors (SNRIs) eg, venlafaxine</td> </tr> <tr> <td class=\"subtitle1_single\">Stimulants (noncatecholamine)</td> </tr> <tr> <td class=\"indent1\">Amphetamines, appetite suppressants (anorexiants)</td> </tr> <tr> <td class=\"subtitle1_single\">Other</td> </tr> <tr> <td class=\"indent1\">Trimethoprim-sulfamethoxazole (cotrimoxazole)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: Drugs listed in this table have the potential to induce acute angle-closure glaucoma or worsen chronic angle-closure glaucoma among physiologically predisposed individuals (ie, eyes with narrow anterior chamber angles which inhibit drainage of the aqueous fluid). Patients with signs and symptoms suggesting an acute attack of angle-closure glaucoma require emergency treatment by an ophthalmologist.</div><div class=\"graphic_footnotes\">* Available as an over-the-counter medicine for treatment of congestion and cough-cold symptoms.</div><div class=\"graphic_reference\">Courtesy of authors with additional data from Lai JS, Gangwani RA. Medication induced acute angle-closure attack. Hong Kong Med J 2012; 18:139.</div><div id=\"graphicVersion\">Graphic 97120 Version 3.0</div></div></div>"},"97123":{"type":"graphic_picture","displayName":"Active compression test for SLAP injuries","title":"Active compression test for SLAP injuries","html":"<div class=\"graphic\"><div style=\"width: 675px\" class=\"figure\"><div class=\"ttl\">Active compression test for SLAP injuries</div><div class=\"cntnt\"><img style=\"width:655px; height:259px;\" src=\"images/EM/97123_Activ_compression_test_SLAP.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The active compression test is used to help diagnose SLAP lesions of the shoulder labrum. It is performed first with the patient's thumb pointed down (image A) and then with the thumb up (image B).</div><div class=\"graphic_footnotes\">SLAP: superior labrum anterior to posterior.</div><div class=\"graphic_reference\">Reproduced with permission from: McFarland EG, Johansen JA, Freehill MT, et al. Physical examination of the shoulder and elbow in the baseball player. In: Sports Medicine of Baseball, Dine JS, Altchek DW, Andrews JR, et al (eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 97123 Version 4.0</div></div></div>"},"97135":{"type":"graphic_diagnosticimage","displayName":"Knee osteoarthritis with replacement","title":"Osteoarthritis of the knee before and after replacement","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Osteoarthritis of the knee before and after replacement</div><div class=\"cntnt\"><img style=\"width:511px; height:478px;\" src=\"images/RHEUM/97135_Knee_osteoarthritis_replace.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Panel A shows a radiograph of a knee with osteoarthritis. Panel B shows the same knee after a total knee arthroplasty. In panel A, the arrow shows the narrowed space between the femur and the tibia. Marginal osteophytes are also present. In panel B, the femur and tibia each have new metal end-pieces. The arrow shows that the space between the two bones has been widened with a polyethylene spacer.</div><div id=\"graphicVersion\">Graphic 97135 Version 2.0</div></div></div>"},"97136":{"type":"graphic_table","displayName":"Warm AIHA characteristics","title":"Baseline characteristics of 60 patients with warm agglutinin autoimmune hemolytic anemia (AIHA)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Baseline characteristics of 60 patients with warm agglutinin autoimmune hemolytic anemia (AIHA)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td>Mean age at AIHA onset</td> <td>53.6 &#177; 22.8 years (mean &#177; SD)</td> </tr> <tr> <td>Percent females</td> <td>50%</td> </tr> <tr> <td>Clinical symptoms at onset</td> <td>87%</td> </tr> <tr> <td class=\"indent1\">Anemia-related symptoms</td> <td>75%</td> </tr> <tr> <td class=\"indent1\">Jaundice/dark urine</td> <td>33%</td> </tr> <tr> <td class=\"indent1\">Chest pain/coronary syndrome</td> <td>7%</td> </tr> <tr> <td>Venous thrombosis</td> <td>20%</td> </tr> <tr> <td>Mean hemoglobin at onset</td> <td>6.4 &#177; 1.7 g/dL</td> </tr> <tr> <td>Mean reticulocytes at onset</td> <td>285 &#177; 175 x 10<sup>3</sup>/microL</td> </tr> <tr> <td>MCV at onset</td> <td>108 &#177; 14 fL</td> </tr> <tr> <td>Decreased haptoglobin</td> <td>93%</td> </tr> <tr> <td>Increased LDH</td> <td>93%</td> </tr> <tr> <td>Increased bilirubin</td> <td>82%</td> </tr> <tr> <td>Spherocytes at onset</td> <td>41%</td> </tr> <tr> <td>Immune thrombocytopenia</td> <td>5%</td> </tr> <tr> <td>Hypergammaglobulinemia</td> <td>31%</td> </tr> <tr> <td>Hypogammaglobulinemia</td> <td>20%</td> </tr> <tr> <td>Monoclonal immunoglobulin</td> <td>30%</td> </tr> <tr> <td>Antinuclear antibodies</td> <td>30%</td> </tr> <tr> <td>Direct antiglobulin test positivity</td> <td>100% (eligibility requirement)</td> </tr> <tr> <td class=\"indent1\">IgG only</td> <td>40%</td> </tr> <tr> <td class=\"indent1\">IgG plus C3d</td> <td>57%</td> </tr> <tr> <td class=\"indent1\">Other</td> <td>3% (one each of C3d only and IgA only)</td> </tr> <tr> <td>Secondary cause present</td> <td>62%</td> </tr> <tr> <td class=\"indent1\">Lymphoproliferative disorder</td> <td>33%</td> </tr> <tr> <td class=\"indent1\">Autoimmune disorder</td> <td>14%</td> </tr> <tr> <td class=\"indent1\">Miscellaneous disorders</td> <td>14% (ulcerative colitis, immunodeficiency, HCV, carcinoma, drug)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AIHA: autoimmune hemolytic anemia; MCV: mean corpuscular volume; LDH: lactate dehydrogenase; HCV: hepatitis C virus.</div><div class=\"graphic_reference\">Data from: Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients. Am J Hematol 2014; 89:E150.</div><div id=\"graphicVersion\">Graphic 97136 Version 1.0</div></div></div>"},"97140":{"type":"graphic_table","displayName":"Forms of status epilepticus","title":"Forms of status epilepticus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Forms of status epilepticus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Convulsive</td> </tr> <tr> <td class=\"subtitle2\">Generalized</td> <td class=\"subtitle2\">Focal</td> </tr> <tr> <td>Generalized convulsive&nbsp;status epilepticus <ul class=\"decimal_heading\"> <li>Primary generalized convulsive SE </li> <li>Secondarily generalized convulsive SE (focal onset) </li> </ul> <p>Myoclonic</p> <p>Tonic (may also have focal onset)</p> <p>Clonic (may also have focal onset)</p> Atonic (very rare for SE in adults; may also have focal onset)</td> <td>Focal motor&nbsp;status epilepticus&nbsp;(includes epilepsia partialis continua) </td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Nonconvulsive </td> </tr> <tr> <td> <p>Typical (\"classic\") absence SE</p> <p>Atypical absence SE</p> <p>Other primary generalized NCSE</p> Other generalized NCSE,&nbsp;with a&nbsp;focal onset</td> <td> <p>Complex partial SE, with prolonged or repeated focal seizures with impaired or altered awareness</p> Other focal SE with nonmotor features, eg, aphasic, sensory</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SE: status epilepticus; NCSE: nonconvulsive status epilepticus.</div><div id=\"graphicVersion\">Graphic 97140 Version 2.0</div></div></div>"},"97153":{"type":"graphic_table","displayName":"Monitoring children during treatment for diabetic ketoacidosis","title":"Monitoring of children during treatment for diabetic ketoacidosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Monitoring of children during treatment for diabetic ketoacidosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Parameter</td> <td class=\"subtitle1\">Frequency</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Vital signs</td> <td>Hourly</td> <td>Decreased resting heart rate or increased blood pressure suggest possible cerebral edema.</td> </tr> <tr> <td>Fluid input and output</td> <td>Hourly</td> <td>Include oral fluids.</td> </tr> <tr> <td>Neurological status</td> <td>At least hourly</td> <td> <p>Assess with Glasgow coma scale.</p> Assess for headache, decreased heart rate, age-inappropriate incontinence, as well as vomiting, restlessness, irritability, or drowsiness (refer to table describing the neurological evaluation in DKA).</td> </tr> <tr> <td>Blood glucose</td> <td>Hourly</td> <td>Use a point-of-care meter, but cross-check with laboratory tests, to ensure correlation.</td> </tr> <tr> <td>Blood beta-hydroxybutyrate</td> <td>Every two hours</td> <td> <p>Perform if test is available.</p> Resolution of DKA is indicated by beta-hydroxybutyrate &#8804;1 mmol/L (10.4 mg/dL) on two successive occasions.</td> </tr> <tr> <td>Electrolytes, BUN, calcium, magnesium, phosphorus, hematocrit, venous blood gas</td> <td>At least every two hours</td> <td> <p>Timing of initiating potassium replacement depends on initial serum potassium level (see topic text).</p> <strong>Calculate the anion gap:</strong> <ul class=\"decimal_heading\"> <li>Anion gap = Sodium &ndash; (chloride + bicarbonate) </li> <li>Normal anion gap = 12&#177;2; indicates resolution of DKA </li> </ul> <strong>Calculate the corrected sodium concentration:</strong> <ul class=\"decimal_heading\"> <li>Corrected Sodium = measured sodium + [&#916;SG &#247; 42] </li> <li>Where &#916;SG is the increment above normal in serum glucose concentration, in mg/dL. </li> </ul> </td> </tr> <tr> <td>ECG monitoring</td> <td>Continuous, if available</td> <td>Initiate monitoring for patients with severe DKA or abnormal serum potassium concentrations. Monitor for T-wave flattening and inversion, or prolonged PR interval, which indicate hypokalemia.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DKA: diabetic ketoacidosis; BUN: blood urea nitrogen; SG: serum glucose; ECG: electrocardiogram.</div><div id=\"graphicVersion\">Graphic 97153 Version 3.0</div></div></div>"},"97156":{"type":"graphic_table","displayName":"Complications of epidural versus intrathecal opioids cancer pain","title":"Comparison of complications from epidural versus intrathecal administration of opioids for cancer pain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of complications from epidural versus intrathecal administration of opioids for cancer pain</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Factors</td> <td class=\"subtitle1\">Intrathecal administration</td> <td class=\"subtitle1\">Epidural administration</td> </tr> <tr> <td>Infection rate</td> <td>No difference</td> <td>No difference</td> </tr> <tr> <td>Pain relief</td> <td>Recommended for long term</td> <td>Recommended for short term</td> </tr> <tr> <td>Medication dose</td> <td>Lower</td> <td>Higher</td> </tr> <tr> <td>Pump refill interval</td> <td>Less often</td> <td>More often</td> </tr> <tr> <td>Adverse effects</td> <td>Fewer</td> <td>More</td> </tr> <tr> <td>Technical complications first 20 days</td> <td>25%</td> <td>8%</td> </tr> <tr> <td>Technical complications long term</td> <td>5%</td> <td>55%</td> </tr> <tr> <td>Catheter fibrosis</td> <td>Minimal</td> <td>More likely</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Birthi P, Sloan P. Interventional treatment of refractory cancer pain. Cancer J 2013; 19:390. DOI: <a href=\"http://journals.lww.com/journalppo/pages/articleviewer.aspx?year=2013&amp;issue=09000&amp;article=00004&amp;type=abstract\" target=\"_blank\">10.1097/PPO.0b013e3182a631a2</a>. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 97156 Version 2.0</div></div></div>"},"97157":{"type":"graphic_table","displayName":"Protein precursor of amyloid deposits","title":"Protein precursor of amyloid deposits","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Protein precursor of amyloid deposits</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Protein class</td> <td class=\"subtitle1\">Precursor protein (abbreviation)</td> <td class=\"subtitle1\">Amyloid type</td> <td class=\"subtitle1\">Clinical type</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">High-density apolipoproteins</td> <td>(Apo) serum AA</td> <td>AA</td> <td>Associated with amyloid-complicating chronic infections or inflammatory diseases, and some heredofamilial periodic fever syndromes such as familial Mediterranean fever.</td> </tr> <tr> <td>Apolipoprotein A-I (ApoAI)</td> <td>AApoAI</td> <td>Age-related amyloid occurring in the aortic intima, and some hereditary neuropathic or cardiopathic amyloidoses<sup>[1,2]</sup>. May deposit in heart, liver, or kidney; C-terminal variants deposit in larynx and skin.</td> </tr> <tr> <td>Apolipoprotein A-II (ApoAII)</td> <td>AApoAII</td> <td>Some hereditary nephropathic amyloidoses<sup>[3]</sup>.</td> </tr> <tr> <td>Apolipoprotein A-IV (ApoAIV)</td> <td>AApoAIV</td> <td>Renal (medullary) amyloidosis.</td> </tr> <tr> <td>Apolipoprotein C-II (ApoCII)</td> <td>AApoCII</td> <td>Some hereditary nephropathic amyloidoses<sup>[4]</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td>Apolipoprotein C-III (ApoCIII)</td> <td>AApoCIII</td> <td>Some hereditary nephropathic amyloidoses<sup>[5]</sup>.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Immunoglobulin (Ig) gene superfamily</td> <td>Ig L chain/Ig H chains (IgL/IgH)</td> <td>AL/AH</td> <td>Primary and myeloma-associated amyloidosis.</td> </tr> <tr class=\"divider_bottom\"> <td>Beta-2 microglobulin</td> <td>Abeta2m</td> <td>Dialysis amyloidosis. Variant molecule has been described in a family affected by gastrointestinal disease, autonomic neuropathy, and sicca syndrome due to amyloid<sup>[6]</sup>.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Neuroendocrine</td> <td>(Pro)Calcitonin</td> <td>ACal</td> <td>Amyloid complicating C-cell thyroid tumors.</td> </tr> <tr> <td>Islet amyloid</td> <td>AIAPP</td> <td>Islet cell amyloid in insulinomas, type II diabetes mellitus, and aging<sup>[7]</sup>.</td> </tr> <tr> <td>Atrial natriuretic peptide</td> <td>AANF</td> <td>Isolated atrial amyloidosis of aging.</td> </tr> <tr> <td>Prolactin/Apro</td> <td>APro</td> <td>Prolactinomas/aging.</td> </tr> <tr class=\"divider_bottom\"> <td>Insulin</td> <td>Alns</td> <td>Local amyloid complicating use of the insulin pump.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Cytoskeleton-related</td> <td>Gelsolin</td> <td>AGel</td> <td>Hereditary neuropathic amyloid associated with corneal lattice dystrophy and cutis laxa (Meretoja syndrome)<sup>[8]</sup>.</td> </tr> <tr> <td>Keratin</td> <td>Does not yet have nomenclature designated</td> <td>Cutaneous amyloid.</td> </tr> <tr class=\"divider_bottom\"> <td>Keratoepithelin</td> <td>AKer</td> <td>Hereditary granular, lattice, and Avellino corneal dystrophies<sup>[9]</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td>Transport protein</td> <td>Transthyretin (TTR; prealbumin)</td> <td>ATTR</td> <td>Hereditary neuropathic and/or cardiopathic amyloids; vitreous amyloidosis; leptomeningeal or renal amyloid in some kindreds; senile systemic amyloidosis<sup>[10]</sup>.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Cerebrovascular/neurodegeneration</td> <td>Amyloid precursor protein (APP)</td> <td>ABeta</td> <td>Hereditary and sporadic Alzheimer disease; congophilic cerebral angiopathy<sup>[11,12]</sup>.</td> </tr> <tr> <td>Prion protein (PRP)</td> <td>APrPsc</td> <td>Hereditary and sporadic spongiform encephalopathies<sup>[13]</sup>.</td> </tr> <tr> <td>BRI gene product</td> <td>ABri/ADan</td> <td>Hereditary dementias (British and Danish types)<sup>[14]</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td>Cystatin C (Cys - C)</td> <td>ACys</td> <td>Hereditary cerebrovascular hemorrhage with amyloidosis (Icelandic type)<sup>[15]</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td>Coagulation protein</td> <td>Fibrinogen alpha chain</td> <td>AFib</td> <td>Hereditary nephropathic amyloidosis<sup>[16]</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td>Enzyme</td> <td>Lysozyme</td> <td>ALys</td> <td>Hereditary nephropathic amyloidosis; may have marked hepatic, splenic and gastrointestinal amyloid deposits<sup>[16]</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td>Very low-density lipoprotein (LDL)/Chylomicron-associated apolipoprotein</td> <td>Apolipoprotein IV (Apo AIV)</td> <td>AApoAIV</td> <td>Renal medulla and systemic disease<sup>[17]</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td>Lung surfactant protein</td> <td>Lung surfactant protein</td> <td>ASPC</td> <td>Interstitial lung disease<sup>[18]</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td>Galectin</td> <td>Galectin 7</td> <td>AGAI7</td> <td>Localized skin<sup>[19]</sup>.</td> </tr> <tr> <td rowspan=\"9\">Other</td> <td>Keratoepithelin</td> <td>AKer</td> <td>Various familial corneal dystrophies<sup>[9]</sup>.</td> </tr> <tr> <td>Lactoferrin</td> <td>ALac</td> <td>Corneal amyloidosis associated with trichiasis.</td> </tr> <tr> <td>Odontogenic ameloblast-associated protein</td> <td>AOaap</td> <td>Calcifying epithelial odontogenic tumors (CEOTs).</td> </tr> <tr> <td>Semenogelin 1</td> <td>ASem1</td> <td>Senile seminal vesicle amyloid.</td> </tr> <tr> <td>Lactadherin</td> <td>AMed</td> <td>Senile aortic amyloid; media deposition.</td> </tr> <tr> <td>Leukocyte chemotactic factor 2</td> <td>ALect2</td> <td>Amyloid nephropathy; hepatic amyloid.</td> </tr> <tr> <td>Corneodesmosin</td> <td>ACor</td> <td>Localized amyloid involving cornified epithelia, hair follicles.</td> </tr> <tr> <td>Enfuvirtide</td> <td>AEnf</td> <td>Localized amyloid occurring at the injection site of an HIV therapeutic<sup>[20]</sup>.</td> </tr> <tr> <td>p53 (tumor suppressor)</td> <td>Ap53</td> <td>Amyloid aggregates in tumor cell lines and breast tumors<sup>[21]</sup>.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Mucchiano GI, Haggqvist B, Sletten K, Westermark P. Apolipoprotein A-1-derived amyloid in atherosclerotic plaques of the human aorta. J Pathol 2001; 193:270.</li>&#xD;&#xA;    <li>de Sousa MM, Vital C, Ostler D, et al. Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis. Am J Pathol 2000; 156:1911.</li>&#xD;&#xA;    <li>Benson MD, Liepnieks JJ, Yazaki M, et al. A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene. Genomics 2001; 72:272.</li>&#xD;&#xA;    <li>Nasr SH, Dasari S, Hasadsri L, et al. Novel type of renal amyloidosis derived from apolipoprotein-CII. J Am Soc Nephrol 2016.</li>&#xD;&#xA;    <li>Valleix S, Verona G, Jourde-Chiche N, et al. D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile. Nat Commun 2016; 7:10353.</li>&#xD;&#xA;    <li>Valleix S, Gillmore JD, Bridoux F, et al. Hereditary systemic amyloidosis due to Asp76Asn variant &beta;2-microglobulin. N Engl J Med 2012; 366:2276.</li>&#xD;&#xA;    <li>H&ouml;ppener JW, Ahr&eacute;n B, Lips CJ. Islet amyloid and type 2 diabetes mellitus. N Engl J Med 2000; 343:411.</li>&#xD;&#xA;    <li>Kiuru S. Gelsolin-related familial amyloidosis, Finnish type (FAF), and its variants found worldwide. Amyloid 1998; 5:55.</li>&#xD;&#xA;    <li>Klintworth GK. The molecular genetics of the corneal dystrophies--current status. Front Biosci 2003; 8:d687.</li>&#xD;&#xA;    <li>Connors LH, Lom A, Prokaeva T, et al. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003; 10:160.</li>&#xD;&#xA;    <li>Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Revs 2001; 81:741.</li>&#xD;&#xA;    <li>Revesz T, Ghiso J, Lashley T, et al. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol 2003; 62:885.</li>&#xD;&#xA;    <li>Prusiner SB. Shattuck lecture--neurodegenerative diseases and prions. N Engl J Med 2001; 344:1516.</li>&#xD;&#xA;    <li>Vidal R, Frangione B, Rostagno A, et al. A stop-codon mutation in the BRI gene associated with familial British dementia. Nature 1999; 399:776 and Gibson G, Gunasekera N, Lee M, et al. Oligomerization and neurotoxicity of the amyloid ADan peptide implicated in familial Danish dementia. J Neurochem 2004; 88:281.</li>&#xD;&#xA;    <li>Olafsson I, Grubb A. Hereditary cystatin C amyloid angiopathy. Amyloid 2000; 7:70.</li>&#xD;&#xA;    <li>Hawkins PN. Hereditary systemic amyloidosis with renal involvement. J Nephrol 2003; 16:443.</li>&#xD;&#xA;    <li>Said SM, Sethi S, Valeri AM, et al. Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol 2013; 8:1515.</li>&#xD;&#xA;    <li>Willander H, Askarieh G, Landreh M, et al. High-resolution structure of a BRICHOS domain and its implications for anti-amyloid chaperone activity on lung surfactant protein C. Proc Natl Acad Sci U S A 2012; 109:2325.</li>&#xD;&#xA;    <li>Miura Y, Harumiya S, Ono K, et al. Galectin-7 and actin are components of amyloid deposit of localized cutaneous amyloidosis. Exp Dermatol 2013; 22:36.</li>&#xD;&#xA;    <li>Naujokas A, Vidal CI, Mercer CE, et al. A novel form of amyloid deposited at the site of enfuvirtide injection. J Cutan Pathol 2012; 39:220.</li>&#xD;&#xA;    <li>Levy CB, Stumbo AC, Ano Bom APD, et al. Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors. Int J Biochem Cell Biol 2011; 43:60.</li>&#xD;&#xA;</ol>&#xD;&#xA;Adapted from: Sipe JD, Benson MD, Buxbaum JN, et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 2014; 21:221.</div><div id=\"graphicVersion\">Graphic 97157 Version 4.0</div></div></div>"},"97160":{"type":"graphic_table","displayName":"Risk factors for bleeding with anticoagulant therapy","title":"Risk factors for bleeding with anticoagulant therapy and estimated risk of major bleeding in low, moderate, and high risk categories","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for bleeding with anticoagulant therapy and estimated risk of major bleeding in low, moderate, and high risk categories</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Risk factors*</td> </tr> <tr class=\"divider_top\"> <td class=\"indent1\" colspan=\"4\">Age &#62;65 years</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Age &#62;75 years</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Previous bleeding</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Cancer</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Metastatic cancer</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Renal failure</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Liver failure</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Thrombocytopenia</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Previous stroke</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Diabetes</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Anemia</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Antiplatelet therapy</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Poor anticoagulant control</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Comorbidity and reduced functional capacity</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Recent surgery<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">Frequent falls</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\">Alcohol abuse</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Estimated absolute risk of major bleeding (%)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\">Categorization of risk of bleeding<sup>&#916;</sup></td> <td class=\"subtitle2_left\">Low risk<sup>&#9674;</sup> (0 risk factors)</td> <td class=\"subtitle2_left\">Moderate risk<sup>&#9674;</sup> (1 risk factor)</td> <td class=\"subtitle2_left\">High risk<sup>&#9674;</sup> (&#8805;2 risk factors)</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Anticoagulation 0 to 3 months<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent2\">Baseline risk (%)</td> <td>0.6</td> <td>1.2</td> <td>4.8</td> </tr> <tr> <td class=\"indent2\">Increased risk (%)</td> <td>1</td> <td>2</td> <td>8</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Total risk (%)</td> <td>1.6<sup>&#167;</sup></td> <td>3.2</td> <td>12.8<sup>&#165;</sup></td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Anticoagulation after first 3 months<sup>&#135;</sup></td> </tr> <tr> <td class=\"indent2\">Baseline risk (%/years)</td> <td>0.3<sup>&#134;</sup></td> <td>0.6</td> <td>&#8805;2.5</td> </tr> <tr> <td class=\"indent2\">Increased risk (%/years)</td> <td>0.5</td> <td>1</td> <td>&#8805;4</td> </tr> <tr> <td class=\"indent2\">Total risk (%/years)</td> <td>0.8**</td> <td>1.6**</td> <td>&#8805;6.5</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The increase in bleeding associated with a risk factor will vary with (1) severity of the risk factor (eg, location and extent of metastatic disease, platelet count), (2) temporal relationships (eg, interval from surgery or a previous bleeding episode), and (3) how effectively a previous cause of bleeding was corrected (eg, upper-GI bleeding).<br />&para; Important for parenteral anticoagulation (eg, first 10 days), but less important for long-term or extended anticoagulation.<br />&Delta; Although there is evidence that risk of bleeding increases with the prevalence of risk factors, this categorization scheme has not been validated. Furthermore, a single risk factor, when severe, will result in a high risk of bleeding (eg, major surgery within the past two days, severe thrombocytopenia).<br /><span class=\"lozenge\">&loz;</span> Compared with low risk patients, moderate risk patients are assumed to have a twofold risk and high risk patients an eightfold risk of major bleeding.<br />&sect; The 1.6% corresponds to the average of major bleeding with initial UFH or LMWH therapy followed by VKA therapy. We estimated baseline risk by assuming a 2.6 relative risk of major bleeding with anticoagulation (refer to footnote &Dagger;).<br />&yen; Consistent with frequency of major bleeding observed by Hull et al in high risk patients<sup>[1]</sup>.<br />&Dagger; We estimate that anticoagulation is associated with a 2.6-fold increase in major bleeding based on comparison of extended anticoagulation with no extended anticoagulation. The relative risk of major bleeding during the first three months of therapy may be greater than during extended VKA therapy because (1) the intensity of anticoagulation with initial parenteral therapy may be greater than with VKA therapy; (2) anticoagulant control will be less stable during the first three months; and (3) predispositions to anticoagulant-induced bleeding may be uncovered during the first three months of therapy. However, studies of patients with acute coronary syndromes do not suggest a &ge;2.6 relative risk of major bleeding with parenteral anticoagulation (eg, UFH or LMWH) compared with control.<br />&dagger; Our estimated baseline risk of major bleeding for low risk patients (and adjusted up for moderate and high risk groups as per footnote &loz;).<br />** Consistent with frequency of major bleeding during prospective studies of extended anticoagulation for VTE.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322:1260.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97160 Version 3.0</div></div></div>"},"97188":{"type":"graphic_figure","displayName":"Intracardiac and vascular cannulae utilized during CPB","title":"Intracardiac and vascular cannulae utilized during cardiopulmonary bypass","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Intracardiac and vascular cannulae utilized during cardiopulmonary bypass</div><div class=\"cntnt\"><img style=\"width:468px; height:580px;\" src=\"images/CARD/97188_Cannulae_for_CPB.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Left ventricular vent enters right upper pulmonary vein then passes into left ventricle through mitral valve.<br /><FONT class=bullet>•</FONT> Retrograde cardioplegia cannula enters right atrium and passes into coronary sinus.<br />Δ Aortic root vent allows suction to be applied to the aortic root, thereby indirectly emptying the left ventricle.</div><div class=\"graphic_reference\">UpToDate would like to thank Bruce Searles, MS, CCP, and Kit Hefner, MS, SUNY Upstate Medical University, for their assistance with this illustration.</div><div id=\"graphicVersion\">Graphic 97188 Version 5.0</div></div></div>"},"97192":{"type":"graphic_table","displayName":"Single-agent chemotherapy for GTN","title":"Single-agent regimens for low-risk gestational trophoblastic neoplasms (GTN)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Single-agent regimens for low-risk gestational trophoblastic neoplasms (GTN)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Methotrexate (MTX) regimens*</td> <td class=\"subtitle1\">Primary remission rates (%)</td> </tr> <tr class=\"divider_bottom\"> <td>1) MTX five-day regimen: 0.3 to 0.5 mg/kg IV or IM daily for five days every two weeks (maximum 25 mg per dose)</td> <td class=\"centered\">87 to 93</td> </tr> <tr class=\"divider_bottom\"> <td>2) MTX weekly regimen: 30 to 50 mg/m<sup>2</sup> IM weekly</td> <td class=\"centered\">49 to 74</td> </tr> <tr> <td>3) MTX-Leucovorin<sup>&#182;&nbsp;</sup>eight-day regimen:</td> <td class=\"divider_bottom centered\" rowspan=\"3\">74 to 90</td> </tr> <tr> <td class=\"indent1\">MTX 1 mg/kg IM or IV on days 1, 3, 5, and 7</td> </tr> <tr> <td class=\"divider_bottom indent1\">Leucovorin<sup>&#182;</sup>&nbsp;15 mg&nbsp;orally on days 2, 4, 6, and 8 given 24 hours after each MTX dose</td> </tr> <tr> <td>4) High-dose IV MTX-Leucovorin<sup>&#182;</sup></td> <td class=\"divider_bottom centered\" rowspan=\"4\">69 to 90</td> </tr> <tr> <td class=\"indent1\">MTX 100 mg/m<sup>2</sup> IV over 30 minutes followed by</td> </tr> <tr> <td class=\"indent1\">MTX 200 mg/m<sup>2</sup> IV infusion over 12 hours</td> </tr> <tr> <td class=\"divider_bottom indent1\">Leucovorin<sup>&#182; </sup>15 mg every 12 hours in six doses IM or orally beginning 24 hours after starting MTX</td> </tr> <tr> <td class=\"subtitle1\">Dactinomycin&nbsp;regimens<br /> (Vesicant: If administered peripherally, give through free-flowing IV)</td> <td class=\"subtitle1\">&nbsp;</td> </tr> <tr> <td>1)&nbsp;Dactinomycin 10 to 12 micrograms/kg IV push daily for five days</td> <td class=\"centered\">77 to 94</td> </tr> <tr> <td>2)&nbsp;Dactinomycin 1.25 mg/m<sup>2</sup> IV push every two weeks</td> <td class=\"centered\">69 to 90</td> </tr> <tr> <td><strong>Sequential chemotherapy</strong></td> <td class=\"centered\"><strong>100</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Recommendations for monitoring response and determining the duration of treatment are provided in the topic.</div><div class=\"graphic_footnotes\">MTX: methotrexate; IV: intravenous; IM: intramuscular.<br />* Several different single-agent regimens are used based upon local experience as there is a lack of consensus on the optimal dosing regimen. Available data suggest the&nbsp;five or&nbsp;eight-day schedule for methotrexate is more effective than pulsed regimens. Refer to topic. <br />¶ Also known as folinic acid. <br /></div><div class=\"graphic_reference\"><P class=MsoNormal style=\"MARGIN: 0in 0in 0pt; LINE-HEIGHT: normal\">Courtesy of Ross Berkowitz, MD; Donald Goldstein, MD; and Neil Horowitz, MD. Complete references are provided within the topic.</P></div><div id=\"graphicVersion\">Graphic 97192 Version 1.0</div></div></div>"},"97193":{"type":"graphic_table","displayName":"Subsequent pregnancy outcomes following chemotherapy","title":"Outcomes following subsequent pregnancy in women treated for gestational trophoblastic neoplasia at the New England Trophoblast Center, 1965 to 2013","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Outcomes following subsequent pregnancy in women treated for gestational trophoblastic neoplasia at the New England Trophoblast Center, 1965 to 2013</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Outcome</td> <td class=\"subtitle1\">Number</td> <td class=\"subtitle1\">Percent</td> </tr> <tr class=\"divider_bottom\"> <td>Total pregnancies</td> <td class=\"centered\">667</td> <td class=\"centered\">100</td> </tr> <tr class=\"divider_bottom\"> <td>Total deliveries</td> <td class=\"centered\">500</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Term live</td> <td class=\"centered\">446</td> <td class=\"centered\">66.9</td> </tr> <tr> <td class=\"indent1\">Pre-term live</td> <td class=\"centered\">44</td> <td class=\"centered\">6.6</td> </tr> <tr> <td class=\"indent1\">Stillbirth</td> <td class=\"centered\">10</td> <td class=\"centered\">1.5</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Congenital anomalies</td> <td class=\"centered\">12</td> <td class=\"centered\">1.4</td> </tr> <tr class=\"divider_bottom\"> <td>Spontaneous miscarriage</td> <td class=\"centered\">123</td> <td class=\"centered\">18.3</td> </tr> <tr class=\"divider_bottom\"> <td>Induced abortion</td> <td class=\"centered\">28</td> <td class=\"centered\">4.2</td> </tr> <tr class=\"divider_bottom\"> <td>Ectopic</td> <td class=\"centered\">7</td> <td class=\"centered\">1.0</td> </tr> <tr> <td>Repeat molar pregnancy</td> <td class=\"centered\">10</td> <td class=\"centered\">1.5</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 97193 Version 1.0</div></div></div>"},"97195":{"type":"graphic_table","displayName":"Urgent-start PD catheter placement postprocedure orders","title":"Example of postprocedure orders for urgent-start peritoneal dialysis catheter placement","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Example of postprocedure orders for urgent-start peritoneal dialysis catheter placement</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Do not remove or replace catheter dressing for seven days (unless soaked with blood, loose, or soiled).</td> </tr> <tr> <td>Assess catheter function:</td> </tr> <tr> <td class=\"indent1\">Infuse and drain 500 mL of 1.5% dextrose dialysate into catheter with patient supine (no dwelling of dialysate required).</td> </tr> <tr> <td class=\"indent1\">If the effluent is clear and the catheter demonstrates normal function, drain effluent and leave abdomen empty.</td> </tr> <tr> <td class=\"indent1\">If effluent is blood tinged (pink or fruit-punch color), repeat exchanges with heparin (500 units/liter) until effluent clears.</td> </tr> <tr> <td class=\"indent1\">If effluent is frankly bloody or becoming increasingly bloody with exchanges, perform exchanges without heparin.</td> </tr> <tr> <td class=\"indent1\">If effluent is bloody after the fourth exchange, inform physician, fill catheter lumen with heparin (heparin 1000 units/mL), and stop additional exchanges.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Original figure modified for this publication. Ghaffari A. Urgent-start peritoneal dialysis: A quality improvement report. Am J Kidney Dis 2012; 59:400. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97195 Version 1.0</div></div></div>"},"97196":{"type":"graphic_table","displayName":"Treatment outcomes for low-risk GTN stage I at the NETDC","title":"Outcomes of treatment for low-risk stage I gestational trophoblastic neoplasia at the New England Trophoblastic Center, 1965 to 2016","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Outcomes of treatment for low-risk stage I gestational trophoblastic neoplasia at the New England Trophoblastic Center, 1965 to 2016</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Stage I results</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">Number of patients</td> <td class=\"subtitle2\">Number of remissions</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td class=\"centered\"><strong>634</strong></td> <td class=\"centered\"><strong>634 (100 percent)</strong></td> </tr> <tr> <td><strong>Initial therapy</strong></td> <td>&nbsp;</td> <td class=\"centered\"><strong>529 (83.4 percent)</strong></td> </tr> <tr> <td class=\"indent1\">Sequential MTX/ActD</td> <td>&nbsp;</td> <td class=\"centered\">487</td> </tr> <tr> <td class=\"indent1\">Combination chemotherapy*</td> <td>&nbsp;</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Hysterectomy<sup>&#182;</sup></td> <td>&nbsp;</td> <td class=\"centered\">39</td> </tr> <tr> <td><strong>Resistant therapy</strong></td> <td>&nbsp;</td> <td class=\"centered\"><strong>105 (16.6 percent)</strong></td> </tr> <tr> <td class=\"indent1\">Combination chemotherapy<sup>&#916;</sup></td> <td>&nbsp;</td> <td class=\"centered\">79</td> </tr> <tr> <td class=\"indent1\">Hysterectomy/local resection<sup>&#182;</sup></td> <td>&nbsp;</td> <td class=\"centered\">19</td> </tr> <tr> <td class=\"indent1\">Other</td> <td>&nbsp;</td> <td class=\"centered\">7</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MTX: methotrexate; ActD: actinomycin D; MAC: methotrexate, actinomycin D, cyclophosphamide; EMA: etoposide, methotrexate, actinomycin D; CO: cyclophosphamide plus vincristine.<br />* MAC.<br />¶ With adjunctive chemotherapy.<br />Δ MAC, EMA, EMA/CO.</div><div id=\"graphicVersion\">Graphic 97196 Version 4.0</div></div></div>"},"97197":{"type":"graphic_table","displayName":"Treatment outcomes for low-risk GTN stage II to III at the NETDC","title":"Outcomes of treatment for low-risk stage II to III gestational trophoblastic neoplasia at the New England Trophoblastic Center, 1965 to 2016","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Outcomes of treatment for low-risk stage II to III gestational trophoblastic neoplasia at the New England Trophoblastic Center, 1965 to 2016</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Stage II results</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">Number of patients</td> <td class=\"subtitle2\">Number of remissions</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td class=\"centered\"><strong>37</strong></td> <td class=\"centered\"><strong>37 (100 percent)</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Low-risk</strong></td> <td class=\"centered\"><strong>21</strong></td> <td class=\"centered\"><strong>21 (100 percent)</strong></td> </tr> <tr> <td><strong>Initial therapy</strong></td> <td>&nbsp;</td> <td class=\"centered\"><strong>17 (80.9 percent)</strong></td> </tr> <tr> <td class=\"indent1\">Sequential MTX/ActD</td> <td>&nbsp;</td> <td class=\"centered\">16</td> </tr> <tr> <td class=\"indent1\">Combination chemotherapy*</td> <td>&nbsp;</td> <td class=\"centered\">1</td> </tr> <tr> <td><strong>Resistant therapy</strong></td> <td>&nbsp;</td> <td class=\"centered\"><strong>4 (19.1 percent)</strong></td> </tr> <tr> <td class=\"indent1\">Combination chemotherapy*</td> <td>&nbsp;</td> <td class=\"centered\">3</td> </tr> <tr> <td class=\"indent1\">Salvage therapy<sup>&#182;</sup></td> <td>&nbsp;</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"3\">Stage III results</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">Number of patients</td> <td class=\"subtitle2\">Number of remissions</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td class=\"centered\"><strong>230</strong></td> <td class=\"centered\"><strong>229 (99 percent)</strong></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Low-risk</strong></td> <td class=\"centered\"><strong>155</strong></td> <td class=\"centered\"><strong>155 (100 percent)</strong></td> </tr> <tr> <td><strong>Initial therapy</strong></td> <td>&nbsp;</td> <td class=\"centered\"><strong>121 (78.6 percent)</strong></td> </tr> <tr> <td class=\"indent1\">Sequential MTX/ActD</td> <td>&nbsp;</td> <td class=\"centered\">114</td> </tr> <tr> <td class=\"indent1\">Combination chemotherapy<sup>&#916;</sup></td> <td>&nbsp;</td> <td class=\"centered\">7</td> </tr> <tr> <td><strong>Resistant therapy</strong></td> <td class=\"centered\"><strong>34</strong></td> <td class=\"centered\"><strong>34 (21.4 percent)</strong></td> </tr> <tr> <td class=\"indent1\">Sequential MTX/ActD</td> <td>&nbsp;</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Combination chemotherapy<sup>&#916;</sup></td> <td>&nbsp;</td> <td class=\"centered\">33</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Two patients alive with disease; one death.</div><div class=\"graphic_footnotes\">MTX: methotrexate; ActD: actinomycin D; MAC: methotrexate, actinomycin D, cyclophosphamide; EMA: etoposide, methotrexate, actinomycin D; CO: cyclophosphamide plus vincristine; EP: etoposide, cisplatin.<br />* MAC, EMA, EMA/CO.<br />¶ EMA/CO, EMA/EP.<br />Δ MAC, EMA, EMA/CO.</div><div id=\"graphicVersion\">Graphic 97197 Version 3.0</div></div></div>"},"97217":{"type":"graphic_picture","displayName":"Botryomycosis histopathology","title":"Botryomycosis histopathology","html":"<div class=\"graphic\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">Botryomycosis histopathology</div><div class=\"cntnt\"><img style=\"width:656px; height:267px;\" src=\"images/ID/97217_Botryomycosis_histopatholgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A photomicrograph showing (A) (H&amp;E x40) granular bodies in the deep dermis (B) (H&amp;E x400) remarkable Splendore-Hoeppli phenomenon.</div><div class=\"graphic_reference\">Reproduced with permission from: Barreiros HM, Cunha H, Bartolo E. Photoletter to the editor: Botryomycosis in an immunocompetent woman. J Dermatol Case Rep 2013; 7:29. Copyright &copy; 2013 Specjalisci Dermatolodzy. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97217 Version 1.0</div></div></div>"},"97225":{"type":"graphic_picture","displayName":"Botryomycosis radiography","title":"Pulmonary botryomycosis","html":"<div class=\"graphic\"><div style=\"width: 814px\" class=\"figure\"><div class=\"ttl\">Pulmonary botryomycosis</div><div class=\"cntnt\"><img style=\"width:794px; height:349px;\" src=\"images/ID/97225_Botryomycosis_radiography.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Postero-anterior chest radiograph: atelectasis of the right lower lobe.<br />(B) Chest computed tomography: right infrahilar mass and atelectasis of the right lower lobe.</div><div class=\"graphic_reference\">Panel A reproduced with permission from: Khan AN, Al-Jahdali H, AL-Ghanem S, Gouda A. Reading chest radiographs in the critically ill (Part II): Radiography of lung pathologies common in the ICU patient. Ann Thorac Med. 2009 Jul-Sep; 4(3): 149. Copyright &copy; 2009 Annals of Thoracic Medicine.<br />Panel B reproduced with permission from: Jin SL, Lee HP, Kim JI, et al. A Case of Endobronchial Actinomycosis. Korean J Intern Med, 2000: 15(3). Copyright &copy; 2000 The Korean Association of Internal Medicine.</div><div id=\"graphicVersion\">Graphic 97225 Version 1.0</div></div></div>"},"97226":{"type":"graphic_table","displayName":"Monitoring for complications in children with type 1 diabetes","title":"Routine monitoring of children and adolescents with type 1 diabetes for complications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Routine monitoring of children and adolescents with type 1 diabetes for complications</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Evaluation</td> <td class=\"subtitle1\">Purpose</td> <td class=\"subtitle1\">Initiate screening</td> <td class=\"subtitle1\">Repeat at least</td> <td class=\"subtitle1\">Abnormal result</td> <td class=\"subtitle1\">Usual treatment</td> </tr> <tr class=\"divider_bottom\"> <td>Hypoglycemia assessment</td> <td>Ask about episodes of hypoglycemia and associated symptoms, and review records of blood glucose monitoring. Evaluate for hypoglycemia unawareness.</td> <td>At diagnosis of diabetes</td> <td>Every 3 months</td> <td>Frequent episodes of hypoglycemia (blood glucose level &#60;70 mg/dL), especially with hypoglycemia unawareness.</td> <td>Review insulin and monitoring regimen, educate regarding prevention of and response to hypoglycemia; consider using less stringent A1C target.</td> </tr> <tr class=\"divider_bottom\"> <td>Psychosocial assessment</td> <td>Screen for depression, family conflict, risk-taking behaviors, or other psychosocial dysfunction</td> <td>At diagnosis of diabetes</td> <td>Every 3 months</td> <td>Clinical symptoms of depression or psychosocial dysfunction.</td> <td>Refer to mental health professional.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Blood pressure</td> <td class=\"divider_bottom\" rowspan=\"2\">Screen for hypertension</td> <td class=\"divider_bottom\" rowspan=\"2\">At diagnosis of diabetes</td> <td class=\"divider_bottom\" rowspan=\"2\">Every 3 months</td> <td> <p>Hypertension definition<sup>3</sup></p> <ul> <li>&#60;13 years:&nbsp;<br /> BP &#8805;95th percentile for age </li> <li>&#8805;13 years:<br /> BP &#8805;130/80 mmHg </li> </ul> <p>(measured on 3 occasions)</p> </td> <td>Pharmacologic intervention, usually with ACE inhibitor.*</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Elevated BP (prehypertension)<sup>3</sup></p> <ul> <li>&#60;13 years:<br /> BP &#8805;90-95 percentile </li> <li>&#8805;13 years:<br /> SBP 120-129 mmHg and<br /> DBP &#60;80 mmHg </li> </ul> <p>(measured on 3 occasions)</p> </td> <td>Nonpharmacologic intervention (diet and exercise, with weight reduction if appropriate). Initiate pharmacologic intervention if BP remains in prehypertensive range despite intervention for 3 to 6 months.</td> </tr> <tr class=\"divider_bottom\"> <td>Foot exam with testing for vibration (tuning fork) and pressure (10 g monofilament)</td> <td>Screen for polyneuropathy</td> <td>At 10 years (or onset of puberty, if earlier) and if the youth has had diabetes for 5 years</td> <td>Annually</td> <td>Diminished sensation for vibration or pressure.</td> <td>Optimize glycemic control with blood glucose monitoring and insulin administration (see topic text).</td> </tr> <tr class=\"divider_bottom\"> <td>Urine albumin/creatinine ratio (spot specimen)</td> <td>Screen for nephropathy</td> <td>When the youth has had diabetes for 5 years</td> <td>Annually</td> <td>&#62;30 mg albumin/g creatinine.<sup>&#182;</sup></td> <td>ACE inhibitor.</td> </tr> <tr class=\"divider_bottom\"> <td>Hemoglobin A1C</td> <td>Glycemic control</td> <td>At diagnosis of diabetes</td> <td>Every 3 months</td> <td>Goal A1C &#60;7.5% for most children and adolescents.<sup>&#916;</sup><sup>[2]</sup></td> <td>Optimize glycemic control with blood glucose monitoring and insulin administration (see topic text).</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Lipid profile </td> <td class=\"divider_bottom\" rowspan=\"3\">Screen for dyslipidemia</td> <td>Age 10 years (or onset of puberty, if earlier)<sup>&#9674;</sup></td> <td class=\"divider_bottom\" rowspan=\"3\">Every 3 to 5 years if normal; annually if abnormal</td> <td>LDL &#8805;100 mg/dL</td> <td>Nonpharmacologic intervention: optimize glycemic control; exercise and diet to limit dietary cholesterol and maintain healthy body weight.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Screen younger children (2 to 10 years) if additional risk factors are present<sup>&#9674;</sup><sup>&#167;</sup></td> <td>LDL &#8805;130 to 159 mg/dL</td> <td>Pharmacologic intervention IF CVD risk factors are present (obesity, tobacco use, family history of early CVD), if nonpharmacologic intervention is not successful.</td> </tr> <tr class=\"divider_bottom\"> <td>LDL &#8805;160 mg/dL</td> <td>Pharmacologic intervention (statins), if nonpharmacologic intervention is not successful.</td> </tr> <tr class=\"divider_bottom\"> <td>TSH</td> <td>Screen for hypothyroidism caused by autoimmune thyroiditis</td> <td>At diagnosis of diabetes<sup>&#9674;</sup></td> <td>Every 1 to 2 years, or if symptoms of hypothyroidism develop</td> <td>Elevated TSH</td> <td>Treatment with levothyroxine as needed.</td> </tr> <tr class=\"divider_bottom\"> <td>Tissue transglutaminase (tTG), IgA</td> <td>Screen for celiac disease</td> <td>At diagnosis of diabetes</td> <td>Repeat within&nbsp;2 years of diagnosis, then after 5 years, or if gastrointestinal symptoms develop<sup>&#165;</sup></td> <td>Positive results of antibody test.</td> <td>Evaluate further with upper endoscopy, <em>before</em> beginning a gluten-free diet.</td> </tr> <tr> <td>Dilated eye examination</td> <td>Screen for retinopathy</td> <td>Age 10 years (or onset of puberty, if earlier), and the child has had diabetes for 3 to 5 years</td> <td>Annually in most cases</td> <td>Background, preproliferative, or proliferative retinopathy.</td> <td>Optimizing glycemic control may reverse background retinopathy; laser therapy for more advanced disease. </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table reflects recommendations for routine monitoring of children and adolescents with type 1 diabetes, as outlined by the American Diabetes Association.<sup>[1]</sup></div><div class=\"graphic_footnotes\">A1C: hemoglobin A1c (glycated hemoglobin); BP: blood pressure; SBP: systolic blood pressure; DBP: diastolic blood pressure; ACE: angiotensin converting enzyme; LDL: low density lipoprotein; CVD: cardiovascular disease; TSH: thyroid stimulating hormone; tTG: tissue transglutaminase; IgA: immunoglobulin A.<br />* ACE inhibitors (eg, lisinopril or enalapril) have teratogenic potential, so appropriate reproductive counseling should be given.<br />¶ Transient albuminuria is common in children. Abnormal results should be confirmed on at least two occasions, ruling out orthostatic albuminuria, or with a 24 hour urine collection.<br />Δ More or less stringent goals may be appropriate for individual patients, depending on their personal history of severe hyperglycemia and severe hypoglycemia, hypoglycemia unawareness.<br /><FONT class=lozenge>◊</FONT> Glycemic control should be established before performing the lipid profile or thyroid screening. The American Diabetes Association (ADA) suggests that antibodies to thyroid peroxidase (TPO) and thyroglobulin should be measured at diagnosis. <br />§ Risk factors for CVD that should prompt screening in prepubertal children are: family history of hypercholesterolemia (defined as total cholesterol ≥240 mg/dL, [6.2 mmol/L]), or family history of a CVD event before 55 years of age, or if the family history is unknown. Screening is also recommended if the child is overweight or obese.<br />¥ More frequent screening for celiac disease may be appropriate for children who have a first-degree relative with celiac disease. Antibody testing is only valid if performed on a gluten-containing diet.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Chiang JL, Kirkman MS, Laffel LM, et al. Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association. Diabetes Care 2014; 37:2034.</LI>&#xD;&#xA;<LI>American Diabetes Association. 12. Children and Adolescents: Standards of Medical Care in Diabetes-2018. Diabetes Care 2018; 41:S126.</LI>&#xD;&#xA;<LI>Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 2017; 140.</LI></OL></div><div id=\"graphicVersion\">Graphic 97226 Version 10.0</div></div></div>"},"97228":{"type":"graphic_table","displayName":"Series of patients with nasal cavity and paranasal sinus tumors","title":"Contemporary series of patients with nasal cavity and paranasal sinus tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contemporary series of patients with nasal cavity and paranasal sinus tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td class=\"subtitle1\">Site:</td> <td class=\"subtitle1\">MSKCC<sup>[1]</sup></td> <td class=\"subtitle1\">UCSF<sup>[2]</sup></td> <td class=\"subtitle1\">MDACC<sup>[3]</sup></td> <td class=\"subtitle1\">UF<sup>[4]</sup></td> <td class=\"subtitle1\">Ghent University<sup>[5]</sup></td> <td class=\"subtitle1\">UCLA and Geneva Switzerland<sup>[6]</sup></td> <td class=\"subtitle1\">&nbsp;UFHPTI<sup>[7]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Year</td> <td class=\"centered\">2007</td> <td class=\"centered\">2007</td> <td class=\"centered\">2008</td> <td class=\"centered\">2009</td> <td class=\"centered\">2012</td> <td class=\"centered\">2012</td> <td class=\"centered\">2016</td> </tr> <tr class=\"divider_bottom\"> <td>Number of patients</td> <td class=\"centered\">85</td> <td class=\"centered\">127</td> <td class=\"centered\">68</td> <td class=\"centered\">109</td> <td class=\"centered\">130</td> <td class=\"centered\">220</td> <td class=\"centered\">84</td> </tr> <tr class=\"divider_bottom\"> <td>Patients with nasal cavity tumors&nbsp;(%)</td> <td class=\"centered\">28</td> <td class=\"centered\">28</td> <td class=\"centered\">100</td> <td class=\"centered\">63</td> <td class=\"centered\">24</td> <td class=\"centered\">30</td> <td class=\"centered\">80</td> </tr> <tr> <td class=\"divider_bottom\" colspan=\"7\"><strong>Stage (%)</strong></td> <td class=\"divider_bottom\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">T1-T2</td> <td class=\"centered\">12</td> <td class=\"centered\">13</td> <td class=\"centered\">60</td> <td class=\"centered\">39</td> <td class=\"centered\">30</td> <td class=\"centered\">34</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"indent1\">T3-T4</td> <td class=\"centered\">81</td> <td class=\"centered\">87</td> <td class=\"centered\">34</td> <td class=\"centered\">61</td> <td class=\"centered\">62</td> <td class=\"centered\">65</td> <td class=\"centered\">94</td> </tr> <tr> <td class=\"indent1\">Tx</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">6</td> <td class=\"centered\">-</td> <td class=\"centered\">8</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> </tr> <tr> <td class=\"indent1\">Node positive</td> <td class=\"centered\">7</td> <td class=\"centered\">9</td> <td class=\"centered\">9</td> <td class=\"centered\">10</td> <td class=\"centered\">3</td> <td class=\"centered\">2</td> <td class=\"centered\">9</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Recurrent</td> <td class=\"centered\">7</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">8</td> </tr> <tr> <td class=\"divider_bottom\" colspan=\"7\"><strong>Histology (%)</strong></td> <td class=\"divider_bottom\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Squamous cell </td> <td class=\"centered\">49</td> <td class=\"centered\">65</td> <td class=\"centered\">66</td> <td class=\"centered\">29</td> <td class=\"centered\">18</td> <td class=\"centered\">57</td> <td class=\"centered\">26</td> </tr> <tr> <td class=\"indent1\">Adenoid cystic </td> <td class=\"centered\">13</td> <td class=\"centered\">22</td> <td class=\"centered\">18</td> <td class=\"centered\">15</td> <td class=\"centered\">4</td> <td class=\"centered\">16</td> <td class=\"centered\">17</td> </tr> <tr> <td class=\"indent1\">Adenocarcinoma</td> <td class=\"centered\">-</td> <td class=\"centered\">13</td> <td class=\"centered\">12</td> <td class=\"centered\">8</td> <td class=\"centered\">63</td> <td class=\"centered\">11</td> <td class=\"centered\">10</td> </tr> <tr> <td class=\"indent1\">Sarcoma</td> <td class=\"centered\">11</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> </tr> <tr> <td class=\"indent1\">Sinonasal undifferentiated carcinoma</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">4</td> <td class=\"centered\">13</td> <td class=\"centered\">6</td> <td class=\"centered\">14</td> <td class=\"centered\">8</td> </tr> <tr> <td class=\"indent1\">Olfactory neuroblastoma</td> <td class=\"centered\">8</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">20</td> <td class=\"centered\">8</td> <td class=\"centered\">-</td> <td class=\"centered\">27</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other</td> <td class=\"centered\">20</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">15</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">12</td> </tr> <tr> <td class=\"divider_bottom\" colspan=\"7\"><strong>Treatment (%)</strong></td> <td class=\"divider_bottom\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">RT alone</td> <td class=\"centered\">-</td> <td class=\"centered\">16</td> <td class=\"centered\">47</td> <td class=\"centered\">52</td> <td class=\"centered\">22</td> <td class=\"centered\">28</td> <td class=\"centered\">13&nbsp;</td> </tr> <tr> <td class=\"indent1\">Preoperative RT</td> <td class=\"centered\">-</td> <td class=\"centered\">7</td> <td class=\"centered\">4</td> <td class=\"centered\">7</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> </tr> <tr> <td class=\"indent1\">Postoperative RT</td> <td class=\"centered\">100</td> <td class=\"centered\">77</td> <td class=\"centered\">49</td> <td class=\"centered\">41</td> <td class=\"centered\">78</td> <td class=\"centered\">52</td> <td class=\"centered\">87</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Surgery without RT</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">20</td> <td class=\"centered\">-</td> </tr> <tr class=\"divider_bottom\"> <td>Median RT dose</td> <td class=\"centered\">63 Gy</td> <td class=\"centered\">RT alone, 66 Gy;<br /> Post-op RT, 63 Gy</td> <td class=\"centered\">RT alone, 65 Gy;<br /> Post-op RT, 58 Gy</td> <td class=\"centered\">RT alone, 70 Gy;<br /> Post-op RT, 64.8 Gy</td> <td class=\"centered\">70 Gy</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">73.8 Gy (RBE) protons</td> </tr> <tr class=\"divider_bottom\"> <td>Five-year local control (%)</td> <td class=\"centered\">62</td> <td class=\"centered\">62</td> <td class=\"centered\">86</td> <td class=\"centered\">63</td> <td class=\"centered\">59</td> <td class=\"centered\">57</td> <td class=\"centered\">&nbsp;83 (three years)</td> </tr> <tr class=\"divider_bottom\"> <td>Five-year regional control (%)</td> <td class=\"centered\">87</td> <td class=\"centered\">-</td> <td class=\"centered\">92</td> <td class=\"centered\">91</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">94 (three years)&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Five-year disease-free survival (%)</td> <td class=\"centered\">55</td> <td class=\"centered\">54</td> <td class=\"centered\">86</td> <td class=\"centered\">-</td> <td class=\"centered\">43</td> <td class=\"centered\">-</td> <td class=\"centered\">73 (three years)&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Five-year overall survival (%)</td> <td class=\"centered\">67</td> <td class=\"centered\">52</td> <td class=\"centered\">82</td> <td class=\"centered\">55</td> <td class=\"centered\">64</td> <td class=\"centered\">63</td> <td class=\"centered\">63 (three years)&nbsp;</td> </tr> <tr> <td>Notes</td> <td>Worse outcomes for squamous cell carcinoma, cribriform plate or orbit invasion, and positive nodes.</td> <td>16% of postoperative RT patients had gross residual disease; 15% of all patients received chemotherapy. GTR improved local control compared with STR (65 versus 44%).</td> <td>Worse outcomes for nonsquamous cell histologies and T3-4 tumors.</td> <td>19% distant metastasis rate; 30% severe complications rate. Outcomes significantly improved with post-op RT compared with RT alone.</td> <td>Only two regional failures. Intensity-modulated RT improved outcomes.</td> <td>Only 3% of patients failed in nodes. Worse prognosis in nonnasal cavity primaries, squamous cell, and undifferentiated histologies, as well as advanced T stage.</td> <td>90% local control in patients without gross disease. 24% grade 3 or worse toxicity.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MSKCC: Memorial Sloan-Kettering Cancer Center (New York, NY); MDACC: MD Anderson Cancer Center (Houston, TX); UCSF: University of California San Francisco (San Francisco, CA);&nbsp; UF: University of Florida (Gainesville, FL); UCLA: University of California Los Angeles (Los Angeles, CA); UFHPTI: University of Florida Health Proton Therapy Institute (Jacksonville, FL); RT: radiotherapy; Post-op: postoperative; RBE: relative biological effectiveness; GTR: gross total resection; STR: subtotal resection.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Hoppe BS, Stegman LD, Zelefsky MJ, et al. Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting--the MSKCC experience. Int J Radiat Oncol Biol Phys 2007; 67:691.</LI>&#xD;&#xA;<LI>Chen AM, Daly ME, Bucci MK, et al. Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement? Int J Radiat Oncol Biol Phys 2007; 69:141.</LI>&#xD;&#xA;<LI>Allen MW, Schwartz DL, Rana V, et al. Long-term radiotherapy outcomes for nasal cavity and septal cancers. Int J Radiat Oncol Biol Phys 2008; 71:401.</LI>&#xD;&#xA;<LI>Mendenhall WM, Amdur RJ, Morris CG, et al. Carcinoma of the nasal cavity and paranasal sinuses. Laryngoscope 2009; 119:899.</LI>&#xD;&#xA;<LI>Duprez F, Madani I, Morbee L, et al. IMRT for sinonasal tumors minimizes severe late ocular toxicity and preserves disease control and survival. Int J Radiat Oncol Biol Phys 2012; 83:252.</LI>&#xD;&#xA;<LI>Dulguerov P, Jacobsen MS, Allal AS, et al. Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer 2001; 92:3012.</LI>&#xD;&#xA;<LI>Dagan R, Bryant C, Li Z, et al. Outcomes of sinonasal cancer treated with proton therapy. Int J Radiat Oncol Biol Phys 2016; 95:377.</LI></OL></div><div id=\"graphicVersion\">Graphic 97228 Version 3.0</div></div></div>"},"97246":{"type":"graphic_table","displayName":"Reassigning EDD based on date-ultrasound discrepancy","title":"Reassigning EDD based on date-ultrasound discrepancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reassigning EDD based on date-ultrasound discrepancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gestational age range based on LMP</td> <td class=\"subtitle1\">Biometric parameter(s) for ultrasound dating</td> <td class=\"subtitle1\">Discrepancy between ultrasound dating and LMP dating that supports redating</td> </tr> <tr> <td>&#8804;13<sup>6/7</sup> weeks</td> <td class=\"divider_bottom\" rowspan=\"3\">CRL</td> <td>&nbsp;</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>&#8804;8<sup>6/7</sup> weeks </li> </ul> </td> <td> <ul> <li>More than&nbsp;five days </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>9<sup>0/7</sup> to 13<sup>6/7 </sup>weeks </li> </ul> </td> <td> <ul> <li>More than&nbsp;seven days </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>14<sup>0/7</sup> to 15<sup>6/7</sup> weeks</td> <td>BPD, HC, AC, FL</td> <td>More than&nbsp;seven days</td> </tr> <tr class=\"divider_bottom\"> <td>16<sup>0/7</sup> to 21<sup>6/7</sup> weeks</td> <td>BPD, HC, AC, FL</td> <td>More than 10 days</td> </tr> <tr class=\"divider_bottom\"> <td>22<sup>0/7</sup> to 27<sup>6/7</sup> weeks</td> <td>BPD, HC, AC, FL</td> <td>More than 14 days</td> </tr> <tr> <td>28<sup>0/7</sup> weeks and beyond<sup>&#182;</sup></td> <td>BPD, HC, AC, FL</td> <td>More than 21 days</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EDD: estimated date of delivery; LMP: last menstrual period; CRL: crown-rump length; BPD: biparietal diameter; HC: head circumference; AC: abdominal circumference; FL: femur length.<br />¶ Because of the risk of redating a small fetus that may be growth restricted, management decisions based on third-trimester ultrasonography alone are especially problematic and need to be guided by careful consideration of the entire clinical picture and close surveillance.</div><div class=\"graphic_reference\">Reprinted with permission from Methods for estimating the due date. Committee Opinion No. 700. American College of Obstetricians and Gynecologists. Obstet Gynecol 2017; 129:e150-4. Copyright © 2017.</div><div id=\"graphicVersion\">Graphic 97246 Version 5.0</div></div></div>"},"97247":{"type":"graphic_picture","displayName":"Dermoscopy CMN reticular","title":"Dermoscopic image of congenital melanocytic nevus","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of congenital melanocytic nevus</div><div class=\"cntnt\"><img style=\"width:470px; height:712px;\" src=\"images/DERM/97247_Dermoscopy_CMN_reticular.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Congenital melanocytic nevus showing focal network thickening on dermoscopic examination.</div><div class=\"graphic_reference\">Courtesy of Ashfaq A Marghoob, MD.</div><div id=\"graphicVersion\">Graphic 97247 Version 2.0</div></div></div>"},"97248":{"type":"graphic_picture","displayName":"Dermoscopy CMN perifollicular hypopigmentation","title":"Dermoscopic features of congenital melanocytic nevi","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of congenital melanocytic nevi</div><div class=\"cntnt\"><img style=\"width:586px; height:388px;\" src=\"images/DERM/97248_Dermo_CMN_perifol_hypopigm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypertrichosis and perifollicular hypopigmentation are characteristic of congenital melanocytic nevi.</div><div id=\"graphicVersion\">Graphic 97248 Version 1.0</div></div></div>"},"97249":{"type":"graphic_picture","displayName":"Dermoscopy CMN hypertrichosis","title":"Dermoscopic features of congenital melanocytic nevi","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of congenital melanocytic nevi</div><div class=\"cntnt\"><img style=\"width:586px; height:387px;\" src=\"images/DERM/97249_Dermscpy_CMN_hypertrichosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypertrichosis is typical of congenital melanocytic nevi.</div><div id=\"graphicVersion\">Graphic 97249 Version 1.0</div></div></div>"},"97250":{"type":"graphic_picture","displayName":"Dermoscopy CMN targets","title":"Dermoscopic features of congenital melanocytic nevi","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of congenital melanocytic nevi</div><div class=\"cntnt\"><img style=\"width:586px; height:410px;\" src=\"images/DERM/97250_Dermoscopy_CMN_targets.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Target-like globules are visible in this congenital melanocytic nevus.</div><div id=\"graphicVersion\">Graphic 97250 Version 1.0</div></div></div>"},"97251":{"type":"graphic_picture","displayName":"Dermoscopy CMN hyphal network","title":"Dermoscopic features of congenital melanocytic nevi","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of congenital melanocytic nevi</div><div class=\"cntnt\"><img style=\"width:585px; height:388px;\" src=\"images/DERM/97251_Dermoscopy_CMN_hyphal_ntwrk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A hyphal network and perifollicular hypopigmentation characterize this congenital melanocytic nevus.</div><div id=\"graphicVersion\">Graphic 97251 Version 1.0</div></div></div>"},"97252":{"type":"graphic_picture","displayName":"Dermoscopy CMN target vessels","title":"Dermoscopic features of congenital melanocytic nevi","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Dermoscopic features of congenital melanocytic nevi</div><div class=\"cntnt\"><img style=\"width:586px; height:389px;\" src=\"images/DERM/97252_Dermoscopy_CMN_trgt_vssls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tiny target-like vessels are vsible in the center of the lesion. Diffuse hypopigmented areas are also present.</div><div id=\"graphicVersion\">Graphic 97252 Version 1.0</div></div></div>"},"97253":{"type":"graphic_picture","displayName":"Knodell mild inflammation","title":"Knodell score: Mild lobular inflammation","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Knodell score: Mild lobular inflammation</div><div class=\"cntnt\"><img style=\"width:584px; height:288px;\" src=\"images/GAST/97253_Knodell_mild_inflammation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrows point to scattered foci of lobular necroinflammation. The inflammatory cells are composed mostly of mature lymphocytes. These foci are also termed spotty necrosis. Note the portal tract on the left has minimal inflammation and no interface hepatitis (formerly known as piecemeal necrosis).</div><div id=\"graphicVersion\">Graphic 97253 Version 1.0</div></div></div>"},"97254":{"type":"graphic_table","displayName":"K-levels","title":"\"K-levels\" and Medicare eligibility for lower limb prosthetics","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">\"K-levels\" and Medicare eligibility for lower limb prosthetics</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">K-level</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Foot/ankle components</td> <td class=\"subtitle1\">Knee components</td> </tr> <tr> <td>K0</td> <td>Patient does not have the ability or potential to ambulate or transfer safely without assistance, and a prosthesis does not enhance their quality of life or mobility.</td> <td>Not eligible</td> <td>Not eligible</td> </tr> <tr> <td>K1</td> <td>Patient has ability or potential to use prosthesis for transfers or ambulation on level surfaces at fixed cadence - a typical limited or unlimited household ambulator.</td> <td>External keel, SACH feet, or single-axis ankle/feet</td> <td>Single-axis, constant-friction knee</td> </tr> <tr> <td>K2</td> <td>Patient has the ability or potential for ambulation with the ability to traverse low-level environmental barriers, such as curbs, stairs, or uneven surfaces - a typical community ambulator.</td> <td>Flexible-keel feet and multi-axial ankle/feet</td> <td>Single-axis, constant-friction knee</td> </tr> <tr> <td>K3</td> <td>Patient has the ability or potential for ambulation with variable cadence - a typical community ambulator with the ability to traverse most environmental barriers and may have vocational, therapeutic, or exercise activity that demands prosthetic use beyond simple locomotion.</td> <td>Flex-foot and flex-walk systems, energy-storing feet, multi-axial ankle/feet or dynamic response feet</td> <td>Fluid and pneumatic control knees</td> </tr> <tr> <td>K4</td> <td>Patient has the ability or potential for prosthetic ambulation that exceeds basic ambulation skills, exhibiting high impact, stress, or energy levels - typical of&nbsp;the prosthetic demands of a child, active adult, or athlete.</td> <td>Any ankle/foot system</td> <td>Any knee system</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">K-levels are defined by Medicare based on an individual's ability or potential to ambulate and navigate their environment. Once it is determined in which K-level an individual resides, it can be determined which prosthetic components are covered by Medicare.</div><div class=\"graphic_footnotes\">SACH: solid ankle cushion heel</div><div class=\"graphic_reference\">Information available through the Centers for Medicare &amp; Medicaid Services.</div><div id=\"graphicVersion\">Graphic 97254 Version 1.0</div></div></div>"},"97255":{"type":"graphic_table","displayName":"Efficacy of methods used to treat tobacco dependence","title":"Effectiveness of methods used to treat tobacco dependence","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effectiveness of&nbsp;methods used to treat tobacco dependence</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Nonpharmacologic methods</td> </tr> <tr> <td class=\"subtitle2\">Method<br /> (number of trials)</td> <td class=\"subtitle2\"> <p>Versus minimal or usual care unless otherwise noted</p> Risk ratio (95% CI)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Behavioral counseling</td> </tr> <tr> <td class=\"indent1\">Individual counseling<sup>[1]</sup> (22)</td> <td>1.39 (1.24-1.57)</td> </tr> <tr> <td class=\"indent1\">Group counseling<sup>[2]</sup> (13)</td> <td>1.98 (1.60-2.46)</td> </tr> <tr> <td class=\"indent1\">Telephone quit line counseling<sup>[3]</sup> (9)</td> <td>1.37 (1.26-1.50)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">Physician counseling<sup>[4]</sup></td> </tr> <tr> <td class=\"indent1\">Brief advice (17)</td> <td>1.66 (1.42-1.94)</td> </tr> <tr> <td class=\"indent1\">Brief counseling (11)</td> <td>1.86 (1.60-2.15)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Brief counseling [versus brief advice] (15)</td> <td>1.37 (1.20-1.56)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Pharmacologic methods</td> </tr> <tr> <td class=\"subtitle2\">Method<br /> (number of trials)</td> <td class=\"subtitle2\"> <p>Versus placebo unless otherwise noted</p> Risk ratio (95% CI)</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\">First-line pharmacotherapies<sup>*</sup></td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"2\">Nicotine replacement<sup>[5]</sup></td> </tr> <tr> <td class=\"indent2\">Combination [versus individual products]<sup>[6]</sup> (9)</td> <td>1.34 (1.18-1.51)</td> </tr> <tr> <td class=\"indent2\">Patch (43)</td> <td>1.64 (1.52-1.78)</td> </tr> <tr> <td class=\"indent2\">Gum (56)</td> <td>1.49 (1.40-1.60)</td> </tr> <tr> <td class=\"indent2\">Lozenge (7)</td> <td>1.95 (1.61-2.36)</td> </tr> <tr> <td class=\"indent2\">Inhaler (4)</td> <td>1.90 (1.36-2.67)</td> </tr> <tr> <td class=\"indent2\">Nasal spray (4)</td> <td>2.02 (1.49-2.73)</td> </tr> <tr> <td class=\"indent1\">Varenicline<sup>[6]</sup> (14)</td> <td>2.27 (2.02-2.55)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bupropion SR<sup>[6]</sup> (36)</td> <td>1.69 (1.53-1.85)</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SR: sustained release.<br />* First-line drugs as recommended by the 2008 US Public Health Service guideline.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005; 2:CD001292.</li>&#xD;&#xA;    <li>Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev 2005; 2:CD001007.</li>&#xD;&#xA;    <li>Stead LF, Hartmann-Boyce J, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev 2013; 8:CD002850.</li>&#xD;&#xA;    <li>Stead LF, Buitrago D, Preciado N, et al. Physician advice for smoking cessation. Cochrane Database Syst Rev 2013; 5:CD000165.</li>&#xD;&#xA;    <li>Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012; 11:CD000146.</li>&#xD;&#xA;    <li>Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013; 5:CD009329.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 97255 Version 3.0</div></div></div>"},"97259":{"type":"graphic_table","displayName":"First-line medications used to treat tobacco dependence","title":"First-line medications used to treat tobacco dependence in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">First-line medications used to treat tobacco dependence in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"13%\"></colgroup><colgroup width=\"4%\"></colgroup><colgroup span=\"2\" width=\"13%\"></colgroup><colgroup width=\"4%\"></colgroup><colgroup span=\"4\" width=\"13%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">OTC?(US)</td> <td class=\"subtitle1\">Dosing</td> <td class=\"subtitle1\">Administration<sup>&#134;</sup></td> <td class=\"subtitle1\">Common adverse effects</td> <td class=\"subtitle1\">Advantages</td> <td class=\"subtitle1\">Disadvantages and precautions</td> <td class=\"subtitle1\">Other notes</td> </tr> <tr class=\"divider_bottom\"> <td>Nicotine patch</td> <td class=\"centered\">Yes</td> <td> <p>21 mg for &#62;10 cigarettes/day</p> <p>14 mg for &#8804;10 cigarettes/day</p> 7 mg used when tapering</td> <td> <p>Apply&nbsp;one new patch daily</p> <p>May start patch before quit date</p> Rotate application site</td> <td>Skin irritation, insomnia, vivid dreams</td> <td> <p>Provides steady nicotine level</p> Easiest nicotine product to use</td> <td>User cannot alter nicotine level in case of craving</td> <td>If removed before bedtime, takes 0.5 to&nbsp;three hours&nbsp;after reapplication to reach effective levels</td> </tr> <tr class=\"divider_bottom\"> <td>Nicotine gum</td> <td class=\"centered\">Yes</td> <td> <p>2 mg for &#60;25 cigarettes/day</p> 4 mg for &#8805;25 cigarettes/day</td> <td> <p>One&nbsp;piece every hour</p> <p>Maximum: &#8804;24 pieces/day</p> No food or drink for 30 minutes before and during use</td> <td>Mouth irritation, jaw soreness, heartburn, hiccups, or nausea (gastrointestinal side effects usually due to overly vigorous chewing)</td> <td> <p>User controls nicotine dose</p> Oral substitute for cigarettes</td> <td> <p>Unpleasant taste</p> <p>Can damage dental work</p> Difficult for denture wearers to use</td> <td>Proper chewing technique required (chew and park)</td> </tr> <tr class=\"divider_bottom\"> <td>Nicotine lozenge</td> <td class=\"centered\">Yes</td> <td> <p>2 mg if first cigarette &#8805;30 min after waking</p> 4 mg if first cigarette &#60;30 min after waking</td> <td> <p>One&nbsp;piece every&nbsp;one to two&nbsp;hours</p> <p>Maximum:</p> <p>Five&nbsp;lozenges/six hours</p> <p>20 lozenges/day</p> No food or drink for 30 minutes before and during use</td> <td>Mouth irritation, hiccups, heartburn, or nausea</td> <td> <p>User controls nicotine dose</p> <p>Oral substitute for cigarettes</p> Can be used by smokers with poor dentition or dentures</td> <td>Unpleasant taste</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Nicotine inhaler</td> <td class=\"centered\">No</td> <td>10 mg per cartridge</td> <td> <p>Inhale as needed (eg, every one to two hours)</p> Maximum: 16 cartridges/day</td> <td>Mouth and throat irritation</td> <td> <p>User controls nicotine dose</p> Oral substitute for cigarettes</td> <td> <p>Device visible when being used</p> Use caution in reactive airway disease</td> <td>Frequent puffing required</td> </tr> <tr class=\"divider_bottom\"> <td>Nicotine nasal spray</td> <td class=\"centered\">No</td> <td> <p>0.5 mg per spray</p> <p>(10 mg/mL)</p> </td> <td> <p>Apply one spray to each nostril every one to two hours</p> <p>Maximum:</p> <p>10 sprays/hour</p> <p>80 sprays/day</p> </td> <td>Nasal and throat irritation, rhinitis, sneezing, cough, or teary eyes</td> <td> <p>User controls nicotine dose</p> Most rapid delivery of nicotine among nicotine-replacement products</td> <td>Local irritation to nasal mucosa is difficult for many to tolerate</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Varenicline</td> <td class=\"centered\">No</td> <td>0.5 mg pill</td> <td> <p>0.5 mg/day for&nbsp;three days, then 0.5 mg twice a day for&nbsp;four days, then 1 mg twice a day</p> <p>Start&nbsp;one to two&nbsp;weeks before quit date</p> <p>May be started up to four weeks prior to quit date</p> </td> <td>Nausea, insomnia, abnormal dreams, headache, skin rash (&#8804;3%)</td> <td> <p>Dual action: relieves nicotine withdrawal and blocks reward from smoking</p> Oral agent (pill)</td> <td> <p>Reduced dose in severe renal insufficiency</p> <p>Avoid in patients with unstable psychiatric status or history of suicidal ideation</p> Monitor for neuropsychiatric symptoms*</td> <td>&nbsp;</td> </tr> <tr> <td>Bupropion sustained release</td> <td class=\"centered\">No</td> <td>150 mg pill</td> <td> <p>150 mg/day for&nbsp;three days, then 150 mg twice a day</p> Start&nbsp;one to two&nbsp;weeks before quit date</td> <td>Insomnia, agitation, dry mouth, headache</td> <td> <p>Blunts postcessation weight gain while being used</p> Oral agent (pill)</td> <td> <p>Monitor for neuropsychiatric symptoms*</p> Contraindicated in patients with seizure disorder or predisposition</td> <td>A lower dose of 150 mg per day is an option for patients who do not tolerate the full dose</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OTC: over-the-counter (nonprescription) sale; US: United States.<br />* Neuropsychiatric symptoms include: behavioral changes, hostility, agitation, depressed mood, suicidal ideation and attempts.<br />† All pharmacologic agents may be continued for&nbsp;three to six&nbsp;months. </div><div class=\"graphic_reference\"><OL>&#xD;&#xA;<LI>Rigotti NA. Strategies to help a smoker who is struggling to quit. JAMA 2012; 308:1573.</LI>&#xD;&#xA;<LI>Shahab L, Brose LS, West R. Novel delivery systems for nicotine replacement therapy as an aid to smoking cessation and for harm reduction: rationale, and evidence for advantages over existing systems. CNS Drugs 2013; 27:10079</LI></OL></div><div id=\"graphicVersion\">Graphic 97259 Version 3.0</div></div></div>"},"97269":{"type":"graphic_picture","displayName":"Knodell moderate inflammation","title":"Knodell score: Moderate interface hepatitis","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Knodell score: Moderate interface hepatitis</div><div class=\"cntnt\"><img style=\"width:586px; height:332px;\" src=\"images/GAST/97269_Knodell_moderate_inflammat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A portion of a portal tract with moderate lymphocytic inflammation. Note the arrows pointing at inflammatory cells that are spilling over into the limiting plate, termed interface hepatitis. The process involves &lt;50 percent&nbsp;of the entire portal tract circumference.</div><div id=\"graphicVersion\">Graphic 97269 Version 1.0</div></div></div>"},"97270":{"type":"graphic_picture","displayName":"Knodell marked portal inflammation","title":"Knodell score: Marked portal inflammation","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Knodell score: Marked portal inflammation</div><div class=\"cntnt\"><img style=\"width:586px; height:298px;\" src=\"images/GAST/97270_Knodell_mark_portal_inflam.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A portal tract is occupied by a large lymphoid aggregate (thick arrow) and the rest is occupied by a dense infiltrate of lymphocytes. Note that there is also marked interface hepatitis (denoted by thin&nbsp;arrows).</div><div id=\"graphicVersion\">Graphic 97270 Version 1.0</div></div></div>"},"97271":{"type":"graphic_picture","displayName":"Knodell multilobular necrosis","title":"Knodell score: Multilobular necrosis","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Knodell score: Multilobular necrosis</div><div class=\"cntnt\"><img style=\"width:585px; height:302px;\" src=\"images/GAST/97271_Knodell_multilobul_necrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The central portion of the photomicrograph shows confluent necrosis with no remaining viable parenchyma except for the two viable foci denoted by arrows at the periphery. The area of parenchymal collapse is occupied by dense inflammatory infiltrates.</div><div id=\"graphicVersion\">Graphic 97271 Version 1.0</div></div></div>"},"97272":{"type":"graphic_picture","displayName":"METAVIR F1","title":"METAVIR F1 fibrosis: Portal fibrosis without fibrous septa","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">METAVIR F1 fibrosis: Portal fibrosis without fibrous septa</div><div class=\"cntnt\"><img style=\"width:582px; height:435px;\" src=\"images/GAST/97272_METAVIR_F1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The portal tract is expanded by fibrosis, but there are no septa. At the center is a dense lymphoid aggregate. Trichrome stain.</div><div id=\"graphicVersion\">Graphic 97272 Version 1.0</div></div></div>"},"97276":{"type":"graphic_diagnosticimage","displayName":"Bladder herniation associated with gastroschisis","title":"Bladder herniation associated with gastroschisis","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Bladder herniation associated with gastroschisis</div><div class=\"cntnt\"><img style=\"width:586px; height:355px;\" src=\"images/OBGYN/97276_Blad_hernia_assoc_gastrosch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prenatal ultrasound examination in fetus with gastroschisis (not shown). Bladder is protruding anteriorly and in line with the perineum.</div><div id=\"graphicVersion\">Graphic 97276 Version 1.0</div></div></div>"},"97277":{"type":"graphic_diagnosticimage","displayName":"Gastroschisis with herniated bowel loops","title":"Gastroschisis with herniated bowel loops floating freely in amniotic fluid","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Gastroschisis with herniated bowel loops floating freely in amniotic fluid</div><div class=\"cntnt\"><img style=\"width:586px; height:352px;\" src=\"images/OBGYN/97277_Gastroschis_hrntd_bwl_loops.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 97277 Version 1.0</div></div></div>"},"97278":{"type":"graphic_algorithm","displayName":"Approach to the management of node positive HNSCC post-RT","title":"Approach to the risk-adapted management of node positive HNSCC post-RT","html":"<div class=\"graphic\"><div style=\"width: 666px\" class=\"figure\"><div class=\"ttl\">Approach to the risk-adapted management of node positive HNSCC post-RT</div><div class=\"cntnt\"><img style=\"width:646px; height:440px;\" src=\"images/ONC/97278_Guid_rsk_mng_NHNSCC_postRT.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">N+HNSCC: node positive head and neck squamous cell carcinoma; RT: radiation therapy; PET: positron emission tomography; CT: computed tomography; HPV: human papilloma virus; OPSCC: oropharyngeal squamous cell carcinoma.<br />* High risk: where the perceived risk of residual nodal disease is high, such as sub-optimally treated patients due to premature cessation of treatment, unplanned treatment interruptions or the presence of high-risk primary disease, such as non-OPSCC.<br />&para; Low risk: where the perceived risk of residual nodal disease is low, such as HPV-associated OPSCC treated optimally.<br />&Delta; Ongoing clinical and imaging observation until residuum is &lt;1 to 1.5 cm or stable for &gt;6 months.<br /><span class=\"lozenge\">&loz;</span> Frequency of follow-up based on institutional policy.</div><div id=\"graphicVersion\">Graphic 97278 Version 3.0</div></div></div>"},"97279":{"type":"graphic_picture","displayName":"METAVIR F2","title":"METAVIR F2 fibrosis: Portal fibrosis with few septa","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">METAVIR F2 fibrosis: Portal fibrosis with few septa</div><div class=\"cntnt\"><img style=\"width:585px; height:375px;\" src=\"images/GAST/97279_METAVIR_F2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power magnification showing a few portal tracts that are fibrotic, while others are not expanded. Trichrome stain.</div><div id=\"graphicVersion\">Graphic 97279 Version 1.0</div></div></div>"},"97280":{"type":"graphic_picture","displayName":"METAVIR F4","title":"METAVIR F4 fibrosis: Cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">METAVIR F4 fibrosis: Cirrhosis</div><div class=\"cntnt\"><img style=\"width:582px; height:524px;\" src=\"images/GAST/97280_METAVIR_F4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">At the center is a well-formed nodule completely enclosed by dense connective tissue indicative of cirrhosis. The adjacent parenchyma is also occupied by various-sized cirrhotic nodules. Trichrome stain.</div><div id=\"graphicVersion\">Graphic 97280 Version 1.0</div></div></div>"},"97281":{"type":"graphic_picture","displayName":"METAVIR F3","title":"METAVIR F3 fibrosis: Portal fibrosis with numerous septa without cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">METAVIR F3 fibrosis: Portal fibrosis with numerous septa without cirrhosis</div><div class=\"cntnt\"><img style=\"width:586px; height:366px;\" src=\"images/GAST/97281_METAVIR_F3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this photomicrograph, all portal tracts are expanded by fibrosis with fibrous septa extending and sometimes linking adjacent portal tracts. Trichrome stain.</div><div id=\"graphicVersion\">Graphic 97281 Version 1.0</div></div></div>"},"97282":{"type":"graphic_picture","displayName":"Ishak confluent necrosis","title":"Ishak score: Focal confluent necrosis","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Ishak score: Focal confluent necrosis</div><div class=\"cntnt\"><img style=\"width:460px; height:320px;\" src=\"images/GAST/97282_Ishak_confluent_necrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An arrow points to the lumen of a central venule. There is dropout of some hepatocytes surrounding this venule accompanied by an infiltrate of plasma cells and lymphocytes.</div><div id=\"graphicVersion\">Graphic 97282 Version 1.0</div></div></div>"},"97283":{"type":"graphic_picture","displayName":"Ishak score 0","title":"Ishak score 0: Normal portal tract","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Ishak score 0: Normal portal tract</div><div class=\"cntnt\"><img style=\"width:582px; height:435px;\" src=\"images/GAST/97283_Ishak_score_0.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A small portal tract containing a triad of a&nbsp;bile duct, artery, and portal venule. The amount of fibroconnective tissue comprising the portal area is within normal limits. Trichrome stain.</div><div id=\"graphicVersion\">Graphic 97283 Version 1.0</div></div></div>"},"97284":{"type":"graphic_picture","displayName":"Microtia","title":"Microtia","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Microtia</div><div class=\"cntnt\"><img style=\"width:596px; height:272px;\" src=\"images/ALLRG/97284_Microtia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Grade I<br />(B) Grade II<br />(C) Grade III</div><div id=\"graphicVersion\">Graphic 97284 Version 1.0</div></div></div>"},"97285":{"type":"graphic_table","displayName":"SJS TEN triggers PI","title":"Medicines that can cause Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) and closely related medicines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medicines that can cause Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) and closely related medicines</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">If you had SJS or TEN with one of these, you must avoid all other medicines that are in the same group and closely related medicines</td> </tr> <tr> <td class=\"subtitle2\">Generic name</td> <td class=\"subtitle2\">US brand names</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\"><strong>GROUP 1: Used to prevent gout attacks</strong></td> </tr> <tr> <td class=\"indent1\">Allopurinol</td> <td>Aloprim, Zyloprim, Duzallo</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">There are no known closely related medicines to allopurinol</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">GROUP 2: Some anti-epileptic drugs&nbsp;<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; color: #1f497d;\">&ndash;</span> used to prevent seizures or pain</td> </tr> <tr> <td class=\"indent1\">Carbamazepine</td> <td>Tegretol, Carbatrol, Epitol, Equetro</td> </tr> <tr> <td class=\"indent1\">Fosphenytoin</td> <td>Cerebyx</td> </tr> <tr> <td class=\"indent1\">Lamotrigine</td> <td>Lamictal</td> </tr> <tr> <td class=\"indent1\">Phenobarbital (phenobarbitone)</td> <td>Luminal</td> </tr> <tr> <td class=\"indent1\">Phenytoin</td> <td>Dilantin, Dilantin Infatabs, Phenytek</td> </tr> <tr> <td class=\"indent1\">Primidone</td> <td>Mysoline</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Following are closely related to above anti-epileptic drugs and must also be avoided:</td> </tr> <tr> <td class=\"indent2\">Eslicarbazepine</td> <td>Aptiom</td> </tr> <tr> <td class=\"indent2\">Felbamate</td> <td>Felbatol</td> </tr> <tr> <td class=\"indent2\">Oxcarbazepine</td> <td>Trileptal, Oxtellar XR</td> </tr> <tr> <td class=\"indent2\">Phenobarbital combinations for stomach problems</td> <td>Donnatal</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Zonisamide</td> <td>Zonegran</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">GROUP 3: \"Sulfa\" antibiotics&nbsp;<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; color: #1f497d;\">&ndash;</span> used for treating infections</td> </tr> <tr> <td class=\"indent1\">Trimethoprim-sulfamethoxazole (also called cotrimoxazole and TMP-SMX)</td> <td>Bactrim, Septra, Sulfatrim</td> </tr> <tr> <td class=\"indent1\">Sulfadiazine</td> <td>No brand (generic only)</td> </tr> <tr> <td class=\"indent1\">Sulfadoxine and pyrimethamine</td> <td>Fansidar</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Following are closely related to above \"sulfa\" antibiotics and must also be avoided:</td> </tr> <tr> <td class=\"indent2\">Erythromycin-sulfisoxazole</td> <td>Pediazole</td> </tr> <tr> <td class=\"indent2\">Silver sulfadiazine cream</td> <td>Silvadene, SSD, Thermazene</td> </tr> <tr> <td class=\"indent2\">Sulfacetamide containing skin products including cleansers, creams, foams, gels, lotions, pads, washes and shampoos</td> <td>APOP, AVAR, Klaron, Claris, Ovace, Plexion, Prascion, Rosanil, Seb-Prev, SSS, Sulfacet-R, Sulfacleanse, Sumadan, Sumaxin, Verti-sulf, Zencia, others</td> </tr> <tr> <td class=\"indent2\">Sulfacetamide containing eye drops, eye ointments and ear drops</td> <td>Bleph-10, Blephamide</td> </tr> <tr> <td class=\"indent2\">Sulfacetamide, sulfanilamide and/or sulfathiazole vaginal products</td> <td>AVS, VVS, Triple Sulfa Vaginal</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Sulfasalazine used for treating colitis or rheumatoid arthritis</td> <td>Azulfidine, Sulfazine, Salazopyrin</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\"><strong>GROUP 4: Nonsteroidal drugs (also called \"NSAIDs\")&nbsp;<span style=\"font-size: 11pt; font-family: 'Calibri',sans-serif; color: #1f497d;\">&ndash;</span> used to treat pain or inflammation</strong></td> </tr> <tr> <td class=\"indent1\">Meloxicam</td> <td>Mobic</td> </tr> <tr> <td class=\"indent1\">Piroxicam</td> <td>Feldene</td> </tr> <tr> <td class=\"indent1\">Tenoxicam (not available in the United States)</td> <td>Brand depends on country</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\"> <p>Other NSAIDs should in general be avoided:</p> Note: Carefully check <strong>all</strong> medicine labels, including pain relievers, cough or cold medicines, shots, ointments, creams, gels, patches, eye drops and nose sprays to be sure they contain <strong>no</strong> NSAID.</td> </tr> <tr> <td class=\"indent2\">Ibuprofen</td> <td>Advil, Motrin</td> </tr> <tr> <td class=\"indent2\">Naproxen</td> <td>Aleve</td> </tr> <tr> <td class=\"indent2\">Celecoxib</td> <td>Celebrex</td> </tr> <tr> <td class=\"indent2\">Ketorolac</td> <td>Toradol, Sprix, Acular, Acuvail</td> </tr> <tr> <td class=\"indent2\">Diclofenac</td> <td>Voltaren, Flector, Pennsaid</td> </tr> <tr> <td class=\"indent2\">Indomethacin</td> <td>Indocin</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\">Note: Many other&nbsp;prescription and non-prescription medicines contain NSAIDs. Have your doctor, nurse, or pharmacist confirm that any medicine you are thinking of using does <strong>not</strong> contain an NSAID.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI><SPAN style=\"COLOR: black\">An HIV medicine called nevirapine (brand name: Viramune),&nbsp;which is not&nbsp;used often in most countries, has been linked to SJS/TEN.&nbsp;</SPAN></LI>&#xD;&#xA;<LI><FONT color=blue><SPAN style=\"COLOR: black\">Some&nbsp;other medicines have also been very rarely linked to SJS/TEN</SPAN>.</FONT></LI></UL></div><div id=\"graphicVersion\">Graphic 97285 Version 4.0</div></div></div>"},"97288":{"type":"graphic_picture","displayName":"Keep casts dry PI","title":"Using plastic bags to keep a cast dry","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Using plastic bags to keep a cast dry</div><div class=\"cntnt\"><img style=\"width:433px; height:577px;\" src=\"images/PI/97288_Keep_casts_dry_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To keep a cast dry, cover it with two plastic bags, and tape each bag&nbsp;– separately&nbsp;– to the skin with duct tape. In young children, you can use rubber bands instead of tape. This is because removing the tape from the skin can be painful for children.</div><div id=\"graphicVersion\">Graphic 97288 Version 2.0</div></div></div>"},"97296":{"type":"graphic_picture","displayName":"Ishak score 1","title":"Ishak score 1: Fibrous expansion of a portal tract","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Ishak score 1: Fibrous expansion of a portal tract</div><div class=\"cntnt\"><img style=\"width:580px; height:434px;\" src=\"images/GAST/97296_Ishak_score_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photomicrograph shows periportal fibrosis, illustrated by mild deposition of connective tissue within the portal tract resulting in expansion of the portal area. Trichrome stain.</div><div id=\"graphicVersion\">Graphic 97296 Version 1.0</div></div></div>"},"97297":{"type":"graphic_picture","displayName":"Ishak score 2","title":"Ishak score 2: Fibrous expansion of most portal areas","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Ishak score 2: Fibrous expansion of most portal areas</div><div class=\"cntnt\"><img style=\"width:586px; height:290px;\" src=\"images/GAST/97297_Ishak_score_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power magnification showing that the majority of portal tracts are expanded and most of them with fibrous septa extending out into the lobules. Trichrome stain.</div><div id=\"graphicVersion\">Graphic 97297 Version 1.0</div></div></div>"},"97298":{"type":"graphic_picture","displayName":"Ishak score 3","title":"Ishak score 3: Fibrous expansion of most portal tracts with occasional bridging portal to portal zones","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Ishak score 3: Fibrous expansion of most portal tracts with occasional bridging portal to portal zones</div><div class=\"cntnt\"><img style=\"width:584px; height:389px;\" src=\"images/GAST/97298_Ishak_score_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An arrow points to a septum that links two fibrotic portal tracts. The portal tract on the left has fibrous septa but does not show bridging fibrosis. Trichrome stain.</div><div id=\"graphicVersion\">Graphic 97298 Version 1.0</div></div></div>"},"97299":{"type":"graphic_picture","displayName":"Ishak score 4","title":"Ishak score 4: Fibrous expansion of portal areas with marked bridging (portal to portal as well as portal to central)","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Ishak score 4: Fibrous expansion of portal areas with marked bridging (portal to portal as well as portal to central)</div><div class=\"cntnt\"><img style=\"width:585px; height:294px;\" src=\"images/GAST/97299_Ishak_score_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrows point to septa that link portal to portal and portal to central zones. Trichrome stain.</div><div id=\"graphicVersion\">Graphic 97299 Version 1.0</div></div></div>"},"97300":{"type":"graphic_picture","displayName":"Ishak score 5","title":"Ishak fibrosis score 5: Marked bridging fibrosis with occasional nodules","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Ishak fibrosis score 5: Marked bridging fibrosis with occasional nodules</div><div class=\"cntnt\"><img style=\"width:580px; height:435px;\" src=\"images/GAST/97300_Ishak_score_5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photomicrograph demonstrates marked bridging fibrosis that links portal to portal zones, with an incomplete nodule surrounded by dense connective tissue. Trichrome stain.</div><div id=\"graphicVersion\">Graphic 97300 Version 1.0</div></div></div>"},"97301":{"type":"graphic_picture","displayName":"Ishak score 6","title":"Ishak fibrosis score 6: Cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Ishak fibrosis score 6: Cirrhosis</div><div class=\"cntnt\"><img style=\"width:586px; height:337px;\" src=\"images/GAST/97301_Ishak_score_6.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An example of established cirrhosis in which each nodule is completely enclosed by dense fibroconnective tissue. Trichrome stain.</div><div id=\"graphicVersion\">Graphic 97301 Version 1.0</div></div></div>"},"97302":{"type":"graphic_picture","displayName":"Scheuer stage 1","title":"Scheuer score: Stage 1 hepatic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Scheuer score: Stage 1 hepatic fibrosis</div><div class=\"cntnt\"><img style=\"width:586px; height:295px;\" src=\"images/GAST/97302_Scheuer_stage_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Enlarged portal tract as demonstrated by periportal expansion by fibrous tissue.</div><div id=\"graphicVersion\">Graphic 97302 Version 1.0</div></div></div>"},"97303":{"type":"graphic_picture","displayName":"Scheuer stage 2","title":"Scheuer score: Stage 2 hepatic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Scheuer score: Stage 2 hepatic fibrosis</div><div class=\"cntnt\"><img style=\"width:585px; height:336px;\" src=\"images/GAST/97303_Scheuer_stage_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two portal tracts are shown, both showing portal and periportal fibrosis with fibrous septa. An additional finding in this photo is the presence of steatosis. Trichrome stain.</div><div id=\"graphicVersion\">Graphic 97303 Version 1.0</div></div></div>"},"97304":{"type":"graphic_picture","displayName":"Scheuer stage 3","title":"Scheuer score: Stage 3 hepatic fibrosis","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Scheuer score: Stage 3 hepatic fibrosis</div><div class=\"cntnt\"><img style=\"width:585px; height:327px;\" src=\"images/GAST/97304_Scheuer_stage_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stage 3 fibrosis. Most portal tracts are expanded by fibrous tissue with linking fibrous septa, resulting&nbsp;in distortion of the architecture. Trichrome stain.</div><div id=\"graphicVersion\">Graphic 97304 Version 1.0</div></div></div>"},"97305":{"type":"graphic_picture","displayName":"Scheuer stage 4","title":"Scheuer score: Stage 4 hepatic fibrosis (probable or definite cirrhosis)","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Scheuer score: Stage 4 hepatic fibrosis (probable or definite cirrhosis)</div><div class=\"cntnt\"><img style=\"width:586px; height:346px;\" src=\"images/GAST/97305_Scheuer_stage_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this photomicrograph, there is fragmentation of the specimen and nodules. Septa surround most of the nodules. Both the fragmentation and the rounded edges of the nodules are highly suggestive of cirrhosis. Trichrome stain.</div><div id=\"graphicVersion\">Graphic 97305 Version 1.0</div></div></div>"},"97306":{"type":"graphic_figure","displayName":"Anatomy head and neck","title":"Anatomy of the head and neck","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Anatomy of the head and neck</div><div class=\"cntnt\"><img style=\"width:523px; height:515px;\" src=\"images/ONC/97306_Anatomy_head_and_neck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An illustration showing possible cancer sites in different regions of the head and neck. <br />· The following sites are part of the oral cavity: the lip, floor of the mouth, oral tongue, alveolar ridge, retromolar trigone, hard palate, and buccal mucosa<br /> · The following sites are part of the oropharynx: the soft palate, tonsil, posterior and lateral pharyngeal walls, and base of the tongue<br /> · The following sites are part of the hypopharynx: the pyriform fossa, lateral and posterior hypopharyngeal walls, and postcricoid region<br /> · The following sites are part of the larynx: the supraglottic, glottic, and subglottic larynx</div><div id=\"graphicVersion\">Graphic 97306 Version 1.0</div></div></div>"},"97326":{"type":"graphic_picture","displayName":"HCC vascular invasion histology","title":"Histologic demonstration of vascular invasion in hepatocellular carcinoma","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Histologic demonstration of vascular invasion in hepatocellular carcinoma</div><div class=\"cntnt\"><img style=\"width:581px; height:436px;\" src=\"images/ONC/97326_HCC_vascular_invasion_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodules of hepatocellular carcinoma in vascular spaces (arrows) representing portal vein invasion.</div><div class=\"graphic_footnotes\">HCC: hepatocellular carcinoma.</div><div id=\"graphicVersion\">Graphic 97326 Version 1.0</div></div></div>"},"97328":{"type":"graphic_picture","displayName":"Well-differentiated HCC, higher power histology","title":"High power histology of a well-differentiated hepatocellular carcinoma","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">High power histology of a well-differentiated hepatocellular carcinoma</div><div class=\"cntnt\"><img style=\"width:596px; height:225px;\" src=\"images/ONC/97328_Wll_dffr_HCC_hghr_pwr_hstlg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Well-differentiated hepatocellular carcinoma, which is composed of tumor cells with mild atypia, a higher nuclear to cytoplasmic ratio than seen in normal hepatocytes, and rare pseudoglandular structures (arrows).<br />(B) At higher power, the tumor is composed of polygonal tumor cells with eosinophilic cytoplasm, arranged in trabeculae that are more than two cells thick.</div><div class=\"graphic_footnotes\">HCC: hepatocellular carcinoma.</div><div id=\"graphicVersion\">Graphic 97328 Version 1.0</div></div></div>"},"97329":{"type":"graphic_picture","displayName":"Well-differentiated HCC producing bile, histology","title":"Histology of a well-differentiated hepatocellular cancer making bile","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Histology of a well-differentiated hepatocellular cancer making bile</div><div class=\"cntnt\"><img style=\"width:585px; height:439px;\" src=\"images/ONC/97329_Wll_dffr_HCC_prdc_ble_hstlg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brown-green bile in dilated bile canaliculi in HCC.</div><div class=\"graphic_footnotes\">HCC: hepatocellular carcinoma.</div><div id=\"graphicVersion\">Graphic 97329 Version 1.0</div></div></div>"},"97330":{"type":"graphic_picture","displayName":"Well-differentiated HCC with cytoplasmic fat, histology","title":"Histology of a well-differentiated hepatocellular carcinoma with cytoplasmic fat globules","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Histology of a well-differentiated hepatocellular carcinoma with cytoplasmic fat globules</div><div class=\"cntnt\"><img style=\"width:586px; height:438px;\" src=\"images/ONC/97330_Wll_dffr_HCC_cytplstmc_hstl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HCC with cytoplasmic fat globules, resembling fatty liver.</div><div class=\"graphic_footnotes\">HCC: hepatocellular carcinoma.</div><div id=\"graphicVersion\">Graphic 97330 Version 2.0</div></div></div>"},"97331":{"type":"graphic_picture","displayName":"Well-differentiated HCC with cytoplasmic glycogen, histology","title":"Histology of a well-differentiated hepatocellular carcinoma containing cytoplasmic glycogen","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Histology of a well-differentiated hepatocellular carcinoma containing cytoplasmic glycogen</div><div class=\"cntnt\"><img style=\"width:586px; height:439px;\" src=\"images/ONC/97331_Wll_dffr_HCC_cytplsmc_glycg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Well-differentiated hepatocellular carcinoma with clear cell appearance because of cytoplasmic glycogen content.</div><div id=\"graphicVersion\">Graphic 97331 Version 2.0</div></div></div>"},"97332":{"type":"graphic_picture","displayName":"Well-differentiated HCC with Mallory-Denk hyalins, histology","title":"Histology of a well-differentiated hepatocellular carcinoma with Mallory-Denk hyalins","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Histology of a well-differentiated hepatocellular carcinoma with Mallory-Denk hyalins</div><div class=\"cntnt\"><img style=\"width:585px; height:437px;\" src=\"images/ONC/97332_Wll_HCC_Mllr_Dnk_hyln_hstl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hepatocellular carcinoma with numerous eosinophilic irregular Mallory-Denk hyalins (arrows).</div><div id=\"graphicVersion\">Graphic 97332 Version 1.0</div></div></div>"},"97334":{"type":"graphic_picture","displayName":"Well-differentiated HCC containing fibrinogen, histology","title":"Histology of a well-differentiated hepatocellular carcinoma containing intracytoplasmic fibrinogen","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Histology of a well-differentiated hepatocellular carcinoma containing intracytoplasmic fibrinogen</div><div class=\"cntnt\"><img style=\"width:586px; height:438px;\" src=\"images/ONC/97334_Wll_dffr_HCC_cntn_fbrn_hstl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Well-differentiated hepatocellular carcinoma containing intracytoplasmic fibrinogen inclusions (arrows).</div><div id=\"graphicVersion\">Graphic 97334 Version 1.0</div></div></div>"},"97335":{"type":"graphic_picture","displayName":"Well differentiated HCC with trabeculae, histology","title":"Histology of well differentiated hepatocellular carcinoma with prominent trabecular pattern","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Histology of well differentiated hepatocellular carcinoma with prominent trabecular pattern</div><div class=\"cntnt\"><img style=\"width:586px; height:438px;\" src=\"images/ONC/97335_Wll_dffrnt_HCC_trbcl_hstlgy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 97335 Version 1.0</div></div></div>"},"97336":{"type":"graphic_picture","displayName":"Well-differentiated HCC, pseudoglandular pattern, histology","title":"Histology of a well-differentiated hepatocellular carcinoma, pseudoglandular pattern","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Histology of a well-differentiated hepatocellular carcinoma, pseudoglandular pattern</div><div class=\"cntnt\"><img style=\"width:585px; height:439px;\" src=\"images/ONC/97336_Wll_dfr_HCC_psdgl_ptr_hstlg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dilated bile canaliculi producing the pseudoglandular pattern in hepatocellular carcinoma.</div><div class=\"graphic_footnotes\">HCC: hepatocellular carcinoma.</div><div id=\"graphicVersion\">Graphic 97336 Version 1.0</div></div></div>"},"97337":{"type":"graphic_picture","displayName":"Moderately differentiated HCC, histology","title":"Histology of a moderately differentiated hepatocellular carcinoma","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Histology of a moderately differentiated hepatocellular carcinoma</div><div class=\"cntnt\"><img style=\"width:586px; height:438px;\" src=\"images/ONC/97337_Mdrtly_dffrnttd_HCC_hstlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Moderately differentiated hepatocellular carcinoma showing tumor cells in a thick trabecular pattern. </div><div class=\"graphic_footnotes\">HCC: hepatocellular carcinoma.</div><div id=\"graphicVersion\">Graphic 97337 Version 1.0</div></div></div>"},"97338":{"type":"graphic_picture","displayName":"Poorly differentiated HCC, histology","title":"Histology of a poorly differentiated hepatocellular carcinoma","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Histology of a poorly differentiated hepatocellular carcinoma</div><div class=\"cntnt\"><img style=\"width:585px; height:439px;\" src=\"images/ONC/97338_Poorly_dffrnttd_HCC_hstlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Poorly differentiated hepatocellular carcinoma with tumor cells in a solid growth pattern.</div><div class=\"graphic_footnotes\">HCC: hepatocellular carcinoma.</div><div id=\"graphicVersion\">Graphic 97338 Version 1.0</div></div></div>"},"97339":{"type":"graphic_picture","displayName":"Hepatocellular carcinoma with positive staining for CD34","title":"Histology of a well differentiated hepatocellular carcinoma positive for CD34 immunohistochemical staning","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Histology of a well differentiated hepatocellular carcinoma positive for CD34 immunohistochemical staning</div><div class=\"cntnt\"><img style=\"width:586px; height:438px;\" src=\"images/ONC/97339_Hptclllr_crcnm_pos_stn_CD34.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CD34-positive brown staining of endothelial cells that outline the trabecular of hepatocellular carcinoma.&nbsp;</div><div id=\"graphicVersion\">Graphic 97339 Version 1.0</div></div></div>"},"97340":{"type":"graphic_picture","displayName":"Well-differentiated HCC with canalicular diff by CEA staining","title":"Histology of a well-differentiated hepatocellular carcinoma with canalicular differentiation ","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Histology of a well-differentiated hepatocellular carcinoma with canalicular differentiation </div><div class=\"cntnt\"><img style=\"width:585px; height:439px;\" src=\"images/ONC/97340_Wll_dffr_HCC_cnllr_CEA_stn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">pCEA brown staining in the dilated bile canaliculi and small dot-like brown staining pattern indicating canalicular differentiation in HCC.</div><div class=\"graphic_footnotes\">HCC: hepatocellular carcinoma; pCEA: polyclonal carcinoembryonic antigen.</div><div id=\"graphicVersion\">Graphic 97340 Version 1.0</div></div></div>"},"97341":{"type":"graphic_picture","displayName":"Hepatocellular carcinoma and HepPar1 immunostaining","title":"Histology of HepPar1-positive hepatocellular carcinoma","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Histology of HepPar1-positive hepatocellular carcinoma</div><div class=\"cntnt\"><img style=\"width:586px; height:438px;\" src=\"images/ONC/97341_Hepato_crcnma_HepPar1_immun.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HepPar1 cytoplasmic brown staining in hepatocellular carcinoma. </div><div id=\"graphicVersion\">Graphic 97341 Version 1.0</div></div></div>"},"97342":{"type":"graphic_table","displayName":"Clinical studies investigating the efficacy and safety of S-ICD","title":"Summary of major clinical studies investigating the efficacy and safety of the subcutaneous implantable cardioverter-defibrillator (S-ICD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of major clinical studies investigating the efficacy and safety of the subcutaneous implantable cardioverter-defibrillator (S-ICD)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Author (year)</td> <td class=\"subtitle1\">Number of patients (n)</td> <td class=\"subtitle1\">Appropriate detection rate (%)</td> <td class=\"subtitle1\">Inappropriate shock rate (%)</td> <td class=\"subtitle1\">Successful conversion with defibrillator function testing (%)</td> <td class=\"subtitle1\">Complications requiring intervention (%)</td> <td class=\"subtitle1\">Mean follow-up duration (months)</td> </tr> <tr> <td>Lambiase et al (2014)<sup>[1]</sup></td> <td class=\"centered\">472</td> <td class=\"centered\">NR</td> <td class=\"centered\">7%</td> <td class=\"centered\">99.7%</td> <td class=\"centered\">6.4%</td> <td class=\"centered\">18</td> </tr> <tr> <td>Weiss et al (2013)<sup>[2]</sup></td> <td class=\"centered\">314</td> <td class=\"centered\">99.8%</td> <td class=\"centered\">14%</td> <td class=\"centered\">100%</td> <td class=\"centered\">1.3%</td> <td class=\"centered\">11</td> </tr> <tr> <td>K&#246;be et al (2013)<sup>[3]</sup></td> <td class=\"centered\">69</td> <td class=\"centered\">NR</td> <td class=\"centered\">4%</td> <td class=\"centered\">95.5%</td> <td class=\"centered\">4%</td> <td class=\"centered\">7</td> </tr> <tr> <td>Jarman et al (2013)<sup>[4]</sup></td> <td class=\"centered\">111</td> <td class=\"centered\">100%</td> <td class=\"centered\">15%</td> <td class=\"centered\">100%</td> <td class=\"centered\">16%</td> <td class=\"centered\">12</td> </tr> <tr> <td>Jarman et al (2012)<sup>[5]</sup></td> <td class=\"centered\">16</td> <td class=\"centered\">100%</td> <td class=\"centered\">25%</td> <td class=\"centered\">100%</td> <td class=\"centered\">19%</td> <td class=\"centered\">9</td> </tr> <tr> <td>Aydin et al (2012)<sup>[6]</sup></td> <td class=\"centered\">40</td> <td class=\"centered\">NR</td> <td class=\"centered\">5%</td> <td class=\"centered\">97.5%</td> <td class=\"centered\">13%</td> <td class=\"centered\">8</td> </tr> <tr> <td>Olde Nordkamp et al (2012)<sup>[7]</sup></td> <td class=\"centered\">118</td> <td class=\"centered\">NR</td> <td class=\"centered\">13%</td> <td class=\"centered\">100%</td> <td class=\"centered\">14%</td> <td class=\"centered\">18</td> </tr> <tr> <td>Dabiri et al (2011)<sup>[8]</sup></td> <td class=\"centered\">31</td> <td class=\"centered\">100%</td> <td class=\"centered\">16%</td> <td class=\"centered\">100%</td> <td class=\"centered\">10%</td> <td class=\"centered\">9</td> </tr> <tr> <td>Bardy et al (2010)<sup>[9]</sup></td> <td class=\"centered\">55</td> <td class=\"centered\">100%</td> <td class=\"centered\">9%</td> <td class=\"centered\">98%</td> <td class=\"centered\">11%</td> <td class=\"centered\">10</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Lambiase PD, Barr C, Theuns DAMJ, et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry. Eur Heart J 2014; 35:1657. </li>&#xD;&#xA;    <li>Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation 2013; 128:944.</li>&#xD;&#xA;    <li>K&ouml;be J, Reinke F, Meyer C, et al. Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter-defibrillators: a multicenter case-control study. Heart Rhythm 2013; 10:29.</li>&#xD;&#xA;    <li>Jarman JWE, Todd DM. United Kingdom national experience of entirely subcutaneous implantable cardioverter-defibrillator technology: important lessons to learn. Europace 2013; 15:1158. </li>&#xD;&#xA;    <li>Jarman JWE, Lascelles K, Wong T, et al. Clinical experience of entirely subcutaneous implantable cardioverter-defibrillators in children and adults: cause for caution. Eur Heart J 2012; 33:1351.</li>&#xD;&#xA;    <li>Aydin A, Hartel F, Schl&uuml;ter M, et al. Shock efficacy of subcutaneous implantable cardioverter-defibrillator for prevention of sudden cardiac death: initial multicenter experience. Circ Arrhythm Electrophysiol 2012; 5:913.</li>&#xD;&#xA;    <li>Olde Nordkamp LRA, Dabiri Abkenari L, Boersma LVA, et al. The entirely subcutaneous implantable cardioverter-defibrillator: initial clinical experience in a large Dutch cohort. J Am Coll Cardiol 2012; 60:1933.</li>&#xD;&#xA;    <li>Dabiri Abkenari L, Theuns DAMJ, Valk SDA, et al. Clinical experience with a novel subcutaneous implantable defibrillator system in a single center. Clin Res Cardiol 2011; 100:737.</li>&#xD;&#xA;    <li>Bardy GH, Smith WM, Hood MA, Crozier IG, Melton IC, Jordaens L, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010; 363:36.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 97342 Version 1.0</div></div></div>"},"97343":{"type":"graphic_picture","displayName":"Hepatocelllular carcinoma with positive staining for TTF1","title":"Histology of a TTF1-positive hepatocellular carcinoma","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Histology of a TTF1-positive hepatocellular carcinoma</div><div class=\"cntnt\"><img style=\"width:586px; height:439px;\" src=\"images/ONC/97343_Hptcllllr_crcn_pos_stn_TTF1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">TTF-1 cytoplasmic brown staining in a hepatocellular carcinoma.</div><div class=\"graphic_footnotes\">TTF-1: Thyroid transcription factor-1.</div><div id=\"graphicVersion\">Graphic 97343 Version 1.0</div></div></div>"},"97344":{"type":"graphic_picture","displayName":"Scirrhous variant of HCC, histology","title":"Scirrhous variant of HCC, histology","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Scirrhous variant of HCC, histology</div><div class=\"cntnt\"><img style=\"width:586px; height:438px;\" src=\"images/ONC/97344_Well_HCC_scrrhs_sbtyp_hstlg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scirrhous hepatocellular carcinoma with dense desmoplastic stroma (arrows) separating clusters of tumor cells.</div><div class=\"graphic_footnotes\">HCC: hepatocellular carcinoma.</div><div id=\"graphicVersion\">Graphic 97344 Version 2.0</div></div></div>"},"97345":{"type":"graphic_picture","displayName":"Spindle cell variant of HCC, histology","title":"Histology of the spindle cell variant of hepatocellular carcinoma","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Histology of the spindle cell variant of hepatocellular carcinoma</div><div class=\"cntnt\"><img style=\"width:586px; height:438px;\" src=\"images/ONC/97345_Spndl_cll_vrnt_HCC_hstlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HCC, spindle cell variant; morphologically indistinguishable from other sarcomatoid carcinoma or metastatic sarcoma. </div><div class=\"graphic_footnotes\">HCC: hepatocellular carcinoma.</div><div id=\"graphicVersion\">Graphic 97345 Version 2.0</div></div></div>"},"97346":{"type":"graphic_picture","displayName":"Giant cell variant of HCC, histology","title":"Histology of giant cell variant of hepatocellular carcinoma","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Histology of giant cell variant of hepatocellular carcinoma</div><div class=\"cntnt\"><img style=\"width:585px; height:439px;\" src=\"images/ONC/97346_Giant_cell_vrnt_HCC_hstlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hepatocellular carcinoma, giant cell variant, with numerous multinucleated giant cells (arrow) and large pleomorphic tumor cells (arrowheads).</div><div class=\"graphic_footnotes\">HCC: hepatocellular carcinoma.</div><div id=\"graphicVersion\">Graphic 97346 Version 1.0</div></div></div>"},"97349":{"type":"graphic_table","displayName":"Highly toxic rodenticides: Clinical manifestations and treatment","title":"Highly toxic rodenticides: Appearance, minimum lethal dose, clinical manifestations, and management","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Highly toxic rodenticides: Appearance, minimum lethal dose, clinical manifestations, and management</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"10%\"></colgroup><colgroup span=\"2\" width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Substance</td> <td class=\"subtitle1\">Appearance</td> <td class=\"subtitle1\">Minimum lethal dose</td> <td class=\"subtitle1\">Clinical findings</td> <td class=\"subtitle1\">Management</td> </tr> <tr> <td>Thallium</td> <td> <p>Odorless, tasteless powder</p> Radiopaque</td> <td>8 mg/kg</td> <td> <p>Early: abdominal pain, vomiting, constipation, tachycardia, hypertension, and chest pain</p> <p>Intermediate: painful stocking-glove paresthesias, ptosis, nystagmus, ataxia, chorea, delirium, psychosis, coma, alopecia, erythema of palms and soles</p> Other: Acute kidney injury, hepatotoxicity, anemia with thrombocytopenia, hyperchloremic metabolic acidosis</td> <td> <ul> <li>Gastric lavage*</li> <li>Administer activated charcoal*</li> <li>Enhance elimination with multiple dose activated charcoal or Prussian blue</li> <li>Early initiation of renal replacement therapy (hemodialysis, charcoal hemoperfusion, or continuous renal replacement)</li> </ul> </td> </tr> <tr> <td>Sodium monofluoroacetate or fluoroacetamide</td> <td>Odorless, tasteless, white powder</td> <td>2 mg/kg</td> <td>Respiratory distress, refractory shock, agitation, hypocalcemia with seizures and cardiac arrhythmias, severe lactic acidosis, vomiting, diarrhea, and abdominal pain, paresthesias</td> <td> <ul> <li>Gastric lavage*</li> <li>Administer activated charcoal*</li> <li>Treat hypocalcemia and metabolic acidosis</li> <li>Consult a regional poison center or medical toxicologist regarding proposed antidotes</li> </ul> </td> </tr> <tr> <td>Strychnine<sup>&#182;</sup></td> <td>Colorless, odorless, bitter when dissolved in water.</td> <td>1 mg/kg</td> <td>Rapid onset of hyperreflexia, clonus, stiffness of facial and neck muscles, repetitive grimacing (risus sardonicus), trismus, opisthotonus</td> <td> <ul> <li>Control muscle activity with high benzodiazepines (high doses may be required) and, if not responsive, phenobarbital and, in intubated patients, propofol</li> <li>Endotracheal intubation and paralysis for rhabdomyolysis, severe acidosis, or hyperthermia</li> <li>IV hydration and monitoring for rhabdomyolysis</li> </ul> </td> </tr> <tr> <td>Zinc or aluminium phosphide</td> <td> <p>Gray or black powder; Gray, green, or turquoise pellets or tablets</p> Radiopaque</td> <td>~50 mg/kg (Not well established) </td> <td>Vomiting with fishy odor, hematemesis, chest and abdominal pain, refractory shock, brady- and tachyarrhythmias, hemorrhagic pulmonary edema</td> <td> <ul> <li>Supportive care</li> <li>Treat hypomagnesemia</li> </ul> </td> </tr> <tr> <td>White (yellow) phosphorus</td> <td>Yellow, waxy solid compound</td> <td>1 mg/kg</td> <td> <p>Perioral, mucosal, and skin burns, vomiting, diarrhea, garlic odor on breath, phosphorescent emesis or stool, delayed liver failure, acute kidney injury</p> Lung irritation with inhalation</td> <td> <ul> <li>Flammable in air, soak clothing with water and avoid contact with elemental phosphorus emesis, or stools<sup>&#165;</sup></li> <li>Irrigate skin burns with water and cover with soaked gauze</li> <li>Monitor for and treat hypocalcemia and hyperkalemia</li> <li>Supportive care</li> </ul> </td> </tr> <tr> <td>Arsenic<sup>&#916;</sup></td> <td> <p>White powder, odorless and tasteless</p> Radiopaque</td> <td>1 mg/kg</td> <td> <p>Acute: Vomiting, watery diarrhea, garlic odor on breath, QTc prolongation, torsades de pointes, coma, seizures</p> Chronic: Refer to UpToDate topic on Arsenic poisoning</td> <td> <ul> <li>Irrigate skin as needed</li> <li>Chelation with British anti-Lewisite after acute poisoning</li> <li>Chelation with meso-2,3-dimercaptosuccinic acid (DMSA) or 2,3-dimercapto-1-propane sulfonate (DMPS)<sup>&#167;</sup> after chronic poisoning </li> <li>Renal replacement therapy in patients with renal failure</li> </ul> </td> </tr> <tr> <td>Barium carbonate</td> <td>White powder</td> <td>20 mg/kg</td> <td>Vomiting, diarrhea, abdominal pain, severe hypokalemia with weakness, paralysis, and ventricular arrhythmias, hypertension</td> <td> <ul> <li>Magnesium sulfate orally<sup>&#9674;</sup></li> <li>Potassium supplementation (high doses may be required)</li> <li>Renal replacement therapy for refractory hypokalemia or paralysis</li> </ul> </td> </tr> <tr> <td>Vacor</td> <td>Similar to cornmeal, peanut odor</td> <td>5 mg/kg</td> <td>Hyperglycemia, ketoacidosis, postural hypertension, weakness, cranial neuropathy, lethargy, delirium</td> <td> <ul> <li>Administer activated charcoal*</li> <li>Nicotinamide<sup>&#9674;</sup></li> <li>IV fluids, mineralocorticoids, and dihydroergotamine for orthostatic hypotension</li> </ul> </td> </tr> <tr> <td>Tetramine (banned but available, especially in China)</td> <td>Odorless, tasteless, white powder</td> <td>&#60;0.1 mg/kg</td> <td>Refractory status epilepticus</td> <td> <ul> <li>Gastric lavage*</li> <li>Administer activated charcoal*</li> <li>Manage status epilepticus<sup>&#135;</sup></li> </ul> </td> </tr> <tr> <td>Aldicarb (banned, but available, especially in Latin America)</td> <td>Sulfur odor, solid pellets, gray to black</td> <td>&#60;0.8 mg/kg</td> <td>Bronchorrhea, bronchospasm, bradycardia, salivation, diarrhea, vomiting, small pupils, urination; weakness and paralysis with high doses</td> <td> <ul> <li>With topical exposure, remove clothing and irrigate exposed areas in well-ventilated area<sup>&#134;</sup></li> <li>Atropine and pralidoxime<sup>&#9674;</sup></li> <li>Administer activated charcoal*</li> </ul> </td> </tr> <tr> <td>Alpha-chloralose</td> <td>White powder</td> <td>Not established in humans</td> <td>Respiratory depression, coma, myoclonus</td> <td> <ul> <li>Gastric lavage*</li> <li>Supportive care</li> </ul> </td> </tr> <tr> <td>Salmonella-based (most available in South America, withdrawn from Europe and US markets)</td> <td>Rice grains</td> <td>Not established in humans</td> <td>Salmonella enteritis and invasive Salmonella disease</td> <td>Refer to UpToDate topics on management of non-typhoid Salmonella enteritis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Patients with altered mental status or other potential airway compromise should undergo endotracheal intubation prior to gastric lavage or administration of activated charcoal. Refer to UpToDate topics on gastrointestinal decontamination in adults and children for a description of the gastric lavage procedure, dosing for activated charcoal, and additional precautions necessary to avoid complications such as aspiration.<br />&para; Refer to UpToDate topics on strychnine poisoning.<br />&Delta; Refer to UpToDate topics on arsenic poisoning.<br /><span class=\"lozenge\">&loz;</span> For dosing of these antidotes refer to UpToDate topics on rodenticide poisoning or, for atropine and pralidoxime, organophosphate and carbamate poisoning.<br />&sect; Not available as an approved medication in the United States.<br />&yen; Ensure all elemental phosphorus on clothing, in emesis, or in stools is kept wet to avoid fire or explosion.<br />&Dagger; Refer to UpToDate topics on status epilepticus. First line therapy consists of benzodiazepines. Second line therapy with phenobarbital rather than other medications is suggested. High dose pyridoxine (eg, 70 mg/kg, maximum dose 5 g) has also been associated with cessation of refractory status epilepticus after tetramine poisoning when combined with intramuscular administration of 2,3-dimercaptopropane-1- sulfonate (DMPS). However, DMPS is not an approved medication in the United States<br />&dagger; Health care providers may develop secondary poisoning from inhalation or dermal exposure. Special care should be taken when touching the patient or handling emesis, stools, or contaminated clothing or bed linens.</div><div class=\"graphic_reference\">Prepared with data from selected UpToDate topics and the following sources:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Mercurio-Zappala M, Hoffman RS. Thallium. In: Goldfrank's Toxicologic Emergencies, 9th edition, Nelson LS, Lewin NA, Howland MA, et al.&nbsp; (Eds), McGraw Hill Medical, New York 2011. p.1326.</li>&#xD;&#xA;    <li>Thompson DF. Management of thallium poisoning. Clin Toxicol 1981; 18:979.</li>&#xD;&#xA;    <li>Tromme I, Van Neste D, Dobbelaere F, et al. Skin signs in the diagnosis of thallium poisoning. Br J Dermatol 1998; 138:321.</li>&#xD;&#xA;    <li>Proudfoot AT, Bradberry SM, Vale JA. Sodium fluoroacetate poisoning. Toxicol Rev 2006; 25:213. 5. Proudfoot AT. Aluminium and zinc phosphide poisoning. Clin Toxicol (Phila) 2009; 47:89.</li>&#xD;&#xA;    <li>Chugh SN, Kumar P, Aggarwal HK, et al. Efficacy of magnesium sulphate in aluminium phosphide poisoning--comparison of two different dose schedules. J Assoc Physicians India 1994; 42:373.</li>&#xD;&#xA;    <li>Beuhler MC. Phosphorus. In: Goldfrank's Toxicologic Emergencies, 9th, Nelson LS, Lewin NA, Howland MA et al. (Eds), McGraw Hill Medical, New York 2011. p.1440.</li>&#xD;&#xA;    <li>Koch M, Appoloni O, Haufroid V, et al. Acute barium intoxication and hemodiafiltration. J Toxicol Clin Toxicol 2003; 41:363.</li>&#xD;&#xA;    <li>Johnson D, Kubic P, Levitt C. Accidental ingestion of Vacor rodenticide: the symptoms and sequelae in a 25-month-old child. Am J Dis Child 1980; 134:161.</li>&#xD;&#xA;    <li>Whitlow KS, Belson M, Barrueto F, et al. Tetramethylenedisulfotetramine: old agent and new terror. Ann Emerg Med 2005; 45:609.</li>&#xD;&#xA;    <li>Nelson LS, Perrone J, DeRoos F, et al. Aldicarb poisoning by an illicit rodenticide imported into the United States: Tres Pasitos. J Toxicol Clin Toxicol 2001; 39:447.</li>&#xD;&#xA;    <li>Thomas HM, Simpson D, Prescott LF. The toxic effects of alpha-chloralose. Hum Toxicol 1988; 7:285. 13. Painter JA, M&oslash;lbak K, Sonne-Hansen J, et al. Salmonella-based rodenticides and public health. Emerg Infect Dis 2004; 10:985.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 97349 Version 1.0</div></div></div>"},"97355":{"type":"graphic_picture","displayName":"Dysplastic foci in liver with small cell change, histology","title":"Histology of dysplastic foci in liver, demonstrating small cell change","html":"<div class=\"graphic\"><div style=\"width: 623px\" class=\"figure\"><div class=\"ttl\">Histology of dysplastic foci in liver, demonstrating small cell change</div><div class=\"cntnt\"><img style=\"width:603px; height:440px;\" src=\"images/ONC/97355_Dsplsc_fci_lvr_sml_chg_hstl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dysplastic foci in the liver with small cell change (arrows); compare with normal hepatocytes on the left (arrowheads).</div><div id=\"graphicVersion\">Graphic 97355 Version 1.0</div></div></div>"},"97357":{"type":"graphic_picture","displayName":"Dysplastic foci in liver with large cell change, histology","title":"Histology of dysplastic foci in liver with large cell change","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">Histology of dysplastic foci in liver with large cell change</div><div class=\"cntnt\"><img style=\"width:609px; height:439px;\" src=\"images/ONC/97357_Dyspl_lvr_lrg_cll_chng_hstl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large cell change in the right field (arrows) demonstrates enlarged hepatocytes maintaining their nuclear to cytoplasmic ratio.</div><div id=\"graphicVersion\">Graphic 97357 Version 1.0</div></div></div>"},"97360":{"type":"graphic_picture","displayName":"Early HCC, histology","title":"Histology, early hepatocellular carcinoma","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Histology, early hepatocellular carcinoma</div><div class=\"cntnt\"><img style=\"width:585px; height:439px;\" src=\"images/ONC/97360_Early_HCC_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Entrapped portal tracts (arrow) in early hepatocellular carcinoma as the result of stromal invasion.</div><div class=\"graphic_footnotes\">HCC: hepatocellular carcinoma.</div><div id=\"graphicVersion\">Graphic 97360 Version 1.0</div></div></div>"},"97362":{"type":"graphic_picture","displayName":"Fibrolamellar carcinoma, histology","title":"Histology of fibrolamellar carcinoma of the liver","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Histology of fibrolamellar carcinoma of the liver</div><div class=\"cntnt\"><img style=\"width:585px; height:439px;\" src=\"images/ONC/97362_Fibrolamellar_crcnma_hstlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large polygonal cells separated by parallel bands of hyaline fibrous tissue in fibrolamellar carcinoma. </div><div id=\"graphicVersion\">Graphic 97362 Version 1.0</div></div></div>"},"97363":{"type":"graphic_picture","displayName":"Fibrolamellar carcinoma with bile or mucin, histology","title":"Histology, fibrolamellar carcinoma with bile and/or mucin","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Histology, fibrolamellar carcinoma with bile and/or mucin</div><div class=\"cntnt\"><img style=\"width:585px; height:438px;\" src=\"images/ONC/97363_Fbrlmllr_crcnm_ble_mcn_hstl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fibrolamellar carcinoma showing pseudoglandular pattern with bile (arrow) or mucin-like material (arrowheads).</div><div id=\"graphicVersion\">Graphic 97363 Version 1.0</div></div></div>"},"97365":{"type":"graphic_picture","displayName":"Combined hepatocellular-cholangiocellular carcinoma, histology","title":"Histology of combined hepatocellular-cholangiocellular carcinoma","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Histology of combined hepatocellular-cholangiocellular carcinoma</div><div class=\"cntnt\"><img style=\"width:586px; height:441px;\" src=\"images/ONC/97365_Cmbnd_hptcllr_chlngclr_crcn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Combined hepatocellular-cholangiocarcinoma shows histologic features of hepatocellular carcinoma (arrows) and cholangiocarcinoma (arrowheads). Gland formation in cholangiocarcinoma in a background of desmoplastic fibrous stroma is seen in the left lower field (dashed arrows).</div><div id=\"graphicVersion\">Graphic 97365 Version 1.0</div></div></div>"},"97368":{"type":"graphic_algorithm","displayName":"Algorithm for choosing subcutaneous ICD","title":"Algorithm for choosing subcutaneous ICD","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm for choosing subcutaneous ICD</div><div class=\"cntnt\"><img style=\"width:343px; height:425px;\" src=\"images/CARD/97368_AlgrthmchsingsbctnsICD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ICD: implantable cardioverter-defibrillator; CRT: cardiac resynchronization therapy; TV: transvenous; ATP: antitachycardia pacing; S-ICD: subcutaneous ICD.</div><div id=\"graphicVersion\">Graphic 97368 Version 3.0</div></div></div>"},"97370":{"type":"graphic_picture","displayName":"Batts-ludwig grade 1","title":"Batts-Ludwig system for hepatic inflammation: Grade 1 (minimal activity)","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Batts-Ludwig system for hepatic inflammation: Grade 1 (minimal activity)</div><div class=\"cntnt\"><img style=\"width:471px; height:349px;\" src=\"images/GAST/97370_Batts_ludwig_grade_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The short arrow is pointing at a group of inflammatory cells representing spotty necrosis. The thin arrow is pointing at two acidophilic (apoptotic) bodies. In grade 1, there is no interface hepatitis (not shown).</div><div id=\"graphicVersion\">Graphic 97370 Version 1.0</div></div></div>"},"97371":{"type":"graphic_picture","displayName":"Batts-ludwig grade 2","title":"Batts-Ludwig system for hepatic inflammation: Grade 2 (mild activity)","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Batts-Ludwig system for hepatic inflammation: Grade 2 (mild activity)</div><div class=\"cntnt\"><img style=\"width:586px; height:468px;\" src=\"images/GAST/97371_Batts_ludwig_grade_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A portal tract showing mild chronic inflammation consisting mainly of lymphocytes and a few plasma cells. Arrows point to foci of interface hepatitis.</div><div id=\"graphicVersion\">Graphic 97371 Version 1.0</div></div></div>"},"97372":{"type":"graphic_diagnosticimage","displayName":"PA and lateral chest radiograph of the S-ICD","title":"Posteroanterior (PA) and lateral chest radiographs of a subcutaneous implantable cardioverter-defibrillator (S-ICD)","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Posteroanterior (PA) and lateral chest radiographs of a subcutaneous implantable cardioverter-defibrillator (S-ICD)</div><div class=\"cntnt\"><img style=\"width:596px; height:317px;\" src=\"images/CARD/97372_PA_ltrl_chst_rdgph_sbct_ICD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posteroanterior (PA) and lateral chest radiographs of a subcutaneous implantable cardioverter-defibrillator (S-ICD) with the defibrillation lead visible adjacent to the sternum and the pulse generator in the axilla.</div><div id=\"graphicVersion\">Graphic 97372 Version 2.0</div></div></div>"},"97373":{"type":"graphic_picture","displayName":"Batts-ludwig grade 3","title":"Batts-Ludwig system for hepatic inflammation: Grade 3 (moderate activity)","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Batts-Ludwig system for hepatic inflammation: Grade 3 (moderate activity)</div><div class=\"cntnt\"><img style=\"width:586px; height:438px;\" src=\"images/GAST/97373_Batts_ludwig_grade_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One portal tract showing interface hepatitis involving more than half of its circumference (arrows). In moderate activity, most portal tracts are involved by active inflammation. White asterisks indicate areas of lobular necroinflammation.</div><div id=\"graphicVersion\">Graphic 97373 Version 1.0</div></div></div>"},"97374":{"type":"graphic_picture","displayName":"Batts-ludwig grade 4 interface hepatitis","title":"Batts-Ludwig system for hepatic inflammation: Grade 4 (severe activity)","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Batts-Ludwig system for hepatic inflammation: Grade 4 (severe activity)</div><div class=\"cntnt\"><img style=\"width:586px; height:438px;\" src=\"images/GAST/97374_Btt_ldwg_grde_4_intrfc_hptt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">One portal tract showing spillage of inflammation involving its entire circumference (severe interface hepatitis).</div><div id=\"graphicVersion\">Graphic 97374 Version 1.0</div></div></div>"},"97375":{"type":"graphic_picture","displayName":"Batts-ludwig grade 4 confluent necrosis","title":"Batts-Ludwig system for hepatic inflammation: Grade 4 (severe activity)","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Batts-Ludwig system for hepatic inflammation: Grade 4 (severe activity)</div><div class=\"cntnt\"><img style=\"width:585px; height:329px;\" src=\"images/GAST/97375_Btts_ldwg_grde_4_cnfln_ncrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An example of grade 4 activity showing the presence of confluent necrosis.</div><div id=\"graphicVersion\">Graphic 97375 Version 1.0</div></div></div>"},"97376":{"type":"graphic_picture","displayName":"Batts-ludwig stage 4","title":"Batts-Ludwig system for hepatic fibrosis: Stage 4 (cirrhosis)","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Batts-Ludwig system for hepatic fibrosis: Stage 4 (cirrhosis)</div><div class=\"cntnt\"><img style=\"width:586px; height:401px;\" src=\"images/GAST/97376_Batts_ludwig_stage_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A cirrhotic nodule surrounded by dense fibrous septa. The arrow points to a small lymphoid aggregate.</div><div id=\"graphicVersion\">Graphic 97376 Version 1.0</div></div></div>"},"97377":{"type":"graphic_picture","displayName":"Batts-ludwig grade 2 stage 4","title":"Batts-Ludwig system for hepatic inflammation and fibrosis: Chronic hepatitis C with mild activity (grade 2) and cirrhosis (stage 4)","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Batts-Ludwig system for hepatic inflammation and fibrosis: Chronic hepatitis C with mild activity (grade 2) and cirrhosis (stage 4)</div><div class=\"cntnt\"><img style=\"width:585px; height:438px;\" src=\"images/GAST/97377_Batt_ludwig_grade_1_stage_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Arrows point to small lymphoid aggregates in portal areas.</div><div id=\"graphicVersion\">Graphic 97377 Version 1.0</div></div></div>"},"97379":{"type":"graphic_picture","displayName":"Laennec 4A","title":"Laennec staging system of cirrhosis: Stage 4A","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Laennec staging system of cirrhosis: Stage 4A</div><div class=\"cntnt\"><img style=\"width:586px; height:359px;\" src=\"images/GAST/97379_Laennec_4A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cirrhotic nodules are enclosed by thin fibrous septa.</div><div id=\"graphicVersion\">Graphic 97379 Version 1.0</div></div></div>"},"97380":{"type":"graphic_picture","displayName":"Laennec 4B","title":"Laennec staging system of cirrhosis: Stage 4B","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Laennec staging system of cirrhosis: Stage 4B</div><div class=\"cntnt\"><img style=\"width:586px; height:304px;\" src=\"images/GAST/97380_Laennec_4B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cirrhotic nodules are enclosed by broad fibrous septa. Arrows point to wide bands of connective tissue surrounding cirrhotic nodules.</div><div id=\"graphicVersion\">Graphic 97380 Version 1.0</div></div></div>"},"97381":{"type":"graphic_picture","displayName":"Laennec 4C","title":"Laennec staging system of cirrhosis: Stage 4C","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Laennec staging system of cirrhosis: Stage 4C</div><div class=\"cntnt\"><img style=\"width:585px; height:384px;\" src=\"images/GAST/97381_Laennec_4C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">More than half of the biopsy is comprised of micronodules. In this photomicrograph, a small cirrhotic nodule (micronodule) is shown in the center. The rest of the specimen shows dense fibrotic parenchyma.</div><div id=\"graphicVersion\">Graphic 97381 Version 1.0</div></div></div>"},"97382":{"type":"graphic_picture","displayName":"Intrahepatic cholangiocarcinoma, histology","title":"Histology, intrahepatic cholangiocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Histology, intrahepatic cholangiocarcinoma</div><div class=\"cntnt\"><img style=\"width:586px; height:441px;\" src=\"images/ONC/97382_Intrhptc_chlngcrcnm_hstlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intrahepatic cholangiocarcinoma composed of neoplastic glands with cuboidal to low columnar epithelial cells.</div><div id=\"graphicVersion\">Graphic 97382 Version 2.0</div></div></div>"},"97387":{"type":"graphic_table","displayName":"Sensitivities for IHC markers in DDX of intrahepatic adenoCA","title":"Sensitivities for various immunohistochemical markers in differentiating hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sensitivities for various immunohistochemical markers in differentiating hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">HCC</td> <td class=\"subtitle1\">CC</td> <td class=\"subtitle1\">MA</td> </tr> <tr> <td><strong>Hep Par 1</strong></td> <td>86-96%</td> <td>0-12.5%</td> <td>0-14%</td> </tr> <tr> <td><strong>GPC3</strong></td> <td>75-88%</td> <td>0-19%</td> <td>0-6%</td> </tr> <tr> <td><strong>pCEA*</strong></td> <td>50-96%</td> <td>100%</td> <td>93-96%</td> </tr> <tr> <td><strong>MOC 31</strong></td> <td>0-14%</td> <td>67-100%</td> <td>66-100%</td> </tr> <tr> <td><strong>CK7</strong></td> <td>7-21%</td> <td>78-100%</td> <td>3-36%</td> </tr> <tr> <td><strong>CK8/18</strong></td> <td>70%</td> <td>20%</td> <td>&nbsp;</td> </tr> <tr> <td><strong>CK19</strong></td> <td>0-10%</td> <td>44-80%</td> <td>29-64%</td> </tr> <tr> <td><strong>CK20</strong></td> <td>0-5%</td> <td>10-11%</td> <td>30-74%</td> </tr> <tr> <td><strong>CD34</strong><sup>&#182;</sup></td> <td>94-95%</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IHC: immunohistochemical; adenoCA: adenocarcinoma; HCC: hepatocellular carcinoma; CC: cholangiocarcinoma; MA: metastatic adenocarcinoma; Hep Par 1: hepatocyte paraffin 1; GPC3: glypican-3; pCEA: polyclonal carcinoembryonic antigen; CK: cytokeratin.<br />* Positive pCEA staining is canalicular in HCC and membranous and/or cytoplasmic in CC and MA.<br />¶ Positive CD34 staining is a complete/diffuse staining pattern of the sinusoidal endothelial cells.</div><div class=\"graphic_reference\">Original figure modified for this publication. Chan ES, Yeh MM. The use of immunohistochemistry in liver tumors. Clin Liver Dis 2010; 14:687. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97387 Version 1.0</div></div></div>"},"97388":{"type":"graphic_table","displayName":"Management of hemoptysis in CF patients","title":"Management of hemoptysis in patients with cystic fibrosis (CF); summary of consensus statement","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of hemoptysis in patients with cystic fibrosis (CF); summary of consensus statement</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">scant</td> <td class=\"subtitle1\">mild or moderate</td> <td class=\"subtitle1\">massive</td> </tr> <tr> <td class=\"divider_bottom\"><strong>Systemic antibiotics</strong></td> <td class=\"centered\">Start</td> <td class=\"centered\">Start</td> <td class=\"centered\">Start</td> </tr> <tr class=\"divider_bottom\"> <td><strong>NSAIDs</strong></td> <td class=\"centered\">Stop</td> <td class=\"centered\">Stop</td> <td class=\"centered\">Stop</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Airway clearance techniques (eg, chest physiotherapy)</strong></td> <td class=\"centered\">Continue</td> <td class=\"centered\">No consensus*</td> <td class=\"centered\">Stop</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Aerosol therapies</strong></td> </tr> <tr> <td class=\"indent1\">Hypertonic saline or dornase alpha</td> <td class=\"centered\">Continue</td> <td class=\"centered\">Stop<sup>&#182;</sup></td> <td class=\"centered\">Stop</td> </tr> <tr> <td class=\"indent1\">Antibiotics</td> <td class=\"centered\">Continue</td> <td class=\"centered\">Continue<sup>&#182;</sup></td> <td class=\"centered\">Continue? (no consensus<sup>&#916;</sup>)</td> </tr> <tr> <td class=\"indent1\">Bronchodilators</td> <td class=\"centered\">Continue</td> <td class=\"centered\">Continue<sup>&#182;</sup></td> <td class=\"centered\">Continue? (no consensus<sup>&#916;</sup>)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table summarizes the conclusions of a consensus panel convened by the Cystic Fibrosis Foundation's Pulmonary Therapies Committee.</div><div class=\"graphic_footnotes\">NSAIDs: Non-steroidal antiinflammatory drugs.<br />* No good consensus was reached for this issue.<br />¶ Consensus for this recommendation was good, but with some reservations and considerations specific to the individual patient.<br />Δ No good consensus was reached for this issue, but the panel felt that benefits of continuing often outweigh the risks.</div><div class=\"graphic_reference\">Data from: Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med 2010; 182:298.</div><div id=\"graphicVersion\">Graphic 97388 Version 2.0</div></div></div>"},"97389":{"type":"graphic_picture","displayName":"Cholangiolocellular carcinoma, histology","title":"Histology of cholangiolocellular carcinoma","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Histology of cholangiolocellular carcinoma</div><div class=\"cntnt\"><img style=\"width:586px; height:439px;\" src=\"images/ONC/97389_Chlngcllr_crcnm_hstlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cholangiolocellular carcinoma is composed of anastomosing small well-differentiated glands (arrows) in a background of dense fibrous stroma (arrowheads).</div><div id=\"graphicVersion\">Graphic 97389 Version 2.0</div></div></div>"},"97392":{"type":"graphic_picture","displayName":"Intraductal papillary neoplasm of the bile duct, histology","title":"Histology, intraductal papillary neoplasm of the bile duct","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Histology, intraductal papillary neoplasm of the bile duct</div><div class=\"cntnt\"><img style=\"width:586px; height:441px;\" src=\"images/ONC/97392_Intrdct_ppllry_nplsm_bl_dct.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 97392 Version 1.0</div></div></div>"},"97393":{"type":"graphic_picture","displayName":"Biliary mucinous cystic neoplasm, low and high-grade, histology","title":"Biliary mucinous cystic neoplasm, low-grade (cystadenoma) and high-grade (cystadenomarcinoma)","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Biliary mucinous cystic neoplasm, low-grade (cystadenoma) and high-grade (cystadenomarcinoma)</div><div class=\"cntnt\"><img style=\"width:610px; height:244px;\" src=\"images/ONC/97393_Blr_mcns_cstc_nplsm_lw_hghg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Mucinous cystic neoplasm, low-grade (cystadenoma) showing bland neoplastic epithelial cells (arrow) and underlying compact spindle-cell \"ovarian-type\" stroma (arrowheads).<br />(B) Mucinous cystic neoplasm, high-grade (cystadenocarcinoma) composed of multiloculated cysts (arrows) that are lined by pleomorphic neoplastic cells with cribriform pattern.</div><div id=\"graphicVersion\">Graphic 97393 Version 1.0</div></div></div>"},"97394":{"type":"graphic_picture","displayName":"Hepatoblastoma, histology","title":"Histology of hepatoblastoma","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Histology of hepatoblastoma</div><div class=\"cntnt\"><img style=\"width:594px; height:449px;\" src=\"images/ONC/97394_Hepatoblastoma_histology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Hepatoblastoma is composed of fetal-type and embryonal-type cells, productng the characteristic \"light and dark\" pattern in hematoxylin and eosin-stained tissue sections.<br />(B) The fetal-type cells in the upper field (arrow) are lighter-stained with granular cytoplasm while the embryonal cells in the lower field (arrowhead) are darker with hyperchromatic nuclei.<br />(C) Osteoid formation in a hepatoblastome (arrow).<br />(D) Gray cartilaginous stroma in hepatoblastoma (arrow).</div><div id=\"graphicVersion\">Graphic 97394 Version 1.0</div></div></div>"},"97396":{"type":"graphic_table","displayName":"International consensus classification hepatoblastoma","title":"International consensus classification of histologic subtypes of hepatoblastoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">International consensus classification of histologic subtypes of hepatoblastoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Subtype/definition</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Epithelial</td> </tr> <tr> <td class=\"indent1\">Fetal</td> <td> <ul> <li>Well differentiated and uniform (10-20 &#181;m diameter), round nuclei, cords with minimal mitotic activity, EMH </li> <li>Crowded or mitotically active (&#62;2 per 10 400x microscopic fields); conspicuous nucleoli (usually less glycogen) </li> <li>Pleomorphic, poorly differentiated<br /> Moderate anisonucleosis, high N/C, nucleoli </li> <li>Anaplastic with marked nuclear enlargement and pleomorphism, hyperchromasia, abnormal mitoses </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Embryonal</td> <td> <ul> <li>10-15 &#181;m diameter, high N/C, angular, primitive tubules, EMH </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Macrotrabecular</td> <td> <ul> <li>Epithelial HB (fetal or embryonal) growing in clusters of &#62;5 cells between sinusoids </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Small cell undifferentiated (SCU)</td> <td> <ul> <li>(5-10 &#181;m diameter) no architectural pattern, minimal pale amphophilic cytoplasm, round to oval nuclei with fine chromatin and inconspicuous nucleoli, +/&ndash; mitoses; +/&ndash; INI* </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cholangioblastic</td> <td> <ul> <li>Bile ducts, usually at periphery of epithelial islands, can predominate </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Mixed</td> </tr> <tr> <td class=\"indent1\">Stromal derivatives</td> <td> <ul> <li>Spindle cells (blastema), osteoid, skeletal muscle, cartilage </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Teratoid</td> <td> <ul> <li>Mixed, plus primitive endoderm; neural derivatives, melanin, squamous and glandular elements </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EMH: extramedullary hematopoiesis; N/C: nuclear:cytoplasmic ratio; HB: hepatoblastoma;&nbsp;INI: integrase interactor 1 immunohistochemical staining.<br />* Pure small cell undifferentiated needs to be differentiated from malignant rhabdoid tumors (discohesive, eccentric irregular nuclei, prominent nucleoli, abundant cytoplasmic filaments including cytokeratin and vimentin, negative nuclear INI).</div><div class=\"graphic_reference\">Reproduced with permission from: Czauderna P1, Lopez-Terrada D, Hiyama E, et al. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr 2014; 26:19. DOI: <a href=\"http://journals.lww.com/co-pediatrics/pages/articleviewer.aspx?year=2014&amp;issue=02000&amp;article=00005&amp;type=abstract\" target=\"_blank\">10.1097/MOP.0000000000000046</a>. Copyright &copy; 2014 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 97396 Version 2.0</div></div></div>"},"97397":{"type":"graphic_picture","displayName":"Hepatic epithelioid hemangioendothelioma, histology","title":"Histology of hepatic epithelioid hemangioendothelioma","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Histology of hepatic epithelioid hemangioendothelioma</div><div class=\"cntnt\"><img style=\"width:586px; height:439px;\" src=\"images/ONC/97397_Epthld_hmngndthlm_hstlgy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 97397 Version 1.0</div></div></div>"},"97398":{"type":"graphic_picture","displayName":"Hepatic angiosarcoma, histology","title":"Histology of hepatic angiosarcoma","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Histology of hepatic angiosarcoma</div><div class=\"cntnt\"><img style=\"width:596px; height:226px;\" src=\"images/ONC/97398_Hepatic_angsrcm_hstlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Angiosarcoma is composed of dilated cavernous vascular spaces (arrows) that are lined by markedly pleomorphic neoplastic cells (arrowheads).<br />(B) Higher-power view of a hematoxylin and eosin-stained tissue section.</div><div id=\"graphicVersion\">Graphic 97398 Version 1.0</div></div></div>"},"97402":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of placental lacunae in placenta increta","title":"Placental lacunae in placenta increta","html":"<div class=\"graphic\"><div style=\"width: 671px\" class=\"figure\"><div class=\"ttl\">Placental lacunae in placenta increta</div><div class=\"cntnt\"><img style=\"width:651px; height:338px;\" src=\"images/RADIOL/97402_USplcntllcnplcntincrt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A transverse transabdominal ultrasound (A) demonstrates tortuous placental lacunae (arrow) confirmed on the color flow Doppler study (B, arrow).</div><div class=\"graphic_reference\">Courtesy of Ronak Patel, MD.</div><div id=\"graphicVersion\">Graphic 97402 Version 3.0</div></div></div>"},"97403":{"type":"graphic_diagnosticimage","displayName":"MRI of placenta increta","title":"Placenta increta on MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Placenta increta on MRI</div><div class=\"cntnt\"><img style=\"width:313px; height:755px;\" src=\"images/RADIOL/97403_MRI_placenta_increta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal T2 weighted images through the placenta (A) show an abnormal uterine contour (arrow) with discontinuity of the hypointense inner myometrial layer (arrowhead). T2 low signal placental bands are also noted (arrowhead). Image B is a magnified view of image A and shows the normal hypointense myometrium (arrowhead) with discontinuity of the muscle layer and an abnormal uterine contour (arrow). The outer layer of the myometrium is intact. There are thick and irregular placental bands (dashed arrow). Placenta increta was documented at delivery. Axial T2 images through the placenta demonstrate T2 low signal placental bands, which are irregular and thicker than normal placental septae.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div class=\"graphic_reference\">Courtesy of Ronak Patel, MD.</div><div id=\"graphicVersion\">Graphic 97403 Version 1.0</div></div></div>"},"97419":{"type":"graphic_picture","displayName":"NAS score 2","title":"NAFLD activity score: Steatosis score of 2","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">NAFLD activity score: Steatosis score of 2</div><div class=\"cntnt\"><img style=\"width:586px; height:437px;\" src=\"images/GAST/97419_NAS_score_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Steatotic vacuoles occupy approximately 50 percent&nbsp;of the hepatic parenchyma.</div><div class=\"graphic_footnotes\">NAFLD: Nonalcoholic fatty liver disease.</div><div id=\"graphicVersion\">Graphic 97419 Version 1.0</div></div></div>"},"97420":{"type":"graphic_picture","displayName":"NAS score 6","title":"NAFLD activity score: Steatosis score of 3 (>66 percent), lobular inflammation score of 2 (2 to 4 foci per 200X field) and ballooning score of 1","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">NAFLD activity score: Steatosis score of 3 (&gt;66 percent), lobular inflammation score of 2 (2 to 4 foci per 200X field) and ballooning score of 1</div><div class=\"cntnt\"><img style=\"width:580px; height:343px;\" src=\"images/GAST/97420_NAS_score_6.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The long arrow points to two groups of inflammatory cells, and the short arrow is pointing at ballooned hepatocytes. In this case, the NAS score = 6.</div><div class=\"graphic_footnotes\">NAFLD: Nonalcoholic fatty liver disease; NAS: NAFLD activity score.</div><div id=\"graphicVersion\">Graphic 97420 Version 2.0</div></div></div>"},"97421":{"type":"graphic_picture","displayName":"NAS score 4","title":"NAFLD activity score: Steatosis score of 3 and ballooning score of 1","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">NAFLD activity score: Steatosis score of 3 and ballooning score of 1</div><div class=\"cntnt\"><img style=\"width:586px; height:439px;\" src=\"images/GAST/97421_NAS_score_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The short arrows point to ballooned hepatocytes and&nbsp;the long arrow points to a Mallory-Denk hyaline. No significant inflammation is present. NAS score = 4.</div><div class=\"graphic_footnotes\">NAFLD: nonalcoholic fatty liver disease; NAS: NAFLD activity score.</div><div id=\"graphicVersion\">Graphic 97421 Version 2.0</div></div></div>"},"97422":{"type":"graphic_picture","displayName":"ALD expansive fibrosis","title":"Alcoholic liver disease scoring system: Expansive fibrosis (0 points)","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Alcoholic liver disease scoring system: Expansive fibrosis (0 points)</div><div class=\"cntnt\"><img style=\"width:586px; height:438px;\" src=\"images/GAST/97422_ALD_expnsv_fibrosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive perisinusoidal and pericellular fibrosis (chicken-wire) is shown in this photo. The hepatocytes within are undergoing ballooning degeneration. Trichrome stain.</div><div id=\"graphicVersion\">Graphic 97422 Version 1.0</div></div></div>"},"97423":{"type":"graphic_picture","displayName":"ALD bridging fibrosis or cirrhosis","title":"Alcoholic liver disease scoring system: Bridging fibrosis or cirrhosis (+3 points)","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Alcoholic liver disease scoring system: Bridging fibrosis or cirrhosis (+3 points)</div><div class=\"cntnt\"><img style=\"width:584px; height:462px;\" src=\"images/GAST/97423_ALD_brdgng_fbrss_crrhss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is extensive fibrous tissue deposition, creating marked distortion of the architecture. Only minimal steatosis remains but pericellular fibrosis is still seen (arrow). Trichrome stain.</div><div id=\"graphicVersion\">Graphic 97423 Version 1.0</div></div></div>"},"97424":{"type":"graphic_table","displayName":"Anesthetic goals aortic stenosis","title":"Key points for anesthetic and hemodynamic management during labor and delivery in aortic stenosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key points for anesthetic and hemodynamic management during labor and delivery in aortic stenosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Hemodynamic goals</td> <td class=\"subtitle1\">Avoid</td> <td class=\"subtitle1\">Monitor</td> <td class=\"subtitle1\">Intervention</td> </tr> <tr class=\"divider_bottom\"> <td>Sinus rhythm</td> <td>Atrial fibrillation</td> <td> <p>5-lead ECG</p> <p>Place external defibrillator pads</p> </td> <td>Management of new-onset atrial fibrillation: <ul class=\"decimal_heading\"> <li>Heart rate control </li> <li>Cardioversion for hemodynamic compromise</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Normal heart rate</td> <td>Tachycardia</td> <td> <p>5-lead ECG</p> Pulse oximetry with visible waveform</td> <td> <p>Prevent pain-induced tachycardia by minimizing or eliminating labor pain with effective analgesia.</p> <p>Manage tachycardia related to hypotension with phenylephrine (or norepinephrine) and fluid administration.</p> Heart rate can be slowed with beta blockers, if necessary.</td> </tr> <tr class=\"divider_bottom\"> <td>Maintain afterload</td> <td> <p>Hypotension</p> Sympathectomy (eg, spinal anesthesia)</td> <td>Intra-arterial blood pressure</td> <td>Administer phenylephrine (or norepinephrine) to manage hypotension.</td> </tr> <tr> <td>Maintain preload</td> <td>Hypovolemia</td> <td>Hemodynamics and clinical response to fluid boluses</td> <td> <p>Allow oral intake and administer adequate IV fluids to maintain intravascular volume.</p> Rapidly resuscitate postpartum hemorrhage.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; IV: intravenous.</div><div id=\"graphicVersion\">Graphic 97424 Version 6.0</div></div></div>"},"97429":{"type":"graphic_table","displayName":"Symptoms puerperal infection","title":"Symptoms of puerperal infection in group A streptococcal disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptoms of puerperal infection in group A streptococcal disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Typical</td> </tr> <tr> <td class=\"indent1\">Fever or rigors</td> </tr> <tr> <td class=\"indent1\">Uterine pain</td> </tr> <tr> <td class=\"indent1\">Malodorous vaginal discharge</td> </tr> <tr> <td class=\"subtitle1_single\">Atypical</td> </tr> <tr> <td class=\"indent1\">Swelling or pain in extremities or joints</td> </tr> <tr> <td class=\"indent1\">Nausea and vomiting</td> </tr> <tr> <td class=\"indent1\">Copious nonfoul smelling vaginal discharge</td> </tr> <tr> <td class=\"indent1\">Bloody secretions from wound</td> </tr> <tr> <td class=\"indent1\">General malaise</td> </tr> <tr> <td class=\"indent1\">Headache</td> </tr> <tr> <td class=\"indent1\">Myalgias</td> </tr> <tr> <td class=\"indent1\">Dyspnea</td> </tr> <tr> <td class=\"indent1\">Rash</td> </tr> <tr> <td class=\"indent1\">Pharyngitis</td> </tr> <tr> <td class=\"indent1\">Confusion or combativeness</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Anderson BL. Puerperal group A streptococcal infection: beyond Semmelweis. Obstet Gynecol 2014; 123:874. DOI: <a href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2014&amp;issue=04000&amp;article=00021&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/AOG.0000000000000175</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 American College of Obstetricians and Gynecologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 97429 Version 2.0</div></div></div>"},"97435":{"type":"graphic_table","displayName":"Anesthetic goals for mitral stenosis","title":"Key points for anesthetic and hemodynamic management during labor and delivery in mitral stenosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key points for anesthetic and hemodynamic management during labor and delivery in mitral stenosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Hemodynamic goals</td> <td class=\"subtitle1\">Avoid</td> <td class=\"subtitle1\">Monitor</td> <td class=\"subtitle1\">Intervention</td> </tr> <tr class=\"divider_bottom\"> <td>Sinus rhythm</td> <td> <p>Atrial fibrillation</p> Tachyarrhythmias</td> <td>5-lead ECG</td> <td>Management of new-onset atrial fibrillation or other SVT: <ul class=\"decimal_heading\"> <li>Heart rate control </li> <li>Cardioversion, if appropriate, for hemodynamic compromise </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Slow to normal heart rate</td> <td>Tachycardia</td> <td> <p>5-lead ECG</p> Pulse oximetry with visible waveform</td> <td> <p>Prevent pain-induced tachycardia by minimizing or eliminating labor pain with effective analgesia.</p> <p>Manage tachycardia related to hypotension with phenylephrine (or norepinephrine).</p> Heart rate can be slowed with beta blockers, if necessary.</td> </tr> <tr class=\"divider_bottom\"> <td>Maintain afterload</td> <td> <p>Hypotension</p> Sympathectomy (eg, spinal anesthesia)</td> <td>Intra-arterial blood pressure</td> <td>Administer phenylephrine (or norepinephrine) to manage hypotension.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Adequate preload</td> <td>Hypervolemia</td> <td> <p>Clinical course and oxygenation</p> Development of flash pulmonary edema (may present as acute coughing and hypoxemia in the awake patient)</td> <td>Management of pulmonary edema: <ul class=\"decimal_heading\"> <li>Treat hypoxemia related to pulmonary edema immediately with 100% oxygen, PEEP, and, if necessary, intubation and controlled ventilation </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Hypovolemia</td> <td>Hemodynamics</td> <td>Allow oral intake and administer maintenance IV fluids, if necessary, to maintain adequate preload.</td> </tr> <tr> <td>Minimize pulmonary vascular resistance (optimize oxygenation and ventilation)</td> <td>Hypoxemia or hypercarbia</td> <td>Pulse oximetry with visible waveform in labor room or operating room</td> <td>Minimize risk of hypoxemia and hypercarbia by: <ul class=\"decimal_heading\"> <li>Administering supplemental oxygen throughout labor and delivery </li> <li>Avoiding oversedation </li> <li>Ensuring well-controlled ventilation, if intubated </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; SVT: supraventricular tachyarrhythmia; PEEP: positive end-expiratory pressure; IV: intravenous.</div><div id=\"graphicVersion\">Graphic 97435 Version 7.0</div></div></div>"},"97437":{"type":"graphic_table","displayName":"Anesthetic goals for AR and MR","title":"Key points for anesthetic and hemodynamic management during labor and delivery in mitral regurgitation or aortic regurgitation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key points for anesthetic and hemodynamic management during labor and delivery in mitral regurgitation or aortic regurgitation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Hemodynamic goals</td> <td class=\"subtitle1\">Avoid</td> <td class=\"subtitle1\">Monitor</td> <td class=\"subtitle1\">Intervention</td> </tr> <tr class=\"divider_bottom\"> <td>Normal to fast heart rate</td> <td>Bradycardia</td> <td> <p>5-lead ECG</p> Pulse oximetry with visible waveform</td> <td>Management of bradycardia: <ul class=\"decimal_heading\"> <li>Ephedrine</li> <li>Glycopyrrolate, if necessary</li> </ul> </td> </tr> <tr> <td>Reduce afterload</td> <td>Hypertension</td> <td>Intra-arterial blood pressure</td> <td> <p>Prevent hypertension due to labor pain by providing effective analgesia.</p> Treat hypotension with careful titration of ephedrine.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram.</div><div id=\"graphicVersion\">Graphic 97437 Version 5.0</div></div></div>"},"97438":{"type":"graphic_table","displayName":"Anesthetic goals for CHD","title":"Key points for anesthetic and hemodynamic management during labor and delivery in cyanotic congenital heart disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key points for anesthetic and hemodynamic management during labor and delivery in cyanotic congenital heart disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Hemodynamic goals</td> <td class=\"subtitle1\">Avoid</td> <td class=\"subtitle1\">Monitor</td> <td class=\"subtitle1\">Intervention</td> </tr> <tr class=\"divider_bottom\"> <td>Maintain afterload</td> <td> <p>Hypotension (worsens cyanosis)</p> Sympathectomy (eg, spinal anesthesia)</td> <td>Intra-arterial blood pressure</td> <td>Treat hypotension with phenylephrine (or norepinephrine).</td> </tr> <tr class=\"divider_bottom\"> <td>Maintain preload</td> <td>Hypovolemia</td> <td>Hemodynamics and clinical response to fluid boluses</td> <td>Allow oral intake and administer adequate IV fluids to maintain intravascular volume.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Sinus rhythm</td> <td>Tachyarrhythmias</td> <td>5-lead ECG</td> <td>Tachyarrhythmia: <ul class=\"decimal_heading\"> <li>Prevent pain-induced tachycardia by minimizing or eliminating labor pain with effective analgesia </li> <li>Manage tachyarrythmias with early cardioversion, if appropriate </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Bradyarrhythmias</td> <td>5-lead ECG</td> <td>Bradyarrhythmia: <ul class=\"decimal_heading\"> <li>Treat bradycardia with ephedrine; glycopyrrolate, if necessary </li> </ul> </td> </tr> <tr> <td>Minimize pulmonary vascular resistance (optimize oxygenation and ventilation)</td> <td>Hypoxemia or hypercarbia</td> <td>Pulse oximetry with visible waveform in labor room or operating room</td> <td>Minimize risk of hypoxemia and hypercarbia by: <ul class=\"decimal_heading\"> <li>Administering supplemental oxygen throughout labor and delivery </li> <li>Avoiding oversedation </li> <li>Ensuring well-controlled ventilation, if intubated </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; ECG: electrocardiogram.</div><div id=\"graphicVersion\">Graphic 97438 Version 5.0</div></div></div>"},"97439":{"type":"graphic_table","displayName":"Anesthetic goals for ischemic heart disease","title":"Key points for anesthetic and hemodynamic management during labor and delivery in ischemic heart disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key points for anesthetic and hemodynamic management during labor and delivery in ischemic heart disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Hemodynamic goals</td> <td class=\"subtitle1\">Avoid</td> <td class=\"subtitle1\">Monitor</td> <td class=\"subtitle1\">Intervention</td> </tr> <tr class=\"divider_bottom\"> <td>Normal heart rate</td> <td>Tachycardia</td> <td> <p>5-lead ECG</p> Pulse oximetry with visible waveform</td> <td> <p>Prevent pain-induced tachycardia by minimizing or eliminating labor pain with effective analgesia.</p> <p>Manage tachycardia related to hypotension with phenylephrine (or norepinephrine) and fluid administration.</p> Heart rate can be slowed with beta blockers, if necessary.</td> </tr> <tr class=\"divider_bottom\"> <td>Sinus rhythm</td> <td>Tachyarrhythmias</td> <td>5-lead ECG</td> <td>Management of new-onset atrial fibrillation or other SVT: <ul class=\"decimal_heading\"> <li>Heart rate control </li> <li>Cardioversion, if appropriate, for hemodynamic compromise </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Maintain afterload</td> <td>Hypotension</td> <td>Intra-arterial blood pressure</td> <td>Administer phenylephrine (or norepinephrine) to manage hypotension.</td> </tr> <tr> <td>Adequate preload</td> <td>Hypovolemia</td> <td>Hemodynamics and clinical response to fluid boluses</td> <td>Allow oral intake and administer maintenance IV fluids to maintain intravascular volume.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; SVT: supraventricular tachyarrhythmia; IV: intravenous.</div><div id=\"graphicVersion\">Graphic 97439 Version 5.0</div></div></div>"},"97440":{"type":"graphic_table","displayName":"Anesthetic goals for dilated cardiomyopathy","title":"Key points for anesthetic and hemodynamic management during labor and delivery in dilated cardiomyopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key points for anesthetic and hemodynamic management during labor and delivery in dilated cardiomyopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Hemodynamic goals</td> <td class=\"subtitle1\">Avoid</td> <td class=\"subtitle1\">Monitor</td> <td class=\"subtitle1\">Intervention</td> </tr> <tr class=\"divider_bottom\"> <td>Sinus rhythm</td> <td>Electromagnetic interference due to electrocautery in patients with an ICD</td> <td>5-lead ECG</td> <td>Management of an ICD: <ul class=\"decimal_heading\"> <li>Keep anti-tachyarrhythmia function of ICD active in labor </li> <li>Assure preparations to suspend this function in the event of emergent cesarean delivery </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Normal heart rate</td> <td>Bradycardia</td> <td> <p>5-lead ECG</p> Pulse oximetry with visible waveform</td> <td>Treat bradycardia with ephedrine; gycopyrrolate if necessary.</td> </tr> <tr class=\"divider_bottom\"> <td>Maintain contractility</td> <td>Myocardial depression</td> <td>Hemoynamics</td> <td>Treat low cardiac output syndrome with milrinone or dobutamine; epinephrine or norepinephrine may be added if necessary to treat hypotension.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Maintain afterload</td> <td>Hypertension</td> <td>Intra-arterial blood pressure</td> <td>Prevent pain-induced hypertension by minimizing or eliminating labor pain with effective analgesia.</td> </tr> <tr class=\"divider_bottom\"> <td>Hypotension</td> <td>Intra-arterial blood pressure</td> <td>Treat hypotension with ephedrine or norepinephrine.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Adequate preload</td> <td>Hypervolemia</td> <td>Clinical course and oxygenation. Development of pulmonary edema (may present as acute coughing and hypoxemia in the awake patient).</td> <td>Management of pulmonary edema: <ul class=\"decimal_heading\"> <li>Treat hypoxemia related to pulmonary edema with 100% oxygen, PEEP, and, if necessary, intubation and controlled ventilation </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Hypovolemia</td> <td>Hemodynamics</td> <td>Allow oral intake and administer maintenance IV fluids, if necessary, to maintain adequate preload.</td> </tr> <tr> <td>Minimize pulmonary vascular resistance (optimize oxygenation and ventilation)</td> <td>Hypoxemia or hypercarbia</td> <td>Pulse oximetry with visible waveform</td> <td>Minimize risk of hypoxemia and hypercarbia by: <ul class=\"decimal_heading\"> <li>Administering supplemental oxygen throughout labor and delivery </li> <li>Avoiding oversedation </li> <li>Ensuring well-controlled ventilation, if intubated </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ICD: implantable cardioverter-defibrillator device; ECG: electrocardiogram; PEEP: positive end-expiratory pressure; IV: intravenous.</div><div id=\"graphicVersion\">Graphic 97440 Version 5.0</div></div></div>"},"97442":{"type":"graphic_table","displayName":"Anesthetic goals for HCM","title":"Key points for anesthetic and hemodynamic management during labor and delivery in hypertrophic cardiomyopathy (HCM)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key points for anesthetic and hemodynamic management during labor and delivery in hypertrophic cardiomyopathy (HCM)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Hemodynamic goals</td> <td class=\"subtitle1\">Avoid</td> <td class=\"subtitle1\">Monitor</td> <td class=\"subtitle1\">Intervention</td> </tr> <tr class=\"divider_bottom\"> <td>Sinus rhythm</td> <td>Atrial fibrillation</td> <td> <p>5-lead ECG</p> <p>Place external defibrillator pads</p> </td> <td>Management of new-onset atrial fibrillation: <ul class=\"decimal_heading\"> <li>Cardioversion for hemodynamic compromise </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Slow to normal heart rate</td> <td>Tachycardia</td> <td> <p>5-lead ECG</p> Pulse oximetry with visible waveform</td> <td> <p>Prevent pain-induced tachycardia by minimizing or eliminating labor pain with effective analgesia.</p> Slow heart rate with beta blockers, as needed.</td> </tr> <tr class=\"divider_bottom\"> <td>Maintain afterload</td> <td>Hypotension</td> <td>Intra-arterial blood pressure</td> <td>Manage hypotension immediately with phenylephrine or, if necessary, vasopressin.</td> </tr> <tr> <td>Augment preload</td> <td>Hypovolemia</td> <td>Hemodynamics and clinical response to fluid boluses</td> <td> <p>Augment intravascular volume with IV fluids.</p> Rapidly resuscitate postpartum hemorrhage.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; IV: intravenous.</div><div id=\"graphicVersion\">Graphic 97442 Version 7.0</div></div></div>"},"97443":{"type":"graphic_table","displayName":"Anesthetic goals for aortic aneurysm","title":"Key points for anesthetic and hemodynamic management during labor and delivery in aortic aneurysm (Marfan syndrome)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key points for anesthetic and hemodynamic management during labor and delivery in aortic aneurysm (Marfan syndrome)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Hemodynamic goals</td> <td class=\"subtitle1\">Avoid</td> <td class=\"subtitle1\">Monitor</td> <td class=\"subtitle1\">Intervention</td> </tr> <tr> <td>Reduce afterload</td> <td>Hypertension and aortic wall stress</td> <td>Intra-arterial blood pressure</td> <td>Minimize aortic wall stress with: <ul class=\"decimal_heading\"> <li>Beta blockade (esmolol or labetalol) </li> <li>Vasodilators (nitroglycerin or nicardipine) if necessary </li> <li>Effective analgesia to minimize or eliminate pain </li> <li>Adequate doses of anesthetic agents to block sympathetic responses if general anesthesia is necessary </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 97443 Version 6.0</div></div></div>"},"97444":{"type":"graphic_movie","displayName":"Bladder injection of botulinim A toxin","title":"Bladder injection of botulinim A toxin","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Bladder injection of botulinim A toxin</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/OBGYN/97444_BladderinjecbotAtoxvid.mp4\" style=\"width:512px;height:400px\"></div><img style=\"width:504px; height:291px;\" src=\"images/OBGYN/97444_BladderinjecbotAtoximg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Sangeeta Mahajan, MD.</div><div id=\"graphicVersion\">Graphic 97444 Version 2.0</div></div></div>"},"97445":{"type":"graphic_table","displayName":"Causes bone marrow necrosis","title":"Reported causes of bone marrow necrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reported causes of bone marrow necrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Hematologic malignancies (206)</td> </tr> <tr> <td class=\"indent1\">Acute lymphoblastic leukemia (66)</td> </tr> <tr> <td class=\"indent1\">Acute myeloid leukemia (49)</td> </tr> <tr> <td class=\"indent1\">Non-Hodgkin lymphoma (44)</td> </tr> <tr> <td class=\"indent1\">Hodgkin lymphoma (17)</td> </tr> <tr> <td class=\"indent1\">Chronic myeloid leukemia (16)</td> </tr> <tr> <td class=\"indent1\">Chronic lymphocytic leukemia (2)</td> </tr> <tr> <td class=\"indent1\">Post-transplant lymphoproliferative disorder (2)</td> </tr> <tr> <td class=\"indent1\">Myelofibrosis (3)</td> </tr> <tr> <td class=\"indent1\">Multiple myeloma (2)</td> </tr> <tr> <td class=\"subtitle1_single\">Other hematologic disorders (22)</td> </tr> <tr> <td class=\"indent1\">Homozygous sickle cell disease (8)</td> </tr> <tr> <td class=\"indent1\">Other sickle cell syndromes (12)</td> </tr> <tr> <td class=\"subtitle1_single\">Carcinomas and sarcomas (74)</td> </tr> <tr> <td class=\"indent1\">Gastric carcinoma (22)</td> </tr> <tr> <td class=\"indent1\">Carcinoma of unknown primary (15)</td> </tr> <tr> <td class=\"indent1\">Nasopharyngeal carcinoma (7)</td> </tr> <tr> <td class=\"indent1\">Lung carcinoma (7)</td> </tr> <tr> <td class=\"indent1\">Prostate carcinoma (6)</td> </tr> <tr> <td class=\"indent1\">Colon carcinoma (3)</td> </tr> <tr> <td class=\"indent1\">Breast carcinoma (2)</td> </tr> <tr> <td class=\"indent1\">Neuroblastoma (5)</td> </tr> <tr> <td class=\"subtitle1_single\">Infections (31)</td> </tr> <tr> <td class=\"indent1\">Leishmaniasis (8)</td> </tr> <tr> <td class=\"indent1\">Parvovirus B19 (6)</td> </tr> <tr> <td class=\"indent1\">Mycobacterium tuberculosis (5)</td> </tr> <tr> <td class=\"indent1\">Salmonella typhi (2)</td> </tr> <tr> <td class=\"indent1\">Staphylococcus aureus (2)</td> </tr> <tr> <td class=\"subtitle1_single\">Drugs and other agents (32)</td> </tr> <tr> <td class=\"indent1\">Imatinib (5)</td> </tr> <tr> <td class=\"indent1\">Tretinoin (5)</td> </tr> <tr> <td class=\"indent1\">Arsenic trioxide (4)</td> </tr> <tr> <td class=\"indent1\">Interferon (3)</td> </tr> <tr> <td class=\"indent1\">Fludarabine (3)</td> </tr> <tr> <td class=\"indent1\">Hydroxyurea (3)</td> </tr> <tr> <td class=\"indent1\">Filgrastim (3)</td> </tr> <tr> <td class=\"subtitle1_single\">Autoimmune disorders (13)</td> </tr> <tr> <td class=\"indent1\">Antiphospholipid antibody syndrome (11)</td> </tr> <tr> <td class=\"subtitle1_single\">Other conditions (19)</td> </tr> <tr> <td class=\"indent1\">Anorexia nervosa/starvation (9)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The numbers of reported cases are shown in parentheses. Of the 397 identified causes in this report, only those conditions found in two or more subjects have been included in this table.</div><div class=\"graphic_reference\">Data from: Parekh HD, Reese JA, Cobb PW, George JN. Bone marrow necrosis discovered in a patient with suspected thrombotic thrombocytopenia purpura (supplementary information). Am J Hematol 2014.</div><div id=\"graphicVersion\">Graphic 97445 Version 1.0</div></div></div>"},"97448":{"type":"graphic_table","displayName":"Target attainments by drug","title":"Targets of %fT>MIC for sub-classes of beta-lactams and gram-negative organisms","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Targets of %fT&gt;MIC for sub-classes of beta-lactams and gram-negative organisms</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Bacteria-killing mechanism</td> <td class=\"subtitle1\">Penicillins (%)</td> <td class=\"subtitle1\">Cephalosporins (%)</td> <td class=\"subtitle1\">Carbapenems (%)</td> </tr> <tr> <td>Bacteriostatic</td> <td class=\"centered\">30%</td> <td class=\"centered\">35-40%</td> <td class=\"centered\">20%</td> </tr> <tr> <td>Bacteriocidal</td> <td class=\"centered\">50%</td> <td class=\"centered\">60-70%</td> <td class=\"centered\">40%</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">%fT&gt;MIC: percentage of the dosing interval that the concentration of free drug remains about the minimum inhibitory concentration of the pathogen.</div><div class=\"graphic_reference\">Data from: Lodise TP, Lomaestro BM, Drusano GL, Society of Infectious Diseases Pharmacists. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006; 26:1320 and Craig WA, Ebert S, and Wantabe&nbsp;Y. Differences in time above MIC required for efficacy of beta-lactams in animal infection models. Presented at&nbsp;the 33rd Interscience Conference on Animicrobial Agents and Chemotherapy, San Francisco CA, 1993, Abstract #86.</div><div id=\"graphicVersion\">Graphic 97448 Version 1.0</div></div></div>"},"97451":{"type":"graphic_table","displayName":"Spectrum of biomarkers for Alzheimer disease","title":"Spectrum of widely investigated biomarkers for Alzheimer disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Spectrum of widely investigated biomarkers for Alzheimer disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"34%\"></colgroup><colgroup span=\"3\" width=\"22%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Pathophysiologic marker</td> <td class=\"subtitle1\">Topographic marker</td> <td class=\"subtitle1\">Marker of neuronal injury/degeneration</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Cerebrospinal fluid</td> </tr> <tr> <td class=\"indent1\">A&#946;42 or A&#946;42:A&#946;40 ratio</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> </tr> <tr> <td class=\"indent1\">Total tau, phospho-tau</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">PET</td> </tr> <tr> <td class=\"indent1\">Amyloid tracer uptake</td> <td class=\"centered\">Yes</td> <td class=\"centered\">No</td> <td class=\"centered\">No</td> </tr> <tr> <td class=\"indent1\">Fluorodeoxyglucose</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Structural MRI</td> </tr> <tr> <td class=\"indent1\">Medial temporal lobe atrophy</td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">A&beta;: beta-amyloid; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 97451 Version 2.0</div></div></div>"},"97452":{"type":"graphic_figure","displayName":"Preclinical AD staging framework","title":"Proposed staging framework for preclinical Alzheimer disease","html":"<div class=\"graphic\"><div style=\"width: 715px\" class=\"figure\"><div class=\"ttl\">Proposed staging framework for preclinical Alzheimer disease</div><div class=\"cntnt\"><img style=\"width:695px; height:333px;\" src=\"images/NEURO/97452_Sperling_figure_5.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Graphic representation of the proposed staging framework for preclinical AD. Note that some individuals will not progress beyond Stage 1 or Stage 2. Individuals in Stage 3 are postulated to be more likely to progress to MCI and AD dementia.</div><div class=\"graphic_footnotes\">AD: Alzheimer's disease; Aβ: amyloid beta; PET: position emission tomography; CSF: cerebrospinal fluid; FDG: fluorodeoxyglucose; fMRI: functional magnetic resonance imaging; sMRI: structural magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced from: Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:280. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97452 Version 2.0</div></div></div>"},"97453":{"type":"graphic_algorithm","displayName":"Treatment of MM algorithm","title":"Initial treatment of multiple myeloma by risk stratification","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Initial treatment of multiple myeloma by risk stratification</div><div class=\"cntnt\"><img style=\"width:648px; height:402px;\" src=\"images/HEME/97453_Treatment_MM_algorithm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm illustrates our general approach to the treatment of a patient with newly diagnosed multiple myeloma. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</div><div class=\"graphic_footnotes\">FISH: fluorescence in situ hybridization; VRd: bortezomib, lenalidomide, low-dose dexamethasone; KRd: carfilzomib, lenalidomide, low-dose dexamethasone; Rd: lenalidomide plus low-dose dexamethasone; HCT: hematopoietic cell transplantation.<br />* All myeloma patients are risk-stratified at initial diagnosis based on FISH studies on the bone marrow. If FISH is unavailable, conventional cytogenetics can be used as an alternative but is much less sensitive.</div><div id=\"graphicVersion\">Graphic 97453 Version 6.0</div></div></div>"},"97454":{"type":"graphic_picture","displayName":"ALD canalicular and hepatocellular cholestasis","title":"Alcoholic liver disease scoring system: Canalicular and hepatocellular cholestasis (+2 points)","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Alcoholic liver disease scoring system: Canalicular and hepatocellular cholestasis (+2 points)</div><div class=\"cntnt\"><img style=\"width:585px; height:374px;\" src=\"images/GAST/97454_ALD_cnlclr_hptclllr_chlstss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Asterisks indicate canalicular cholestasis, and arrows indicate the presence of cholestasis within hepatocytes resulting in feathery degeneration.</div><div id=\"graphicVersion\">Graphic 97454 Version 1.0</div></div></div>"},"97455":{"type":"graphic_picture","displayName":"ALD megamitochondria","title":"Alcoholic liver disease scoring system: Megamitochondria (0 points)","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Alcoholic liver disease scoring system: Megamitochondria (0 points)</div><div class=\"cntnt\"><img style=\"width:585px; height:337px;\" src=\"images/GAST/97455_ALD_megamitochondria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Minimal steatosis is present; however, there are megamitochondria seen (arrows).</div><div id=\"graphicVersion\">Graphic 97455 Version 1.0</div></div></div>"},"97456":{"type":"graphic_table","displayName":"IIEF-5 questionnaire","title":"The IIEF-5 questionnaire","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The IIEF-5 questionnaire</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"5\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"6\">Over the past&nbsp;six months:</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">1. How do you rate your confidence that you could get and keep an erection?</td> <td class=\"centered\"><strong>Very low</strong></td> <td class=\"centered\"><strong>Low</strong></td> <td class=\"centered\"><strong>Moderate</strong></td> <td class=\"centered\"><strong>High</strong></td> <td class=\"centered\"><strong>Very high</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">2. When you had erections with sexual stimulation, how often were your erections hard enough for penetration?</td> <td class=\"centered\"><strong>Almost never or never</strong></td> <td class=\"centered\"> <p><strong>A few times</strong></p> <p><strong></strong>(much less than half the time)</p> </td> <td class=\"centered\"> <p><strong>Sometimes</strong></p> <p><strong></strong>(about half the time)</p> </td> <td class=\"centered\"> <p><strong>Most times</strong></p> <p><strong></strong>(much more than half the time)</p> </td> <td class=\"centered\"><strong>Almost always or always</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">3. During sexual intercourse, how often were you able to maintain your erection after you had penetrated your partner?</td> <td class=\"centered\"><strong>Almost never or never</strong></td> <td class=\"centered\"> <p><strong>A few times</strong></p> <p><strong></strong>(much less than half the time)</p> </td> <td class=\"centered\"> <p><strong>Sometimes</strong></p> <p><strong></strong>(about half the time)</p> </td> <td class=\"centered\"> <p><strong>Most times</strong></p> <p><strong></strong>(much more than half the time)</p> </td> <td class=\"centered\"><strong>Almost always or always</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">4. During sexual intercourse, how difficult was it to maintain your erection to completion of intercourse?</td> <td class=\"centered\"><strong>Extremely difficult</strong></td> <td class=\"centered\"><strong>Very difficult</strong></td> <td class=\"centered\"><strong>Difficult</strong></td> <td class=\"centered\"><strong>Slightly difficult</strong></td> <td class=\"centered\"><strong>Not difficult</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">5. When you attempted sexual intercourse, how often was it satisfactory for you?</td> <td class=\"centered\"><strong>Almost never or never</strong></td> <td class=\"centered\"> <p><strong>A few times</strong></p> <p><strong></strong>(much less than half the time)</p> </td> <td class=\"centered\"> <p><strong>Sometimes</strong></p> <p><strong></strong>(about half the time)</p> </td> <td class=\"centered\"> <p><strong>Most times</strong></p> <p><strong></strong>(much more than half the time)</p> </td> <td class=\"centered\"><strong>Almost always or always</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> <td class=\"centered\">5</td> </tr> <tr> <td rowspan=\"2\">&nbsp;</td> <td class=\"subtitle2_left\" colspan=\"5\">Total score:</td> </tr> <tr> <td>1 to 7: Severe ED</td> <td>8 to 11: Moderate ED</td> <td>12 to 16: Mild-moderate ED</td> <td>17 to 21: Mild ED</td> <td>22 to 25: No ED</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IIEF: International index of erectile dysfunction; ED: erectile dysfunction.</div><div class=\"graphic_reference\">Reprinted with permission from Macmillan Publishers Ltd: International Journal of Impotence Research. Rosen RC, Cappelleri JC, Smith MD, et al. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11:319. Copyright &copy; 1999. <a href=\"http://www.nature.com/ijir\" spellcheck=\"true\" target=\"_blank\">www.nature.com/ijir</a>.</div><div id=\"graphicVersion\">Graphic 97456 Version 3.0</div></div></div>"},"97457":{"type":"graphic_picture","displayName":"PBC florid duct lesion portal hepatitis","title":"Primary biliary cholangitis stage 1: Florid duct lesion and portal hepatitis","html":"<div class=\"graphic\"><div style=\"width: 654px\" class=\"figure\"><div class=\"ttl\">Primary biliary cholangitis stage 1: Florid duct lesion and portal hepatitis</div><div class=\"cntnt\"><img style=\"width:634px; height:427px;\" src=\"images/GAST/97457_PBC_flrd_dct_lsn_prtl_hptts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A bile duct (arrow) is surrounded by lymphocytes and histiocytes. The bile duct has an irregular contour due to the basement membrane having been breached by inflammatory cells and partially destroyed. Note the dense lymphoplasmacytic infiltrate occupying almost the entire portal tract.</div><div id=\"graphicVersion\">Graphic 97457 Version 2.0</div></div></div>"},"97458":{"type":"graphic_picture","displayName":"PBC proliferation bile ductules","title":"Primary biliary cholangitis stage 2: Proliferation of bile ductules","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Primary biliary cholangitis stage 2: Proliferation of bile ductules</div><div class=\"cntnt\"><img style=\"width:584px; height:438px;\" src=\"images/GAST/97458_PBC_prlfrtn_bile_dctls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Irregular anastomosing ductal structures are seen (arrows). The bile duct in the center is destroyed.</div><div id=\"graphicVersion\">Graphic 97458 Version 2.0</div></div></div>"},"97459":{"type":"graphic_picture","displayName":"PBC scarring","title":"Primary biliary cholangitis stage 3: Scarring","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Primary biliary cholangitis stage 3: Scarring</div><div class=\"cntnt\"><img style=\"width:585px; height:369px;\" src=\"images/GAST/97459_PBC_scarring.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypocellular fibrous septa are seen to link adjacent portal areas. Note the presence of ductular reaction. Very few interlobular bile ducts remain.</div><div id=\"graphicVersion\">Graphic 97459 Version 2.0</div></div></div>"},"97460":{"type":"graphic_picture","displayName":"PBC with cirrhosis","title":"Primary biliary cholangitis stage 4: Cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Primary biliary cholangitis stage 4: Cirrhosis</div><div class=\"cntnt\"><img style=\"width:504px; height:353px;\" src=\"images/GAST/97460_PBC_cirrhosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Biliary-type cirrhosis characterized by well-formed cirrhotic nodules surrounded by wide hypocellular fibrous septa. The edge of each cirrhotic nodule is lighter in color, resulting in a halo effect. This is due to chronic cholate stasis.</div><div id=\"graphicVersion\">Graphic 97460 Version 2.0</div></div></div>"},"97461":{"type":"graphic_picture","displayName":"PSC stage 1 onion-skin fibrosis","title":"Primary sclerosing cholangitis stage 1: Onion-skin fibrosis","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Primary sclerosing cholangitis stage 1: Onion-skin fibrosis</div><div class=\"cntnt\"><img style=\"width:510px; height:337px;\" src=\"images/GAST/97461_PSC_stg_1_onion_skn_fbrss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A medium-sized bile duct is surrounded by layers of fibrous tissue (arrow).</div><div id=\"graphicVersion\">Graphic 97461 Version 1.0</div></div></div>"},"97462":{"type":"graphic_picture","displayName":"PSC stage 1 portal edema bile duct proliferation","title":"Primary sclerosing cholangitis stage 1: Portal edema and proliferation of bile ductules","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Primary sclerosing cholangitis stage 1: Portal edema and proliferation of bile ductules</div><div class=\"cntnt\"><img style=\"width:586px; height:350px;\" src=\"images/GAST/97462_PSC_stg1_prtl_edm_ble_prlfr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The bile duct (arrow) shows scalloping of the lumen.</div><div id=\"graphicVersion\">Graphic 97462 Version 1.0</div></div></div>"},"97463":{"type":"graphic_table","displayName":"Types of primary liver tumors","title":"Premalignant and malignant hepatocellular and biliary lesions of the liver and intrahepatic bile ducts","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Premalignant and malignant hepatocellular and biliary lesions of the liver and intrahepatic bile ducts</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Hepatocellular lesions</td> </tr> <tr> <td class=\"subtitle2_single\">Malignancy-associated and premalignant lesions</td> </tr> <tr> <td class=\"indent2\">Large cell change (formerly \"dysplasia\")</td> </tr> <tr> <td class=\"indent2\">Small cell change (formerly \"dysplasia\")</td> </tr> <tr> <td class=\"indent2\">Low-grade dysplastic nodule</td> </tr> <tr> <td class=\"indent2\">High-grade dysplastic nodule</td> </tr> <tr> <td class=\"subtitle2_single\">Malignant lesions</td> </tr> <tr> <td class=\"indent2\">Hepatocellular carcinoma</td> </tr> <tr> <td class=\"indent2\">Hepatocellular carcinoma, fibrolamellar variant</td> </tr> <tr> <td class=\"indent2\">Hepatoblastoma, epithelial variants</td> </tr> <tr> <td class=\"indent2\">Undifferentiated carcinoma</td> </tr> <tr> <td class=\"subtitle1_single\">Malignancies of mixed origin</td> </tr> <tr> <td class=\"indent2\">Hepatoblastoma, mixed epithelial-mesenchymal</td> </tr> <tr> <td class=\"indent2\">Combined hepatocellular-cholangiocarcinoma</td> </tr> <tr> <td class=\"subtitle1_single\">Bile duct&nbsp;lesions</td> </tr> <tr> <td class=\"subtitle2_single\">Premalignant lesions</td> </tr> <tr> <td class=\"indent2\">Biliary intraepithelial neoplasia, grade 3</td> </tr> <tr> <td class=\"indent2\">Intraductal papillary neoplasm</td> </tr> <tr> <td class=\"indent2\">Mucinous cystic neoplasm</td> </tr> <tr> <td class=\"subtitle2_single\">Malignant lesions</td> </tr> <tr> <td class=\"indent2\">Intrahepatic cholangiocarcinoma</td> </tr> <tr> <td class=\"indent2\">Intraductal papillary neoplasm with invasive carcinoma</td> </tr> <tr> <td class=\"indent2\">Mucinous cystic neoplasm with invasive carcinoma</td> </tr> <tr> <td class=\"subtitle1_single\">Malignant mesenchymal tumors</td> </tr> <tr> <td class=\"indent2\">Epithelioid hemangioendothelioma</td> </tr> <tr> <td class=\"indent2\">Angiosarcoma</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Tumors of the liver and intrahepatic bile ducts. In: WHO Classification of Tumours of the Digestive System, Bosman F, Carneiro F, Hruban R, Theise N (Eds), IARC, Lyon 2010.</div><div id=\"graphicVersion\">Graphic 97463 Version 1.0</div></div></div>"},"97465":{"type":"graphic_figure","displayName":"Anterior axio-appendicular muscles","title":"Anterior axio-appendicular muscles","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Anterior axio-appendicular muscles</div><div class=\"cntnt\"><img style=\"width:576px; height:468px;\" src=\"images/EM/97465_Antrraxioappendiculrmscl.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 97465 Version 3.0</div></div></div>"},"97466":{"type":"graphic_table","displayName":"Anterior axio-appendicular muscles and descriptions","title":"Anterior axio-appendicular muscles and descriptions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anterior axio-appendicular muscles and descriptions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Muscle</td> <td class=\"subtitle1\">Proximal attachment</td> <td class=\"subtitle1\">Distal attachment</td> <td class=\"subtitle1\">Innervation*</td> <td class=\"subtitle1\">Main action</td> </tr> <tr> <td>Pectoralis major</td> <td> <p>Clavicular head: anterior surface of medial half of clavicle</p> Sternocostal head: anterior surface of sternum, superior six costal cartilages, aponeurosis of external oblique muscle</td> <td>Lateral lip of intertubercular sulcus of humerus</td> <td>Lateral and medial pectoral nerves; clavicular head (C5, <strong>C6</strong>), sternocostal head (<strong>C7</strong>, <strong>C8</strong>, T1)</td> <td> <p>Adducts and medially rotates humerus; draws scapula anteriorly and inferiorly</p> Acting alone, clavicular head flexes humerus and sternocostal head extends it from the flexed position</td> </tr> <tr> <td>Pectoralis minor</td> <td>3rd - 5th ribs near their costal cartilages</td> <td>Medial border and superior surface of coracoid process of scapula</td> <td>Medial pectoral nerve (C8, T1)</td> <td>Stabilizes scapula by drawing it inferiorly and anteriorly against thoracic wall</td> </tr> <tr> <td>Subclavius</td> <td>Junction of 1st rib and its costal cartilage</td> <td>Inferior surface of middle third of clavicle</td> <td>Nerve to subclavius (<strong>C5</strong>, C6)</td> <td>Anchors and depresses clavicle</td> </tr> <tr> <td>Serratus anterior</td> <td>External surfaces of lateral parts of 1st - 8th ribs</td> <td>Anterior surface of medial border of scapula</td> <td>Long thoracic nerve (C5, <strong>C6</strong>, <strong>C7</strong>)</td> <td>Protracts scapula and holds it against thoracic wall; rotates scapula</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The spinal cord segmental innervation is indicated (eg, \"C5, C6\" means that the nerves supplying the subclavius are derived from the fifth and sixth cervical segments of the spinal cord). Numbers in boldface (C5) indicate the main segmental innervation. Damage to one or more of the listed spinal cord segments or to the motor nerve roots arising from them results in paralysis of the muscles concerned.</div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 97466 Version 3.0</div></div></div>"},"97467":{"type":"graphic_figure","displayName":"Posterior axio-appendicular muscles","title":"Posterior axio-appendicular muscles","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Posterior axio-appendicular muscles</div><div class=\"cntnt\"><img style=\"width:576px; height:350px;\" src=\"images/EM/97467_Pstrraxioappndclrmscl.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 97467 Version 3.0</div></div></div>"},"97468":{"type":"graphic_table","displayName":"Posterior axio-appendicular muscles and descriptions","title":"Posterior axio-appendicular muscles and descriptions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Posterior axio-appendicular muscles and descriptions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Muscle</td> <td class=\"subtitle1\">Proximal attachment</td> <td class=\"subtitle1\">Distal attachment</td> <td class=\"subtitle1\">Innervation*</td> <td class=\"subtitle1\">Main action</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Superficial posterior axio-appendicular (extrinsic shoulder) muscles</td> </tr> <tr> <td class=\"indent1\">Trapezius</td> <td>Medial third of superior nuchal line; external occipital protuberance; nuchal ligament; spinous processes of C7 - T12 vertebrae</td> <td>Lateral third of clavicle; acromion and spine of scapula</td> <td>Spinal accessory nerve (CN XI) (motor fibers) and C3, C4 spinal nerves (pain and proprioceptive fibers)</td> <td>Descending part elevates; ascending part depresses; and middle part (or all parts together) retracts scapula; descending and ascending parts act together to rotate glenoid cavity superiorly</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Latissimus dorsi</td> <td>Spinous processes of inferior 6 thoracic vertebrae, thoracolumbar fascia, iliac crest, and inferior 3 or 4 ribs</td> <td>Floor of intertubercular sulcus of humerus</td> <td>Thoracodorsal nerve (<strong>C6</strong>, <strong>C7</strong>, C8)</td> <td>Extends, adducts, and medially rotates humerus; raises body toward arms during climbing</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Deep posterior axio-appendicular (extrinsic shoulder) muscles</td> </tr> <tr> <td class=\"indent1\">Levator scapulae</td> <td>Posterior tubercles of transverse processes of C1 - C4 vertebrae</td> <td>Medial border of scapula superior to root of scapular spine</td> <td>Dorsal scapular (C4, C5) and cervical (C3, C4) nerves</td> <td>Elevates scapula and rotates its glenoid cavity inferiorly by rotating scapula</td> </tr> <tr> <td class=\"indent1\">Rhomboid minor and major</td> <td> <p>Minor: nuchal ligament; spinous processes of C7 and T1 vertebrae</p> Major: spinous processes of T2 - T5 vertebrae</td> <td> <p>Minor: smooth triangular area at medial end of scapular spine</p> Major: medial border of scapula from level of spine to inferior angle</td> <td>Dorsal scapular nerve (C4, <strong>C5</strong>)</td> <td>Retract scapula and rotate its glenoid cavity inferiorly; fix scapula to thoracic wall</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The spinal cord segmental innervation is indicated (eg, \"C4, C5\" means that the nerves supplying the rhomboids are derived from the fourth and fifth cervical segments of the spinal cord). Numbers in boldface (C5) indicate the main segmental innervation. Damage to one or more of the listed spinal cord segments or to the motor nerve roots arising from them results in paralysis of the muscles concerned.</div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 97468 Version 3.0</div></div></div>"},"97469":{"type":"graphic_figure","displayName":"Scapulohumeral muscles","title":"Scapulohumeral muscles","html":"<div class=\"graphic\"><div style=\"width: 652px\" class=\"figure\"><div class=\"ttl\">Scapulohumeral muscles</div><div class=\"cntnt\"><img style=\"width:632px; height:410px;\" src=\"images/EM/97469_Scapulohumeralmuscles.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These muscles pass from the scapula to the humerus and act on the glenohumeral joint. Not included here is the deltoid.</div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 97469 Version 3.0</div></div></div>"},"97470":{"type":"graphic_table","displayName":"Scapulohumeral muscles (intrinsic shoulder) muscles","title":"Scapulohumeral muscles (intrinsic shoulder) muscles","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Scapulohumeral muscles (intrinsic shoulder) muscles</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Muscle</td> <td class=\"subtitle1\">Proximal attachment</td> <td class=\"subtitle1\">Distal attachment</td> <td class=\"subtitle1\">Innervation*</td> <td class=\"subtitle1\">Main action</td> </tr> <tr> <td>Deltoid</td> <td>Lateral third of clavicle; acromion and spine of scapula</td> <td>Deltoid tuberosity of humerus</td> <td>Axillary nerve (<strong>C5</strong>, C6)</td> <td> <p>Clavicular (anterior) part: flexes and medially rotates arm</p> <p>Acromial (middle) part: abducts arm</p> Spinal (posterior) part: extends and laterally rotates arm</td> </tr> <tr> <td>Supraspinatus<sup>&#182;</sup></td> <td>Supraspinous fossa of scapula</td> <td>Superior facet of greater tubercle of humerus</td> <td>Suprascapular nerve (C4, <strong>C5</strong>, C6)</td> <td>Initiates and assists deltoid in abduction of arm and acts with rotator cuff muscles<sup>&#182;</sup></td> </tr> <tr> <td>Infraspinatus<sup>&#182;</sup></td> <td>Infraspinous fossa of scapula</td> <td>Middle facet of greater tubercle of humerus</td> <td>Suprascapular nerve (<strong>C5</strong>, C6)</td> <td>Laterally rotates arm; and acts with rotator cuff muscles<sup>&#182;</sup></td> </tr> <tr> <td>Teres minor<sup>&#182;</sup></td> <td>Middle part of lateral border of scapula</td> <td>Inferior facet of greater tubercle of humerus</td> <td>Axillary nerve (<strong>C5</strong>, C6)</td> <td>Laterally rotates arm; and acts with rotator cuff muscles<sup>&#182;</sup></td> </tr> <tr> <td>Teres major</td> <td>Posterior surface of inferior angle of scapula</td> <td>Medial lip of intertubercular sulcus of humerus</td> <td>Lower subscapular nerve (C5, <strong>C6</strong>)</td> <td>Adducts and medially rotates arm</td> </tr> <tr> <td>Subscapularis<sup>&#182;</sup></td> <td>Subscapular fossa (most of anterior surface of scapula)</td> <td>Lesser tubercle of humerus</td> <td>Upper and lower subscapular nerves (C5, <strong>C6</strong>, C7)</td> <td>Medially rotates arm; as part of rotator cuff, helps hold head of humerus in glenoid cavity</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The spinal cord segmental innervation is indicated (eg, \"C5, C6\" means that the nerves supplying the deltoid are derived from the fifth and sixth cervical segments of the spinal cord). Numbers in boldface (C5) indicate the main segmental innervation. Damage to one or more of the listed spinal cord segments or to the motor nerve roots arising from them results in paralysis of the muscles concerned.<br />&#182; Collectively, the supraspinatus, infraspinatus, teres minor, and subscapularis muscles are referred to as the rotator cuff, or SITS, muscles. Their primary function during all movements of the glenohumeral (shoulder) joint is to hold the humeral head in the glenoid cavity of the scapula.</div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 97470 Version 3.0</div></div></div>"},"97471":{"type":"graphic_figure","displayName":"Relationship of radial nerve to brachialis and supinator muscles","title":"Relationship of radial nerve to brachialis and supinator muscles","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Relationship of radial nerve to brachialis and supinator muscles</div><div class=\"cntnt\"><img style=\"width:480px; height:556px;\" src=\"images/EM/97471_Rltnsrdlnrvbrchspnmscl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the cubital fossa, lateral to the brachialis, the radial nerve divides into deep (motor) and superficial (sensory) branches. The deep branch penetrates the supinator muscle and emerges in the posterior compartment of the forearm as the posterior interosseous nerve. It joins the artery of the same name to run in the plane between the superficial and the deep extensors of the forearm.</div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 97471 Version 3.0</div></div></div>"},"97472":{"type":"graphic_figure","displayName":"Anatomical snuff box","title":"Anatomical snuff box","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Anatomical snuff box</div><div class=\"cntnt\"><img style=\"width:506px; height:610px;\" src=\"images/EM/97472_Anatomicalsnuffbox.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) When the thumb is extended, a triangular hollow appears between the tendon of the extensor pollicis longus (EPL) medially and the tendons of the extensor pollicis brevis (EPB) and abductor pollicis longus (APL) laterally. <br />(B) The floor of the snuff box, formed by the scaphoid and trapezium bones, is crossed by the radial artery as it passes diagonally from the anterior surface of the radius to the dorsal surface of the hand.</div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 97472 Version 3.0</div></div></div>"},"97473":{"type":"graphic_figure","displayName":"Elbow and proximal radio-ulnar joints","title":"Elbow and proximal radio-ulnar joints","html":"<div class=\"graphic\"><div style=\"width: 655px\" class=\"figure\"><div class=\"ttl\">Elbow and proximal radio-ulnar joints</div><div class=\"cntnt\"><img style=\"width:635px; height:483px;\" src=\"images/EM/97473_Elbwprxmlrdulnrjnt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The thin anterior aspect of the joint capsule has been removed to reveal the articulating surfaces of the bones inside. The strong collateral ligaments were left intact.<br />(B) Radiograph of the extended elbow joint.<br />(C) The fibrous layer and synovial membrane of the joint capsule, the subtendinous and subcutaneous olecranon bursae, and humero-ulnar articulation of the elbow joint.<br />(D) Radiograph of the flexed elbow joint.</div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 97473 Version 3.0</div></div></div>"},"97474":{"type":"graphic_figure","displayName":"Collateral ligaments of elbow joint","title":"Collateral ligaments of elbow joint","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Collateral ligaments of elbow joint</div><div class=\"cntnt\"><img style=\"width:535px; height:651px;\" src=\"images/EM/97474_Clltrllgmntelbwjnt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The fan-like radial collateral is attached to the anular ligament of the radius, but its superficial fibers continue on to the ulna.<br />(B) The ulnar collateral ligament has a strong, round, cord-like anterior band (part), which is taut when the elbow joint is extended, and a weak, fan-like posterior band, which is taut when the joint is flexed. The oblique fibers merely deepen the socket for the trochlea of the humerus. The tubercle on the coronoid process is also known as the \"sublime tubercle of the ulna\". </div><div class=\"graphic_footnotes\">Of: oblique fibers. </div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 97474 Version 5.0</div></div></div>"},"97475":{"type":"graphic_figure","displayName":"Avulsion of medial epicondyle","title":"Avulsion of medial epicondyle","html":"<div class=\"graphic\"><div style=\"width: 504px\" class=\"figure\"><div class=\"ttl\">Avulsion of medial epicondyle</div><div class=\"cntnt\"><img style=\"width:484px; height:356px;\" src=\"images/EM/97475_Avulsionmedialepicondyle.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Clinically Oriented Anatomy, 7th ed, Moore KL, Agur AM, Dalley AF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 97475 Version 3.0</div></div></div>"},"97476":{"type":"graphic_picture","displayName":"Tracheoesophageal voice prosthesis in situ","title":"Tracheoesophageal voice prosthesis in situ","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Tracheoesophageal voice prosthesis in situ</div><div class=\"cntnt\"><img style=\"width:582px; height:433px;\" src=\"images/ONC/97476_Trchsphgl_vce_prsthss_situ.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 97476 Version 2.0</div></div></div>"},"97477":{"type":"graphic_picture","displayName":"Intraluminal attachment stenting tracheostoma","title":"Intraluminal attachment stenting tracheostoma, optimal positioning of tracheoesophageal prosthesis","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Intraluminal attachment stenting tracheostoma, optimal positioning of tracheoesophageal prosthesis</div><div class=\"cntnt\"><img style=\"width:585px; height:389px;\" src=\"images/ONC/97477_Intrlmnl_attchmnt_stnt_trch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note optimal positioning of tracheoesophageal prosthesis behind button to prevent obstruction of airflow through prosthesis.</div><div id=\"graphicVersion\">Graphic 97477 Version 2.0</div></div></div>"},"97478":{"type":"graphic_picture","displayName":"Attachment of hands-free tracheostoma speaking valve","title":"Attachment of hands-free tracheostoma speaking valve for automatic tracheoesophageal speech production","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Attachment of hands-free tracheostoma speaking valve for automatic tracheoesophageal speech production</div><div class=\"cntnt\"><img style=\"width:255px; height:241px;\" src=\"images/ONC/97478_Attch_hndfree_trchs_spk_vlv.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 97478 Version 2.0</div></div></div>"},"97479":{"type":"graphic_table","displayName":"Staging system primary nodal lymphomas","title":"Revised staging system for primary nodal lymphomas (Lugano classification)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Revised staging system for primary nodal lymphomas (Lugano classification)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"2\" width=\"37%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Involvement</td> <td class=\"subtitle1\">Extranodal (E) status</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Limited</td> </tr> <tr> <td class=\"indent1\">I</td> <td>One node or a group of adjacent nodes</td> <td>Single extranodal lesions without nodal involvement</td> </tr> <tr> <td class=\"indent1\">II</td> <td>Two or more nodal groups on the same side of the diaphragm</td> <td>Stage I or II by nodal extent with limited contiguous extranodal involvement</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">II bulky*</td> <td>II as above with \"bulky\" disease</td> <td>Not applicable</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Advanced</td> </tr> <tr> <td class=\"indent1\">III</td> <td>Nodes on both sides of the diaphragm; nodes above the diaphragm with spleen involvement</td> <td>Not applicable</td> </tr> <tr> <td class=\"indent1\">IV</td> <td>Additional noncontiguous extralymphatic involvement</td> <td>Not applicable</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Extent of disease is determined by positron emission tomograph/computed tomography (PET/CT) for avid lymphomas and CT for nonavid histologies. Tonsils, Waldeyer's ring, and spleen are considered nodal tissue.</div><div class=\"graphic_footnotes\">* Whether stage II bulky disease is treated as limited or advanced disease may be determined by histology and a number of prognostic factors.</div><div class=\"graphic_reference\">Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 2014; 32(27):3059-67. Reprinted with permission. Copyright &copy; 2014 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97479 Version 3.0</div></div></div>"},"97480":{"type":"graphic_table","displayName":"2014 treatment response criteria for lymphoma","title":"Lugano criteria for response assessment in lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Lugano criteria for response assessment in lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Response and site</td> <td class=\"subtitle1\">PET/CT-based response</td> <td class=\"subtitle1\">CT-based response</td> </tr> <tr class=\"divider_bottom\"> <td>Complete</td> <td>Complete metabolic response</td> <td>Complete radiologic response (all of the following)</td> </tr> <tr> <td class=\"indent1\">Lymph nodes and extralymphatic sites</td> <td> <p>Score 1, 2, or 3* with or without a residual mass on 5PS<sup>&#182;</sup></p> It is recognized that in Waldeyer's ring or extranodal sites with high physiologic uptake or with activation within spleen or marrow (eg, with chemotherapy or myeloid colony-stimulating factors), uptake may be greater than normal mediastinum and/or liver. In this circumstance, complete metabolic response may be inferred if uptake at sites of initial involvement is no greater than surrounding normal tissue even if the tissue has high physiologic uptake.</td> <td> <p>Target nodes/nodal masses must regress to &#8804;1.5 cm in LDi</p> No extralymphatic sites of disease</td> </tr> <tr> <td class=\"indent1\">Nonmeasured lesions</td> <td>Not applicable</td> <td>Absent</td> </tr> <tr> <td class=\"indent1\">Organ enlargement</td> <td>Not applicable</td> <td>Regress to normal</td> </tr> <tr> <td class=\"indent1\">New lesions</td> <td>None</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bone marrow</td> <td>No evidence of FDG-avid disease in marrow</td> <td>Normal by morphology; if indeterminate, IHC negative</td> </tr> <tr class=\"divider_bottom\"> <td>Partial</td> <td>Partial metabolic response</td> <td>Partial remission (all of the following)</td> </tr> <tr> <td class=\"indent1\">Lymph nodes and extralymphatic sites</td> <td> <p>Score 4 or 5<sup>&#182;</sup> with reduced uptake compared with baseline and residual mass(es) of any size</p> <p>At interim, these findings suggest responding disease</p> At end of treatment, these findings indicate residual disease</td> <td> <p>&#8805;50 percent&nbsp;decrease in SPD of up to six target measurable nodes and extranodal sites</p> <p>When a lesion is too small to measure on CT, assign 5 mm x 5 mm as the default value</p> <p>When no longer visible, 0 x 0 mm</p> For a node &#62;5 mm x 5 mm, but smaller than normal, use actual measurement for calculation</td> </tr> <tr> <td class=\"indent1\">Nonmeasured lesions</td> <td>Not applicable</td> <td>Absent/normal, regressed, but no increase</td> </tr> <tr> <td class=\"indent1\">Organ enlargement</td> <td>Not applicable</td> <td>Spleen must have regressed by &#62;50 percent&nbsp;in length beyond normal</td> </tr> <tr> <td class=\"indent1\">New lesions</td> <td>None</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bone marrow</td> <td>Residual uptake higher than uptake in normal marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed). If there are persistent focal changes in the marrow in the context of a nodal response, consideration should be given to further evaluation with MRI or biopsy or an interval scan.</td> <td>Not applicable</td> </tr> <tr class=\"divider_bottom\"> <td>No response or stable disease</td> <td>No metabolic response</td> <td>Stable disease</td> </tr> <tr> <td class=\"indent1\">Target nodes/nodal masses, extranodal lesions</td> <td>Score 4 or 5 with no significant change in FDG uptake from baseline at interim or end of treatment</td> <td>&#60;50 percent&nbsp;decrease from baseline in SPD of up to six dominant, measurable nodes and extranodal sites; no criteria for progressive disease are met</td> </tr> <tr> <td class=\"indent1\">Nonmeasured lesions</td> <td>Not applicable</td> <td>No increase consistent with progression</td> </tr> <tr> <td class=\"indent1\">Organ enlargement</td> <td>Not applicable</td> <td>No increase consistent with progression</td> </tr> <tr> <td class=\"indent1\">New lesions</td> <td>None</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bone marrow</td> <td>No change from baseline</td> <td>Not applicable</td> </tr> <tr class=\"divider_bottom\"> <td>Progressive disease</td> <td>Progressive metabolic disease</td> <td>Progressive disease requires at least one of the following</td> </tr> <tr> <td class=\"indent1\">Individual target nodes/nodal masses</td> <td>Score 4 or 5 with an increase in intensity of uptake from baseline and/or</td> <td>PPD progression</td> </tr> <tr> <td class=\"indent1\">Extranodal lesions</td> <td>New FDG-avid foci consistent with lymphoma at interim or end-of-treatment assessment</td> <td> <p>An individual node/lesion must be abnormal with: LDi &#62;1.5 cm and</p> <p>Increase by &#8805;50 percent&nbsp;from PPD nadir and</p> <p>An increase in LDi or SDi from nadir</p> <p>0.5 cm for lesions &#8804;2 cm</p> <p>1.0 cm for lesions &#62;2 cm</p> <p>In the setting of splenomegaly, the splenic length must increase by &#62;50 percent&nbsp;of the extent of its prior increase beyond baseline (eg, a 15 cm spleen must increase to &#62;16 cm). If no prior splenomegaly, must increase by at least 2 cm from baseline.</p> New or recurrent splenomegaly</td> </tr> <tr> <td class=\"indent1\">Nonmeasured lesions</td> <td>None</td> <td>New or clear progression of preexisting nonmeasured lesions</td> </tr> <tr> <td class=\"indent1\">New lesions</td> <td>New FDG-avid foci consistent with lymphoma rather than another etiology (eg, infection, inflammation). If uncertain regarding etiology of new lesions, biopsy or interval scan may be considered</td> <td> <p>Regrowth of previously resolved lesions</p> <p>A new node &#62;1.5 cm in any axis</p> <p>A new extranodal site &#62;1.0 cm in any axis; if &#60;1.0 cm in any axis, its presence must be unequivocal and must be attributable to lymphoma</p> Assessable disease of any size unequivocally attributable to lymphoma</td> </tr> <tr> <td class=\"indent1\">Bone marrow</td> <td>New or recurrent FDG-avid foci</td> <td>New or recurrent involvement</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">5PS: 5-point scale; CT: computed tomography; FDG: fluorodeoxyglucose; IHC: immunohistochemistry; LDi: longest transverse diameter of a lesion; MRI: magnetic resonance imaging; PET: positron emission tomography; PPD: cross product of the LDi and perpendicular diameter; SDi: shortest axis perpendicular to the LDi; SPD: sum of the product of the perpendicular diameters for multiple lesions.<br />* A score of 3 in many patients indicates a good prognosis with standard treatment, especially if at the time of an interim scan. However, in trials involving PET where de-escalation is investigated, it may be preferable to consider a score of 3 as inadequate response (to avoid undertreatment). Measured dominant lesions: Up to six of the largest dominant nodes, nodal masses, and extranodal lesions selected to be clearly measurable in two diameters. Nodes should preferably be from disparate regions of the body and should include, where applicable, mediastinal and retroperitoneal areas. Non-nodal lesions include those in solid organs (eg, liver, spleen, kidneys, lungs), GI involvement, cutaneous lesions, or those noted on palpation. Nonmeasured lesions: Any disease not selected as measured, dominant disease and truly assessable disease should be considered not measured. These sites include any nodes, nodal masses, and extranodal sites not selected as dominant or measurable or that do not meet the requirements for measurability but are still considered abnormal, as well as truly assessable disease, which is any site of suspected disease that would be difficult to follow quantitatively with measurement, including pleural effusions, ascites, bone lesions, leptomeningeal disease, abdominal masses, and other lesions that cannot be confirmed and followed by imaging. In Waldeyer's ring or in extranodal sites (eg, GI tract, liver, bone marrow), FDG uptake may be greater than in the mediastinum with complete metabolic response, but should be no higher than surrounding normal physiologic uptake (eg, with marrow activation as a result of chemotherapy or myeloid growth factors).<br />¶ PET 5PS: 1, no uptake above background; 2, uptake ≤ mediastinum; 3, uptake &gt; mediastinum but ≤ liver; 4, uptake moderately &gt; liver; 5, uptake markedly higher than liver and/or new lesions; X, new areas of uptake unlikely to be related to lymphoma.</div><div class=\"graphic_reference\">Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 2014; 32(27):3059-67. Reprinted with permission. Copyright &copy; 2014 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97480 Version 4.0</div></div></div>"},"97481":{"type":"graphic_table","displayName":"PEACE tool","title":"PEACE* tool for symptom management in palliative care","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PEACE* tool for symptom management in palliative care</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"6\" width=\"13%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"7\">The answers to the questions are intended to be quantified (scale 0 - 10) with the PEACE Tool Distress Thermometer.</td> </tr> <tr> <td class=\"subtitle2\" rowspan=\"2\">In the past week, how much have you been bothered by or suffered from:</td> <td class=\"subtitle2\" colspan=\"6\">Date/Initials</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>1. Pain</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>2. Appetite loss</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>3. Incontinence of bladder or bowel</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>4. Nausea, vomiting, constipation or other bowel problems</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>5. Breathing problems or cough</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>6. Ulcers, dryness or mouth sores</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>7. Lesser (diminishing) ability to carry out daily activities and functions (cleaning, showering, lifting, walking, etc.)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>8. Feeling weak or tired or having low energy</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>9. Feeling sleepy during day and/or not sleeping at night</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>10. Feeling anxious, nervous, uneasy, tense or frightened</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>11. Feeling sad, depressed, helpless or unable to enjoy things</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>12. Feeling confused, restless or agitated</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>13. Feeling <strong>not</strong> in control of your care and/or <strong>not</strong> being understood what you want</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>14. Feeling <strong>not</strong> prepared for, and/or fearing what is still ahead of you</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>15. Feeling more need for support than your family, friends or insurance can provide</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>16. Feeling abandoned or punished by God or <strong>not</strong> supported by your church/faith</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>From the list above, which problem are you suffering the most</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>From the list above, which problem are you suffering the second most</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td colspan=\"7\">Notes (are there any <strong>other</strong> problems that have bothered you recently?) <p>&nbsp;</p> &nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*PEACE is an acronym, which stands for the Physical; Emotive; Autonomy; Communication; Economic; and Transcendent domains of quality of life.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2012 Marshfield Clinic.</div><div id=\"graphicVersion\">Graphic 97481 Version 2.0</div></div></div>"},"97484":{"type":"graphic_figure","displayName":"Model of intraabdominal abscess formation","title":"Model of intraabdominal abscess formation","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Model of intraabdominal abscess formation</div><div class=\"cntnt\"><img style=\"width:516px; height:391px;\" src=\"images/OBGYN/97484_Model_intrbdmnl_abscess_frm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mortality and abscess formation in 106 male Wistar rats receiving inoculum obtained from meat-fed animals. Mortality is expressed as cumulative percent.</div><div class=\"graphic_reference\">From: Weinstein WM, Onderdonk AB, Bartlett JG, Gorbach SL. Experimental intraabdominal abscesses in rats: Development of an experimental model. Infect Immun 1974; 10:1250. Copyright &copy; 1974. Reproduced with permission from American Society for Microbiology.</div><div id=\"graphicVersion\">Graphic 97484 Version 1.0</div></div></div>"},"97485":{"type":"graphic_table","displayName":"Antimicrobial regimens for posthysterectomy pelvic abscess","title":"Parenteral empiric antibiotic options for posthysterectomy abscess","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Parenteral empiric antibiotic options for posthysterectomy abscess</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antibiotic regimen</td> <td class=\"subtitle1\">Adult dose*</td> </tr> <tr> <td>Piperacillin-tazobactam<sup>&#182;</sup></td> <td>3.375 g IV every 6 hours</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td>Clindamycin</td> <td>900 mg IV every 8 hours</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\"><strong>PLUS</strong></td> </tr> <tr> <td>Ceftriaxone</td> <td>2 g IV every 24 hours</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td>Metronidazole</td> <td>500 mg IV every 8 hours</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\"><strong>PLUS</strong></td> </tr> <tr> <td>Ceftriaxone</td> <td>2 g IV every 24 hours</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>OR</strong></td> </tr> <tr> <td>Ertapenem<sup>&#916;</sup></td> <td>1 g IV every 24 hours</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"><strong>OR</strong></td> </tr> <tr class=\"divider_bottom\"> <td>Ticarcillin-clavulanate<sup>&#9674;</sup></td> <td>3.1 g IV every 6 hours</td> </tr> <tr> <td colspan=\"2\"><strong>Option for patients with severe hypersensitivity to penicillins or cephalosporins</strong></td> </tr> <tr> <td class=\"indent1\">Aztreonam</td> <td>1 g IV every 8 hours</td> </tr> <tr> <td class=\"sublist2\" colspan=\"2\"><strong>PLUS</strong></td> </tr> <tr> <td class=\"indent1\">Clindamycin</td> <td>900 mg IV every 8 hours</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These options reflect the expert opinion of UpToDate contributors and are not an exclusive list. The choice of antibiotic agent and dose should be individualized on the basis of patient history, local practice patterns, local community resistance prevalence, and availability.</div><div class=\"graphic_footnotes\">IV: intravenously.<br />* The doses recommended above are intended for patients with normal renal function; the doses of some of these agents must be adjusted in patients with renal insufficiency.<br />¶ This is our preferred regimen. An extended infusion of piperacillin-tazobactam (eg, 3.375 g infused over four hours every eight hours) is an alternative dosing strategy for critically ill patients or for pathogens with elevated but susceptible minimum inhibitory concentrations. Benefits over standard dosing have been suggested by some studies but not all. The extended infusion dosing regimen is at least equivalent to standard dosing and may be superior in selected patient populations.<br />Δ Ertapenem and other carbapenems are generally reserved for patients who have suspected or documented infection with resistant gram-negative bacilli, such as extended-spectrum beta-lactamase (ESBL) producing <EM>Escherichia coli </EM>or <EM>Klebsiella pneumoniae</EM>.<br /><FONT class=lozenge>◊</FONT> Ticarcillin-clavulanate is not available in the United States.</div><div class=\"graphic_reference\">Adapted from: Jaiyeoba O. Postoperative infections in obstetrics and gynecology. Clin Obstet Gynecol 2012; 55:904.</div><div id=\"graphicVersion\">Graphic 97485 Version 1.0</div></div></div>"},"97486":{"type":"graphic_picture","displayName":"PSC stage 2","title":"Primary sclerosing cholangitis: Stage 2","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Primary sclerosing cholangitis: Stage 2</div><div class=\"cntnt\"><img style=\"width:586px; height:438px;\" src=\"images/GAST/97486_PSC_stage_1_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In addition to ductular reaction (thin arrows), there is expansion of portal tracts by fibrosis extending into the surrounding parenchyma. The short arrow points to a bile duct with periductal fibrosis.</div><div id=\"graphicVersion\">Graphic 97486 Version 2.0</div></div></div>"},"97487":{"type":"graphic_picture","displayName":"PSC stage 4 cirrhosis","title":"Primary sclerosing cholangitis stage 4: Biliary cirrhosis","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Primary sclerosing cholangitis stage 4: Biliary cirrhosis</div><div class=\"cntnt\"><img style=\"width:587px; height:313px;\" src=\"images/GAST/97487_PSC_stage_4_cirrhosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this photomicrograph, the cirrhotic nodules are completely enclosed by wide, acellular fibrous septa. Note the total loss of interlobular bile ducts resulting in severe cholestasis.</div><div id=\"graphicVersion\">Graphic 97487 Version 1.0</div></div></div>"},"97492":{"type":"graphic_algorithm","displayName":"Algorithm for management of posthysterectomy abscess","title":"Algorithm for management of posthysterectomy abscess","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Algorithm for management of posthysterectomy abscess</div><div class=\"cntnt\"><img style=\"width:451px; height:155px;\" src=\"images/OBGYN/97492_Alg_mng_psthystrct_abscss.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Minimally invasive drainage is preferred if abscess is accessible, regardless of the abscess size.</div><div id=\"graphicVersion\">Graphic 97492 Version 1.0</div></div></div>"},"97493":{"type":"graphic_diagnosticimage","displayName":"Pancreatic adenocarcinoma CEUS","title":"Pancreatic ductal adenocarcinoma on contrast-enhanced ultrasound","html":"<div class=\"graphic\"><div style=\"width: 644px\" class=\"figure\"><div class=\"ttl\">Pancreatic ductal adenocarcinoma on contrast-enhanced ultrasound</div><div class=\"cntnt\"><img style=\"width:624px; height:510px;\" src=\"images/GAST/97493_Pncrtc_adenocarcinoma_CEUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pancreatic ductal adenocarcinomas are characterized by a relatively low mean vascular density, resulting in hypoenhancement on contrast-enhanced ultrasound during all vascular phases.</div><div class=\"graphic_footnotes\">DW: duct of Wirsung (main pancreatic duct); TU: tumor.</div><div id=\"graphicVersion\">Graphic 97493 Version 1.0</div></div></div>"},"97495":{"type":"graphic_diagnosticimage","displayName":"Pancreatic neuroendocrine tumor CEUS","title":"Pancreatic neuroendocrine tumor on contrast-enhanced ultrasound","html":"<div class=\"graphic\"><div style=\"width: 741px\" class=\"figure\"><div class=\"ttl\">Pancreatic neuroendocrine tumor on contrast-enhanced ultrasound</div><div class=\"cntnt\"><img style=\"width:721px; height:458px;\" src=\"images/GAST/97495_Pncrtc_nrndcrn_tumor_CEUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pancreatic neuroendocrine tumors typically present as hyperenhancing focal pancreatic lesions in the early arterial phase (A), owing to their abundant arterial vascularization. During the venous phase, rapid wash-out resulting in a hypoechoic appearance has been reported (B).</div><div class=\"graphic_footnotes\">PV: portal vein; TU: tumor.</div><div id=\"graphicVersion\">Graphic 97495 Version 1.0</div></div></div>"},"97496":{"type":"graphic_diagnosticimage","displayName":"Pancreatic serous cystadenoma CEUS","title":"Pancreatic serous cystadenoma seen on contrast-enhanced ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pancreatic serous cystadenoma seen on contrast-enhanced ultrasound</div><div class=\"cntnt\"><img style=\"width:308px; height:608px;\" src=\"images/GAST/97496_Pncrtc_srs_cystadenoma_CEUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pancreatic serous cystadenomas are characterized by microcysts that are smaller than 20 mm. The typical vascular architecture is characterized by a centrally located arterial blood supply (A - Doppler imaging). The lesion is hyperenhancing on contrast-enhanced ultrasound (B - transcutaneous ultrasound; C - endoscopic ultrasound).</div><div class=\"graphic_footnotes\">SCA: serous cystadenoma.</div><div id=\"graphicVersion\">Graphic 97496 Version 1.0</div></div></div>"},"97497":{"type":"graphic_diagnosticimage","displayName":"Main duct IPMN CEUS","title":"Main duct intraductal papillary mucinous neoplasm on contrast-enhanced ultrasound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Main duct intraductal papillary mucinous neoplasm on contrast-enhanced ultrasound</div><div class=\"cntnt\"><img style=\"width:432px; height:722px;\" src=\"images/GAST/97497_Main_duct_IPMN_CEUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Macrocystic lesions with wall thickening with visible nodules and septae are shown using a transcutaneous approach (A) and endoscopic ultrasound (B). By contrast, pseudocysts are nonenhancing (C).</div><div id=\"graphicVersion\">Graphic 97497 Version 1.0</div></div></div>"},"97498":{"type":"graphic_diagnosticimage","displayName":"Gallbladder neoplasia CEUS","title":"Gallbladder neoplasm seen on contrast-enhanced ultrasound","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Gallbladder neoplasm seen on contrast-enhanced ultrasound</div><div class=\"cntnt\"><img style=\"width:715px; height:394px;\" src=\"images/GAST/97498_Gallbladder_neoplasia_CEUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The first panel demonstrates the gallbladder on transcutaneous B-mode ultrasound. Contrast-enhanced ultrasound is performed to differentiate between gallbladder sludge and neoplasia (second panel). In the arterial phase of contrast enhancement, gallbladder neoplasms are typically enhancing (area between plus signs), whereas sludge is nonenhancing.</div><div id=\"graphicVersion\">Graphic 97498 Version 1.0</div></div></div>"},"97499":{"type":"graphic_diagnosticimage","displayName":"Intestinal abscess fistula CEUS","title":"Intestinal abscesses and fistula seen on contrast-enhanced ultrasound","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Intestinal abscesses and fistula seen on contrast-enhanced ultrasound</div><div class=\"cntnt\"><img style=\"width:726px; height:236px;\" src=\"images/GAST/97499_Intstnl_abscess_fistul_CEUS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Contrast-enhanced ultrasound is mainly helpful for distinguishing abscesses (A) from (peri-) intestinal vascularized inflammatory masses, including fistulas (B).</div><div class=\"graphic_footnotes\">Abs: abscess; BW: bowel wall; F: fistula; ??: unidentified structure.</div><div id=\"graphicVersion\">Graphic 97499 Version 1.0</div></div></div>"},"97500":{"type":"graphic_table","displayName":"Known familial AL and MDS","title":"The known familial acute leukemia and myelodysplastic syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The known familial acute leukemia and myelodysplastic syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Name of syndrome</td> <td class=\"subtitle1\">Causative gene(s)</td> <td class=\"subtitle1\">Pattern of inheritance</td> <td class=\"subtitle1\">Characteristic hematologic malignancies</td> <td class=\"subtitle1\">Other hematopoietic abnormalities</td> <td class=\"subtitle1\">Susceptibility to other malignancies</td> <td class=\"subtitle1\">Other organ systems affected</td> <td class=\"subtitle1\">CLIA-approved testing available</td> <td class=\"subtitle1\">Recommended diagnostic test</td> </tr> <tr class=\"divider_bottom\"> <td>Familial platelet disorder with propensity to myeloid malignancies (OMIM 601399)</td> <td><em>RUNX1</em></td> <td>AD</td> <td>MDS/AML/T cell ALL</td> <td>Thrombocytopenia (mild to moderate); bleeding propensity due to aspirin-like platelet dysfunction</td> <td>None</td> <td>None</td> <td>Yes</td> <td><em>RUNX1</em> exon sequencing and gene rearrangement testing</td> </tr> <tr class=\"divider_bottom\"> <td>Thrombocytopenia 2 (OMIM 188000)</td> <td><em>ANKRD26</em></td> <td>AD</td> <td>MDS/AML</td> <td>Thrombocytopenia (moderate); bleeding propensity due to platelet dysfunction</td> <td>None</td> <td>None</td> <td>No</td> <td>5'UTR and exon sequencing of <em>ANKRD26</em></td> </tr> <tr class=\"divider_bottom\"> <td>Familial AML with mutated <em>CEBPA</em> (OMIM 116897)</td> <td><em>CEBPA</em></td> <td>AD</td> <td>AML</td> <td>None</td> <td>None</td> <td>None</td> <td>Yes</td> <td><em>CEBPA</em> exon sequencing</td> </tr> <tr class=\"divider_bottom\"> <td>Familial AML with mutated <em>DDX41</em></td> <td><em>&nbsp;DDX41</em></td> <td>&nbsp;AD</td> <td>&nbsp;MDS/AML, CMML</td> <td>None</td> <td>None</td> <td>None</td> <td>Yes</td> <td>Full gene sequencing of <em>DDX41</em></td> </tr> <tr class=\"divider_bottom\"> <td>Thrombocytopenia 5 (OMIM 616216)&nbsp;</td> <td><em>ETV</em>6</td> <td>AD</td> <td>MDS/AML, CMML, B cell ALL, multiple myeloma</td> <td>Aplastic anemia</td> <td>Unclear</td> <td>None</td> <td>Yes</td> <td>Full gene sequencing of <em>ETV6</em></td> </tr> <tr class=\"divider_bottom\"> <td>Familial MDS/AML with mutated <em>GATA2</em> (OMIM 137295)</td> <td><em>GATA2</em></td> <td>AD</td> <td>MDS/AML/CMML</td> <td> <p>None</p> <p><strong>or</strong></p> Neutropenia, monocytopenia, NK cell, dendritic cell, B cell, and/or CD4+ T cell lymphopenia</td> <td>None</td> <td>Sensorineural deafness, immunodeficiency, cutaneous warts, atypical mycobacterial/viral/fungal infections, primary lymphedema, pulmonary alveolar proteinosis</td> <td>Yes</td> <td><em>GATA2</em> exon sequencing, intron 5 enhancer region sequencing, and gene rearrangement testing</td> </tr> <tr class=\"divider_bottom\"> <td>Telomere syndromes due to mutation in <em>TERC</em> (OMIM 127550) or <em>TERT</em> (OMIM 187270)</td> <td><em>TERC/TERT</em></td> <td> <p>AD</p> AR (TERT)</td> <td>MDS/AML</td> <td>Macrocytosis; mild to moderate single or multiple cytopenias; aplastic anemia</td> <td>Squamous cell carcinomas of the head/neck and anogenital regions</td> <td> <p>Pulmonary fibrosis, hepatic cirrhosis, nail dystrophy, oral leukoplakia, skin hypo- or hyperpigmentation, premature gray hair, dental caries</p> Severe AR form: cerebellar hypoplasia, immunodeficiency, developmental delay</td> <td>Yes</td> <td> <p>Full gene sequencing of <em>TERT</em> and <em>TERC</em></p> Telomere length studies of lymphocyte subsets via flow FISH can also be performed as initial screening test</td> </tr> <tr class=\"divider_bottom\"> <td>Familial aplastic anemia/MDS with <em>SRP72</em> mutation (OMIM 602122)</td> <td><em>SRP72</em></td> <td>AD</td> <td>MDS</td> <td>Aplastic anemia</td> <td>None</td> <td>Deafness</td> <td>No</td> <td><em>SRP72</em> exon sequencing</td> </tr> <tr class=\"divider_bottom\"> <td>Myeloid neoplasms with germline predisposition due to duplications of <em>ATG2B</em> and <em>GSKIP</em>&nbsp;</td> <td><em>ATG2B</em> and <em>GSKIP</em>&nbsp;</td> <td>AD&nbsp;</td> <td>AML, ET,&nbsp;CMML, myelofibrosis, CML, aCML&nbsp;</td> <td>None</td> <td>None</td> <td>None</td> <td>No</td> <td>SNP array</td> </tr> <tr class=\"divider_bottom\"> <td>Familial B cell ALL due to <em>PAX5</em> mutation (OMIM 615545)</td> <td><em>PAX5</em></td> <td>AD</td> <td>Familial ALL</td> <td>None</td> <td>None</td> <td>None</td> <td>Yes</td> <td><em>PAX5</em> exon sequencing</td> </tr> <tr class=\"divider_bottom\"> <td>Germline <em>SH2B3</em> mutation (OMIM 605093)</td> <td>SH2B3</td> <td>AR</td> <td>Familial ALL</td> <td>None</td> <td>None</td> <td>Developmental delay, autoimmunity, chronic hepatitis</td> <td>No</td> <td><em>SH2B3</em> exon sequencing</td> </tr> <tr> <td>Familial ALL due to <em>TP53</em> mutation: rare Li Fraumeni syndrome presentation (OMIM 151623)</td> <td><em>TP53</em></td> <td>AD</td> <td>Familial ALL, especially hypodiploid</td> <td>None</td> <td>None</td> <td>Breast cancer, sarcomas, malignant brain tumors, adrenocortical carcinomas</td> <td>Yes</td> <td><em>TP53</em> exon sequencing and gene rearrangement testing</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CLIA: Clinical Laboratory Improvement Amendments; aCML: atypical chronic myeloid leukemia; AD: autosomal dominant; ET: essential thrombocytosis; MDS: myelodysplastic syndrome; AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; CML: chronic myeloid leukemia; CMML: chronic myelomonocytic leukemia; AR: autosomal recessive; FISH: fluorescent in situ hybridization.</div><div class=\"graphic_reference\">Adapted from: West AH, Godley LA, Churpek JE. Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations. Ann N Y Acad Sci 2014; 1310:111.</div><div id=\"graphicVersion\">Graphic 97500 Version 3.0</div></div></div>"},"97501":{"type":"graphic_table","displayName":"Tissue source germline genetic testing in familial AL and MDS","title":"Practical considerations in selecting a tissue source for germline genetic testing in individuals with a suspected familial acute leukemia and myelodysplastic syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Practical considerations in selecting a tissue source for germline genetic testing in individuals with a suspected&nbsp;familial acute leukemia and myelodysplastic syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tissue source</td> <td class=\"subtitle1\">Major advantage</td> <td class=\"subtitle1\">Major disadvantage</td> <td class=\"subtitle1\">Cost</td> <td class=\"subtitle1\">Time required to obtain sample</td> <td class=\"subtitle1\">Tumor contamination</td> <td class=\"subtitle1\">Interpretation of genetic testing results</td> <td class=\"subtitle1\">Additional comments</td> </tr> <tr> <td>Skin fibroblasts</td> <td>Gold standard for source of germline DNA</td> <td>Requires specialized expertise</td> <td class=\"centered\">$$$</td> <td>Three to four weeks</td> <td class=\"centered\">None</td> <td>Germline</td> <td> <p>Fibroblasts are cultured from skin in a clinical laboratory</p> <p>Can be obtained easily at the site of a bone marrow biopsy</p> Required if patient had prior allogeneic stem cell transplant</td> </tr> <tr> <td>Skin</td> <td>&nbsp;</td> <td>&nbsp;</td> <td class=\"centered\">$$</td> <td>Immediate</td> <td class=\"centered\">+</td> <td>Germline or tumor*</td> <td>DNA is made directly from skin biopsy</td> </tr> <tr> <td>Saliva</td> <td>Readily available, inexpensive</td> <td>Potential tumor contamination</td> <td class=\"centered\">$</td> <td>Immediate</td> <td class=\"centered\">+</td> <td>Germline or tumor*</td> <td>&nbsp;</td> </tr> <tr> <td>Buccal swab</td> <td>Readily available, inexpensive</td> <td>Potential tumor contamination</td> <td class=\"centered\">$</td> <td>Immediate</td> <td class=\"centered\">+</td> <td>Germline or tumor*</td> <td>&nbsp;</td> </tr> <tr> <td>Peripheral blood</td> <td>Easy to obtain</td> <td>Potential tumor contamination</td> <td class=\"centered\">$</td> <td>Immediate</td> <td class=\"centered\">++</td> <td>Germline or tumor*</td> <td>&nbsp;</td> </tr> <tr> <td>Bone marrow</td> <td>&nbsp;</td> <td>Potential tumor contamination</td> <td class=\"centered\">$$$</td> <td>At time of procedure</td> <td class=\"centered\">++</td> <td>Germline or tumor*</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Depending on the depth of remission. It is important to note that even with a morphologic remission, the bone marrow may still contain clonal populations with gene mutations, and therefore gene mutations found when patients are in clinical remission cannot be assumed to be germline. For these reasons, we consider only skin fibroblasts to provide an unequivocal source of germline DNA.</div><div id=\"graphicVersion\">Graphic 97501 Version 1.0</div></div></div>"},"97502":{"type":"graphic_figure","displayName":"Suspected familial acute leukemia and MDS","title":"Evaluation of suspected familial acute leukemia and myelodysplastic syndrome","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Evaluation of suspected familial acute leukemia and myelodysplastic syndrome</div><div class=\"cntnt\"><img style=\"width:561px; height:719px;\" src=\"images/HEME/97502_Familial_acute_leukemia.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MDS: myelodysplastic syndrome; AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; AL: acute leukemia; AA: aplastic anemia; FPD: familial platelet disorder with propensity to myeloid malignancies.</div><div id=\"graphicVersion\">Graphic 97502 Version 2.0</div></div></div>"},"97503":{"type":"graphic_movie","displayName":"Throwing phases - Movie","title":"Throwing phases","html":"<div class=\"graphic normal\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Throwing phases</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/97503_Throwingphasesmovievid.mp4\" style=\"width:592px;height:352px\"></div><img style=\"width:590px; height:444px;\" src=\"images/EM/97503_Throwingphasesmovieimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 97503 Version 1.0</div></div></div>"},"97520":{"type":"graphic_algorithm","displayName":"Management of statin myopathy","title":"Management of statin myopathy","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Management of statin myopathy</div><div class=\"cntnt\"><img style=\"width:612px; height:1119px;\" src=\"images/PC/97520_Managementstatinmyopathy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CK: creatine kinase.<br />* Pravastatin and fluvastatin appear to be less likely to cause muscle toxicity than other statins.</div><div id=\"graphicVersion\">Graphic 97520 Version 3.0</div></div></div>"},"97521":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of tophus","title":"Phalangeal cartilage with tophus on ultrasound and gross anatomy","html":"<div class=\"graphic\"><div style=\"width: 877px\" class=\"figure\"><div class=\"ttl\">Phalangeal cartilage with tophus on ultrasound and gross anatomy</div><div class=\"cntnt\"><img style=\"width:857px; height:261px;\" src=\"images/RADIOL/97521_Ultrasound_tophus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The images are from a cadaveric specimen with tophaceous deposit over a proximal phalangeal joint.<br />(A) Ultrasound in transverse view of the phalangeal cartilage shows tophus (arrowhead) as a hyperechoic deposit of heterogenous echo texture with hypoechoic rim, located next to a double contour sign (arrow). The monosodium urate crystals (arrow) are seen as a fine superficial echogenic line (arrow) and the cartilage is the deeper thicker hypoechoic line (dashed arrow).<br />(B) Correlative gross anatomic photograph shows the tophus (arrowhead) and monosodium urate deposits (arrows) on the hyaline cartilage (dashed arrow).</div><div class=\"graphic_reference\">Courtesy of Eugene Kissin, MD.</div><div id=\"graphicVersion\">Graphic 97521 Version 2.0</div></div></div>"},"97523":{"type":"graphic_figure","displayName":"Feedback loops myelopoiesis","title":"Emergency and basal feedback loops regulating myelopoiesis","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Emergency and basal feedback loops regulating myelopoiesis</div><div class=\"cntnt\"><img style=\"width:531px; height:643px;\" src=\"images/HEME/97523_Feedback_loops_myelopoiesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Feedback loops regulate myelopoiesis during the acute response to infection and in the steady state. Refer to UpToDate topics on myelopoieisis for further details.</div><div class=\"graphic_footnotes\">HSC: hematopoieitic stem cell; CMP: common myeloid progenitor cell; CFU-GM: colony forming unit, granulocyte/macrophage; CFU-M: colony forming unit, macrophage; CFU-G: colony forming unit, granulocyte; T-reg: regulatory T cell; G-CSF: granulocyte colony-stimulating factor; C-CSFR: granulocyte colony-stimulating factor receptor; TLR4: toll-like receptor 4.</div><div class=\"graphic_reference\">Based on a figure created by Colin A Sieff, MB, BCh, FRCPath. </div><div id=\"graphicVersion\">Graphic 97523 Version 1.0</div></div></div>"},"97524":{"type":"graphic_picture","displayName":"Triatomine bugs PI","title":"Triatomine bugs","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Triatomine bugs</div><div class=\"cntnt\"><img style=\"width:428px; height:728px;\" src=\"images/PI/97524_Triatomine_bugs_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pictures A-E show different types of triatomine bugs. These bugs can carry the parasite that causes Chagas disease.&nbsp;As adults, they can grow to be about 1 inch long.</div><div class=\"graphic_reference\">Centers for Disease Control and Prevention. Available online at: <a href=\"http://www.cdc.gov/chagas/resources/visual_triatomine_aid.pdf\" target=\"_blank\">http://www.cdc.gov/chagas/resources/visual_triatomine_aid.pdf</a>.</div><div id=\"graphicVersion\">Graphic 97524 Version 1.0</div></div></div>"},"97525":{"type":"graphic_table","displayName":"A comparison of type 1 diabetes, type 2 diabetes and CFRD","title":"A comparison of type 1 diabetes, type 2 diabetes and cystic fibrosis-related diabetes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">A comparison of type 1 diabetes, type 2 diabetes and cystic fibrosis-related diabetes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Type 1 diabetes</td> <td class=\"subtitle1\">Type 2 diabetes</td> <td class=\"subtitle1\">CFRD</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Onset</strong></td> <td>Acute</td> <td>Insidious</td> <td>Insidious</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Peak age of onset</strong></td> <td>Children and adolescents</td> <td>Adults</td> <td>18 to 24 years</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Autoantibodies (+)</strong>*</td> <td>Yes</td> <td>No</td> <td>Rare</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Insulin secretion</strong></td> <td>Eventually absent</td> <td>Decreased</td> <td>Severely decreased but not absent</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Insulin sensitivity</strong></td> <td>Somewhat decreased</td> <td>Severely decreased</td> <td>Somewhat decreased<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td><strong>Treatment</strong></td> <td>Insulin</td> <td> <p>Diet, oral meds</p> Insulin</td> <td>Insulin</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Ketosis prone</strong></td> <td>Yes</td> <td>Rarely</td> <td>Rarely</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Microvascular complications</strong></td> <td>Yes</td> <td>Yes</td> <td>Yes (but less)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Macrovascular complications</strong></td> <td>Yes</td> <td>Yes</td> <td>Rare (case reports)<sup>[1,2]</sup></td> </tr> <tr> <td><strong>Cause of death</strong></td> <td> <p>Cardiovascular disease</p> Nephropathy</td> <td>Cardiovascular disease</td> <td>Pulmonary disease</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CFRD: cystic fibrosis-related diabetes.<br />* Islet cell autoantibodies are characteristic of type 1 diabetes mellitus, and include antibodies directed at insulin, glutamic acid decarboxylase (GAD65), the 40K fragment of tyrosine phosphatase (IA2), and/or zinc transporter 8 (ZnT8).<br />&#182; Insulin sensitivity becomes severely decreased during acute illness.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Onady GM, Farinet CL. An adult cystic fibrosis patient presenting with persistent dyspnea: case report. BMC Pulm Med 2006; 6:9.</li>&#xD;&#xA;    <li>Aratari MT, Venuta F, De Giacomo T, Rendina EA, Anile M, Diso D, et al. Lung transplantation for cystic fibrosis: ten years of experience. Transplant Proc 2008; 40:2001.</li>&#xD;&#xA;</ol>&#xD;&#xA;Modified from: O'Riordan SM, Robinson PD, Donaghue KC, Moran A. Management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes 2009; 10:43. <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1399-5448.2009.00587.x/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1111/j.1399-5448.2009.00587.x/abstract</a>. Copyright &copy; 2009. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 97525 Version 2.0</div></div></div>"},"97528":{"type":"graphic_table","displayName":"Categories of abnormal glucose tolerance in CF","title":"Categories of abnormal glucose tolerance in cystic fibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Categories of abnormal&nbsp;glucose tolerance in cystic fibrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Fasting plasma glucose before test</td> <td class=\"subtitle1\">Plasma glucose 2 hours after ingestion of 1.75 g/kg glucose</td> <td class=\"subtitle1\">Clinical outcomes</td> </tr> <tr class=\"divider_bottom\"> <td>Normal glucose tolerance (NGT)</td> <td> <p>&#60;100 mg/dL</p> (5.6 mmol/L)</td> <td> <p>&#60;140 mg/dL</p> (7.8 mmol/L)</td> <td>In general, clinically stable</td> </tr> <tr class=\"divider_bottom\"> <td>Indeterminate glycemia (INDET)</td> <td> <p>&#60;100 mg/dL</p> (5.6 mmol/L)</td> <td>&#60;140 mg/dL (7.8 mmol/L), with a mid-point peak &#62;200 mg/dL (11.1 mmol/L)</td> <td rowspan=\"2\">Clinical impact unclear but evidence suggests increased risk of morbidity</td> </tr> <tr class=\"divider_bottom\"> <td>Impaired glucose tolerance (IGT)</td> <td> <p>&#60;100 mg/dL</p> (5.6 mmol/L)</td> <td> <p>140 to 200 mg/dL</p> (7.8 to 11.1 mmol/L)</td> </tr> <tr> <td class=\"divider_bottom\">CFRD without fasting hyperglycemia</td> <td class=\"divider_bottom\"> <p>&#60;126 mg/dL</p> (7 mmol/L)</td> <td class=\"divider_bottom\"> <p>&#8805;200 mg/dL</p> (11.1 mmol/L)</td> <td rowspan=\"2\">Increased morbidity and mortality</td> </tr> <tr> <td>CFRD with fasting hyperglycemia</td> <td> <p>&#8805;126 mg/dL</p> (7 mmol/L)</td> <td>OGTT not necessary</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CFRD: cystic fibrosis-related diabetes; OGTT: oral glucose tolerance test.</div><div class=\"graphic_reference\">Modified from: Moran A, Hardin D, Rodman D, Allen HF, Beall RJ, Borowitz D, et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Research Clin Practice 1999; 45:61.</div><div id=\"graphicVersion\">Graphic 97528 Version 2.0</div></div></div>"},"97529":{"type":"graphic_picture","displayName":"Nodular scleroderma","title":"Nodular scleroderma","html":"<div class=\"graphic\"><div style=\"width: 693px\" class=\"figure\"><div class=\"ttl\">Nodular scleroderma</div><div class=\"cntnt\"><img style=\"width:673px; height:501px;\" src=\"images/DERM/97529_Nodularscleroderma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented nodules and plaques on the chest of a 51-year-old man with nodular scleroderma.</div><div class=\"graphic_reference\">From: Wriston CC, Rubin AI, Elenitsas R, Crawford GH. Nodular scleroderma:&nbsp;A report of 2 cases. Am J Dermatopathol 2008; 30:385. DOI: <a href=\"http://journals.lww.com/amjdermatopathology/pages/articleviewer.aspx?year=2008&amp;issue=08000&amp;article=00011&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/DAD.0b013e3181766177</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2008 International Society of Dermatopathology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 97529 Version 2.0</div></div></div>"},"97530":{"type":"graphic_figure","displayName":"Complications of CF by age","title":"Common complications of cystic fibrosis by age in the United States","html":"<div class=\"graphic\"><div style=\"width: 760px\" class=\"figure\"><div class=\"ttl\">Common complications of cystic fibrosis by age in the United States</div><div class=\"cntnt\"><img style=\"width:740px; height:308px;\" src=\"images/PEDS/97530_Complications_of_CF_by_age.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CF: cystic fibrosis; CFRD: cystic fibrosis-related diabetes.</div><div class=\"graphic_reference\">Reproduced with permission from: Cystic Fibrosis Foundation Patient Registry. 2012 Annual Data Report. Bethesda, Maryland. Copyright © 2013 Cystic Fibrosis Foundation. Available at:&nbsp;<A href=\"http://www.cysticfibrosisdata.org/ReportsUS.html\">http://www.cysticfibrosisdata.org/ReportsUS.html</A> (Accessed on August 31st, 2016).</div><div id=\"graphicVersion\">Graphic 97530 Version 3.0</div></div></div>"},"97532":{"type":"graphic_table","displayName":"Insulin regimens for CFRD","title":"Approach to insulin therapy for cystic fibrosis related diabetes (CFRD)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to insulin therapy for&nbsp;cystic fibrosis related diabetes (CFRD)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Indication</td> <td class=\"subtitle1\">Suggested starting doses for insulin&nbsp;</td> </tr> <tr> <td>Patient with&nbsp;high blood glucose on OGTT, or random hyperglycemia with worsening lung function and weight loss</td> <td> <p>Long-acting (basal) insulin 0.1 units/kg every morning. For patients on glucocorticoids, use starting dose&nbsp;of insulin 0.2 units/kg.</p> <p>Increase dose by increments of 0.1 units, aiming for postprandial blood glucose &#60;140 mg/dL (7.8 mmol/L), without hypoglycemia.</p> </td> </tr> <tr> <td>Hypoglycemia&nbsp;prior to the midday meal when basal insulin is given in the morning, or&nbsp;postprandial blood glucose is in target range, but A1C is high&nbsp;</td> <td>Split the&nbsp;basal insulin twice per day (2/3 in morning, 1/3 in evening), and increase the dose incrementally&nbsp;up to a maximum of&nbsp;0.5 units/kg. &nbsp;</td> </tr> <tr> <td>Inability to reach glycemic targets on basal insulin alone&nbsp;&nbsp;</td> <td>Add prandial insulin (0.5 units rapid-acting insulin for each 15 g carbohydrate, given just prior to the meal),&nbsp;in addition to basal insulin. &nbsp;</td> </tr> <tr> <td>Hyperglycemia in hospital for infection or pulmonary exacerbation, <span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">or patient on glucocorticoids.</span></td> <td><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">Increase starting dose of basal insulin to 0.2 units/kg. Most patients also require prandial insulin during intercurrent infections</span>. &nbsp;</td> </tr> <tr> <td>High blood glucose in patient on overnight enteral feeds</td> <td>Basal insulin 0.1 units/kg at bedtime, or combination of short-acting and intermediate-acting insulin.</td> </tr> <tr> <td><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">Difficulties reaching glycemic goals with above regimens, and/or desire for more convenient or </span>physiological insulin replacement</td> <td>Continuous subcutaneous insulin infusion (insulin pump).&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CFRD: cystic fibrosis related diabetes; OGTT: oral glucose tolerance test; A1C: hemoglobin A1C (glycated hemoglobin).</div><div id=\"graphicVersion\">Graphic 97532 Version 1.0</div></div></div>"},"97533":{"type":"graphic_table","displayName":"Monitoring of patients with CFRD","title":"Monitoring of patients with suspected or established cystic fibrosis-related diabetes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Monitoring of patients with suspected or established cystic fibrosis-related diabetes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td>Blood glucose </td> <td> <ul> <li>Post prandial &#8212; Target &#60;140 mg/dL (7.8 mmol/L) at one to two hours. </li> <li>Fasting blood glucose&nbsp;&#8212; Target&nbsp;70 to 90 mg/dL (3.9 to 5 mmol/L), when on basal insulin. </li> </ul> </td> </tr> <tr> <td>Hemoglobin A1c</td> <td>Check every three months. Aim for low-normal values (eg, &#60;5.5 percent). A1C values should decrease after initiating insulin.</td> </tr> <tr> <td>Continuous glucose monitoring&nbsp;</td> <td> <ul> <li>For screening&nbsp;&#8212;&nbsp;May be helpful&nbsp;if a patient has dysglycemia and indications for insulin treatment are unclear. </li> <li>For treatment&nbsp;&#8212; Suggested if a patient is on insulin but has poor growth.&nbsp; </li> </ul> </td> </tr> <tr> <td>Complications screening<sup>[1]</sup></td> <td> <p>Blood pressure measurement at all routine visits.&nbsp;&nbsp;</p> <p>Annual screening for microvascular complications, beginning five years after the diagnosis of CFRD:</p> <ul> <li>Dilated eye examination for retinopathy </li> <li>Urine albumin/creatinine ratio (spot specimen) </li> <li>Foot exam with testing for vibration (tuning fork) and pressure (10 g monofilament) </li> <li>Lipid profile for selected patients with&nbsp;risk factors for hyperlipidemia (post transplantation, obesity, or family history of early coronary artery disease)&nbsp;&nbsp; </li> </ul> </td> </tr> <tr> <td>Pulmonary function testing</td> <td>Perform&nbsp;every three months&nbsp;to&nbsp;assess lung function. Optimal therapy for CFRD tends to improve pulmonary function.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">A1C: hemoglobin A1C (glycated hemoglobin); CFRD: cystic fibrosis related diabetes.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>​Moran A, Brunzell C, Cohen RC, et al. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010; 33:2697.</LI></OL></div><div id=\"graphicVersion\">Graphic 97533 Version 2.0</div></div></div>"},"97534":{"type":"graphic_picture","displayName":"Dengue rash","title":"Rash in dengue fever","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Rash in dengue fever</div><div class=\"cntnt\"><img style=\"width:725px; height:250px;\" src=\"images/ID/97534_Dengue_rash.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Undifferentiated macular or maculopapular rash may occur over the face, thorax, abdomen, and extremities during the acute phase of dengue. The rash is typically macular or maculopapular and may be associated with pruritus.<br />(B) Convalescent rash is characterized by confluent erythematous eruption with sparing areas of normal skin. It is often pruritic. The rash typically occurs within one to two days of defervescence and lasts one to five days.<br /></div><div class=\"graphic_reference\">Courtesy of Alan Rothman, MD.</div><div id=\"graphicVersion\">Graphic 97534 Version 2.0</div></div></div>"},"97535":{"type":"graphic_algorithm","displayName":"Approach to pediatric nontraumatic chest pain","title":"Approach to pediatric nontraumatic chest pain","html":"<div class=\"graphic\"><div style=\"width: 858px\" class=\"figure\"><div class=\"ttl\">Approach to pediatric nontraumatic chest pain</div><div class=\"cntnt\"><img style=\"width:838px; height:950px;\" src=\"images/EM/97535_Apprch_pdtrc_atrmtc_chst_pn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PALS: pediatric advanced life support.<br />* For example, history of congenital heart disease, heart transplant, Kawasaki disease in the patient or family history of cardiomyopathy or relatives who died suddenly before the age of 50 years.<br />&para; Risk factors for PE in children include immobility, oral contraceptive use, pregnancy termination, ventriculoatrial shunts for hydrocephalus, central venous catheters, solid tumors, heart disease, infection, dehydration, hypercoagulable states, low cardiac output, and obesity.</div><div id=\"graphicVersion\">Graphic 97535 Version 2.0</div></div></div>"},"97536":{"type":"graphic_table","displayName":"Presentations of factitious disorder","title":"Presentations of factitious disorder with predominantly physical signs and symptoms with means of simulation and possible methods of detection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Presentations of factitious disorder with predominantly physical signs and symptoms with means of simulation and possible methods of detection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Presentation</td> <td class=\"subtitle1\">Means of simulation that have been reported</td> <td class=\"subtitle1\">Possible methods of detection</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Autoimmune</td> </tr> <tr> <td class=\"indent1\">Goodpasture's syndrome</td> <td>False history, adding blood to urine</td> <td>Bronchoalveolar lavage negative for hemosiderin-laden cells</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Systemic lupus erythematosus</td> <td>Malar rash simulated through cosmetics, feigning joint pain</td> <td>Negative antinuclear antibody test, removability of rash</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Dermatological</td> </tr> <tr> <td class=\"indent1\">Burns</td> <td>Chemical agents such as oven cleaner</td> <td>Unnatural shape of lesions, streaks left by chemicals, minor injury to fingers</td> </tr> <tr> <td class=\"indent1\">Excoriations</td> <td>Self-infliction</td> <td>Found on accessible parts of the body, or, eg, a preponderance of left-sided lesions in a right-handed person</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Lesions</td> <td>Injection of exogenous material such as talc, milk, or gasoline</td> <td>Puncture marks left by needles, discovery of syringes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Endocrine</td> </tr> <tr> <td class=\"indent1\">Cushing's syndrome</td> <td>Steroid ingestion</td> <td>Evidence of exogenous steroid use</td> </tr> <tr> <td class=\"indent1\">Hyperthyroidism</td> <td>Thyroxine or L-iodothyronine ingestion</td> <td>The 24-hr I-131 uptake is suppressed in factitious disease and increased in Graves' disease</td> </tr> <tr> <td class=\"indent1\">Hypoglycemia or insulinoma</td> <td> <ol class=\"numbers_to_nine\"> <li>Insulin injection, </li> <li>ingestion of oral hypoglycemics </li> </ol> </td> <td> <ol class=\"numbers_to_nine\"> <li>Insulin to C-peptide ratio &#62;1, detection of serum insulin antibodies, </li> <li>serum levels of hypoglycemic medication </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pheochromocytomy</td> <td>Epinephrine or metaraminol injection</td> <td>Analysis of urinary catecholamines may reveal epinephrine only or other suspicious findings</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Gastrointestinal</td> </tr> <tr> <td class=\"indent1\">Diarrhea</td> <td>Phenolphthalein or castor oil ingestion</td> <td>Testing of stool for laxatives, increased stool weight</td> </tr> <tr> <td class=\"indent1\">Hemoptysis</td> <td>Contamination of sputum sample, self-induced trauma such as cuts to tongue</td> <td>Collect specimen under observation, examine mouth</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ulcerative colitis</td> <td>Laceration of colon with knitting needle</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Hematological</td> </tr> <tr> <td class=\"indent1\">Aplastic anemia</td> <td>Self-administration of chemotherapeutic agents to suppress bone marrow</td> <td>Hematology/oncology consultation</td> </tr> <tr> <td class=\"indent1\">Anemia</td> <td>Self-induced phlebotomy</td> <td>Blood studies</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Coagulopathy</td> <td>Ingestion of warfarin or other anticoagulants</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Infectious disease</td> </tr> <tr> <td class=\"indent1\">Abdominal abscess</td> <td>Injection of feces into abdominal wall</td> <td>Unusual pathogens in microbiology tests</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">AIDS</td> <td>False history</td> <td>Collateral information</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Neoplastic</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cancer</td> <td>False medical and family history, shaving head to simulate chemotherapy</td> <td>Collateral information, examination</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Neurologic</td> </tr> <tr> <td class=\"indent1\">Paraplegia or quadriplegia</td> <td>Feigning, fictitious history</td> <td>Imaging studies, electromyography</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Seizures</td> <td>Feigning, fictitious history</td> <td>Video electroencephalogram</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Obstetrics/gynecology</td> </tr> <tr> <td class=\"indent1\">Antepartum hemorrhage</td> <td>Vaginal puncture wounds, use of fake blood</td> <td>Examination, test blood</td> </tr> <tr> <td class=\"indent1\">Ectopic pregnancy</td> <td>Feigning abdominal pain while self-injecting human chorionic gonadotropin</td> <td>Ultrasound</td> </tr> <tr> <td class=\"indent1\">Menorrhagia</td> <td>Using stolen blood</td> <td>Type blood</td> </tr> <tr> <td class=\"indent1\">Placenta previa</td> <td>Intravaginal use of hat pin</td> <td>Examination</td> </tr> <tr> <td class=\"indent1\">Premature labor</td> <td>Feigned uterine contractions, manipulation of tocodynamometer</td> <td>Examination</td> </tr> <tr> <td class=\"indent1\">Premature rupture of membranes</td> <td>Voiding urine into vagina</td> <td>Examine fluid</td> </tr> <tr> <td class=\"indent1\">Trophoblastic disease</td> <td>Addition of human chorionic gonadotropin to urine</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Vaginal bleeding</td> <td>Self-mutilation with fingernails, nail files, bleach, knives, tweezers, nutpicks, glass, pencils</td> <td>Examination</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vaginal discharge</td> <td>Applying cigarette ash to underwear</td> <td>Examination</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Systemic</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Fever</td> <td>Warming thermometer against a light bulb or other heat source, drinking hot fluids, friction from mouth or anal sphincter, false recordings, injection of pyrogens such as feces, vaccines, thyroid hormone, or tetanus toxoid</td> <td>Simultaneous taking of temperature from two different locals (orally and rectally), recording the temperature of freshly voided urine, the appearance of cool skin despite high thermometer readings, normal white blood cell count, unusually high or inconsistent temperatures</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Urinary</td> </tr> <tr> <td class=\"indent1\">Bacteriuria</td> <td>Contamination of urethra or specimen</td> <td>Unusual pathogen</td> </tr> <tr> <td class=\"indent1\">Hematuria</td> <td>Contamination of specimen with blood or meat, warfarin ingestion, foreign bodies in bladder (pins)</td> <td>Collect specimen under observation</td> </tr> <tr> <td class=\"indent1\">Proteinuria</td> <td>Inserting egg protein into urethra</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Stones</td> <td>Feigning of renal colic pain, bringing in stones made of exogenous materials or inserting them into urethra</td> <td>Pathology report</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Wang DL, Powsner S, Eisendrath SJ. Factitious Disorder. In: Kaplan and Sadock's Comprehensive Textbook of Psychiatry, Sadock BJ, Sadock VA, Kaplan HI (Eds), Lippincott Williams &amp; Wilkins, 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 97536 Version 2.0</div></div></div>"},"97537":{"type":"graphic_picture","displayName":"Keloids back","title":"Keloids","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Keloids</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/97537_Keloids_back.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with large spontaneous keloids on the upper back.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 97537 Version 1.0</div></div></div>"},"97539":{"type":"graphic_table","displayName":"Dermatologic manifestations of relapsing polychondritis","title":"Dermatologic manifestations of relapsing polychondritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dermatologic manifestations of relapsing polychondritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Dermatologic manifestation</td> <td class=\"subtitle1\">Relapsing polychondritis (no associated disease)<br /> (n = 127)</td> <td class=\"subtitle1\">Relapsing polychondritis with myelodysplastic syndrome (MDS)<br /> (n = 22)</td> <td class=\"subtitle1\">Relapsing polychondritis with (non-MDS) associated disease*<br /> (n = 51)</td> </tr> <tr> <td class=\"subtitle2\">Number (percent)</td> <td class=\"subtitle2\">Number (percent)</td> <td class=\"subtitle2\">Number (percent)</td> </tr> <tr> <td>Total with skin manifestation</td> <td class=\"centered\">45 (35)</td> <td class=\"centered\">20 (91)</td> <td class=\"centered\">&ndash;&ndash;<sup>&#182;</sup></td> </tr> <tr> <td>Oral aphthosis only</td> <td class=\"centered\">14 (11)</td> <td class=\"centered\">2 (9)</td> <td class=\"centered\">4 (8)</td> </tr> <tr> <td>Complex aphthosis</td> <td class=\"centered\">7 (6)</td> <td class=\"centered\">2 (9)</td> <td class=\"centered\">3 (6)</td> </tr> <tr> <td>White oral lesion</td> <td class=\"centered\">0 (0)</td> <td class=\"centered\">1 (5)</td> <td class=\"centered\">0 (0)</td> </tr> <tr> <td>Purpura</td> <td class=\"centered\">13 (10)</td> <td class=\"centered\">9 (41)</td> <td class=\"centered\">4 (8)</td> </tr> <tr> <td>Livedo reticularis</td> <td class=\"centered\">7 (6)</td> <td class=\"centered\">5 (23)</td> <td class=\"centered\">2 (4)</td> </tr> <tr> <td>Urticarial papules</td> <td class=\"centered\">5 (4)</td> <td class=\"centered\">7 (32)</td> <td class=\"centered\">4 (8)</td> </tr> <tr> <td>Bluish-red papules</td> <td class=\"centered\">5 (4)</td> <td class=\"centered\">5 (23)</td> <td class=\"centered\">0 (0)</td> </tr> <tr> <td>Erythema elevatum diutinum</td> <td class=\"centered\">1 (1)</td> <td class=\"centered\">1 (5)</td> <td class=\"centered\">0 (0)</td> </tr> <tr> <td>Nodules on the limbs</td> <td class=\"centered\">19 (15)</td> <td class=\"centered\">9 (41)</td> <td class=\"centered\">7 (14)</td> </tr> <tr> <td>Superficial phlebitis</td> <td class=\"centered\">8 (6)</td> <td class=\"centered\">6 (27)</td> <td class=\"centered\">1 (2)</td> </tr> <tr> <td>Sterile pustules</td> <td class=\"centered\">9 (7)</td> <td class=\"centered\">4 (18)</td> <td class=\"centered\">0 (0)</td> </tr> <tr> <td>Ulcerations on the limbs</td> <td class=\"centered\">6 (5)</td> <td class=\"centered\">3 (14)</td> <td class=\"centered\">3 (6)</td> </tr> <tr> <td>Distal necrosis</td> <td class=\"centered\">4 (3)</td> <td class=\"centered\">1 (5)</td> <td class=\"centered\">2 (4)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Some manifestations may be related to either relapsing polychondritis or the associated disease. Associated diseases include systemic lupus erythematosus, rheumatoid arthritis, mixed connective tissue disease, dermatomyositis, granulomatosus with polyangiitis (Wegener's), autoimmune thyroid disease, spondyloarthritis, multiple myeloma, inflammatory bowel disease, and aseptic abscesses.<br />¶ Total number of patients with any manifestation not provided.</div><div class=\"graphic_reference\">Original data from: Frances C, El Rassi R, Laporte JL, et al. Dermatologic manifestations of relapsing polychondritis: A study of 200 cases at a single center. Medicine 2001; 80:173.</div><div id=\"graphicVersion\">Graphic 97539 Version 2.0</div></div></div>"},"97540":{"type":"graphic_table","displayName":"Systemic diseases associated with relapsing polychondritis","title":"Systemic diseases reported in association with relapsing polychondritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Systemic diseases reported in association with relapsing polychondritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease categories</td> <td class=\"subtitle1\">Subtypes</td> </tr> <tr> <td>Systemic vasculitis</td> <td>ANCA-associated vasculitis, aortitis, Beh&#231;et's disease, hepatitis C, polyarteritis nodosa</td> </tr> <tr> <td>Rheumatoid arthritis</td> <td>Seropositive rheumatoid arthritis, juvenile&nbsp;idiopathic arthritis</td> </tr> <tr> <td>Systemic autoimmune rheumatic diseases (\"connective tissue diseases\")</td> <td>Systemic lupus erythematosus, Sj&#246;gren's syndrome, systemic sclerosis</td> </tr> <tr> <td>Spondyloarthritis</td> <td>Ankylosing spondylitis, reactive arthritis, psoriatic arthritis</td> </tr> <tr> <td>Hematologic diseases</td> <td>Myelodysplastic syndrome, lymphoma</td> </tr> <tr> <td>Gastrointestinal diseases</td> <td>Inflammatory bowel disease, primary biliary cirrhosis</td> </tr> <tr> <td>Miscellaneous inflammatory disorders</td> <td>Sweet syndrome, retroperitoneal fibrosis, meningoencephalitis, familial Mediterranean fever, sarcoidosis, immune restoration with antiretroviral therapy for HIV infection</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ANCA: antineutrophil cytoplasmic antibody; HIV: human immunodeficiency virus.</div><div id=\"graphicVersion\">Graphic 97540 Version 1.0</div></div></div>"},"97541":{"type":"graphic_diagnosticimage","displayName":"Lip gland histopathology in Sjögren’s syndrome","title":"Lip gland histopathology in Sjögren's syndrome","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">Lip gland histopathology in Sj&ouml;gren's syndrome</div><div class=\"cntnt\"><img style=\"width:728px; height:342px;\" src=\"images/RHEUM/97541_Lip_gland_Sjogrens_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) High-power view showing a portion of a normal salivary gland lobule with mucous acini and a striated duct (arrow).<br />(B) Low-power view showing a salivary gland lobule with two focal areas of lymphocytic infiltration (arrows). This histopathologic pattern is known as \"focal lymphocytic sialadenitis\" and is characteristic of Sjögren's syndrome.<br />(C) High-power view of a lymphocytic infiltrate with a germinal center-like structure. These are present in approximately 20% of minor salivary gland biopsies.</div><div class=\"graphic_reference\">Courtesy of Alan Baer, MD.</div><div id=\"graphicVersion\">Graphic 97541 Version 1.0</div></div></div>"},"97543":{"type":"graphic_table","displayName":"Partial versus complete hydatidiform mole","title":"Pathologic and genetic features of hydatidiform mole","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pathologic and genetic features of hydatidiform mole</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Complete</td> <td class=\"subtitle1\">Partial</td> </tr> <tr> <td><strong>Fetal or embryonic tissue</strong></td> <td>Absent</td> <td>Present</td> </tr> <tr> <td><strong>Hydatidiform swelling of chorionic villi</strong></td> <td>Diffuse</td> <td>Focal</td> </tr> <tr> <td><strong>Trophoblastic hyperplasia</strong></td> <td>Diffuse</td> <td>Focal</td> </tr> <tr> <td><strong>Scalloping of chorionic villi</strong></td> <td>Absent</td> <td>Present</td> </tr> <tr> <td><strong>Trophoblastic stromal inclusions</strong></td> <td>Absent</td> <td>Present</td> </tr> <tr> <td><strong>Karyotype</strong></td> <td>46XX; 46XY; all chromosomes are paternal in origin</td> <td>69XXY; 69XYY; <span style=\"font-size: 10pt; font-family: 'Tahoma',sans-serif; color: black;\">69 XXX; </span>extra set of chromosomes is paternal in origin</td> </tr> <tr> <td><strong>Immunochemistry</strong>*</td> <td>p57-negative</td> <td>p57-positive</td> </tr> <tr> <td><strong>Risk of gestational trophoblastic neoplasia</strong></td> <td>15 to 20%</td> <td>1 to 5%</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* p57 is expressed only on the maternal allele.</div><div class=\"graphic_reference\">Adapted from: Berkowitz RS, Goldstein DP. The management of molar pregnancy and gestational trophoblastic tumors. In: Knapp RC, Berkowitz RS, eds. Gynecologic oncology. New York: MacMillan, 1993.</div><div id=\"graphicVersion\">Graphic 97543 Version 2.0</div></div></div>"},"97546":{"type":"graphic_table","displayName":"Stages of MS","title":"Stages of mitral stenosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Stages of mitral stenosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"4\" width=\"20%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Valve anatomy</td> <td class=\"subtitle1\">Valve hemodynamics</td> <td class=\"subtitle1\">Hemodynamic consequences</td> <td class=\"subtitle1\">Symptoms</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">A</td> <td>At risk of MS</td> <td> <ul> <li>Mild valve doming during diastole </li> </ul> </td> <td>Normal transmitral flow velocity</td> <td>None</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">B</td> <td>Progressive MS</td> <td> <ul> <li>Rheumatic valve changes with commissural fusion and diastolic doming of the mitral valve leaflets </li> <li>Planimetered MVA &#62;1.5 cm<sup>2</sup> </li> </ul> </td> <td> <ul> <li>Increased transmitral flow velocities </li> <li>MVA &#62;1.5 cm<sup>2</sup> </li> <li>Diastolic pressure half-time &#60;150 ms </li> </ul> </td> <td> <ul> <li>Mild-to-moderate LA enlargement </li> <li>Normal pulmonary pressure at rest </li> </ul> </td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">C</td> <td>Asymptomatic, severe MS</td> <td> <ul> <li>Rheumatic valve changes with commissural fusion and diastolic doming of the mitral valve leaflets </li> <li>Planimetered MVA &#8804;1.5 cm<sup>2</sup> </li> <li>(MVA &#8804;1 cm<sup>2</sup> with very severe MS) </li> </ul> </td> <td> <ul> <li>MVA &#8804;1.5 cm<sup>2</sup> </li> <li>(MVA &#8804;1 cm<sup>2</sup> with very severe MS) </li> <li>Diastolic pressure half-time &#8805;150 ms </li> <li>(Diastolic pressure half-time &#8805;220 ms with very severe MS) </li> </ul> </td> <td> <ul> <li>Severe LA enlargement </li> <li>Elevated PASP &#62;30 mmHg </li> </ul> </td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">D</td> <td>Symptomatic severe MS</td> <td> <ul> <li>Rheumatic valve changes with commissural fusion and diastolic doming of the mitral valve leaflets </li> <li>Planimetered MVA &#8804;1.5 cm<sup>2</sup> </li> </ul> </td> <td> <ul> <li>MVA &#8804;1.5 cm<sup>2</sup> </li> <li>(MVA &#8804;1 cm<sup>2</sup> with very severe MS) </li> <li>Diastolic pressure half-time &#8805;150 ms </li> <li>(Diastolic pressure half-time &#8805;220 ms with very severe MS) </li> </ul> </td> <td> <ul> <li>Severe LA enlargement </li> <li>Elevated PASP &#62;30 mmHg </li> </ul> </td> <td> <ul> <li>Decreased exercise tolerance </li> <li>Exertional dyspnea </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The transmitral mean pressure gradient should be obtained to further determine the hemodynamic effect of the MS and is usually &gt;5 to 10 mmHg in severe MS; however, due to the variability of the mean pressure gradient with heart rate and forward flow, it has not been included in the criteria for severity.</div><div class=\"graphic_footnotes\">LA: left atrial; LV: left ventricular; MS: mitral stenosis; MVA: mitral valve area; PASP: pulmonary artery systolic pressure.</div><div class=\"graphic_reference\">Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97546 Version 2.0</div></div></div>"},"97548":{"type":"graphic_picture","displayName":"MR tractography of axonal regeneration","title":"Magnetic resonance tractography demonstrating axonal regeneration","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance tractography demonstrating axonal regeneration</div><div class=\"cntnt\"><img style=\"width:597px; height:722px;\" src=\"images/NEURO/97548_MRtractogrphyaxonalrgnrt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Operative exploration of the left peroneal nerve identified a damaged, scarred deep peroneal nerve branch (arrow, panel A) and relatively preserved superficial peroneal nerve branch (asterisk, panels A and B). The deep peroneal nerve branch was resected and the resulting defect bridged with three sural nerve grafts (arrowheads, panel B). A thresholded fractional anisotropy (FA) map (panel C) is shown fused to the corresponding axial T1-weighted image. The proximal common peroneal nerve is identified as a region of increased FA signal (arrow), and is encircled by a region of interest used to calculate average FA values. Preoperative magnetic resonance (MR) tractography demonstrates the proximal stump of the deep peroneal nerve branch with no axons identified distal to the point of transection (arrow, panel D), and T2-weighted, fat-suppressed imaging of the proximal left leg identifies denervation edema in deep-peroneal innervated muscles (tibialis anterior and extensor digitorum longus, arrowhead). Repeat MR tractography performed one month after surgical repair identifies sparse, disorganized axons distal to the proximal graft neurorrhaphy (arrow), and persistent muscle edema (panel E). Tractography performed 13 months after nerve graft repair demonstrates an organized bundle of fibers traversing the nerve grafts and resolution of muscle edema (panel F).</div><div class=\"graphic_reference\">From: Simon NG, Narvid J, Cage T, et al. Visualizing axon regeneration after peripheral nerve injury with magnetic resonance tractography. Neurology 2014; 83:1382. DOI: <A spellcheck=true href=\"http://www.neurology.org/content/83/15/1382.extract\" target=_blank>10.1212/WNL.0000000000000861</A>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright © 2014 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 97548 Version 3.0</div></div></div>"},"97549":{"type":"graphic_diagnosticimage","displayName":"Radiograph of myositis ossificans of the quadriceps","title":"Myositis ossificans of the quadriceps on plain radiograph","html":"<div class=\"graphic\"><div style=\"width: 861px\" class=\"figure\"><div class=\"ttl\">Myositis ossificans of the quadriceps on plain radiograph</div><div class=\"cntnt\"><img style=\"width:841px; height:381px;\" src=\"images/RADIOL/97549_Rdgrph_mysts_ossfcns_qdrcp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The A-P (A) and frog leg lateral (B) views of the right hip show extensive soft tissue calcification (arrows) of the right quadriceps muscle. A history of trauma was elicited.</div><div class=\"graphic_footnotes\">A-P: anteroposterior.</div><div class=\"graphic_reference\">Courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 97549 Version 1.0</div></div></div>"},"97550":{"type":"graphic_diagnosticimage","displayName":"CT scan of myositis ossificans in the quadriceps","title":"Myositis ossificans of the quadriceps on CT","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Myositis ossificans of the quadriceps on CT</div><div class=\"cntnt\"><img style=\"width:374px; height:468px;\" src=\"images/RADIOL/97550_CT_scn_mysts_ossfcns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The coronal reconstruction of a CT scan of the right thigh shows heterotopic bone formation within the soft tissues of the quadriceps muscle (arrows) with bridging to the pelvis (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 97550 Version 1.0</div></div></div>"},"97567":{"type":"graphic_picture","displayName":"Tourniquet test","title":"Tourniquet test","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Tourniquet test</div><div class=\"cntnt\"><img style=\"width:586px; height:439px;\" src=\"images/ID/97567_Tourniquet_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Microvascular fragility may be demonstrated by a positive \"tourniquet test\"; this test is performed by inflating a blood pressure cuff on the arm to midway between systolic and diastolic blood pressures for five minutes. The pressure is released for at least one minute and the skin below the cuff is examined for petechiae. A finding of 10 or more petechiae in a one square inch area is considered positive.</div><div class=\"graphic_reference\">Courtesy of Siripen Kalayanarooj, MD.</div><div id=\"graphicVersion\">Graphic 97567 Version 2.0</div></div></div>"},"97569":{"type":"graphic_figure","displayName":"S-ICD pulse generator and electrode","title":"Subcutaneous implantable cardioverter-defibrillator (S-ICD) pulse generator and electrode","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Subcutaneous implantable cardioverter-defibrillator (S-ICD) pulse generator and electrode</div><div class=\"cntnt\"><img style=\"width:516px; height:582px;\" src=\"images/CARD/97569_Pulse_generator_electrode.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photograph showing the pulse generator (center) and electrode for a subcutaneous implantable cardioverter-defibrillator (S-ICD).</div><div class=\"graphic_reference\">Image provided courtesy of Boston Scientific. Copyright &copy; 2014 Boston Scientific Corporation or its affiliates. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97569 Version 1.0</div></div></div>"},"97570":{"type":"graphic_figure","displayName":"Chlamydia rates of reported cases by race/ethnicity US 2012-2016","title":"Chlamydia: Rates of reported cases by race/ethnicity, United States, 2012-2016","html":"<div class=\"graphic\"><div style=\"width: 806px\" class=\"figure\"><div class=\"ttl\">Chlamydia: Rates of reported cases by race/ethnicity, United States, 2012-2016</div><div class=\"cntnt\"><img style=\"width:786px; height:327px;\" src=\"images/ID/97570_Chlamydiaraceethncty2016.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">NOTE: Includes 46 states reporting race/ethnicity data in Office of Management and Budget compliant formats during 2012-2016.</div><div class=\"graphic_footnotes\">AI/AN: American Indians/Alaska Natives; NH/OPI: Native Hawaiians/Other Pacific Islanders.</div><div class=\"graphic_reference\">Reproduced from: Sexually Transmitted Disease Surveillance 2016. Centers for Disease Control and Prevention. Available at: <A href=\"https://www.cdc.gov/std/stats16/chlamydia.htm\" target=_blank>https://www.cdc.gov/std/stats16/chlamydia.htm</A> (Accessed on October 26, 2017).</div><div id=\"graphicVersion\">Graphic 97570 Version 4.0</div></div></div>"},"97571":{"type":"graphic_figure","displayName":"Anatomy for pancreatic adenocarcinoma","title":"Anatomy for pancreatic adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Anatomy for pancreatic adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:520px; height:456px;\" src=\"images/ONC/97571_Anatomy_for_pancreatic_adenocarcinoma.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 97571 Version 1.0</div></div></div>"},"97572":{"type":"graphic_figure","displayName":"Continuum of resectability for pancreatic adenocarcinoma","title":"Continuum of resectability for pancreatic adenocarcinoma","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Continuum of resectability for pancreatic adenocarcinoma</div><div class=\"cntnt\"><img style=\"width:491px; height:442px;\" src=\"images/ONC/97572_Continuum_resectability.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SMV: superior mesenteric vein; SMA: superior mesenteric artery; CT: computed tomography; EUS: endoscopic ultrasound.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology, <a href=\"http://www.nccn.org/\" target=\"_blank\">www.nccn.org</a>.</li>&#xD;&#xA;    <li>Seufferlein T, Bachet JB, Van Cutsem E, et al. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 Suppl 7:vii33.</li>&#xD;&#xA;    <li>Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009; 16:1727.</li>&#xD;&#xA;    <li>Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014; 371:1039.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 97572 Version 3.0</div></div></div>"},"97579":{"type":"graphic_figure","displayName":"Oxygen cascade at sea level and 4300 meters","title":"Oxygen cascade at sea level and 4300 meters","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Oxygen cascade at sea level and 4300 meters</div><div class=\"cntnt\"><img style=\"width:467px; height:477px;\" src=\"images/EM/97579_O2cascade.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: McArdle WD, Katch FI, Katch VL. Exercise Physiology: Nutrition, Energy, and Human Performance, 8th ed, Lippincott Williams &amp; Wilkins,&nbsp;Philadelphia&nbsp;2014. Copyright &copy; 2014 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 97579 Version 4.0</div></div></div>"},"97598":{"type":"graphic_table","displayName":"Contribution of oxaliplatin to treatment of rectal cancer","title":"Contribution of oxaliplatin to treatment of localized rectal cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contribution of oxaliplatin to treatment of localized rectal cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Study<br /> author, year</td> <td class=\"subtitle1\">RT dose, Gy</td> <td class=\"subtitle1\">Chemotherapy during RT</td> <td class=\"subtitle1\">Adjuvant chemotherapy</td> <td class=\"subtitle1\">Long term outcomes</td> </tr> <tr class=\"divider_bottom\"> <td> <p>STAR-01</p> Aschele C, 2011<sup>[1]</sup></td> <td class=\"centered\">50.4</td> <td class=\"centered\"> <p>FU</p> <p>(225 mg/m<sup>2</sup>/day)</p> <p>+/&ndash;</p> <p>oxaliplatin</p> (60 mg/m<sup>2</sup> weekly)</td> <td class=\"centered\">FU-based adjuvant therapy was encouraged but not specified</td> <td class=\"centered\">Not reported</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"> <p>ACCORD/PRODIGE1</p> Gerard JP, 2010, 2012<sup>[2,3]</sup></td> <td class=\"centered\">45</td> <td class=\"centered\"> <p>Capecitabine</p> <p>(800 mg twice daily five days/week)</p> <strong>versus</strong></td> <td class=\"centered divider_bottom\" rowspan=\"2\"> <p>Left to discretion of participating institutes</p> <p>+</p> not reported</td> <td class=\"divider_bottom centered\" rowspan=\"2\">No SS difference in OS</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">50</td> <td class=\"centered\"> <p>Capecitabine</p> <p>(800 mg twice daily five days/week)</p> <p>+</p> <p>oxaliplatin</p> (50 mg/m<sup>2</sup> weekly)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"> <p>PETACC-6</p> Schmoll HJ, 2014<sup>[4]</sup></td> <td class=\"centered divider_bottom\" rowspan=\"2\">45 (optional boost to 50.4)</td> <td class=\"centered\"> <p>Capecitabine</p> <p>(825 mg/m<sup>2</sup> twice daily)</p> <strong>versus</strong></td> <td class=\"centered\"> <p>Capecitabine</p> <p>(1000 mg/m<sup>2</sup> twice daily, days 1 to 15 every 21 days x six months)</p> <strong>versus</strong></td> <td class=\"divider_bottom centered\" rowspan=\"2\">No SS difference DFS</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"> <p>Capecitabine</p> <p>+</p> <p>oxaliplatin</p> (50 mg/m<sup>2</sup> weekly)</td> <td class=\"centered\"> <p>Same capecitabine dose</p> <p>+</p> <p>oxaliplatin</p> (130 mg/m<sup>2</sup> every 3 weeks x 6 months)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"> <p>CAO/ARO</p> Rodel C, 2012, 2014<sup>[5,6]</sup></td> <td class=\"centered divider_bottom\" rowspan=\"2\">50.4</td> <td class=\"centered\"> <p>Fluorouracil infusion</p> <p>(1000 mg/m<sup>2</sup>/day, days 1 to 5 and 29 to 33)</p> <strong>versus</strong></td> <td class=\"centered\"> <p>Bolus fluorouracil</p> <p>(500 mg/m<sup>2</sup> days 1 to 5 monthly x four months)</p> <strong>versus</strong></td> <td class=\"divider_bottom centered\" rowspan=\"2\">Three-year DFS 75.9 versus 71.2% HR 0.79 (95% CI 0.64-0.98)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\"> <p>Fluorouracil&nbsp;infusion</p> <p>(250 mg/m<sup>2</sup>/day days 1 to 14 and 22 to 35)</p> <p>+</p> <p>oxaliplatin</p> (50 mg/m<sup>2</sup> weekly)</td> <td class=\"centered\"> <p>FOLFOX</p> (day 1 and 15 every 28 days x four months)</td> </tr> <tr> <td rowspan=\"2\"> <p>NSABP R-04</p> Allegra CJ, 2014<sup>[7]</sup></td> <td class=\"centered\" rowspan=\"2\">50.4</td> <td class=\"centered\"> <p>Fluorouracil&nbsp;infusion</p> <p>(225 mg/m<sup>2</sup>/day)</p> <p>+/&ndash;</p> <p>oxaliplatin</p> <p>(50 mg/m<sup>2</sup> weekly)</p> <strong>or</strong></td> <td class=\"centered\" rowspan=\"2\">FU-based adjuvant therapy was encouraged but not specified</td> <td class=\"centered\" rowspan=\"2\">No difference in OS, DFS, or locoregional control</td> </tr> <tr> <td class=\"centered\"> <p>Capecitabine</p> <p>(825 mg/m<sup>2</sup> twice daily)</p> <p>+/&ndash;</p> <p>oxaliplatin</p> (50 mg/m<sup>2</sup> weekly)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RT: radiation therapy; FU: 5-fluorouracil; SS: statistically significant; OS: overall survival; DFS: disease-free survival; FOLFOX: short-term infusional FU plus leucovorin and oxaliplatin; HR: hazard ratio.</div><div class=\"graphic_reference\">Prepared with data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011; 10:29.</li>&#xD;&#xA;    <li>G&eacute;rard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 2010; 28:1638.</li>&#xD;&#xA;    <li>G&eacute;rard JP, Azria D, Gourgou-Bourgade S, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 2012; 30:4558.</li>&#xD;&#xA;    <li>Schmoll HJ, Haustermans K, Price TJ, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine +/- oxaliplatin in locally advanced rectal cancer: Interim analysis. Ann Oncol 2014; 25:iv167.</li>&#xD;&#xA;    <li>R&ouml;del C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012; 13:679.</li>&#xD;&#xA;    <li>R&ouml;del C, Liersch T, Fietkau R, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: Results of the German CAO/ARO/AIO-04 randomized phase III trial (abstract). J Clin Oncol 2014; 32:5s.</li>&#xD;&#xA;    <li>Allegra CJ, Yothers G, O'Connell MJ, et al. Neoadjuvant therapy for rectal cancer. Mature results from NSABP R-04 (abstract). J Clin Oncol 2014; 32:Suppl 3.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 97598 Version 5.0</div></div></div>"},"97603":{"type":"graphic_table","displayName":"General hygienic precautions for hemodialysis","title":"Hygienic precautions for hemodialysis (general)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hygienic precautions for hemodialysis (general)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Definitions</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>A \"dialysis station\" is the space and equipment within a dialysis unit that is dedicated to an individual patient. This may take the form of a well-defined cubicle or room, but there is usually no material boundary separating dialysis stations from each other or from the shared areas of the dialysis unit.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>A \"potentially contaminated\" surface is any item of equipment at the dialysis station that <strong>could</strong> have been contaminated with blood or fluid containing blood since it was last disinfected, even if there is no evidence of contamination.</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Education</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>A program of continuing education covering the mechanisms and prevention of crossinfection should be established for staff caring for hemodialysis patients.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Appropriate information on infection control should also be given to nonclinical staff, patients, caregivers, and visitors.</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Hand hygiene</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Staff should wash their hands with soap or an antiseptic hand-wash and water, before and after contact with a patient or any equipment at the dialysis station. An antiseptic alcohol gel rub may be used instead when their hands are not visibly contaminated.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>In addition to hand washing, staff should wear disposable gloves when caring for a patient or touching any potentially contaminated surfaces at the dialysis station. Gloves should always be removed when leaving the dialysis station.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>When practical, patients should also clean their hands, or use an alcohol gel rub, when arriving at and leaving the dialysis station.</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Equipment management</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Single-use items required in the dialysis process should be disposed of after use on one patient.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Nondisposable items should be disinfected after use on one patient. Items that cannot be disinfected easily (for example, adhesive tape, tourniquets) should be dedicated to a single patient.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>The risks associated with the use of physiologic monitoring equipment (eg, blood pressure monitors, weight scales, access flow monitors) for groups of patients should be assessed and minimized. Blood pressure cuffs should be dedicated to a single patient or made from a light-colored, wipe-clean fabric.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Medications and other supplies should not be moved between patients. Medications provided in multiple-use vials, and those requiring dilution using a multiple-use diluent vial, should be prepared in a dedicated central area and taken separately to each patient. Items that have been taken to the dialysis station should not be returned to the preparation area.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>After each session, all potentially contaminated surfaces at the dialysis station should be wiped clean with a low-level disinfectant if not visibly contaminated. Surfaces that are visibly contaminated with blood or fluid should be disinfected with a commercially available tuberculocidal germicide or a solution containing at least 500 parts per million hypochlorite (a 1:100 dilution of 5% household bleach).</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Waste management</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Needles should be disposed of in closed, unbreakable containers that should not be overfilled. A \"no-touch\" technique should be used to drop the needle into the container as it is likely to have a contaminated surface. If this is difficult due to the design of the container, staff should complete patient care before disposing of needles.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>The used extracorporeal circuit should be sealed as effectively as possible before transporting it from the dialysis station in a fluid-tight waste bag or leak-proof container. If it is necessary to drain the circuit or to remove any components for reprocessing, this should be done in a dedicated area, away from the treatment and preparation areas.</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission from Macmillan Publishers Ltd: Kidney International. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008; 73(Suppl 109):S1. Copyright &copy; 2008. <a href=\"http://www.nature.com/ki\" target=\"_blank\">www.nature.com/ki</a>.</div><div id=\"graphicVersion\">Graphic 97603 Version 1.0</div></div></div>"},"97604":{"type":"graphic_table","displayName":"Dialysis machine hygienic precautions for hemodialysis","title":"Hygienic precautions for hemodialysis (dialysis machines)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hygienic precautions for hemodialysis (dialysis machines)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Definitions</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>The \"transducer protector\" is a filter (normally a hydrophobic 0.2 micrometer filter) that is fitted between the pressure-monitoring line of the extracorporeal circuit and the pressure-monitoring port of the dialysis machine. The filter allows air to pass freely to the pressure transducer that gives the reading displayed by the machine, but it resists the passage of fluid. This protects the patient from microbiologic contamination (as the pressure-monitoring system is not disinfected) and the machine from ingress of blood or dialysate. An external transducer protector is normally fitted to each pressure-monitoring line in the blood circuit. A back-up filter is located inside the machine. Changing the internal filter is a technical job. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>A \"single-pass machine\" is a machine that pumps the dialysate through the dialyzer and then to waste. In general, such machines do not allow fluid to flow between the drain pathway and the fresh pathway, except during disinfection. \"Recirculating\" machines produce batches of fluid that can be passed through the dialyzer several times. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Transducer protectors</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>External transducer protectors should be fitted to the pressure lines of the extracorporeal circuit. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Before commencing dialysis, staff should ensure that the connection between the transducer protectors and the pressure-monitoring ports is tight as leaks can lead to wetting of the filter. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Transducer protectors should be replaced if the filter becomes wet as the pressure reading may be affected. Using a syringe to clear the flooded line may damage the filter and increase the possibility of blood passing into the dialysis machine. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>If wetting of the filter occurs after the patient has been connected, the line should be inspected carefully to see if any blood has passed through the filter. If any fluid is visible on the machine side, the machine should be taken out of service at the end of the session so that the internal filter can be changed and the housing disinfected. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">External cleaning</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>After each session, the exterior of the dialysis machine should be cleaned with a low-level disinfectant, if not visibly contaminated. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>If a blood spillage has occurred, the exterior should be disinfected with a commercially available tuberculocidal germicide or a solution containing at least 500 parts per million hypochlorite (a 1:100 dilution of 5% household bleach), if this is not detrimental to the surface of dialysis machines. Advice on suitable disinfectants, and the concentration and contact time required, should be provided by the manufacturer. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>If blood or fluid is thought to have seeped into inaccessible parts of the dialysis machine (eg, between modules, behind blood pumps), the machine should be taken out of service until it can be dismantled and disinfected. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Disinfection of the internal fluid pathways</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>It is not necessary for the internal pathways of a single-pass dialysis machine to be disinfected between patients, unless a blood leak has occurred, in which case both the internal fluid pathways and the dialysis-to-dialyzer connectors should be disinfected before the next patient. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>If machines are not subjected to an internal disinfection procedure, staff should ensure that sufficient time is available between patients for the external surfaces to be disinfected. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Machines with recirculating dialysate should always be put through an appropriate disinfection procedure between patients. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted with permission from Macmillan Publishers Ltd: Kidney International. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008; 73(Suppl 109):S1. Copyright &copy; 2008. <a href=\"http://www.nature.com/ki\" target=\"_blank\">www.nature.com/ki</a>.</div><div id=\"graphicVersion\">Graphic 97604 Version 1.0</div></div></div>"},"97605":{"type":"graphic_table","displayName":"Spondylolysis prevalence by sport","title":"Spondylolysis prevalence by sport","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Spondylolysis prevalence by sport</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Sport</td> <td class=\"subtitle1\">Prevalence</td> </tr> <tr class=\"divider_bottom\"> <td>Overall competitive sports</td> <td>8 to 15%</td> </tr> <tr class=\"divider_bottom\"> <td>Gymnastics</td> <td>11 to 15%</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Artistic</td> <td>17%</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Rhythmic</td> <td>10%</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Trampoline</td> <td>16%</td> </tr> <tr class=\"divider_bottom\"> <td>Track and field</td> <td>8%</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Throwing</td> <td>27%</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Heptathlon and decathlon</td> <td>13%</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Jumping</td> <td>8%</td> </tr> <tr class=\"divider_bottom\"> <td>Basketball</td> <td>7%</td> </tr> <tr class=\"divider_bottom\"> <td>Judo and wrestling</td> <td>11 to 25%</td> </tr> <tr class=\"divider_bottom\"> <td>Rowing</td> <td>17 to 25%</td> </tr> <tr class=\"divider_bottom\"> <td>Swimming</td> <td>10%</td> </tr> <tr class=\"divider_bottom\"> <td>Volleyball</td> <td>10%</td> </tr> <tr class=\"divider_bottom\"> <td>Weightlifting </td> <td>13 to 30%</td> </tr> <tr class=\"divider_bottom\"> <td>Cricket fast bowler</td> <td>11 to 54%</td> </tr> <tr class=\"divider_bottom\"> <td>Soccer</td> <td>8% (30% professional)</td> </tr> <tr class=\"divider_bottom\"> <td>Tennis</td> <td>11%</td> </tr> <tr class=\"divider_bottom\"> <td>Football</td> <td>11 to 21%</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Lineman</td> <td>50%</td> </tr> <tr class=\"divider_bottom\"> <td>Diving</td> <td>40%</td> </tr> <tr> <td>Baseball</td> <td>5 to 9% (30% professional)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Soler T, Calderón C. The prevalence of spondylolysis in the Spanish elite athlete. Am J Sports Med 2000; 28:57.</LI>&#xD;&#xA;<LI>Rossi F, Dragoni S. [Lumbar spondylolysis and sports. The radiological findings and statistical considerations]. Radiol Med 1994; 87:397.</LI></OL></div><div id=\"graphicVersion\">Graphic 97605 Version 1.0</div></div></div>"},"97608":{"type":"graphic_picture","displayName":"Appearance of acute otitis media","title":"Appearance of the tympanic membrane in three children with acute otitis media","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">Appearance of the tympanic membrane in three children with acute otitis media</div><div class=\"cntnt\"><img style=\"width:728px; height:243px;\" src=\"images/PEDS/97608_Development_AOM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Early acute otitis media with inflammation; subsequently progressed to effusion.<br />(B) Purulent effusion with air fluid level.<br />(C) Bulging purulent effusion filling the middle ear.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 97608 Version 2.0</div></div></div>"},"97611":{"type":"graphic_algorithm","displayName":"Evaluation of male hypogonadism","title":"Evaluation of the male with possible hypogonadism","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Evaluation of the male with possible hypogonadism</div><div class=\"cntnt\"><img style=\"width:414px; height:352px;\" src=\"images/ENDO/97611_Evaluat_male_hypogonadism.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">T: testosterone; LH: luteinizing hormone; FSH: follicle-stimulating hormone; PRL: prolactin; T4: thyroxine; Fe: iron; MRI: magnetic resonance imaging.<br />* This algorithm applies to the evaluation of outpatients. Men with acute or subacute illness should not be assessed for hypogonadism, as they will have a transient functional secondary hypogonadism.<br />&para; Iron and transferrin are measured to assess the possibility that hemochromatosis is the cause of secondary hypogonadism. When an MRI should be performed depends upon several factors. One is the patient's serum T relative to his age. A male &lt;40 years with a serum T &lt;250 ng/dL (8.7 nmol/L) warrants an MRI but in a male &gt;60 years, a value of &lt;150 ng/dL (5.2 nmol/L) would be necessary to warrant it. An MRI should also be performed if other pituitary hormones are abnormal, eg, if serum prolactin is elevated or if serum T4 and/or early morning cortisol are below normal.</div><div class=\"graphic_reference\">Adapted from: ​Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. JCEM 2010; 95:2536.</div><div id=\"graphicVersion\">Graphic 97611 Version 2.0</div></div></div>"},"97612":{"type":"graphic_algorithm","displayName":"Management of recurrent high-grade glioma","title":"Management of recurrent high-grade glioma","html":"<div class=\"graphic\"><div style=\"width: 678px\" class=\"figure\"><div class=\"ttl\">Management of recurrent high-grade glioma</div><div class=\"cntnt\"><img style=\"width:658px; height:365px;\" src=\"images/NEURO/97612_Management_high_grade_gliom.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Participation in clinical trials is encouraged.<br />¶ Systemic therapy options include bevacizumab, bevacizumab plus chemotherapy (eg, nitrosoureas, temozolomide, irinotecan, carboplatin), and chemotherapy alone.<br />Δ For glioblastoma; availability varies by region and center.<br /><FONT class=lozenge>◊</FONT> Implantation of carmustine wafers at the time of resection may be considered in selected patients (eg, those with contraindications to systemic therapy) but may&nbsp;affect eligibility for some clinical trials.<br />§ Optimal candidates for reoperation are younger patients with large but well-circumscribed, symptomatic tumors that have recurred after an extended interval.</div><div id=\"graphicVersion\">Graphic 97612 Version 1.0</div></div></div>"},"97613":{"type":"graphic_picture","displayName":"Mild acne keloidalis nuchae","title":"Acne keloidalis nuchae","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Acne keloidalis nuchae</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/97613_Mild_acne_keloidalis_nuchae.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mild acne keloidalis nuchae. Multiple small, follicular papules on the posterior scalp and posterior upper neck.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 97613 Version 1.0</div></div></div>"},"97614":{"type":"graphic_picture","displayName":"Mild acne keloidalis nuchae 2","title":"Acne keloidalis nuchae","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Acne keloidalis nuchae</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/97614_Mld_acne_keloidalis_nucha_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflamed papules and small keloidal papules on the posterior scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 97614 Version 1.0</div></div></div>"},"97615":{"type":"graphic_picture","displayName":"Acne keloidalis nuchae - keloidal papules","title":"Acne keloidalis nuchae","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Acne keloidalis nuchae</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/97615_Acne_keloidls_nch_kldl_ppls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflamed papules and keloidal papules on the posterior scalp. Coalescence of keloidal papules into a plaque is present in the upper portion of the image.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 97615 Version 1.0</div></div></div>"},"97616":{"type":"graphic_picture","displayName":"Acne keloidalis nuchae - plaque","title":"Acne keloidalis nuchae","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Acne keloidalis nuchae</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/97616_Acne_keloidalis_nuchae_plaq.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple inflamed papules coalescing into plaques on the posterior scalp and posterior upper neck.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 97616 Version 1.0</div></div></div>"},"97617":{"type":"graphic_picture","displayName":"Acne keloidalis nuchae - inflamed plaque","title":"Acne keloidalis nuchae","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Acne keloidalis nuchae</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/97617_Acne_keldls_nch_inflmd_plq.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large inflamed plaque with papules and pustules on the posterior scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 97617 Version 1.0</div></div></div>"},"97618":{"type":"graphic_picture","displayName":"Acne keloidalis nuchae - keloidal papules and plaques","title":"Acne keloidalis nuchae","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Acne keloidalis nuchae</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/97618_Acne_kldls_nch_kldl_ppl_plq.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Alopecia and multiple keloid-like papules coalescing to form larger nodules and plaques.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 97618 Version 1.0</div></div></div>"},"97619":{"type":"graphic_picture","displayName":"Acne keloidalis nuchae - end stage","title":"Acne keloidalis nuchae","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Acne keloidalis nuchae</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/97619_Acne_keloidalis_nch_end_stg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scarred plaque on the posterior scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 97619 Version 1.0</div></div></div>"},"97620":{"type":"graphic_picture","displayName":"Acne keloidalis nuchae - scarring","title":"Acne keloidalis nuchae","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Acne keloidalis nuchae</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/97620_Acne_keloidalis_nuchae_scar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large scarred plaque with keloid-like nodules and alopecia on the posterior scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 97620 Version 1.0</div></div></div>"},"97621":{"type":"graphic_picture","displayName":"Acne keloidalis nuchae - extensive","title":"Acne keloidalis nuchae","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Acne keloidalis nuchae</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/97621_Acne_keloidalis_nuch_extnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large, inflamed, keloid-like plaque with tufted hairs on the posterior scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 97621 Version 1.0</div></div></div>"},"97622":{"type":"graphic_picture","displayName":"Acne keloidalis nuchae - scarring alopecia","title":"Acne keloidalis nuchae","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Acne keloidalis nuchae</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/97622_Acne_keloidls_nch_scrr_alpc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scarring alopecia in a patient with acne keloidalis nuchae. Occasionally, acne keloidalis nuchae extends beyond the posterior upper neck and posterior scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 97622 Version 1.0</div></div></div>"},"97624":{"type":"graphic_table","displayName":"Chronology of a composite patient with factitious disorder","title":"Chronology of a 22-year-old composite female patient with factitious disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chronology of a 22-year-old composite female patient with factitious disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"5\" width=\"18%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Attendance or referral</td> <td class=\"subtitle1\">Symptoms and precipitants</td> <td class=\"subtitle1\">Tests and investigations</td> <td class=\"subtitle1\">Outcome and plan</td> <td class=\"subtitle1\">Key events</td> </tr> <tr class=\"divider_bottom\"> <td><strong>1986</strong><br /> (age 12 years)</td> <td>Hospital A admission</td> <td>Right flank pain</td> <td>Normal laparoscopy</td> <td>Non-specific abdominal pain</td> <td>Death of father</td> </tr> <tr class=\"divider_bottom\"> <td><strong>1987</strong><br /> (age 13 years)</td> <td>Hospital A admission</td> <td>Overdose of analgesics</td> <td>--</td> <td>Referred to social worker; patient stealing money from mother</td> <td>Arguments with mother</td> </tr> <tr class=\"divider_bottom\"> <td><strong>1990</strong><br /> (age 16 years)</td> <td>Hospital B admission</td> <td>Inhalation of smoke from fire after fire setting</td> <td>Normal blood tests</td> <td>Self-discharged</td> <td>Set fire to house; pregnant</td> </tr> <tr class=\"divider_bottom\"> <td><strong>1991</strong><br /> (age 17 years)</td> <td>Neurology outpatient services (B)</td> <td>Episodes of loss of consciousness and muscle twitching</td> <td>Normal EEG and CT scan; normal blood tests</td> <td>Reassured no organic cause</td> <td>--</td> </tr> <tr class=\"divider_bottom\"> <td><strong>1991</strong><br /> (age 17 years)</td> <td>Emergency admission to general surgery (A)</td> <td>Right-sided abdominal pain</td> <td>Normal radiograph</td> <td>Admitted for observation; self-discharged against medical advice</td> <td>--</td> </tr> <tr class=\"divider_bottom\"> <td><strong>June, 1992</strong><br /> (age 18 years)</td> <td>Gynecology outpatient clinic</td> <td>Claims to be pregnant</td> <td>Normal pregnancy test</td> <td>\"She lied to the registrar, saying that she had a positive pregnancy test when she had been told by the GP [general practitioner (family doctor)] that she was not pregnant\"</td> <td>--</td> </tr> <tr class=\"divider_bottom\"> <td><strong>October, 1992</strong><br /> (age 18 years)</td> <td>Emergency admission (A)</td> <td>Overdose of paracetamol in context of excess alcohol</td> <td>Noted abscess on right breast</td> <td>Worried about scarring on right breast; dermatologist considered possibility of artifactual skin disorder</td> <td>Grandfather ill</td> </tr> <tr class=\"divider_bottom\"> <td><strong>1993</strong><br /> (age 19 years)</td> <td>Ear, nose, and throat outpatient clinic (C)</td> <td>Episodes of hemoptysis</td> <td>Normal direct laryngoscopy</td> <td>Followed up in psychiatric outpatients clinic; possibility of personality disorder considered</td> <td>--</td> </tr> <tr class=\"divider_bottom\"> <td><strong>1993</strong><br /> (age 19 years)</td> <td>General medicine outpatient clinic (B), with subsequent admission</td> <td>Unexplained septicemia</td> <td>Isolated blood culture of saprophytic organisms not usually associated with the cause of sepsis in the immunocompetent patient</td> <td>\"Given these findings we feel that there has been deliberate introduction into the body of material from an environmental source\"</td> <td>Boyfriend of 2 years has left her</td> </tr> <tr class=\"divider_bottom\"> <td><strong>1994</strong><br /> (age 20 years)</td> <td>Gynecology outpatient clinic (B)</td> <td>\"Told me she had been sterilized\"</td> <td>Fallopian tubes patent</td> <td>\"When I obtained her notes and showed her this she decided to self-discharge\"</td> <td>--</td> </tr> <tr class=\"divider_bottom\"> <td><strong>1995</strong><br /> (age 21 years)</td> <td>Neurology outpatient clinic on second opinion (C)</td> <td>Recurrent blackouts and odd movements since age 17 years</td> <td>All investigations normal (video telemetry)</td> <td>Diagnosis of psychogenic non-epileptic seizures</td> <td>--</td> </tr> <tr class=\"divider_bottom\"> <td><strong>1995</strong><br /> (age 21 years)</td> <td>Psychiatric outpatient clinic</td> <td>Patient denies that non-epileptic seizures are related to emotional problems; attends clinic with crutches</td> <td>Cognitive behavioral therapy not helping</td> <td>Demands to be kept on carbamazepine despite advice to taper drug</td> <td>Drinking a bottle of vodka every day</td> </tr> <tr class=\"divider_bottom\"> <td><strong>1996</strong><br /> (age 22 years)</td> <td>Emergency admission orthopaedics</td> <td>Pain in right forearm after repeatedly punching wall</td> <td>Substantial soft tissue injury with swelling but no fracture</td> <td>Currently an inpatient on local psychiatric ward; follow-up by mental health team</td> <td>Child born</td> </tr> <tr class=\"divider_bottom\"> <td><strong>1996</strong><br /> (age 22 years)</td> <td>Admission orthopaedics (D)</td> <td>Infection right wrist; demanding oramorph</td> <td>No positive cultures; \"birefringent particles found consistent with foreign material in a distribution incompatible with wound-care procedures\"</td> <td>Planned supportive confrontation; patient self-discharged; family doctor and psychiatric team informed</td> <td>--</td> </tr> <tr> <td><strong>1996</strong><br /> (age 22 years)</td> <td>Pediatric outpatient clinic (B)</td> <td>Worried about 1-year-old son with 3 month history of \"shaking episodes\"</td> <td>Investigations unable to detect any relevant organic cause</td> <td>Patient requesting disability living allowance for son; asking how to hire a wheelchair for herself</td> <td>Case conference convened by social services at surgery of family doctor</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Data anonymized for patient confidentiality. A, B, C, and D represent four different hospitals.</div><div class=\"graphic_reference\">Reproduced from: Bass C, Halligan P. Factitious disorders and malingering: challenges for clinical assessment and management. Lancet 2014; 383:1422. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97624 Version 1.0</div></div></div>"},"97625":{"type":"graphic_table","displayName":"Tools for diagnosing factitious disorder","title":"Tools for diagnosing factitious disorder by specialty and condition","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Tools for diagnosing factitious disorder by specialty and condition</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptom</td> <td class=\"subtitle1\">Laboratory test</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cardiovascular</td> </tr> <tr> <td class=\"indent1\">Angina</td> <td>Definitive test: coronary angiography. Also consider: stress test, ECG, echocardiogram for wall motion abnormalities.</td> <td>History of prior myocardial infarction or cardiac bypass does NOT exclude factitious presentation &ndash; may represent the patient fabricating prior symptoms.</td> </tr> <tr> <td class=\"indent1\">Arrhythmia</td> <td>Consider indirect dysrhythmia though manipulated electrolytes (Mg, K). Supervise telemetry lead placement to avoid manipulation. Digitalis, beta-blockers and calcium channel blockers can be measured in serum.</td> <td>Arrhythmias have also been reported in patients with surreptitious laxative or thyroxine abuse (see below).</td> </tr> <tr> <td class=\"indent1\">Aortic dissection</td> <td>In patients reportedly unable to receive CT aortogram with contrast or MRI, consider transthoracic echocardiogram.</td> <td>Patient's goal may be thoracotomy. Patients have reported an allergy to radiography contrast prohibiting CT imaging. Also allergy to gadolinium or shrapnel residue in their body prohibiting MRI.</td> </tr> <tr> <td class=\"indent1\">Hypotension</td> <td>Serum assays for beta-blockers and calcium channel blockers. Electrochemiluminescence assays detect atenolol and metoprolol in urine samples.</td> <td>Capillary electrophoresis with electrochemiluminescence detection &ndash; assays developed to detect doping in sports.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hypertension</td> <td>Serum or urine assay for pseudoephedrine. Pheochromocytoma can also be simulated.</td> <td>Valsalva maneuver may be used by the patient during BP measurement to produce transient HTN.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Dermatologic</td> </tr> <tr> <td class=\"indent1\">Cheilitis granulomatosa</td> <td>Liver and lymph node biopsies may show histiocytes that contain polyvinylpyrrolidone (PVP) suggesting self-inoculation.</td> <td>PVP, a polymer, is used in hair sprays, skin care products, fruit juices.</td> </tr> <tr> <td class=\"indent1\">Dermatitis artefacta, cheilitis, subcutaneous emphysema</td> <td>Punch biopsy with histopathology &ndash; may reveal evidence of mechanical trauma with areas of necrosis and extravasation of RBCs. Imaging or skin exam can note needle tracks for subcutaneous air.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Erythematous lesion, pemphigus</td> <td>Apply alcohol to lesion. Direct immunofluorescence.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Herpes zoster</td> <td>Negative viral PCR.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Onychodystrophy</td> <td>Microscopy.</td> <td>Nail file to replicate symptoms.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Scabies</td> <td>Scabies PCR, microscopy.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Endocrine</td> </tr> <tr> <td class=\"indent1\">Cushing's syndrome</td> <td>High-pressure liquid chromatography (HPLC) used to distinguish exogenous versus endogenous glucocorticoids. Cortisol and corticosterone are co-secreted, so both should be checked since corticosterone will not be elevated if cortisol is surreptitiously added to urine samples.</td> <td>Surreptitious addition of hydrocortisone requires measurement of upstream metabolites to check for evidence of suppressed pituitary secretion of ACTH.</td> </tr> <tr> <td class=\"indent1\">Hyperaldosteronism</td> <td>Glycyrrhizic acid can be detected in serum.</td> <td>The ingestion of black liquorice has gained particular notoriety on the internet. The sweetener used to make licorice, glycyrrhizic acid can lead to treatment-resistant hypokalemia, metabolic alkalosis and hypernatremia.</td> </tr> <tr> <td class=\"indent1\">Hyperthyroidism</td> <td>TSH, T3, free T4, thyroglobulin, and thyroid autoantibody. Some recommend 24 h radioiodine uptake testing. During thyroid storm factitious hyperthyroidism is the only etiology in which TSH will be low.</td> <td>Some herbal medications contain thyroid hormones. Serum thyroglobulin may less useful as 10 to 20% of people have anti-thyroglobulin antibodies that may affect thyroglobulin measurement.</td> </tr> <tr> <td class=\"indent1\">Hypoglycemia</td> <td>Serum insulin, C-peptide, and proinsulin levels, assays for metformin, meglitinides, sulfonylureas. Novel incretin analogue exenatide and amylin analogue pramlintide not routinely included in hypoglycemic drug screens. Also consider manipulation of testing strips.</td> <td>Urine can be more sensitive than serum and may remain positive for a longer period. Anti-insulin antibodies no longer useful as more human recombinant insulin is used. Also C-peptide is cleared renally and will be elevated in renal failure.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pheochromocytoma</td> <td>Serum chromogranin A useful to identify true pheochromocytoma. Meta-iodobenzylguanidine nuclear scan is probably the gold standard. Vanillylmandelic acid (VMA) should not be used for suspected factitious pheochromocytoma because vanilla extract or foods high in vanillin can elevate VMA.</td> <td>Agents to mimic pheochromocytoma symptoms include self-administration of epinephrine, metaraminol, and isoproterenol. Patients can use the Valsalva maneuver to produce a symptom pattern suggestive of pheochromocytoma.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Gastrointestinal</td> </tr> <tr> <td class=\"indent1\">Diarrhea</td> <td> <p>Surreptitious addition of water to stools detected by measuring fecal fluid osmolality &ndash; if less than 290 mosm/kg, water or hypotonic solution may have been added to stool. Consider 3-day stool collection for 200 g/day volume check.</p> Urine screen for phenolphthaleins, anthraquinones, and bisacodyl plus stool screen for magnesium and phosphate.</td> <td>Urine and stool \"laxative abuse\" screens often need to be performed multiple times due to intermittent laxative use by patients and low sensitivity of the tests.</td> </tr> <tr> <td class=\"indent1\">Gastrointestinal (GI) bleeding</td> <td>Factitious bleeding suggested when nasogastric tube shows blood but no cause found on esophagogastroduodenoscopy. Colonoscopy is less sensitive to elucidate lower GI bleeding. The \"single-stripe\" sign on colonoscopy may indicate non-steroidal anti-inflammatory abuse, which can be detected on high performance liquid chromatography (HPLC).</td> <td>Ingestion of salicylates can also cause factitious lower GI bleeds. Radiolabelling only useful in a patient injecting themselves with blood they had obtained from transfusions in-hospital; discovered when rectal blood was found not to be radiolabelled after a radio-isotope injection.</td> </tr> <tr> <td class=\"indent1\">Nausea/vomiting</td> <td>When produced by ipecac consumption, measure serum or urine emetine levels (detectable by HPLC). Elevated creatine kinase, leukocytosis, and transaminitis also associated with ipecac toxicity. After vomiting episodes, clinicians should see low serum potassium, low chloride after acute vomiting or prolonged episodes of vomiting.</td> <td>Excess ipecac induces myopathic toxicity including skeletal muscle weakness and hypotonia and cardiomyopathy with dysrhythmias, T-wave abnormalities, and prolonged QT interval.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pseudo-obstruction</td> <td>Detect loperamide or another motility slowing agent by HPLC of blood or stool.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Gynecology and obstetrics</td> </tr> <tr> <td class=\"indent1\">False ectopic pregnancy</td> <td>Self-injection of human chorionic gonadotropin (hCG) has been reported. This led to a negative urine beta-hCG and negative ultrasound. Also subsequent serum beta-hCG levels were widely varying.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vaginal discharge</td> <td>Typically the fluids have an inconsistent pH or the vaginal wall shows evidence of trauma/abrasion in patients denying intercourse or instrumentation.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Hematologic</td> </tr> <tr> <td class=\"indent1\">Anemia/bleeding</td> <td>Examination may show evidence of venipuncture or instrumentation, particularly of orifices or the genital-urinary tract or gastrointestinal tract on endoscopy.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Anticoagulation</td> <td> <p>For patients not known to be on warfarin, administer vitamin K, and then re-check PT/INR. Warfarin can be assayed directly but warfarin derivatives such as the rodenticide brodifacoum require use of HPLC.</p> <p>For patients on warfarin, there can be \"false-resistance\" to warfarin that requires extensive clinical input and attention. This must be cautiously approached as genetics can play a large role. If vitamin K and plasma warfarin levels are irregular, consider genetic testing if there is no indication of factitious behavior.</p> Prolonged PTT but normal reptilase time suggest presence of heparin. Another test is to add protamine sulphate or an ion-exchange resin to the blood sample which will indicate the presence of exogenous heparin.</td> <td>The most common hematologic factitious disorder is surreptitious anticoagulation abuse.</td> </tr> <tr> <td class=\"indent1\">Aplastic anemia</td> <td>This has been provoked by the ingestion of alkylating agents such as busulfan or other chemotherapy agents.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Sickle cell disease</td> <td>Confirmation with hemoglobin electrophoresis.</td> <td>Important for patients not known to local clinicians.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Thrombocytopenia/ITP (also see rheumatologic-purpura)</td> <td>Purpura and ITP feigned by quinidine ingestion &ndash; check serum quinidine level. Isolated thrombocytopenia has been caused by quinine ingestion.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Infectious diseases</td> </tr> <tr> <td class=\"indent1\">Bacteremia</td> <td>Polymicrobial bacteremia or unusual organisms in blood cultures should raise suspicion.</td> <td>Case reports note stool flora, pet flora as most common exogenous material.</td> </tr> <tr> <td class=\"indent1\">Fever</td> <td>Directly observed temperature measurement using electronic thermometer.</td> <td>Ensure no recent ingestion of hot beverages, warm wax or wet cotton in ears. In 1979, 9% of patients presenting to an NIH study on fever of unknown origin were found to be suffering from factitious disorder.</td> </tr> <tr> <td class=\"indent1\">HIV/AIDS</td> <td>Repeat HIV ELISA and Western blot, check viral load for acute HIV.</td> <td>Patient with normal CD4 count and undetectable viral load can claim suppression with anti-retrovirals. But antibody should still be positive.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Wounds</td> <td>Apply fluorescein or tetracycline to wound, then examine hands/nails for fluorescence.</td> <td>Non-healing wounds will heal when casted, but this can be circumvented by patients. Substances introduced into wounds include: human/animal feces, household toxins, aquarium water, foreign bodies, milk and others.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Neurologic</td> </tr> <tr> <td class=\"indent1\">Movement disorders</td> <td>EMG and EEG reveal inconsistent amplitude patterns in factitious tremors and myoclonus.</td> <td>Dopaminergic drugs including antipsychotics may be taken to induce Parkinsonian symptoms.</td> </tr> <tr> <td class=\"indent1\">Multiple sclerosis</td> <td> <p>MRI brain demonstrating at least 2 different regions of white matter change.</p> CSF with mild lymphocytosis, oligoclonal bands in IgG region.</td> <td>CSF protein electrophoresis is 90% sensitive in pts with active MS symptoms.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Non-epileptiform seizures</td> <td>Serum prolactin level at baseline (near onset of epileptiform activity) then 20 minutes later. However this can be normal in partial-seizures and elevated in epilepsy. Video EEG useful but this can miss frontal lobe seizures which have movements that can suggest factitious behavior such as pelvic thrusting and cycling movements.</td> <td>One estimate suggests that 15 to 30% of the patients presenting to epilepsy clinics with refractory epilepsy are psychogenic in nature. Most of these patients are unlikely to have factitious disorder.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Nephrologic/urologic</td> </tr> <tr> <td class=\"indent1\">Diuretic abuse/Bartter syndrome</td> <td>Urine assays can detect furosemide, torsemide, and hydrochlorothiazide. HPLC can detect furosemide and other diuretics.</td> <td>Bartter syndrome is a rare inherited defect in the ascending loop of Henle, there are at least 6 reports of factitious presentations of this condition.</td> </tr> <tr> <td class=\"indent1\">Goodpastures syndrome</td> <td>See hematuria and hemoptysis sections.</td> <td>One patient appeared in 3 different peer reviewed articles.</td> </tr> <tr> <td class=\"indent1\">Hematuria</td> <td>Direct observation of urine collection to ensure blood or iodine not added to sample. Three tube test to rule out urethral trauma &ndash; first tube should have most RBCs if self-inflicted urethral trauma is the source of blood. Hematuria can be simulated by introducing foreign bodies such as paper clips or safety pins. This can be detected on x-ray or with direct cystoscopy. Air in the bladder on imaging is also indicative of self-manipulation.</td> <td>Reports suggests that 0.6 to 3% of patients presenting with hematuria have tampered with urine samples to produce false positive tests.</td> </tr> <tr> <td class=\"indent1\">Nephrolithiasis</td> <td>Microscopic exam, infrared spectrophotometry, crystallography, x-ray diffraction to characterize crystals suspected to be non-physiologic.</td> <td>3.5% of stones submitted by patients were found to be artefacts (not all were factitious). One case report of subcutaneously implanted metal in abdomen at level of ureter mimicking stone on plain film in patient who claimed IV contrast allergy.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Proteinuria</td> <td>Surreptitious protein addition to urine or bladder detectable by urine protein electrophoresis revealing abnormal alpha and beta globulin fractions. Egg albumin antibody can be used if this is suspected.</td> <td>Normal serum protein, albumin, creatinine, and BUN levels should raise suspicion in a patient with proteinuria.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Oncology</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cancer</td> <td>Manipulation of records. Multiple case reports of patients claiming to bring records of disease and diagnosis at remote or foreign institutions requiring treatment. Contact the document's authors/institution. If they are not available, police can be asked to assist verification. At least one report of a patient obtaining sample medical reports off of the internet.</td> <td>Multiple cases of prophylactic mastectomy for falsely claiming a strong family history of breast cancer.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Ophthalmology</td> </tr> <tr> <td class=\"indent1\">Mydriasis</td> <td>Homatropine drops detected by identification of homatropine in tears.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other presentations</td> <td>Successful techniques for investigating these injuries include pH testing to detect acidic and alkali chemicals and imaging and skin exam to look for evidence of traumatic puncture to introduce air or foreign body materials.</td> <td>Other ophthalmic presentations include the insertion of foreign body crystals, fungal endophthalmitis, self-induced anterior scleritis, and reports of factious conjunctivitis, primarily by inserting dental plaque as an irritant.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Otolaryngology</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Airway and swallowing difficulties</td> <td>Videoflouroscopy can be useful as well as surface EMG techniques.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Pulmonary</td> </tr> <tr> <td class=\"indent1\">Asthma</td> <td>Lung biopsy specimen analyzed by x-ray energy-dispersive spectroscopy showed talc crystals. Chronic ingestion of aspirin in patients with known salicylate sensitivities.</td> <td>Clear tape has been used to fool pulse oximeters.</td> </tr> <tr> <td class=\"indent1\">Cystic fibrosis</td> <td>Sweat chloride test, but exam should show digital clubbing and abnormal x-rays. In one case the sweat chloride test was manipulated and the patient discovered by evaluation of the sweat potassium.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Hemoptysis</td> <td>Fiberoptic bronchoscopies that don't show even a minute trace of blood in the oral cavity, glottic area or tracheobronchial tree during a presentation of \"active hemoptysis\" should elicit a possibility of factitious hemoptysis. In that case examine the nares, palate and posterior tongue for evidence of self-induced trauma. Also consider ingestion of anti-clotting agents and cough abrasion of the lung.</td> <td>A patient received 25+ admissions to more than 14 hospitals and at least 16 bronchoscopy investigations, all of which were negative.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Respiratory failure</td> <td>Arterial blood gas measurements should demonstrate incongruities.</td> <td>At least 10 reported cases of factitious patients receiving intubation for respiratory failure.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Rheumatologic</td> </tr> <tr> <td class=\"indent1\">Arthritis</td> <td>Insertion of metal fragments into joint detected by diffraction radiology or microscopic analysis of synovial aspirate.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Lupus</td> <td>Feigned usually by symptomatic history +/&ndash; borderline elevation in ANA; repeat serum ANA, anti-dsDNA, anti-Smith antibodies. Seronegative lupus can occur however. Note that in an active flair complement CH50, C3 and C4 levels should be low.</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Vasculitis (also see hematologic &ndash; thrombocytopenia, and nephrologic-Goodpastures)</td> <td>Tissue biopsy of lesions may reveal foreign material (saliva, talcum powder) injected to create purpuric lesions.</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Kenedi CA, Shirey KG, Hoffa M, et al. Laboratory diagnosis of factitious disorder: a systematic review of tools useful in the diagnosis of Munchausen's syndrome. N Z Med J 2011; 124:66. Copyright &copy; 2011 New Zealand Medical Association.</div><div id=\"graphicVersion\">Graphic 97625 Version 1.0</div></div></div>"},"97627":{"type":"graphic_diagnosticimage","displayName":"Navicular stress fracture","title":"Navicular stress fracture","html":"<div class=\"graphic\"><div style=\"width: 803px\" class=\"figure\"><div class=\"ttl\">Navicular stress fracture</div><div class=\"cntnt\"><img style=\"width:783px; height:350px;\" src=\"images/EM/97627_Navicularstressfracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mid-arch pain and tenderness over the&nbsp;\"N spot\"&nbsp;of the superior midfoot suggests a navicular stress fracture and the need for diagnostic imaging. Often, MRI or CT is required to visualize the fracture. Arrow points to a fracture in CT on left that has a free fragment and a Y-shaped fracture line. Arrow points to a small fracture fragment on dorsum of navicular on MRI on right.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 97627 Version 4.0</div></div></div>"},"97628":{"type":"graphic_picture","displayName":"Molluscum contagiosum - extensive","title":"Molluscum contagiosum","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Molluscum contagiosum</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/97628_Molluscum_contagiosm_extnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple papules with umbilication on the face.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 97628 Version 1.0</div></div></div>"},"97629":{"type":"graphic_picture","displayName":"Acne keloidalis nuchae - papules","title":"Acne keloidalis nuchae","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Acne keloidalis nuchae</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/97629_Acne_keloidalis_nuchae_ppls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple dome-shaped keloidal papules on the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 97629 Version 1.0</div></div></div>"},"97630":{"type":"graphic_picture","displayName":"Folliculitis on scalp","title":"Folliculitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Folliculitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/97630_Folliculitis_scalp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple pustules on the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 97630 Version 1.0</div></div></div>"},"97631":{"type":"graphic_table","displayName":"Adverse effects of androgenic steroids","title":"Adverse effects and complications of androgenic steroids","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adverse effects and complications of androgenic steroids</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Cardiovascular</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Coronary heart disease </li> <li>Cardiomyopathy </li> <li>Erythrocytosis </li> <li>Hemostasis/coagulation abnormalities </li> <li>Dyslipidemia </li> <li>Hypertension </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Infection</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>HIV, hepatitis B and C, MRSA <ul> <li>Unsafe needle practices </li> <li>Contaminated products </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Musculoskeletal</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Tendon rupture </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Neuropsychiatric</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Major mood disorders </li> <li>Aggression, violence </li> <li>Dependence </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Men (reproductive)</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Hypogonadism (following withdrawal) </li> <li>Gynecomastia </li> <li>Acne </li> <li>Premature epiphyseal closure (when taken before completion of puberty) </li> <li>Prostate (potential increased risk for cancer) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Women (reproductive)</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Acne </li> <li>Virilization (hirsutism, deepening of voice, clitoromegaly) </li> <li>Irregular menses </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Hepatic (only with oral 17-alpha-alkylated androgens)</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cholestasis </li> <li>Peliosis hepatis </li> <li>Hepatic neoplasms </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; MRSA: methicillin-resistant Staphylococcus aureus.</div><div id=\"graphicVersion\">Graphic 97631 Version 1.0</div></div></div>"},"97646":{"type":"graphic_algorithm","displayName":"Evaluation of erectile dysfunction","title":"Evaluation of erectile dysfunction","html":"<div class=\"graphic\"><div style=\"width: 481px\" class=\"figure\"><div class=\"ttl\">Evaluation of erectile dysfunction</div><div class=\"cntnt\"><img style=\"width:461px; height:354px;\" src=\"images/ENDO/97646_Evaluatio_erectile_dysfnctn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>The most recent set of formal ED management guidelines was published in 2013 by the European Association of Urology (EAU).</li>&#xD;&#xA;    <li>The diagnostic evaluation of patients with ED must include a detailed medical and psychosexual history and focused physical examination.</li>&#xD;&#xA;    <li>The diagnostic evaluation should also include laboratory testing:&#xD;&#xA;    <ul>&#xD;&#xA;        <li>Patients may need a fasting glucose or A1C and lipid profile, if not recently assessed.</li>&#xD;&#xA;        <li>Hormonal tests include a morning sample of total testosterone. If indicated, free testosterone may be needed to corroborate total testosterone measurements. However, the minimum testosterone concentration necessary to maintain ED is low, and ED is usually a symptom of more severe cases of hypogonadism. The correlation between serum testosterone and erectile function is poor at concentrations &gt;8 nmol/L (230 ng/dL).</li>&#xD;&#xA;    </ul>&#xD;&#xA;    </li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">ED: erectile dysfunction; IIEF: International Index of Erectile Dysfunction; A1C: glycated hemoglobin.</div><div class=\"graphic_reference\">Original figure modified for this publication. Wespes E, Eardley I, Guiliano F, et al. European Association of Urology Guidelines on Male Sexual Dysfunction: erectile dysfunction and premature ejaculation. 2013. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97646 Version 2.0</div></div></div>"},"97648":{"type":"graphic_algorithm","displayName":"CV risk sexual activity","title":"Estimate of CV risk with sexual activity: Princeton III Consensus recommendations","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Estimate of CV risk with sexual activity: Princeton III Consensus recommendations</div><div class=\"cntnt\"><img style=\"width:369px; height:376px;\" src=\"images/ENDO/97648_CV_risk_sexual_activity.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Algorithm from the Princeton III Consensus recommendations used to estimate the CV risk associated with sexual activity in patients with ED and known CVD.</div><div class=\"graphic_footnotes\">CV: cardiovascular; ED: erectile dysfunction; CVD: cardiovascular disease; CIMT: Carotid Intima Media Thickness; ABI: ankle-brachial index.<br />* Sexual activity is equivalent to walking 1 mile on the flat in 20 minutes or briskly climbing two flights of stairs in 10 seconds.<br />&para; Sexual activity is equivalent to four minutes of the Bruce treadmill protocol. The option of CIMT and ABI instead is also given.</div><div class=\"graphic_reference\">Original figure modified for this publication. Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012; 87:766. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97648 Version 1.0</div></div></div>"},"97649":{"type":"graphic_algorithm","displayName":"Initial treatment WM","title":"Initial treatment of Waldenström macroglobulinemia","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Initial treatment of Waldenström macroglobulinemia</div><div class=\"cntnt\"><img style=\"width:598px; height:568px;\" src=\"images/HEME/97649_Initial_treatment_WM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm describes our preferred management of patients with newly diagnosed WM. There are other acceptable approaches. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary. Harvest and storage of hematopoietic stem cell harvest is considered after&nbsp;four to&nbsp;six cycles of combination therapy for younger patients (&lt;70 years) who are candidates for autologous hematopoietic cell transplantation at the time of relapse.&nbsp;</div><div class=\"graphic_footnotes\">WM: Waldenström macroglobulinemia. </div><div id=\"graphicVersion\">Graphic 97649 Version 5.0</div></div></div>"},"97650":{"type":"graphic_table","displayName":"Etiologies of erectile dysfunction","title":"Etiologies of erectile dysfunction<sup>[1-3]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologies of erectile dysfunction<sup>[1-3]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Vascular</strong></td> <td>Cardiovascular disease, hypertension, diabetes mellitus, hyperlipidemia, smoking, major surgery (radical prostatectomy) or radiotherapy (pelvis or retroperitoneum)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Neurologic</strong></td> <td>Spinal cord and brain injuries, Parkinson disease, Alzheimer disease, multiple sclerosis, stroke</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Local penile (cavernous) factors</strong></td> <td>Peyronie's disease, cavernous fibrosis, penile fracture</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Hormonal</strong></td> <td>Hypogonadism, hyperprolactinemia, hyper- and hypothyroidism, hyper- and hypocortisolism</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Drug-induced</strong></td> <td>Antihypertensives, antidepressants, antipsychotics, antiandrogens, recreational drugs</td> </tr> <tr> <td><strong>Psychogenic</strong></td> <td>Performance-related anxiety, traumatic past experiences, relationship problems, anxiety, depression, stress</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">ED is classified as organic (ie, vasculogenic, neurogenic, local penile [cavernous] factors, hormonal, drug-induced), psychogenic, or mixed psychogenic and organic. ED usually develops from a mix of psychogenic and organic factors<sup>[1,2]</sup>. Psychological factors are involved in the development of ED and include performance-related issues (eg, performance anxiety), traumatic past experiences, relationship problems, anxiety, depression, and stress<sup>[1-3]</sup>. Taking a comprehensive medical history may reveal one of the many common disorders associated with ED<sup>[1]</sup>.</div><div class=\"graphic_footnotes\">ED: erectile dysfunction.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Hatzimouratidis K, Eardley I, Giuliano F, et al. European Association of Urology Guidelines on Male Sexual Dysfunction: Erectile dysfunction and premature ejaculation. 2015. Available at: <A spellcheck=true href=\"http://uroweb.org/guideline/male-sexual-dysfunction/\">uroweb.org/guideline/male-sexual-dysfunction/</A> (Accessed on April 16, 2015).</LI>&#xD;&#xA;<LI>Shamloul R, Ghanem H. Erectile dysfunction. Lancet 2013; 381:153.</LI>&#xD;&#xA;<LI>Grant P, Jackson G, Baig I, Quin J. Erectile dysfunction in general medicine. Clin Med 2013; 13:136.</LI></OL></div><div id=\"graphicVersion\">Graphic 97650 Version 2.0</div></div></div>"},"97651":{"type":"graphic_table","displayName":"Cardiovascular risks men with ED","title":"Cardiovascular risk stratification in men with erectile dysfunction<sup>[1,2]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cardiovascular risk stratification in men with erectile dysfunction<sup>[1,2]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Low-risk category</td> <td class=\"subtitle1\">Intermediate-risk category</td> <td class=\"subtitle1\">High-risk category</td> </tr> <tr> <td>Asymptomatic, &#60;3 risk factors for CAD (excluding sex)</td> <td>&#8805;3 risk factors for CAD (excluding sex)</td> <td>High-risk arrhythmias</td> </tr> <tr> <td>&nbsp;</td> <td>Mild or moderate, stable angina</td> <td>Unstable or refractory angina</td> </tr> <tr> <td>&nbsp;</td> <td>Previous (&#62;6 to 8 week) or recent (2 to 6 week) MI</td> <td>Recent (&#60;2 week) MI</td> </tr> <tr> <td>LVD/CHF (NYHA class I or II)</td> <td>LVD/CHF (NYHA class III)</td> <td>LVD/CHF (NYHA class IV)</td> </tr> <tr> <td>Post-successful coronary revascularization</td> <td>Noncardiac sequelae of atherosclerotic disease (eg, stroke, peripheral vascular disease)</td> <td>Hypertrophic obstructive and other cardiomyopathies</td> </tr> <tr> <td>Controlled hypertension</td> <td>&nbsp;</td> <td>Uncontrolled hypertension</td> </tr> <tr> <td>Mild valvular disease</td> <td>&nbsp;</td> <td>Moderate-to-severe valvular disease</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The Princeton Consensus (Expert Panel) Conference is dedicated to optimizing sexual function and preserving cardiovascular health<SUP>[1]</SUP>. Patients with ED can be stratified into three cardiovascular risk categories as summarized in this table, which can be used as the basis for a treatment algorithm for initiating or resuming sexual activity<SUP>[1,2]</SUP>.</div><div class=\"graphic_footnotes\">CAD: coronary artery disease; MI: myocardial infarction; LVD: left ventricular dysfunction; CHF: congestive heart failure; NYHA: New York Heart Association; ED: erectile dysfunction.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Wespes E, Eardley I, Guiliano F, et al. European Association of Urology Guidelines on Male Sexual Dysfunction: erectile dysfunction and premature ejaculation. 2013. Available at: <a href=\"http://www.uroweb.org/gls/pdf/14_Male%20Sexual%20Dysfunction_LR.pdf\" spellcheck=\"true\" target=\"_blank\">www.uroweb.org/gls/pdf/14_Male%20Sexual%20Dysfunction_LR.pdf</a> (Accessed on November 24, 2013).</li>&#xD;&#xA;    <li>Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 2012; 87:766.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 97651 Version 2.0</div></div></div>"},"97652":{"type":"graphic_picture","displayName":"Urticarial dermatitis legs","title":"Urticarial dermatitis (dermal hypersensitivity reaction)","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Urticarial dermatitis (dermal hypersensitivity reaction)</div><div class=\"cntnt\"><img style=\"width:584px; height:559px;\" src=\"images/DERM/97652_Urticarial_dermatitis_legs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dull red plaques on the posterior surface of the thighs in a 68-year-old patient with urticarial dermatitis.</div><div class=\"graphic_reference\">Courtesy of Matthew J Zirwas, MD.</div><div id=\"graphicVersion\">Graphic 97652 Version 2.0</div></div></div>"},"97653":{"type":"graphic_picture","displayName":"Urticarial dermatitis trunk","title":"Urticarial dermatitis (dermal hypersensitivity reaction)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urticarial dermatitis (dermal hypersensitivity reaction)</div><div class=\"cntnt\"><img style=\"width:437px; height:726px;\" src=\"images/DERM/97653_Urticarial_dermatitis_trunk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Edematous papules and small plaques along with areas of confluent erythema on the trunk and arms of a 68-year-old patient with urticarial dermatitis.</div><div class=\"graphic_reference\">Courtesy of Matthew J Zirwas, MD.</div><div id=\"graphicVersion\">Graphic 97653 Version 2.0</div></div></div>"},"97654":{"type":"graphic_picture","displayName":"Urticarial dermatitis chest","title":"Urticarial dermatitis (dermal hypersensitivity reaction)","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Urticarial dermatitis (dermal hypersensitivity reaction)</div><div class=\"cntnt\"><img style=\"width:712px; height:490px;\" src=\"images/DERM/97654_Urticarialdermatitischest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small papules coalescing into plaques on the chest and abdomen of a 77-year-old patient with dermal hypersensitivity.</div><div class=\"graphic_reference\">Courtesy of Matthew J Zirwas, MD.</div><div id=\"graphicVersion\">Graphic 97654 Version 3.0</div></div></div>"},"97661":{"type":"graphic_table","displayName":"BMI classification","title":"Classification of body mass index","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of body mass index</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Underweight&nbsp;<span style=\"font-family: Calibri;\">&ndash;</span> BMI &#60;18.5 kg/m<sup>2</sup></td> </tr> <tr> <td>Normal weight&nbsp;<span style=\"font-family: Calibri;\">&ndash;</span> BMI &#8805;18.5 to 24.9 kg/m<sup>2</sup></td> </tr> <tr> <td>Overweight&nbsp;<span style=\"font-family: Calibri;\">&ndash;</span> BMI &#8805;25 to 29.9 kg/m<sup>2</sup></td> </tr> <tr> <td>Obesity&nbsp;<span style=\"font-family: Calibri;\">&ndash;</span> BMI &#8805;30 kg/m<sup>2</sup></td> </tr> <tr> <td class=\"indent1\">Obesity class I&nbsp;<span style=\"font-family: Calibri;\">&ndash;</span> BMI 30 to 34.9 kg/m<sup>2</sup></td> </tr> <tr> <td class=\"indent1\">Obesity class II&nbsp;<span style=\"font-family: Calibri;\">&ndash;</span> BMI 35 to 39.9 kg/m<sup>2</sup></td> </tr> <tr> <td class=\"indent1\">Obesity class III&nbsp;<span style=\"font-family: Calibri;\">&ndash;</span> BMI &#8805;40 kg/m<sup>2</sup> (also referred to as severe, extreme, or massive obesity)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Body mass index (BMI) classifications are based upon risk of cardiovascular disease. These classifications for BMI have been adopted by the National Institutes of Health (NIH) and World Health Organization (WHO) for Caucasian, Hispanic, and black individuals. Because these cut-offs underestimate risk in the Asian and South Asian population, WHO and NIH guidelines for Asians define overweight as a BMI between 23 and 24.9 kg/m<SUP>2</SUP> and obesity as a BMI &gt;25 kg/m<SUP>2</SUP>.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>​Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults –&nbsp;the evidence report. National Institutes of Health. Obes Res 1998; 6 Suppl 2:51S. </LI>&#xD;&#xA;<LI>Obesity: Preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894:i. </LI>&#xD;&#xA;<LI>WHO Expert Consultation. Appropriate body mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363:157.</LI></OL></div><div id=\"graphicVersion\">Graphic 97661 Version 2.0</div></div></div>"},"97667":{"type":"graphic_table","displayName":"Indications for initiation of therapy in WM","title":"Indications for initiation of therapy in patients with Waldenström macroglobulinemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for initiation of therapy in patients with Waldenstr&ouml;m macroglobulinemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Clinical indications for initiation of therapy</td> </tr> <tr> <td class=\"indent1\">Recurrent fever, night sweats, weight loss, fatigue</td> </tr> <tr> <td class=\"indent1\">Hyperviscosity</td> </tr> <tr> <td class=\"indent1\">Lymphadenopathy that is either symptomatic or bulky (&#8805;5 cm in maximum diameter)</td> </tr> <tr> <td class=\"indent1\">Symptomatic hepatomegaly and/or splenomegaly</td> </tr> <tr> <td class=\"indent1\">Symptomatic organomegaly and/or organ or tissue infiltration</td> </tr> <tr> <td class=\"indent1\">Peripheral neuropathy due to WM</td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory indications for initiation of therapy</td> </tr> <tr> <td class=\"indent1\">Symptomatic cryoglobulinemia</td> </tr> <tr> <td class=\"indent1\">Cold agglutinin anemia</td> </tr> <tr> <td class=\"indent1\">Immune hemolytic anemia and/or thrombocytopenia</td> </tr> <tr> <td class=\"indent1\">Nephropathy related to WM</td> </tr> <tr> <td class=\"indent1\">Amyloidosis related to WM</td> </tr> <tr> <td class=\"indent1\">Hemoglobin &#8804;10 g/dL</td> </tr> <tr> <td class=\"indent1\">Platelet count &#60;100 x 10<sup>9</sup>/L</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WM: Waldenstr&ouml;m macroglobulinemia.</div><div class=\"graphic_reference\">Reproduced with permission of the American Society of Hematology, from: Dimopoulos MA, Kastritis E, Owen RG, et al. Treatment recommendations for patients with Waldenstr&ouml;m macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood 2014; 124:1404. Copyright &copy; 2014; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 97667 Version 5.0</div></div></div>"},"97668":{"type":"graphic_table","displayName":"IWWM-7 response criteria WM","title":"IWWM-7 response criteria for Waldenström macroglobulinemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">IWWM-7 response criteria for Waldenstr&ouml;m macroglobulinemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> </tbody> <colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Response category</td> <td class=\"subtitle1\">Description</td> </tr> <tr class=\"divider_bottom\"> <td>Complete response (CR)</td> <td> <ul> <li>Absence of serum monoclonal IgM protein by immunofixation </li> <li>Normal serum IgM level </li> <li>Complete resolution of extramedullary disease, ie, lymphadenopathy and splenomegaly if present at baseline </li> <li>Morphologically normal bone marrow aspirate and trephine biopsy </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Very good partial response (VGPR)</td> <td> <ul> <li>Monoclonal IgM protein is detectable </li> <li>&#8805;90% reduction in serum IgM level from baseline* </li> <li>Complete resolution of extramedullary disease, ie, lymphadenopathy/splenomegaly if present at baseline </li> <li>No new signs or symptoms of active disease </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Partial response (PR)</td> <td> <ul> <li>Monoclonal IgM protein is detectable </li> <li>&#8805;50 but &#60;90% reduction in serum IgM level from baseline* </li> <li>Reduction in extramedullary disease, ie, lymphadenopathy/splenomegaly if present at baseline </li> <li>No new signs or symptoms of active disease </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Minor response (MR)</td> <td> <ul> <li>Monoclonal IgM protein is detectable </li> <li>&#8805;25 but &#60;50% reduction in serum IgM level from baseline* </li> <li>No new signs or symptoms of active disease </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Stable disease</td> <td> <ul> <li>Monoclonal IgM protein is detectable </li> <li>&#60;25% reduction and &#60;25% increase in serum IgM level from baseline* </li> <li>No progression in extramedullary disease, ie, lymphadenopathy/splenomegaly </li> <li>No new signs or symptoms of active disease </li> </ul> </td> </tr> <tr> <td>Progressive disease</td> <td> <ul> <li>&#8805;25% increase in serum IgM level*<sup>&#182;</sup> from lowest nadir (requires confirmation) and/or progression in clinical features attributable to the disease </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgM: immunoglobulin M.<br />* Sequential changes in IgM levels may be determined either by M-protein quantitation by densitometry or total serum IgM quantitation by nephelometry.<br />&para; An absolute increase of &gt;5 g/L (0.5 g/dL) is required when the increase of IgM component is the only applicable criterion.</div><div class=\"graphic_reference\">From: Owen RG, Kyle RA, Stone MJ, et al; VIth International Workshop on Waldenstrom macroglobulinaemia. Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop. Br J Haematol 2013; 160:171. <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/bjh.12102/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1111/bjh.12102/abstract</a>. Copyright &copy; 2013 Blackwell Publishing Ltd. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department on <a href=\"mailto:permissions@wiley.com\">permissions&#64;wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 97668 Version 1.0</div></div></div>"},"97669":{"type":"graphic_table","displayName":"Preferred regimens initial treatment WM","title":"Preferred regimens for initial treatment of Waldenström macroglobulinemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preferred regimens for initial treatment of Waldenström macroglobulinemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical situation/individual patient characteristics </td> <td class=\"subtitle1\">Primary choice(s)</td> <td class=\"subtitle1\">Alternative(s)</td> </tr> <tr> <td>Patients with WM-related cytopenias or organomegaly</td> <td> <p>Rituximab-based combination</p> <p>DRC</p> Bendamustine/Rituximab</td> <td>Bortezomib/Rituximab</td> </tr> <tr> <td>Patients with symptomatic hyperviscosity, cryoglobulinemia or cold agglutinemia</td> <td> <p>Bortezomib followed by bortezomib/rituximab</p> Bendamustine/Rituximab</td> <td>Fludarabine/Rituximab +/&ndash; cyclophosphamide</td> </tr> <tr> <td>Patients with paraprotein-related neuropathy</td> <td> <p>Rituximab alone</p> DRC</td> <td> <p>Fludarabine/Rituximab</p> Bendamustine/Rituximab</td> </tr> <tr> <td>Elderly patients with poor performance status</td> <td> <p>DRC</p> Ibrutinib*</td> <td> <p>Rituximab monotherapy</p> Chlorambucil</td> </tr> <tr> <td>Elderly patients not eligible for systemic intravenous therapy</td> <td>Ibrutinib*</td> <td>Chlorambucil</td> </tr> <tr> <td>Young patients eligible for autologous HCT</td> <td> <p>DRC</p> Bortezomib/Rituximab</td> <td> <p>Bendamustine/Rituximab</p> R-CHOP</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WM: Waldenström macroglobulinemia; DRC: dexamethasone, rituximab, and cyclophosphamide; HCT: hematopoietic cell transplantation.<br />* Original table recommended oral fludarabine; this has been revised to ibrutinib based on current data.</div><div class=\"graphic_reference\">Modified with permission of the American Society of Hematology, from: Dimopoulos MA, Kastritis E, Owen RG, et al. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood 2014; 124:1404. Copyright © 2014; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 97669 Version 6.0</div></div></div>"},"97670":{"type":"graphic_figure","displayName":"HPT axis","title":"Hypothalamic-pituitary-testicular axis","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Hypothalamic-pituitary-testicular axis</div><div class=\"cntnt\"><img style=\"width:503px; height:695px;\" src=\"images/ENDO/97670_HPT_axis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of the hypothalamic-pituitary-testicular axis. GnRH from the hypothalamus stimulates the gonadotroph cells of the pituitary to secrete LH and FSH. LH stimulates the Leydig cells of the testes to secrete testosterone. The high concentration of testosterone within the testes is essential for spermatogenesis within the seminiferous tubules. FSH stimulates the Sertoli cells within the seminiferous tubules to make inhibin B, which also stimulates spermatogenesis. Testosterone inhibits GnRH secretion, and inhibin B inhibits FSH secretion.</div><div class=\"graphic_footnotes\">GnRH: gonadotropin-releasing hormone; FSH: follicle-stimulating hormone; LH: luteinizing hormone.</div><div id=\"graphicVersion\">Graphic 97670 Version 1.0</div></div></div>"},"97673":{"type":"graphic_picture","displayName":"Bullous impetigo - multiple lesions","title":"Bullous impetigo","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Bullous impetigo</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/97673_Bullous_impetigo_mltpl_lsn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erosions with crust in a child with bullous impetigo.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 97673 Version 1.0</div></div></div>"},"97674":{"type":"graphic_picture","displayName":"Ecthyma gangrenosum - eschar","title":"Ecthyma gangrenosum","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Ecthyma gangrenosum</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/97674_Ecthyma_gangrenosum_eschar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Necrotic eschar in ecthyma gangrenosum.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 97674 Version 1.0</div></div></div>"},"97678":{"type":"graphic_picture","displayName":"Hinged knee cast brace part one","title":"Hinged knee cast brace part one","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Hinged knee cast brace part one</div><div class=\"cntnt\"><img style=\"width:540px; height:400px;\" src=\"images/EM/97678_Hinged_knee_cast_brace_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For proximal tibial fractures, the knee may be mobilized with the aid of a hinged cast,&nbsp;which&nbsp;can be&nbsp;applied&nbsp;once the fracture is sufficiently consolidated (typically after six weeks). The hinged cast involves two parts. A fresh cast has to be applied below the knee as well as above. The lever arms of the hinge are incorporated in the plaster cuffs above and below the knee. Great care needs to be taken to align the axis of the hinge with that of the knee joint. Remember that the knee axis&nbsp;lies proximal to the joint line, roughly at the level of the femoral epicondyles, and is perpendicular to the knee's arc of motion.</div><div class=\"graphic_reference\">Reproduced with permission from: AO Surgery Reference. Copyright by AO Foundation, Switzerland. Available at: <a href=\"http://www.aosurgery.org/\" spellcheck=\"true\" target=\"_blank\">www.aosurgery.org</a>. (Accessed on October 27, 2014).</div><div id=\"graphicVersion\">Graphic 97678 Version 2.0</div></div></div>"},"97679":{"type":"graphic_picture","displayName":"Hinged knee cast brace part two","title":"Hinged knee cast brace part two","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Hinged knee cast brace part two</div><div class=\"cntnt\"><img style=\"width:540px; height:400px;\" src=\"images/EM/97679_Hinged_knee_cast_brace_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This knee cast-brace, a form of functional bracing, allows mobilization of the knee joint before the fracture is completely healed. It provides continued protection of the healing fracture,&nbsp;while allowing for&nbsp;progressive partial weight bearing, at the discretion of the treating surgeon. Where materials are available, such functional braces can be made of fiberglass or appropriate thermoplastics. If mobilization of the ankle is desired, a hinged foot support can be used to replace the foot portion of the cast.</div><div class=\"graphic_reference\">Reproduced with permission from: AO Surgery Reference. Copyright by AO Foundation, Switzerland. Available at: <a href=\"http://www.aosurgery.org/\" spellcheck=\"true\" target=\"_blank\">www.aosurgery.org</a>. (Accessed on October 27, 2014).</div><div id=\"graphicVersion\">Graphic 97679 Version 1.0</div></div></div>"},"97684":{"type":"graphic_table","displayName":"ART regimens during pregnancy in resource-rich settings","title":"Favored antiretroviral regimens for treatment-naïve HIV-infected pregnant women in resource-rich settings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Favored antiretroviral regimens for treatment-na&iuml;ve HIV-infected pregnant women in resource-rich settings</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Considerations</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Dual NRTI backbone</td> </tr> <tr> <td class=\"indent1\">Abacavir/lamivudine</td> <td> <ul> <li>Available as a fixed-dose combination </li> <li>Once-daily administration </li> <li>HLA-B5701 testing is required prior to use; abacavir should <strong>not</strong> be used in patients who test positive because of the risk of a hypersensitivity reaction </li> <li>Not recommended if pre-treatment HIV RNA level &#62;100,000 copies/mL </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <p>Tenofovir/emtrictabine</p> <p class=\"indent1\"><strong>or</strong></p> Tenofovir plus lamivudine</td> <td> <ul> <li>Tenofovir/emtricitabine is available as a fixed-dose combination </li> <li>Once-daily administration </li> <li>Tenofovir has potential for renal toxicity; these combinations should be used with caution in patients with renal insufficiency </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Third drug - Protease inhibitors</td> </tr> <tr> <td class=\"indent1\">Atazanavir plus ritonavir</td> <td> <ul> <li>Once-daily administration </li> <li>Extensive experience in pregnancy </li> <li>Maternal indirect hyperbilirubinemia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Darunavir plus ritonavir</td> <td> <ul> <li>Well tolerated </li> <li>Pharmacokinetic data available and increasing experience with use in pregnancy </li> <li>Requires twice-daily administration during pregnancy </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Third drug - Integrase inhibitor</td> </tr> <tr> <td class=\"indent1\">Raltegravir</td> <td> <ul> <li>Rapid viral load reduction </li> <li>Useful when drug interactions with protease inhibitor regimens are a concern </li> <li>Pharmacokinetic data available and increasing experience with use in pregnancy </li> <li>Requires twice-daily administration </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Preferred regimens for antiretroviral treatment (ART) of treatment-naïve HIV-infected pregnant women consist of one of the dual NRTI combinations listed above plus one of the third drugs (a protease inhibitor or integrase inhibitor) listed above.</div><div class=\"graphic_footnotes\">NRTI: nucleoside reverse transcriptase inhibitor; HLA: human leukocyte antigen.</div><div class=\"graphic_reference\">Adapted from: Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at: <A href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf\" target=_blank>https://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf</A> (Accessed on October 26, 2016).</div><div id=\"graphicVersion\">Graphic 97684 Version 3.0</div></div></div>"},"97685":{"type":"graphic_algorithm","displayName":"Diagnostic approach to autosomal dominant LGMD","title":"Diagnostic approach to patients with a limb-girdle pattern of weakness and suspected muscular dystrophy with an autosomal dominant inheritance pattern","html":"<div class=\"graphic\"><div style=\"width: 1110px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to patients with a limb-girdle pattern of weakness and suspected muscular dystrophy with an autosomal dominant inheritance pattern</div><div class=\"cntnt\"><img style=\"width:1090px; height:334px;\" src=\"images/NEURO/97685_DgnstcapprchautsmldomLGMD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">EDMD: Emery-Dreifuss muscular dystrophy; hIBMPFD: hereditary inclusion body myopathy with Paget disease and frontotemporal dementia; LGMD: limb-girdle muscular dystrophy; VCP: valosin-containing protein.<br />* Autosomal dominant, autosomal recessive, or X-linked inheritance may be responsible in sporadic cases.</div><div class=\"graphic_reference\">From: Narayanaswami P, Weiss M, Selcen D, et al. Evidence-based guideline summary: Diagnosis and treatment of limb-girdle and distal dystrophies: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular &amp; Electrodiagnostic Medicine. Neurology 2014; 83:1453. DOI: <a href=\"http://www.neurology.org/content/83/16/1453.long\" spellcheck=\"true\" target=\"_blank\">10.1212/WNL.0000000000000892</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 97685 Version 2.0</div></div></div>"},"97686":{"type":"graphic_algorithm","displayName":"Diagnostic approach to autosomal recessive LGMD","title":"Diagnostic approach to patients with a limb-girdle pattern of weakness and suspected muscular dystrophy with an autosomal recessive inheritance pattern","html":"<div class=\"graphic\"><div style=\"width: 1008px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to patients with a limb-girdle pattern of weakness and suspected muscular dystrophy with an autosomal recessive inheritance pattern</div><div class=\"cntnt\"><img style=\"width:988px; height:486px;\" src=\"images/NEURO/97686_DgnstaprchatsmlrcsvLGMD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LGMD: limb-girdle muscular dystrophy.<br />* Autosomal dominant, autosomal recessive, or X-linked inheritance may be responsible in sporadic cases.</div><div class=\"graphic_reference\">From: Narayanaswami P, Weiss M, Selcen D, et al. Evidence-based guideline summary: Diagnosis and treatment of limb-girdle and distal dystrophies: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular &amp; Electrodiagnostic Medicine. Neurology 2014; 83:1453. DOI: <a href=\"http://www.neurology.org/content/83/16/1453.long\" spellcheck=\"true\" target=\"_blank\">10.1212/WNL.0000000000000892</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 97686 Version 2.0</div></div></div>"},"97687":{"type":"graphic_algorithm","displayName":"Conceptual approach to LGMD","title":"Conceptual approach to a patient with a suspected limb-girdle muscular dystrophy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Conceptual approach to a patient with a suspected limb-girdle muscular dystrophy</div><div class=\"cntnt\"><img style=\"width:404px; height:624px;\" src=\"images/NEURO/97687_ConceptualapproachLGMD.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">EMG: electromyography.</div><div class=\"graphic_reference\">From: Narayanaswami P, Weiss M, Selcen D, et al. Evidence-based guideline summary: Diagnosis and treatment of limb-girdle and distal dystrophies: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular &amp; Electrodiagnostic Medicine. Neurology 2014; 83:1453. DOI: <a href=\"http://www.neurology.org/content/83/16/1453.long\" spellcheck=\"true\" target=\"_blank\">10.1212/WNL.0000000000000892</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 97687 Version 2.0</div></div></div>"},"97690":{"type":"graphic_figure","displayName":"Pelvic anatomy","title":"Anatomy of human pelvic bone","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Anatomy of human pelvic bone</div><div class=\"cntnt\"><img style=\"width:535px; height:378px;\" src=\"images/ID/97690_Pelvic_-anatomy.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 97690 Version 1.0</div></div></div>"},"97703":{"type":"graphic_figure","displayName":"New cases, deaths, and 5-year relative survival","title":"New cases, deaths, and 5-year relative survival","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">New cases, deaths, and 5-year relative survival</div><div class=\"cntnt\"><img style=\"width:605px; height:247px;\" src=\"images/PC/97703_New_cass_dth_5yr_rltv_srvvl.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SEER 9 incidence and United States mortality from 1975 to 2011; all races; females. Rates are age-adjusted.</div><div class=\"graphic_reference\">Reproduced from: SEER Cancer Statistics Factsheets: Cervix Uteri Cancer. National Cancer Institute. Bethesda, MD. Available at: <a href=\"http://seer.cancer.gov/statfacts/html/cervix.html\" spellcheck=\"true\" target=\"_blank\">http://seer.cancer.gov/statfacts/html/cervix.html</a> (Accessed on November 13, 2014).</div><div id=\"graphicVersion\">Graphic 97703 Version 2.0</div></div></div>"},"97704":{"type":"graphic_figure","displayName":"Percent of deaths by age group: Cervix uteri cancer","title":"Percent of deaths by age group: Cervix uteri cancer","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Percent of deaths by age group: Cervix uteri cancer</div><div class=\"cntnt\"><img style=\"width:555px; height:347px;\" src=\"images/PC/97704_Prcnt_dth_age_crvx_utr_cncr.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">United States 2007 to 2011; all races; females.</div><div class=\"graphic_reference\">Reproduced from: SEER Cancer Statistics Factsheets: Cervix Uteri Cancer. National Cancer Institute. Bethesda, MD. Available at: <a href=\"http://seer.cancer.gov/statfacts/html/cervix.html\" spellcheck=\"true\" target=\"_blank\">http://seer.cancer.gov/statfacts/html/cervix.html</a> (Accessed on November 13, 2014).</div><div id=\"graphicVersion\">Graphic 97704 Version 2.0</div></div></div>"},"97705":{"type":"graphic_picture","displayName":"CLL peripheral smear and bone marrow aspirate","title":"Chronic lymphocytic leukemia (CLL) peripheral smear and bone marrow aspirate","html":"<div class=\"graphic\"><div style=\"width: 834px\" class=\"figure\"><div class=\"ttl\">Chronic lymphocytic leukemia (CLL) peripheral smear and bone marrow aspirate</div><div class=\"cntnt\"><img style=\"width:814px; height:338px;\" src=\"images/HEME/97705_CLL_prphrl_smr_mrrw_asprt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peripheral blood smear (A) and bone marrow aspirate (B) from a patient with chronic lymphocytic leukemia. The peripheral blood smear demonstrates a lymphocytosis. The leukemic cells are small, mature-appearing lymphocytes with a dense nucleus, partially aggregated (clumped) chromatin, and without discernible nucleoli (arrows). There is a narrow border of clear to slightly basophilic cytoplasm. The field includes some segmented neutrophils (arrowhead) and a nucleated red blood cell (dashed arrow). The bone marrow aspirate demonstrates an increased percentage of mature-appearing lymphocytes.</div><div id=\"graphicVersion\">Graphic 97705 Version 2.0</div></div></div>"},"97707":{"type":"graphic_figure","displayName":"Diaphragmatic pacer hardware","title":"Diaphragmatic pacer hardware","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Diaphragmatic pacer hardware</div><div class=\"cntnt\"><img style=\"width:404px; height:407px;\" src=\"images/PULM/97707_Diaphragmatic_pace_hardware.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2014 Avery Biomedical Devices, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97707 Version 1.0</div></div></div>"},"97708":{"type":"graphic_picture","displayName":"Grading of spondylolisthesis","title":"Grading of spondylolisthesis","html":"<div class=\"graphic\"><div style=\"width: 588px\" class=\"figure\"><div class=\"ttl\">Grading of spondylolisthesis</div><div class=\"cntnt\"><img style=\"width:568px; height:602px;\" src=\"images/EM/97708_Grading_spondylolisthesis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The diagram above shows grades one through four of the Meyerding classification, which categorizes spondylolisthesis lesions according to what percentage of the cephalad vertebral body extends beyond the anterior border of the caudal vertebra.</div><div class=\"graphic_reference\">Courtesy of&nbsp;Michael d'Hemecourt</div><div id=\"graphicVersion\">Graphic 97708 Version 1.0</div></div></div>"},"97714":{"type":"graphic_figure","displayName":"Multiple microhemorrhages due to amyloid angiopathy","title":"Multiple cerebral microhemorrhages in a patient with amyloid angiopathy and Alzheimer disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Multiple cerebral microhemorrhages in a patient with amyloid angiopathy and Alzheimer disease</div><div class=\"cntnt\"><img style=\"width:437px; height:476px;\" src=\"images/NEURO/97714_Grdnt_ech_MRI_mlt_mcrhmrrhg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gradient echo magnetic resonance imaging (MRI) showing multiple areas of punctate susceptibility artifact&nbsp;consistent with cerebral microhemorrhages (arrows)&nbsp;due&nbsp;to amyloid angiopathy in a patient with Alzheimer's disease.</div><div id=\"graphicVersion\">Graphic 97714 Version 2.0</div></div></div>"},"97715":{"type":"graphic_table","displayName":"Abx unilateral cervical lymphadenitis","title":"Antimicrobial regimens for children with acute unilateral cervical lymphadenitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial regimens for children with acute unilateral cervical lymphadenitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Antimicrobial therapy</td> <td class=\"subtitle1\">Dose*</td> <td class=\"subtitle1\">Spectrum</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Oral therapy</td> </tr> <tr> <td class=\"indent1\"> <p>Amoxicillin-clavulanate<sup>&#182;</sup></p> <p>125 mg/5 mL suspension</p> <p>250 mg/5 mL suspension</p> <p>250 mg tablet<sup>&#916;</sup></p> <p>500 mg tablet</p> </td> <td>40 mg/kg per day&nbsp;orally divided every 8 hours (maximum 1.5 g/day)</td> <td> <p>MSSA</p> <p>GAS</p> Oral anaerobes</td> <td>Anaerobic coverage indicated for associated periodontal disease or poor dental hygiene</td> </tr> <tr> <td class=\"indent1\"> <p>Amoxicillin-clavulanate<sup>&#182;</sup></p> <p>200 mg/5 mL suspension</p> <p>400 mg/5 mL suspension</p> <p>200 mg chewable tablet</p> 400 mg chewable tablet</td> <td>25 to 45 mg/kg per day orally divided every 12 hours (maximum 1.75 g/day)</td> <td> <p>MSSA</p> <p>GAS</p> Oral anaerobes</td> <td>Anaerobic coverage indicated for associated periodontal disease or poor dental hygiene</td> </tr> <tr> <td class=\"indent1\">Cefadroxil</td> <td>30 mg/kg per day orally divided every 12 hours (maximum 2 g/day)</td> <td> <p>MSSA</p> GAS</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Cephalexin</td> <td>25 to 100 mg/kg per day orally divided every 6 or 8 hours (maximum 4 g/day)</td> <td> <p>MSSA</p> GAS</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Clindamycin<sup>&#9674;</sup></td> <td>30 mg/kg per day orally divided every 6 or 8 hours (maximum 1.8 g/day)</td> <td> <p>MSSA<sup>&#9674;</sup></p> <p>CA-MRSA<sup>&#9674;</sup></p> <p>GAS</p> Oral anaerobes</td> <td> <p>Anaerobic coverage indicated for associated periodontal disease or poor dental hygiene</p> Oral suspension may be unpalatable, affecting adherence</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Trimethoprim-sulfamethoxazole<sup>&#167;</sup> (TMP-SMX, cotrimoxazole)</td> <td>10 mg/kg per day orally divided every 12 hours (maximum 320 mg/day)</td> <td> <p>MSSA</p> <p>CA-MRSA</p> <em>Bartonella henselae</em></td> <td>Not active against GAS, so should not be used for empiric therapy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Parenteral therapy</td> </tr> <tr> <td class=\"indent1\">Ampicillin-sulbactam<sup>&#182;</sup></td> <td>100 to 200 mg/kg per day IV divided every 6 hours (maximum&nbsp;8 g/day of ampicillin component)</td> <td> <p>MSSA</p> <p>GAS</p> <p>Oral anaerobes</p> Gram negative organisms</td> <td>Anaerobic coverage indicated for associated periodontal disease or poor dental hygiene</td> </tr> <tr> <td class=\"indent1\">Cefazolin</td> <td>50 to 100 mg/kg per day IV divided every 8 hours (maximum dose 6 g/day)</td> <td> <p>MSSA</p> GAS</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Clindamycin<sup>&#9674;</sup></td> <td>40 mg/kg per day IV divided every 6 or 8 hours (maximum&nbsp;2.7 g/day)</td> <td> <p>MSSA<sup>&#9674;</sup></p> <p>CA-MRSA<sup>&#9674;</sup></p> <p>GAS</p> Oral anaerobes</td> <td> <p>Anaerobic coverage indicated for associated periodontal disease or poor dental hygiene</p> Preferred in communities with low<sup>&#9674;</sup> prevalence of clindamycin-resistant SA</td> </tr> <tr> <td class=\"indent1\">Linezolid</td> <td> <p>&#60;12 years: 30 mg/kg per day IV&nbsp;divided every 8 hours (maximum 1.8 g/day)</p> &#8805;12 years:&nbsp;20 mg/kg per day IV divided every 12 hours (maximum 1.2 g/day)</td> <td> <p>MSSA</p> <p>CA-MRSA</p> GAS</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Nafcillin</td> <td>150 to 200&nbsp;mg/kg per day IV divided every 4 or 6 hours (maximum dose 12 g/day)</td> <td> <p>MSSA</p> GAS</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Oxacillin&nbsp;</td> <td> <p>150 to 200&nbsp;mg/kg per day&nbsp;IV&nbsp;divided every 4 or 6 hours (maximum dose 12 g/day)</p> </td> <td> <p>MSSA</p> <p>GAS</p> </td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Piperacillin-tazobactam<sup>&#165;</sup></td> <td>300 mg/kg per day&nbsp;IV&nbsp;divided every 6 or 8 hours (maximum dose 16 g/day of piperacillin component)</td> <td> <p>MSSA</p> <p>GAS</p> <p>Oral anaerobes</p> Gram negative organisms</td> <td>Anaerobic coverage indicated for associated periodontal disease or poor dental hygiene</td> </tr> <tr> <td class=\"indent1\">Vancomycin</td> <td>45 to 60<sup>&#135;</sup>mg/kg per day IV divided every 6 or 8 hours (maximum 4 g/day)</td> <td> <p>MSSA</p> <p>CA-MRSA</p> GAS</td> <td>Preferred in communities with substantial<sup>&#9674;</sup> prevalence of clindamycin-resistant SA</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MSSA: methicillin-susceptible <EM>Staphylococcus aureus</EM>; GAS: group A <EM>Streptococcus</EM>; CA-MRSA: community associated methicillin-resistant <EM>S. aureus</EM>; IV: intravenously. <br />* The doses recommended above are intended for patients with normal renal function; the doses of some of these agents must be adjusted in patients with renal insufficiency.<br />¶ Dosed according to the amoxicillin or ampicillin component.<br />Δ&nbsp;This tablet is only for children who weigh ≥40 kg.<br />◊ The prevalence of clindamycin-resistant <EM>S. aureus </EM>varies geographically and may be more than 10 percent&nbsp;in some communities. The threshold prevalence of clindamycin-resistant <EM>S. aureus </EM>for choosing vancomycin varies from center to center, usually ranging from 10 to 25 percent, trying to balance the benefit of definitive therapy for the patient with the risk of increasing vancomycin resistance in the community.<br />§&nbsp;Dosed according to the trimethoprim component.<br />¥&nbsp;Dosed according to the piperacillin component.<br />‡&nbsp;60 mg/kg per day is recommended for children with serious infections (eg, toxic-appearing, fluctuant nodes, concomitant cellulitis). Adjustment of dose and frequency may be necessary based upon serum concentration monitoring.</div><div id=\"graphicVersion\">Graphic 97715 Version 1.0</div></div></div>"},"97716":{"type":"graphic_table","displayName":"Acute bilateral cervical adenitis child","title":"Infectious causes of acute bilateral cervical lymphadenitis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infectious causes of acute bilateral cervical lymphadenitis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Infection</td> <td class=\"subtitle1\">Associated clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Common causes</td> </tr> <tr> <td class=\"indent1\">Influenza virus</td> <td>URI symptoms, fever</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr virus*<sup>&#182;</sup></td> <td>Infectious mononucleosis (malaise, headache, fever, tonsillopharyngitis, fatigue, splenomegaly)</td> </tr> <tr> <td class=\"indent1\">Cytomegalovirus*<sup>&#182;</sup></td> <td>Mononucleosis-like illness</td> </tr> <tr> <td class=\"indent1\">Herpes simplex virus</td> <td>Gingivostomatitis or cold sore</td> </tr> <tr> <td class=\"indent1\">Adenovirus</td> <td>URI symptoms, pharyngitis, conjunctivitis</td> </tr> <tr> <td class=\"indent1\">Enterovirus</td> <td>URI symptoms, oral lesions, lesions on hands and feet</td> </tr> <tr> <td class=\"indent1\">Rhinovirus</td> <td>URI symptoms</td> </tr> <tr> <td class=\"indent1\">Group A <em>Streptococcus</em></td> <td>Exudative pharyngitis</td> </tr> <tr> <td class=\"indent1\"><em>Arcanobacterium haemolyticum</em></td> <td>Exudative pharyngitis, scarlatiniform rash; predominantly occurs in adolescents and young adults</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Mycoplasma pneumoniae</em></td> <td>Headache, malaise, fever, pharyngitis, cough</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Uncommon causes</td> </tr> <tr> <td class=\"indent1\">Roseola<sup>&#182;</sup></td> <td>Fever, irritability, rash</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Parvovirus B19<sup>&#182;</sup></td> <td>Fever, \"slapped cheek\" rash</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Rare causes</td> </tr> <tr> <td class=\"indent1\"><em>Corynebacterium diphtheria</em></td> <td>Sore throat, malaise, fever, exudative pharyngitis, pseudomembrane; edema of the soft tissues of the neck</td> </tr> <tr> <td class=\"indent1\">Rubella<sup>&#182;</sup></td> <td>Rash that spreads from face to trunk and extremities</td> </tr> <tr> <td class=\"indent1\">Measles</td> <td>Prodrome of fever, conjunctivitis, coryza, and cough followed by rash that spreads from face to trunk and extremities; lack of immunization, international travel</td> </tr> <tr> <td class=\"indent1\">Mumps<sup>&#182;</sup></td> <td>Tenderness and swelling of parotid gland</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">URI: upper respiratory infection. <br />* Infection can persist and become more chronic in appearance.<br />¶ Often associated with generalized lymphadenopathy. </div><div id=\"graphicVersion\">Graphic 97716 Version 1.0</div></div></div>"},"97718":{"type":"graphic_table","displayName":"Acute unilateral cervical lymphadenitis child","title":"Infectious causes of acute unilateral cervical lymphadenitis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infectious causes of acute unilateral cervical lymphadenitis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Infectious agent</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Common causes</td> </tr> <tr> <td class=\"indent1\"><em>Staphylococcus aureus</em></td> <td>Usually occurs in children &#60;5 years; may have history of recent skin infection, upper respiratory infection, or facial trauma</td> </tr> <tr> <td class=\"indent1\">Group A <em>Streptococcus</em></td> <td>Usually occurs in children &#60;5 years; may have history of recent skin infection, upper respiratory infection, or facial trauma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Anaerobic bacteria (eg, actinomycosis; <em>Spirillum minor</em>)</td> <td>Poor dental hygiene; periodontal disease</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Uncommon causes</td> </tr> <tr> <td class=\"indent1\">Group B <em>Streptococcus</em></td> <td>Occurs in infants &#60;3 months corrected gestational age; fever; irritability; poor feeding</td> </tr> <tr> <td class=\"indent1\">Tularemia*</td> <td>Contact with infected animal (eg, rabbit, pet hamsters) or bite of blood-sucking arthropod; may be papular lesion in the drainage field of the involved node</td> </tr> <tr> <td class=\"indent1\">Alpha <em>Streptococcus</em></td> <td>Oral lesions</td> </tr> <tr> <td class=\"indent1\"><em>Pasteurella multocida</em></td> <td>Cat or dog exposure (bite, lick, scratch)</td> </tr> <tr> <td class=\"indent1\"><em>Yersinia pestis</em><sup>&#182;</sup> (bubonic plague)</td> <td>Intensely inflamed lymph node (red, swollen, tender) without fluctuance; possible, eschar, pustule, or necrotic lesion at site of flea bite</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gram-negative bacilli</td> <td>History of ear, nose, and throat infections; may indicate need to test for underlying immunodeficiency (eg, <em>Serratia</em> spp)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Rare causes</td> </tr> <tr> <td class=\"indent1\"><em>Yersinia enterocolitica</em>*</td> <td>Suppurative lymphadenitis; fever; diarrhea</td> </tr> <tr> <td class=\"indent1\">Anthrax</td> <td>Contact with infected animals or animal products; cuts or abrasions; begins as painless, often pruritic papule that rapidly enlarges and develops a central vesicle or bulla, followed by a painless ulcer</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Infection can persist and become more chronic in appearance.<br />&para; Often associated with generalized lymphadenopathy. </div><div id=\"graphicVersion\">Graphic 97718 Version 3.0</div></div></div>"},"97719":{"type":"graphic_table","displayName":"Subacute and chronic bilateral cervical adenitis child","title":"Infectious causes of subacute/chronic bilateral cervical lymphadenitis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infectious causes of subacute/chronic bilateral cervical lymphadenitis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Infection</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Common causes</td> </tr> <tr> <td class=\"indent1\">Epstein-Barr virus (EBV)*</td> <td>Infectious mononucleosis (fever, exudative pharyngitis, hepatosplenomegaly); positive monospot or EBV serology</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cytomegalovirus (CMV)*</td> <td>Mononucleosis-like illness; positive CMV serology</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Uncommon causes</td> </tr> <tr> <td class=\"indent1\">Human immunodeficiency virus (HIV)*</td> <td>High-risk behavior (unprotected sexual contact, injection drug use, etc)</td> </tr> <tr> <td class=\"indent1\">Toxoplasmosis*</td> <td>Exposure to cat feces; ingestion of poorly cooked meat, soil, or contaminated food; posterior cervical involvement</td> </tr> <tr> <td class=\"indent1\"><em>Mycobacterium tuberculosis</em>*</td> <td>Birth in, travel to, or contact with a visitor from a region endemic for <em>Mycobacterium tuberculosis</em>; tuberculin skin test usually with &#8805;15 mm induration at 48 hours; positive interferon-gamma release assay</td> </tr> <tr> <td class=\"indent1\"><em>Mycobacterium bovis</em></td> <td>Ingestion of unpasteurized dairy products; exposure to cattle</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Syphilis*</td> <td>High-risk sexual behavior</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Rare causes</td> </tr> <tr> <td class=\"indent1\">Brucellosis*</td> <td>Travel to or living in endemic area; ingestion of unpasteurized dairy products</td> </tr> <tr> <td class=\"indent1\">Histoplasmosis*</td> <td>Associated skin lesions</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Often associated with generalized lymphadenopathy.</div><div id=\"graphicVersion\">Graphic 97719 Version 4.0</div></div></div>"},"97720":{"type":"graphic_table","displayName":"Subacute and chronic unilateral cervical adenitis child","title":"Infectious causes of subacute/chronic unilateral cervical lymphadenitis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infectious causes of subacute/chronic unilateral cervical lymphadenitis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Infectious agent</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Common causes</td> </tr> <tr> <td class=\"indent1\">Nontuberculous mycobacteria</td> <td>Usually occurs in children &#60;5 years; frequent involvement of submandibular and tonsillar nodes; nontender; gradual enlargement with fluctuance, violaceous discoloration, and development of sinus tract; lack of response to antistaphylococcal and antistreptococcal antibiotics; TST may show 5 to 15 mm of induration at 48 hours; negative interferon-gamma release assay*</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cat scratch disease</td> <td>Cat exposure; papule at site of inoculation (not always present); possible conjunctivitis; positive <em>Bartonella henselae</em> serology</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Uncommon causes</td> </tr> <tr> <td class=\"indent1\">Toxoplasmosis<sup>&#182;</sup></td> <td>Exposure to cat feces; ingestion of poorly cooked meat, soil, or contaminated food; posterior cervical involvement</td> </tr> <tr> <td class=\"indent1\"><em>Mycobacterium tuberculosis</em><sup>&#182;</sup></td> <td>Birth in, travel to, or contact with a visitor from a region endemic for <em>M. tuberculosis</em>; TST usually with &#8805;15 mm induration at 48 hours; positive interferon-gamma release assay</td> </tr> <tr> <td class=\"indent1\"><em>Mycobacterium bovis</em>&nbsp;</td> <td>Ingestion of unpasteurized dairy products; exposure to cattle</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cervicofacial actinomycosis</td> <td>Slowly progressive nontender indurated mass that evolves into multiple abscesses, fistulae, and draining sinus tracts</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Rare causes</td> </tr> <tr> <td class=\"indent1\"><em>Nocardia brasiliensis</em></td> <td>Cutaneous lesions</td> </tr> <tr> <td class=\"indent1\">Aspergillosis</td> <td>Trauma, including burns and surgical wounds</td> </tr> <tr> <td class=\"indent1\">Sporotrichosis</td> <td>Papule at site of inoculation that usually ulcerates but may remain nodular with overlying erythema; similar lesions along lymphatic channels (\"sporotrichoid spread\")</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">TST: tuberculin skin test.<br />* With rare exception (eg, <EM>Mycobacterium kansasii</EM>, <EM>Mycobacterium marinum</EM>, <EM>Mycobacterium szulgai</EM>, <EM>Mycobacterium gordonae</EM>).<br />¶ Often associated with generalized lymphadenopathy.</div><div id=\"graphicVersion\">Graphic 97720 Version 3.0</div></div></div>"},"97722":{"type":"graphic_table","displayName":"Clues etiology cervical lymphadenopathy child","title":"Important aspects of the history and examination in a child with cervical lymphadenopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the history and examination in a child with cervical lymphadenopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical feature</td> <td class=\"subtitle1\">Potential significance</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">History</td> </tr> <tr> <td class=\"indent1\">Onset, laterality, and duration</td> <td>Helps to narrow etiology</td> </tr> <tr> <td class=\"indent1\">Constitutional symptoms (eg, weight loss, fatigue, malaise)</td> <td>Malignancy, Kikuchi-Fujimoto disease, Castleman disease, sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Recurrent/chronic cough, hemoptysis</td> <td>Tuberculosis</td> </tr> <tr> <td class=\"indent1\">Arthritis/arthralgia</td> <td>Juvenile idiopathic arthritis, systemic lupus erythematosus</td> </tr> <tr> <td class=\"indent1\">Nasal, aural, or sinus obstruction without drainage</td> <td>Rhabdomyosarcoma</td> </tr> <tr> <td class=\"indent1\">Immunizations status</td> <td>Measles, mumps, rubella, diphtheria (if unimmunized); postvaccination lymphadenitis (if recently immunized, particularly with diphtheria-tetanus-pertussis, polio, or typhoid fever vaccine)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Exposures</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Ill contacts </li> </ul> </td> <td>Supports infectious etiology</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Unpasteurized milk </li> </ul> </td> <td>Brucellosis, <em>Mycobacterium bovis</em></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Undercooked meats </li> </ul> </td> <td>Toxoplasmosis</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Animals </li> </ul> </td> <td>Cats (cat scratch disease, <em>Pasteurella multocida</em>, toxoplasmosis); dogs (<em>P. multocida</em>) rabbits (tularemia); hamster (tularemia); goats (brucellosis); prairie dogs (plague)</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Flea or tick bites </li> </ul> </td> <td>Plague, tularemia</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Phenytoin, carbamazepine </li> </ul> </td> <td>Medication related</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Geographic location or travel </li> </ul> </td> <td>May need to consider less common causes (eg, tularemia, plague, tuberculosis)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Examination</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Lymph node qualities</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Soft, small, round, discrete, mobile, minimally tender </li> </ul> </td> <td>Suggestive of \"reactive\" lymphadenopathy</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Isolated, asymmetric, tender, warm, erythematous </li> </ul> </td> <td>Suggestive of infection</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Hard, nontender, fixed, matted to underlying structures </li> </ul> </td> <td>May indicate malignancy</td> </tr> <tr> <td class=\"indent1\">Hepatosplenomegaly and involvement of noncervical nodes</td> <td>Systemic infection (eg, EBV, CMV, HIV, histoplasmosis, tuberculosis, syphilis), juvenile idiopathic arthritis, Castleman disease</td> </tr> <tr> <td class=\"indent1\">Conjunctivitis</td> <td>Cat scratch disease, tularemia, adenovirus, Kawasaki disease, measles</td> </tr> <tr> <td class=\"indent1\">Poor dental hygiene, periodontal disease, dental caries</td> <td>Anaerobic infection</td> </tr> <tr> <td class=\"indent1\">Loose teeth</td> <td>Langerhans cell histiocytosis</td> </tr> <tr> <td class=\"indent1\">Mouth sores/lesions</td> <td>HSV, enterovirus, PFAPA, Kawasaki disease, Langerhans cell histiocytosis</td> </tr> <tr> <td class=\"indent1\">Pharyngitis</td> <td>GAS, EBV, PFAPA, diphtheria</td> </tr> <tr> <td class=\"indent1\">Localized skin lesion</td> <td> <p><strong>More common:</strong> <em>Staphylococcus aureus</em>, GAS, cat scratch disease, tularemia, HSV</p> <strong>Less common:</strong> Nocardia, actinomycosis, sporotrichosis, plague, cutaneous diphtheria</td> </tr> <tr> <td class=\"indent1\">Generalized rash</td> <td>Systemic viral illness (eg, roseola, EBV, measles, rubella, parvovirus B19), Kawasaki disease, juvenile idiopathic arthritis, systemic lupus erythematosus, Langerhans cell histiocytosis, hemophagocytic lymphohistiocytosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EBV: Epstein-Barr virus; CMV: cytomegalovirus, HIV: human immunodeficiency virus; HSV: herpes simplex virus, PFAPA: periodic fever with aphthous stomatitis, pharyngitis, and adenitis; GAS: group A <em>Streptococcus</em>.</div><div id=\"graphicVersion\">Graphic 97722 Version 2.0</div></div></div>"},"97723":{"type":"graphic_picture","displayName":"Parinaud oculoglandular syndrome","title":"Parinaud oculoglandular syndrome","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Parinaud oculoglandular syndrome</div><div class=\"cntnt\"><img style=\"width:593px; height:397px;\" src=\"images/PEDS/97723_Parinaudoculoglandularsyn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Parinaud oculoglandular syndrome. Severe diffuse conjunctival inflammation along with a superotemporal conjunctival granuloma is present in this child with cat-scratch disease. Note the skin abrasions near the nose, which were presumably caused by a cat scratch.</div><div class=\"graphic_reference\">Reproduced with permission from: Conjunctival Infections and Inflammations. In: Wills Eye Institute: Cornea, Rapuano CJ (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 97723 Version 3.0</div></div></div>"},"97744":{"type":"graphic_table","displayName":"Outcome in surgically managed neuroendocrine liver metastases","title":"Selected studies reporting outcome of patients with surgically managed neuroendocrine liver metastases","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected studies reporting outcome of patients with surgically managed neuroendocrine liver metastases</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Study</td> <td class=\"subtitle1\">Time period of study</td> <td class=\"subtitle1\"> <p>Number of patients</p> <p>undergoing surgery</p> </td> <td class=\"subtitle1\">Fraction undergoing combined modality therapy&nbsp;(resection + ablation) (%)</td> <td class=\"subtitle1\">Symptom control (%)</td> <td class=\"subtitle1\">5-year OS (%)</td> <td class=\"subtitle1\">5-year recurrence rates (%)</td> <td class=\"subtitle1\">10-year recurrence rates (%)</td> </tr> <tr> <td>Chamberlain (2000)<sup>[1]</sup></td> <td class=\"centered\">1992-1998&nbsp;</td> <td class=\"centered\">34</td> <td class=\"centered\">-</td> <td class=\"centered\">54</td> <td class=\"centered\">76&nbsp;</td> <td class=\"centered\">-</td> <td class=\"centered\">-&nbsp;</td> </tr> <tr> <td>Elias (2003)<sup>[2]</sup></td> <td class=\"centered\">1985-2000</td> <td class=\"centered\">47</td> <td class=\"centered\">-&nbsp;</td> <td class=\"centered\">-</td> <td class=\"centered\">71&nbsp;</td> <td class=\"centered\"> <p>5-year liver recurrence</p> <p>54</p> </td> <td class=\"centered\"> <p>10-year liver recurrence</p> 75</td> </tr> <tr> <td>Sarmiento (2003)<sup>[3]</sup></td> <td class=\"centered\">1977-1998</td> <td class=\"centered\">170</td> <td class=\"centered\">-</td> <td class=\"centered\">96</td> <td class=\"centered\">61</td> <td class=\"centered\"> <p>84</p> </td> <td class=\"centered\">94</td> </tr> <tr> <td>Osborne (2006)<sup>[4]</sup></td> <td class=\"centered\">2000-2004</td> <td class=\"centered\">61</td> <td class=\"centered\">28</td> <td class=\"centered\">93</td> <td class=\"centered\"> <p>Mean</p> <p>43 months</p> </td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> </tr> <tr> <td>Ahmed (2009)<sup>[5]</sup></td> <td class=\"centered\">1973-2007</td> <td class=\"centered\">50</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> <td class=\"centered\">74</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> </tr> <tr> <td>Glazer (2010)<sup>[6]</sup></td> <td class=\"centered\">1978-2009</td> <td class=\"centered\">144</td> <td class=\"centered\">16</td> <td class=\"centered\">-</td> <td class=\"centered\">77</td> <td class=\"centered\">-</td> <td class=\"centered\">-</td> </tr> <tr> <td>Mayo (2010)<sup>[7]</sup></td> <td class=\"centered\">1985-2010</td> <td class=\"centered\">339</td> <td class=\"centered\">20</td> <td class=\"centered\">-</td> <td class=\"centered\">74</td> <td class=\"centered\"> <p>94</p> </td> <td class=\"centered\">99</td> </tr> <tr> <td>Saxena (2011)<sup>[8]</sup></td> <td class=\"centered\">1992-2009</td> <td class=\"centered\">74</td> <td class=\"centered\">51</td> <td class=\"centered\">-</td> <td class=\"centered\">63</td> <td class=\"centered\"> <p>79</p> </td> <td class=\"centered\">86 (7 years)</td> </tr> <tr> <td>Gaujoux (2012)<sup>[9]</sup></td> <td class=\"centered\">1992-2009</td> <td class=\"centered\">36</td> <td class=\"centered\">-</td> <td class=\"centered\">60 (5-year symptom-free survival)</td> <td class=\"centered\">69</td> <td class=\"centered\"> <p>87</p> </td> <td class=\"centered\">-</td> </tr> <tr> <td>Bagante (2017)<sup>[10]</sup></td> <td class=\"centered\">1990-2014&nbsp;</td> <td class=\"centered\">376&nbsp;</td> <td class=\"centered\">22</td> <td class=\"centered\">-&nbsp;</td> <td class=\"centered\">-</td> <td class=\"centered\">54&nbsp;&nbsp;</td> <td class=\"centered\">-&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OS: overall survival.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000; 190:432.</LI>&#xD;&#xA;<LI>Elias D, Lasser P, Ducreux M, et al. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery 2003; 133:375.</LI>&#xD;&#xA;<LI>Sarmiento JM, HeywoodG, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 2003; 197:29. </LI>&#xD;&#xA;<LI>Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol 2006; 13:572. </LI>&#xD;&#xA;<LI>Ahmed A, Turner G, King B, et al. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 2009; 16:885. </LI>&#xD;&#xA;<LI>Glazer ES, Tseng JF, Al-Refaie W, et al. Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB (Oxford) 2010; 12:427. </LI>&#xD;&#xA;<LI>Mayo SC, de Jong MC, Pulitano C, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 2010; 17:3129. </LI>&#xD;&#xA;<LI>Saxena A, Chua TC, Sarkar A, et al., Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery 2011; 149:209. </LI>&#xD;&#xA;<LI>Gaujoux S, Gonen M, Tang L, et al. Synchronous resection of primary and liver metastases for neuroendocrine tumors. Ann Surg Oncol 2012; 19:4270.</LI>&#xD;&#xA;<LI>Bagante F, Spolverato G, Merath K, et al. Neuroendocrine liver metastases: The chance to be cured after liver surgery. J Surg Oncol 2017; 115:679.</LI></OL></div><div id=\"graphicVersion\">Graphic 97744 Version 2.0</div></div></div>"},"97751":{"type":"graphic_diagnosticimage","displayName":"Misleading US gallstones","title":"Misleading ultrasound in a patient with gallstones","html":"<div class=\"graphic\"><div style=\"width: 633px\" class=\"figure\"><div class=\"ttl\">Misleading ultrasound in a patient with gallstones</div><div class=\"cntnt\"><img style=\"width:613px; height:262px;\" src=\"images/GAST/97751_MisleadingUSgallstones.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This ultrasound was obtained from a patient with a gallbladder that contained numerous gallstones. On ultrasound, the stones appear as one large concretion or gas.<br />(B) Multiple stones were found in the gallbladder after cholecystectomy.</div><div class=\"graphic_reference\">Courtesy of Salam F Zakko, MD, FACP, AGAF.</div><div id=\"graphicVersion\">Graphic 97751 Version 2.0</div></div></div>"},"97759":{"type":"graphic_figure","displayName":"Assessment of skin thickening for SSc","title":"Clinical assessment of skin thickening","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Clinical assessment of skin thickening</div><div class=\"cntnt\"><img style=\"width:520px; height:706px;\" src=\"images/RHEUM/97759_Skin_thickening_SSc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The modified Rodnan skin score. Semiquantitative estimates by clinical palpation of the extent and severity of scleroderma skin change. The total skin surface is divided into 17 different areas, and in each of these areas the skin score is estimated by manual palpation. The total skin score is the sum of the skin scores of the individual areas.</div><div class=\"graphic_reference\">Original figure modified for this publication. Bolster MB, Silver RM. Clinical features of systemic sclerosis. In:&nbsp;Hochberg MC, Silman AJ, Smolen JS, et al. Rheumatology, 5th ed, Mosby (Elsevier), Philadelphia 2010. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97759 Version 1.0</div></div></div>"},"97769":{"type":"graphic_figure","displayName":"Major foot arches","title":"Major foot arches","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Major foot arches</div><div class=\"cntnt\"><img style=\"width:526px; height:638px;\" src=\"images/EM/97769_Major_foot_arches.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 97769 Version 1.0</div></div></div>"},"97777":{"type":"graphic_picture","displayName":"Unilateral heel raise exercise","title":"Unilateral heel raise exercise","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Unilateral heel raise exercise</div><div class=\"cntnt\"><img style=\"width:540px; height:503px;\" src=\"images/RHEUM/97777_Unilateral_heel_raise_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Unilateral heel raises are performed on a step or platform with a towel under the toes to increase dorsal flexion of the toes during heel raises. Each heel raise consists of&nbsp;three seconds going up (concentric phase) and&nbsp;three seconds going down (eccentric phase), with a two-second pause (isometric phase)&nbsp;at the top of the exercise. This can be done up to 12 times in a row. For patients who cannot tolerate the exercise on one leg, it can be performed using both legs. This exercise can be performed every other day. </div><div class=\"graphic_reference\">Modified from: Rathleff MS, Mølgaard CM, Fredberg U, et al. High-load strength training improves outcome in patients with plantar fasciitis: A randomized controlled trial with 12-month follow-up. Scand J Med Sci Sports 2014.</div><div id=\"graphicVersion\">Graphic 97777 Version 1.0</div></div></div>"},"97782":{"type":"graphic_diagnosticimage","displayName":"MRI of subcutaneous dermoid cyst of the scalp","title":"Subcutaneous scalp dermoid cyst on MRI","html":"<div class=\"graphic\"><div style=\"width: 933px\" class=\"figure\"><div class=\"ttl\">Subcutaneous scalp dermoid cyst on MRI</div><div class=\"cntnt\"><img style=\"width:913px; height:500px;\" src=\"images/RADIOL/97782_MRI_sbctns_drmd_cyst_sclp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial T1 weighted image of the vertex (A) shows a left-sided subcutaneous heterogeneous left-sided mass with a complexity of tissues (arrow). Image B is an axial T2 fat suppressed image confirming the dominantly fatty nature of the mass (arrow) but also the presence of heterogeneous components.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 97782 Version 1.0</div></div></div>"},"97783":{"type":"graphic_diagnosticimage","displayName":"Imaging pulmonary strongyloides","title":"Pulmonary <em>Strongyloides </em>on radiography and CT scan","html":"<div class=\"graphic\"><div style=\"width: 473px\" class=\"figure\"><div class=\"ttl\">Pulmonary <em>Strongyloides </em>on radiography and CT scan</div><div class=\"cntnt\"><img style=\"width:453px; height:839px;\" src=\"images/RADIOL/97783_Imgng_plmnry_strngylds.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;posterior-anterior radiograph (A) shows a diffuse reticulonodular pattern scattered diffusely throughout both lung fields. Image B is a magnified view of A and shows extensive micronodularity (arrows) and coarsened interstitial markings. Image C is a coronal reformat of a CT scan and shows multiple peripheral nodules (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Images A and C courtesy of Augustine Andoh-Duku, MD.</div><div id=\"graphicVersion\">Graphic 97783 Version 4.0</div></div></div>"},"97786":{"type":"graphic_diagnosticimage","displayName":"CT necrotizing fasciitis","title":"Necrotizing fasciitis on CT","html":"<div class=\"graphic\"><div style=\"width: 1004px\" class=\"figure\"><div class=\"ttl\">Necrotizing fasciitis on CT</div><div class=\"cntnt\"><img style=\"width:984px; height:499px;\" src=\"images/RADIOL/97786_CT_necrotizing_fasciitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the lower pelvis (A) in a patient with Crohn's disease and a right hip replacement (arrowhead) shows a fistulous tract (arrow) from the rectum to the soft tissues of the right hip. Image B shows bubbles of gas in the swollen hamstring muscles (arrows) and circumferential edema of the thigh (asterisks) compared&nbsp;with the normal-sized left thigh. Image C is a coronal reconstruction of the&nbsp;thighs&nbsp;and exemplifies the difference in size caused by inflammatory edema (asterisk). Image D is a sagittal reconstruction and shows gas bubbles throughout the hamstring musculature (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 97786 Version 3.0</div></div></div>"},"97789":{"type":"graphic_diagnosticimage","displayName":"Imaging extensive renal pelvis TCC","title":"Extensive involvement of renal pelvis with TCC on CT and retrograde pyelography","html":"<div class=\"graphic\"><div style=\"width: 901px\" class=\"figure\"><div class=\"ttl\">Extensive involvement of renal pelvis with TCC on CT and retrograde pyelography</div><div class=\"cntnt\"><img style=\"width:881px; height:446px;\" src=\"images/RADIOL/97789_Img_extnsv_invlvmnt_rnl_plv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan through the kidneys (A) shows extensive involvement and obliteration of the left renal pelvis with a large TCC (arrow). Image B is a retrograde urogram and shows a large filling defect involving the left renal pelvis (arrowhead) and encasement of the ureteropelvic junction and infundibulum (arrow) with secondary upstream hydronephrosis (asterisk).</div><div class=\"graphic_footnotes\">CT: computed tomography; TCC: transitional cell carcinoma.</div><div id=\"graphicVersion\">Graphic 97789 Version 1.0</div></div></div>"},"97790":{"type":"graphic_diagnosticimage","displayName":"Imaging TCC of the ureter","title":"TCC of the ureter on CT and retrograde urogram","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">TCC of the ureter on CT and retrograde urogram</div><div class=\"cntnt\"><img style=\"width:728px; height:390px;\" src=\"images/RADIOL/97790_Imaging_TCC_ureter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT through the kidneys (A) shows hydronephrosis of the right kidney (arrow). Image B shows thickening of the ureter (arrow), while images C and D show an intraluminal mass (arrow). Image E is a retrograde urogram and shows an intraluminal filling defect (arrow) surrounded by contrast creating the \"Champagne glass\" or \"Goblet\" sign.</div><div class=\"graphic_footnotes\">CT: computed tomography; TCC: transitional cell carcinoma.</div><div id=\"graphicVersion\">Graphic 97790 Version 1.0</div></div></div>"},"97793":{"type":"graphic_diagnosticimage","displayName":"Imaging ruptured HCC","title":"HCC on CT and US","html":"<div class=\"graphic\"><div style=\"width: 749px\" class=\"figure\"><div class=\"ttl\">HCC on CT and US</div><div class=\"cntnt\"><img style=\"width:729px; height:521px;\" src=\"images/RADIOL/97793_Imaging_ruptured_HCC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A coronal reconstruction of a CT shows a large hemorrhagic HCC in the dome of the right lobe of the liver (arrow) with perihepatic high-density clot (arrowhead). Image B shows an axial CT through the HCC (arrow) with abnormal vascular channels associated with perihepatic hemorrhage (arrowhead). Image C is an ultrasound showing a heterogeneous mass in the dome of the right lobe of the liver (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography; HCC: hepatocellular carcinoma; US: ultrasound.</div><div id=\"graphicVersion\">Graphic 97793 Version 1.0</div></div></div>"},"97795":{"type":"graphic_diagnosticimage","displayName":"Embolization of hemorrhagic HCC","title":"Hemorrhagic HCC treated with embolization","html":"<div class=\"graphic\"><div style=\"width: 749px\" class=\"figure\"><div class=\"ttl\">Hemorrhagic HCC treated with embolization</div><div class=\"cntnt\"><img style=\"width:729px; height:383px;\" src=\"images/RADIOL/97795_Embolization_hemorrhag_HCC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An angiogram of a hemorrhagic HCC (A) shows a hypervascular mass in the dome of the liver (arrow) with a central region of hypovascularity (arrowhead) likely representing intratumoral clot or necrosis. Image B is an angiogram of the right hepatic artery following microsphere embolization and shows an avascular mass (arrow).</div><div class=\"graphic_footnotes\">HCC: hepatocellular carcinoma.</div><div id=\"graphicVersion\">Graphic 97795 Version 1.0</div></div></div>"},"97798":{"type":"graphic_diagnosticimage","displayName":"Imaging metastatic esophageal carcinoma","title":"Imaging metastatic esophageal carcinoma with CT and PET CT","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Imaging metastatic esophageal carcinoma with CT and PET CT</div><div class=\"cntnt\"><img style=\"width:715px; height:454px;\" src=\"images/RADIOL/97798_Imag_metast_esoph_carcinoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT image through the mid chest shows a large esophageal mass (arrow). Image B is a PET CT and shows a hypermetabolic mass (arrow). Image C is an axial CT image through the thoracic inlet and shows large lymph nodes alongside the brachiocephalic arteries (arrows). Image D is a PET CT showing hypermetabolic activity in the nodes indicating metastatic disease.</div><div class=\"graphic_footnotes\">CT: computed tomography; PET: positron emission tomography.</div><div id=\"graphicVersion\">Graphic 97798 Version 1.0</div></div></div>"},"97799":{"type":"graphic_diagnosticimage","displayName":"Imaging metastatic gastric carcinoma","title":"Imaging metastatic gastric carcinoma with CT and PET CT","html":"<div class=\"graphic\"><div style=\"width: 741px\" class=\"figure\"><div class=\"ttl\">Imaging metastatic gastric carcinoma with CT and PET CT</div><div class=\"cntnt\"><img style=\"width:721px; height:466px;\" src=\"images/RADIOL/97799_Imag_metast_gastric_carcin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT image through the upper abdomen shows gastric wall thickening (arrow) and a group of large lymph nodes in the gastrohepatic ligament (arrowhead). Image B is a PET CT and shows a hypermetabolic mass in the stomach (arrow) and metastatic lymph nodes in the gastrohepatic ligament. Image C is an axial CT image through the thoracic inlet and shows a large lymph node in the&nbsp;supraclavicular region (arrow). Image D is a PET CT showing hypermetabolic activity in the supraclavicular node indicating metastatic disease.</div><div class=\"graphic_footnotes\">CT: computed tomography; PET: positron emission tomography.</div><div id=\"graphicVersion\">Graphic 97799 Version 1.0</div></div></div>"},"97800":{"type":"graphic_picture","displayName":"Out-of-plane needle placement","title":"Out-of-plane needle placement","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Out-of-plane needle placement</div><div class=\"cntnt\"><img style=\"width:486px; height:648px;\" src=\"images/ANEST/97800_Out_of_plane_needle_placmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Christina L. Jeng, MD</div><div id=\"graphicVersion\">Graphic 97800 Version 3.0</div></div></div>"},"97801":{"type":"graphic_picture","displayName":"In-plane needle placement","title":"In-plane needle placement","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">In-plane needle placement</div><div class=\"cntnt\"><img style=\"width:486px; height:648px;\" src=\"images/ANEST/97801_In_plane_needle_placement.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Christina L Jeng, MD</div><div id=\"graphicVersion\">Graphic 97801 Version 4.0</div></div></div>"},"97802":{"type":"graphic_picture","displayName":"Nerve stimulator setup","title":"Nerve stimulator setup","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Nerve stimulator setup</div><div class=\"cntnt\"><img style=\"width:754px; height:558px;\" src=\"images/ANEST/97802_Nervestimulatorsetup.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 97802 Version 3.0</div></div></div>"},"97838":{"type":"graphic_table","displayName":"Selection of RBC for infants with HDFN","title":"Selection of blood products for infants with hemolytic disease of the fetus and newborn (HDFN)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selection of blood products for infants with hemolytic disease of the fetus and newborn (HDFN)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Alloantibody causing HDFN</td> <td class=\"subtitle1\">Key characteristics for RBCs:</td> </tr> <tr> <td>Rh(D) </td> <td> <p>Rh(D) negative</p> <p>Group O* or ABO compatible<sup>&#182;</sup></p> Cross-match compatible</td> </tr> <tr> <td>ABO incompatibility</td> <td> <p>Group O*</p> <p>Rh(D) negative or Rh(D) compatible</p> Cross-match compatible</td> </tr> <tr> <td>Other blood group incompatibility (eg, anti-K, anti-E)</td> <td> <p>Negative for the offending antigen</p> <p>Group O* or ABO compatible<sup>&#182;</sup></p> <p>Rh(D) negative or Rh(D) compatible</p> Cross-match compatible</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For an exchange transfusion, the RBCs described above are reconstituted with AB plasma (this plasma contains no anti-A or anti-B), or with ABO-compatible plasma.</div><div class=\"graphic_footnotes\">Rh(D):&nbsp;Rhesus D;&nbsp;RBCs: red blood cells.<br />* At some institutions, group O RBCs are washed to remove any traces of anti-A or anti-B antibodies. This is most often used for preterm babies because trace amounts of antibodies represent a higher proportion of their blood volume.<br />¶ At some institutions, group O RBCs are used for all newborns and infants&nbsp;younger than&nbsp;four months old, rather than ABO-compatible RBCs. This simplifies and standardizes the blood bank protocol. If non-group O RBCs are used, the newborn must also be tested for \"passive\" anti-A and anti-B (ie, anti-A or anti-B of maternal origin). These antibodies are detected by an indirect antiglobulin (Coombs) test, which can be done on the infant's plasma, serum, or eluate of baby's RBC, tested against A and B cells if a direct antiglobulin (Coombs) test is positive for immunoglobulin G. Cord blood can also be used for this purpose.</div><div class=\"graphic_reference\">Courtesy of Jun Teruya, MD, DSc, FCAP</div><div id=\"graphicVersion\">Graphic 97838 Version 3.0</div></div></div>"},"97842":{"type":"graphic_table","displayName":"ACMG list","title":"American College of Medical Genetics list of genes for which secondary findings should be disclosed","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American College of Medical Genetics list of genes for which&nbsp;secondary findings should be disclosed</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease category</td> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Gene(s)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">Cancer</td> <td>Breast/ovarian cancer</td> <td><em>BRCA1</em>, <em>BRCA2</em></td> </tr> <tr> <td>Li-Fraumeni syndrome, Peutz-Jeghers syndrome; Juvenile polyposis, PTEN hamartoma syndrome</td> <td><em>TP53</em>, <em>STK11</em>, <em>SMAD4</em>*, <em>BMPR1A</em>*, <em>PTEN</em></td> </tr> <tr> <td>Lynch syndrome, familial adenomatous polyposis, MYH-associated polyposis</td> <td><em>MLH1</em>, <em>MSH2</em>, <em>MSH6</em>, <em>PMS2</em>, <em>APC</em>, <em>MUTYH</em></td> </tr> <tr> <td>Von Hippel Lindau syndrome; retinoblastoma, tuberous sclerosis, Wilms tumor</td> <td><em>VHL</em>, <em>RB1</em>, <em>TSC1</em>, <em>TSC2</em>, <em>WT1</em></td> </tr> <tr> <td>Multiple endocrine neoplasia 1 or 2; familial medullary thyroid cancer</td> <td><em>MEN1</em>, <em>RET</em></td> </tr> <tr class=\"divider_bottom\"> <td>Hereditary paraganglionoma-pheochromocytoma syndrome, neurofibromatosis type 2</td> <td><em>SDHD</em>, <em>SDHAF2</em>, <em>SDHC</em>, <em>SDHB</em>, <em>NF2</em></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Cardiovascular disease</td> <td>Hypertrophic or dilated cardiomyopathy</td> <td><em>MYBPC3</em>, <em>MYH7</em>, <em>TNNT2</em>, <em>TNNI3</em>, <em>TPM1</em>, <em>MYL3</em>, <em>ACTC1</em>, <em>PRKAG2</em>, <em>GLA</em>, <em>MYL2</em>, <em>LMNA</em></td> </tr> <tr> <td>Catacholamenergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular cardiomyopathy, Romano-Ward Long QT syndromes, Brugada syndrome</td> <td><em>RYR2</em>, <em>PKP2</em>, <em>DSP</em>, <em>DSC2</em>, <em>TMEM43</em>, <em>DSG2</em>, <em>KCNQ1</em>, <em>KCNH2</em>, <em>SCN5A</em></td> </tr> <tr class=\"divider_bottom\"> <td>Familial hypercholesterolemia</td> <td><em>LDLR</em>, <em>APOB</em>, <em>PCSK9</em></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Connective tissue or vascular integrity</td> <td>Ehlers Danlos syndrome</td> <td><em>COL3A1</em></td> </tr> <tr class=\"divider_bottom\"> <td>Marfan syndrome, Loeys-Dietz syndrome, familial thoracic aortic aneurysms and dissections</td> <td><em>FBN1</em>, <em>TGFBR1</em>, <em>TGFBR2</em>, <em>SMAD3</em>, <em>ACTA2</em>, <em>MYH11<sup>&#182;</sup></em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"divider_bottom\">Malignant hyperthermia sensitivity</td> <td>&nbsp;</td> <td><em>RYR1</em>, <em>CACNA1S</em></td> </tr> <tr> <td rowspan=\"2\">Metabolism</td> <td>Wilson disease (copper metabolism)</td> <td><em>ATP7B</em>*</td> </tr> <tr> <td>Ornithine transcarbamylase deficiency (urea cycle)</td> <td><em>OTC</em>*</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This list includes genes identified by the American College of Medical Genetics and Genomics&nbsp;(ACMG) as clinically actionable when known pathogenic (and, in some cases, expected pathogenic) variants are identified by whole genome or exome sequencing. Refer to UpToDate topics on genetic counseling and&nbsp;secondary&nbsp;findings from&nbsp;genomic testing for further details.</div><div class=\"graphic_footnotes\">ACMG: American College of Medical Genetics and Genomics.<br />* Added in the 2016 revision (ACMG 2.0). <br />¶ <EM>MYLK</EM> was removed in the 2016 revision due to lack of an effective confirmatory test or intervention to improve outcomes.<br /></div><div class=\"graphic_reference\">Prepared with data from:&nbsp;<br /><OL>&#xD;&#xA;<LI>Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013; 15:565.</LI>&#xD;&#xA;<LI>Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0):&nbsp;A policy statement of the American College of Medical Genetics and Genomics. Genet Med 2017; 19:249.</LI></OL></div><div id=\"graphicVersion\">Graphic 97842 Version 3.0</div></div></div>"},"97880":{"type":"graphic_table","displayName":"Paragonimiasis geography","title":"Predominant <em>Paragonimus</em> species lung flukes capable of causing human paragonimiasis and their geographic regions of distribution","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predominant <em>Paragonimus</em> species lung flukes capable of causing human paragonimiasis and their geographic regions of distribution</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\"><em>Paragonimus</em> species</td> <td class=\"subtitle1\">Geographic distribution</td> </tr> <tr> <td><em>P. africanus</em></td> <td>West Africa</td> </tr> <tr> <td><em>P. caliensis</em></td> <td>Central America, South America</td> </tr> <tr> <td><em>P. heterotremus</em></td> <td>Southeast Asia, Thailand, China</td> </tr> <tr> <td><em>P. hueitungensis</em></td> <td>China</td> </tr> <tr> <td><em>P. kellicotti</em></td> <td>North America</td> </tr> <tr> <td><em>P. mexicanus</em></td> <td>Central America, South America</td> </tr> <tr> <td><em>P. miyazakii</em></td> <td>Japan</td> </tr> <tr> <td><em>P. skrjabini</em></td> <td>Southeast Asia, China</td> </tr> <tr> <td><em>P. uterobilateralis</em></td> <td>West Africa</td> </tr> <tr> <td><em>P. westermani</em></td> <td>Asia</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Diaz JH. Paragonimiasis acquired in the United States: Native and nonnative species. Clin Microbiol Rev 2013; 26:493-504. DOI: 10.1128/CMR.00103-12. Reproduced with permission from American Society for Microbiology. Copyright &copy; 2013.</div><div id=\"graphicVersion\">Graphic 97880 Version 1.0</div></div></div>"},"97881":{"type":"graphic_table","displayName":"System for binning of secondary findings from genome sequencing","title":"Proposed system for \"binning\" of secondary findings from genome sequencing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed system for \"binning\" of secondary findings from genome sequencing</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"4%\"></colgroup><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td class=\"subtitle1\">Criteria:</td> <td class=\"subtitle1\">Clinical utility</td> <td class=\"subtitle1\" colspan=\"3\">Clinical validity</td> <td class=\"subtitle1\">Unknown clinical implications</td> </tr> <tr> <td class=\"subtitle1 divider_bottom\" rowspan=\"3\"> <p>G</p> <p>e</p> <p>n</p> <p>e</p> <p>s</p> </td> <td>Bins:</td> <td class=\"centered\"> <p><strong>Bin 1</strong></p> <strong>Medically actionable information</strong></td> <td class=\"centered\"> <p><strong>Bin 2A</strong></p> <strong>Low risk information</strong></td> <td class=\"centered\"> <p><strong>Bin 2B</strong></p> <strong>Medium risk information</strong></td> <td class=\"centered\"> <p><strong>Bin 2C</strong></p> <strong>High risk information</strong></td> <td class=\"centered\" style=\"vertical-align: middle;\" rowspan=\"2\"> <p><strong>Bin 3</strong></p> <strong>All other loci</strong></td> </tr> <tr> <td>Examples:</td> <td class=\"centered\"> <p><em>BRCA1/2</em></p> <p><em>MLH1, MSH2</em></p> <p><em>FBN1</em></p> <em>NF1</em></td> <td class=\"centered\">PGx variants and common risk SNPs</td> <td class=\"centered\"> <p><em>APOE</em></p> <p><em></em>Carrier status for recessive Mendelian disorders</p> </td> <td class=\"centered\"> <p>Huntington disease</p> <p>Familial Creutzfeldt-Jakob disease</p> ALS (SOD1)</td> </tr> <tr class=\"divider_bottom\"> <td>Estimated number of genes/loci:</td> <td class=\"centered\">10s</td> <td class=\"centered\">10s<br /> (eventually 100s-1000s)</td> <td class=\"centered\">1000s</td> <td class=\"centered\">10s</td> <td class=\"centered\">~20,000</td> </tr> <tr class=\"divider_bottom\"> <td class=\"subtitle2\" colspan=\"7\"><sub>&nbsp;</sub><br /> Alleles that would be reportable (YES) or not reportable (NO) in a clinical context</td> </tr> <tr> <td class=\"subtitle1 divider_bottom\" rowspan=\"5\"> <p>V</p> <p>a</p> <p>r</p> <p>i</p> <p>a</p> <p>n</p> <p>t</p> <p>s</p> </td> <td>Pathogenic</td> <td class=\"centered highlight_green_text\">YES</td> <td class=\"centered\"><strong>YES/NO</strong>*</td> <td class=\"centered\"><strong>YES/NO</strong>*</td> <td class=\"centered\"><strong>YES/NO</strong>*</td> <td class=\"centered\">N/A<sup>&#182;</sup></td> </tr> <tr> <td>Likely pathogenic</td> <td class=\"centered highlight_green_text\">YES</td> <td class=\"centered\">N/A<sup>&#916;</sup></td> <td class=\"centered\"><strong>YES/NO</strong>*</td> <td class=\"centered\"><strong>YES/NO</strong>*</td> <td class=\"centered\"><em>NO<sup>&#9674;</sup></em></td> </tr> <tr> <td>Unknown significance (VUS)</td> <td class=\"centered\"><em>NO</em></td> <td class=\"centered\">N/A<sup>&#916;</sup></td> <td class=\"centered\"><em>NO</em></td> <td class=\"centered\"><em>NO</em></td> <td class=\"centered\"><em>NO<sup>&#9674;</sup></em></td> </tr> <tr> <td>Likely&nbsp;benign</td> <td class=\"centered\"><em>NO</em></td> <td class=\"centered\">N/A<sup>&#916;</sup></td> <td class=\"centered\"><em>NO</em></td> <td class=\"centered\"><em>NO</em></td> <td class=\"centered\"><em>NO</em></td> </tr> <tr class=\"divider_bottom\"> <td>Benign</td> <td class=\"centered\"><em>NO</em></td> <td class=\"centered\"><em>NO</em></td> <td class=\"centered\"><em>NO</em></td> <td class=\"centered\"><em>NO</em></td> <td class=\"centered\"><em>NO</em></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on genomic sequencing and disclosure of secondary findings from genetic testing&nbsp;for further details.</div><div class=\"graphic_footnotes\">N/A: not applicable; VUS: variant of unknown significance.<br />* Reporting through decision making with an appropriate provider if elected by the patient.<br />¶ By definition, variants in genes with unknown implications could not be considered deleterious.<br />Δ By definition, SNPs or PGx variants will either be present or absent.<br /><FONT class=lozenge>◊</FONT> Variants in genes with unknown clinical implications would not be reported; however, they may serve as an important substrate for research, potentially uncovering new disease genes.</div><div class=\"graphic_reference\">Adapted by permission from Macmillan Publishers Ltd: Genetics in Medicine. Berg JS, Khoury MJ, Evans JP. Deploying whole genome sequencing in clinical practice and public health: Meeting the challenge one bin at a time. Genet Med 2011; 13:499. Copyright © 2011.</div><div id=\"graphicVersion\">Graphic 97881 Version 3.0</div></div></div>"},"97882":{"type":"graphic_figure","displayName":"Ascending aorta dimensions for men","title":"Ascending aorta dimensions for men","html":"<div class=\"graphic\"><div style=\"width: 775px\" class=\"figure\"><div class=\"ttl\">Ascending aorta dimensions for men</div><div class=\"cntnt\"><img style=\"width:755px; height:385px;\" src=\"images/SURG/97882_Ascend_aorta_dimension_men.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fifth and 95th percentiles based upon echocardiographic leading-edge-to-leading-edge diameters of the sinus of Valsalva and ascending aorta in 815 men with normal cardiac findings on transthoracic echocardiogram.</div><div class=\"graphic_reference\">Reproduced from: Biaggi P, Matthews F, Braun J, et al. Gender, age, and body surface area are the major determinants of ascending aorta dimensions in subjects with apparently normal echocardiograms. J Am Soc Echocardiogr 2009; 22:720. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97882 Version 2.0</div></div></div>"},"97883":{"type":"graphic_figure","displayName":"Ascending aorta dimensions in women","title":"Ascending aorta dimensions in women","html":"<div class=\"graphic\"><div style=\"width: 779px\" class=\"figure\"><div class=\"ttl\">Ascending aorta dimensions in women</div><div class=\"cntnt\"><img style=\"width:759px; height:391px;\" src=\"images/SURG/97883_Ascend_aorta_dimension_wmn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Fifth and 95th percentiles based upon echocardiocardiographic leading-edge-to-leading-edge&nbsp;diameters of the sinus of Valsalva and ascending aorta in 984 women with normal cardiac findings on transthoracic echocardiogram.</div><div class=\"graphic_reference\">Reproduced from: Biaggi P, Matthews F, Braun J, et al. Gender, age, and body surface area are the major determinants of ascending aorta dimensions in subjects with apparently normal echocardiograms. J Am Soc Echocardiogr 2009; 22:720. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97883 Version 2.0</div></div></div>"},"97886":{"type":"graphic_figure","displayName":"Retrobulbar (intraconal) block","title":"Retrobulbar (intraconal) block","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Retrobulbar (intraconal) block</div><div class=\"cntnt\"><img style=\"width:490px; height:314px;\" src=\"images/ANEST/97886_Retrobulbarintraconalblck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retrobulbar (intraconal) block and schematic representation of the intraorbital muscle tone.</div><div class=\"graphic_reference\">Reproduced with permission from: McGoldrick KE, Gayer SI. Anesthesia for ophthalmic surgery. In: Clinical Anesthesia, 7th Edition, Barash PG (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>. This illustration was republished in Clinical Anesthesia, 8th edition (2017).</div><div id=\"graphicVersion\">Graphic 97886 Version 5.0</div></div></div>"},"97887":{"type":"graphic_figure","displayName":"Peribulbar (extraconal) block","title":"Peribulbar (extraconal) block","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Peribulbar (extraconal) block</div><div class=\"cntnt\"><img style=\"width:490px; height:294px;\" src=\"images/ANEST/97887_Peribulbarextraconalblock.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Peribulbar (extraconal) block and schematic representation of the intraorbital muscle cone.</div><div class=\"graphic_reference\">Reproduced with permission from: McGoldrick KE, Gayer SI. Anesthesia for ophthalmic surgery. In: Clinical Anesthesia, 7th Edition, Barash PG (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>. This illustration was republished in Clinical Anesthesia, 8th edition (2017).</div><div id=\"graphicVersion\">Graphic 97887 Version 5.0</div></div></div>"},"97888":{"type":"graphic_figure","displayName":"Sub-Tenon block","title":"Sub-Tenon block","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Sub-Tenon block</div><div class=\"cntnt\"><img style=\"width:504px; height:400px;\" src=\"images/ANEST/97888_Subtenonblock.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sub-Tenon (episcleral) block with blunt cannula.</div><div class=\"graphic_reference\">Reproduced with permission from: McGoldrick KE, Gayer SI. Anesthesia for ophthalmic surgery. In: Clinical Anesthesia, 7th Edition, Barash PG (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>. This illustration was republished in Clinical Anesthesia, 8th edition (2017).</div><div id=\"graphicVersion\">Graphic 97888 Version 5.0</div></div></div>"},"97889":{"type":"graphic_diagnosticimage","displayName":"OEIS","title":"Omphalocele-exstrophy-imperforate anus-spinal dysraphism (OEIS)","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Omphalocele-exstrophy-imperforate anus-spinal dysraphism (OEIS)</div><div class=\"cntnt\"><img style=\"width:712px; height:443px;\" src=\"images/OBGYN/97889_OEIS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">OEIS complex (omphalocele-exstrophy-imperforate anus-spinal dysraphism). Imperforate anus cannot be appreciated in this image. The abdominal-pelvic structures are exteriorized.</div><div class=\"graphic_reference\">Courtesy of Courtney Stephenson, MD.</div><div id=\"graphicVersion\">Graphic 97889 Version 2.0</div></div></div>"},"97895":{"type":"graphic_table","displayName":"RoPE score calculator","title":"RoPE score calculator","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">RoPE score calculator</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"70%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Characteristic</td> <td class=\"subtitle1\">Points</td> <td class=\"subtitle1\">RoPE score</td> </tr> <tr> <td>No history of hypertension</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>No history of diabetes</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>No history of stroke or TIA</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Nonsmoker</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Cortical infarct on imaging</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\">Age, years</td> </tr> <tr> <td class=\"indent1\">18 to 29</td> <td class=\"centered\">5</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">30 to 39</td> <td class=\"centered\">4</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">40 to 49</td> <td class=\"centered\">3</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">50 to 59</td> <td class=\"centered\">2</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">60 to 69</td> <td class=\"centered\">1</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;70</td> <td class=\"centered\">0</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"3\"><strong>Total score (sum of individual points)</strong></td> </tr> <tr> <td class=\"indent1\">Maximum score (a patient &#60;30 years with no hypertension, no diabetes, no history of stroke or TIA, nonsmoker, and cortical infarct)</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">10</td> </tr> <tr> <td class=\"indent1\">Minimum score (a patient &#8805;70 years with hypertension, diabetes, prior stroke, current smoker, and no cortical infarct)</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">0</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RoPE: Risk of Paradoxical Embolism; TIA: transient ischemic attack.</div><div class=\"graphic_reference\">From: Kent DM, Ruthazer R, Weimar C, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology 2013; 81:619. DOI: <a href=\"http://www.neurology.org/content/81/7/619.long\" target=\"_blank\">10.1212/WNL.0b013e3182a08d59</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2013 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 97895 Version 2.0</div></div></div>"},"97896":{"type":"graphic_table","displayName":"PFO attributable fraction","title":"PFO prevalence, attributable fraction, and estimated two-year risk of stroke/TIA","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PFO prevalence, attributable fraction, and estimated two-year risk of stroke/TIA</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"5\" width=\"18%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">RoPE score</td> <td class=\"subtitle1\" colspan=\"3\">Cryptogenic stroke (n = 3023)</td> <td class=\"subtitle1\" colspan=\"2\">CS patients with PFO (n = 1324)</td> </tr> <tr> <td class=\"subtitle2\">Number of patients</td> <td class=\"subtitle2\">Prevalence of patients with a PFO,<br /> percent (95% CI)*</td> <td class=\"subtitle2\">PFO-attributable fraction,<br /> percent (95% CI)*</td> <td class=\"subtitle2\">Number of CS patients with PFO*</td> <td class=\"subtitle2\">Estimated two-year stroke/TIA recurrence rate (Kaplan-Meier),<br /> percent (95% CI)</td> </tr> <tr> <td class=\"centered\">0 to 3</td> <td class=\"centered\">613</td> <td class=\"centered\">23 (19 to 26)</td> <td class=\"centered\">0 (0 to 4)</td> <td class=\"centered\">108</td> <td class=\"centered\">20 (12 to 28)</td> </tr> <tr> <td class=\"centered\">4</td> <td class=\"centered\">511</td> <td class=\"centered\">35 (31 to 39)</td> <td class=\"centered\">38 (25 to 48)</td> <td class=\"centered\">148</td> <td class=\"centered\">12 (6 to 18)</td> </tr> <tr> <td class=\"centered\">5</td> <td class=\"centered\">516</td> <td class=\"centered\">34 (30 to 38)</td> <td class=\"centered\">34 (21 to 45)</td> <td class=\"centered\">186</td> <td class=\"centered\">7 (3 to 11)</td> </tr> <tr> <td class=\"centered\">6</td> <td class=\"centered\">482</td> <td class=\"centered\">47 (42 to 51)</td> <td class=\"centered\">62 (54 to 68)</td> <td class=\"centered\">236</td> <td class=\"centered\">8 (4 to 12)</td> </tr> <tr> <td class=\"centered\">7</td> <td class=\"centered\">434</td> <td class=\"centered\">54 (49 to 59)</td> <td class=\"centered\">72 (66 to 76)</td> <td class=\"centered\">263</td> <td class=\"centered\">6 (2 to 10)</td> </tr> <tr> <td class=\"centered\">8</td> <td class=\"centered\">287</td> <td class=\"centered\">67 (62 to 73)</td> <td class=\"centered\">84 (79 to 87)</td> <td class=\"centered\">233</td> <td class=\"centered\">6 (2 to 10)</td> </tr> <tr> <td class=\"centered\">9 to 10</td> <td class=\"centered\">180</td> <td class=\"centered\">73 (66 to 79)</td> <td class=\"centered\">88 (83 to 91)</td> <td class=\"centered\">150</td> <td class=\"centered\">2 (0 to 4)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CI: confidence interval; CS: cryptogenic stroke; PFO: patent foramen ovale; RoPE: Risk of Paradoxical Embolism; TIA: transient ischemic attack.<br />* NOTE: 95% CI for PFO prevalence and attributable fraction based on normal approximation to the binomial distribution.</div><div class=\"graphic_reference\">From: Kent DM, Ruthazer R, Weimar C, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology 2013; 81:619. DOI: <A spellcheck=true href=\"http://www.neurology.org/content/81/7/619.abstract\" target=_blank>10.1212/WNL.0b013e3182a08d59</A>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright © 2013 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 97896 Version 3.0</div></div></div>"},"97898":{"type":"graphic_figure","displayName":"Endosalpingiosis pelvic cysts","title":"Endosalpingiosis: Pelvic cysts","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Endosalpingiosis: Pelvic cysts</div><div class=\"cntnt\"><img style=\"width:726px; height:485px;\" src=\"images/OBGYN/97898_Endosalpingiosis_pelvic_cysts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transvaginal ultrasound showed cystic formations in the areas of the right fallopian tube (A) and fundus uteri (B). The maximum diameter of the cysts was 7.5 cm. Laparoscopic presentation of the cystic mass (C); uterus (front) with right tube and right abdominal wall (background).</div><div class=\"graphic_reference\">Reproduced from: Scheel AH, Frasunek J, Meyer W, Strobel P. Cystic endosalpingiosis presenting as chronic back pain, a case report. Diagn Pathol 2013; 8:196. Copyright © 2013 Scheel et al; licensed by BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<A spellcheck=true href=\"http://creativecommons.org/licenses/by/2.0\" target=_blank>http://creativecommons.org/licenses/by/2.0</A>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</div><div id=\"graphicVersion\">Graphic 97898 Version 3.0</div></div></div>"},"97899":{"type":"graphic_picture","displayName":"Urticarial dermatitis histo","title":"Histopathologic features of urticarial dermatitis","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Histopathologic features of urticarial dermatitis</div><div class=\"cntnt\"><img style=\"width:526px; height:419px;\" src=\"images/DERM/97899_Urticarial_dermatitis_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urticarial dermatitis is characterized by normal stratum corneum, mild epidermal edema with minimal spongiosis, and a superficial to mid-dermal perivascular infiltrate of lymphocytes and eosinophils with occasional neutrophils. However, these features are nonspecific and may be seen in a variety of skin conditions, including drug reactions, arthropod assault, viral infections, and prodromal stage of bullous pemphigoid.</div><div class=\"graphic_reference\">Courtesy of Alejandro Gru, MD.</div><div id=\"graphicVersion\">Graphic 97899 Version 1.0</div></div></div>"},"97900":{"type":"graphic_picture","displayName":"Endosalpingiosis bladder cyst","title":"Endosalpingiosis: Bladder cyst","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Endosalpingiosis: Bladder cyst</div><div class=\"cntnt\"><img style=\"width:592px; height:523px;\" src=\"images/OBGYN/97900_Endosalpingiosis_blddr_cyst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cystoscopic findings showing a soft sessile polypoid lesion in the posterior wall of the urinary bladder.</div><div class=\"graphic_reference\">Reproduced with permission from: Maeda K, Kojima F, Ishida M, et al. Case report: Müllerianosis and endosalpingiosis of the urinary bladder: Report of two cases with review of the literature. Int J Clin Exp Pathol 2014; 7:4408. Copyright © 2014 International Journal of Clinical and Experimental Pathology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97900 Version 2.0</div></div></div>"},"97908":{"type":"graphic_picture","displayName":"Detail of urticaria pigmentosa","title":"Detail of urticaria pigmentosa","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Detail of urticaria pigmentosa</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/ALLRG/97908_Detail_urticaria_pigmentosa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urticaria pigmentosa (UP) lesions are small, yellow-tan to reddish-brown macules or slightly raised papules, most commonly on the upper and lower extremities. Lesions of UP display Darier's sign, which is the development of localized urticaria and erythema at the site a few minutes after a lesion is rubbed or scratched. This occurs because UP lesions are rich in mast cells, and physical irritation causes the cells to release inflammatory mediators.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 97908 Version 5.0</div></div></div>"},"97911":{"type":"graphic_picture","displayName":"Bedbug bites on legs","title":"Bedbug bites","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Bedbug bites</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/97911_Bedbug_bites_on_legs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules on the legs.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 97911 Version 2.0</div></div></div>"},"97914":{"type":"graphic_figure","displayName":"Endoscopic necrosectomy WOPN","title":"Direct endoscopic necrosectomy of walled-off pancreatic necrosis","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Direct endoscopic necrosectomy of walled-off pancreatic necrosis</div><div class=\"cntnt\"><img style=\"width:483px; height:326px;\" src=\"images/GAST/97914_Endoscopic_necrosectom_WOPN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Illustration of direct endoscopic necrosectomy of walled-off pancreatic necrosis. After endoscopically creating a cystgastrostomy or cystenterostomy, the cyst cavity is entered and necrotic material is removed using snares, nets, baskets, and forceps.</div><div class=\"graphic_reference\">Reproduced from: Baron TH, Kozarek RA. Endotherapy for organized pancreatic necrosis: Perspectives after 20 years. Clin Gastroenterol Hepatol 2012; 10:1202. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 97914 Version 1.0</div></div></div>"},"97927":{"type":"graphic_picture","displayName":"Acne keloidalis nuchae - fibrosis and inflammation","title":"Acne keloidalis nuchae","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Acne keloidalis nuchae</div><div class=\"cntnt\"><img style=\"width:710px; height:530px;\" src=\"images/DERM/97927_Acn_kldls_nuh_fbrss_inflmtn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dense dermal fibrosis and inflammation of pilosebaceous units.</div><div class=\"graphic_reference\">Courtesy of Sameera Husain, MD.</div><div id=\"graphicVersion\">Graphic 97927 Version 1.0</div></div></div>"},"97928":{"type":"graphic_picture","displayName":"Acne keloidalis nuchae - folliculitis","title":"Acne keloidalis nuchae","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Acne keloidalis nuchae</div><div class=\"cntnt\"><img style=\"width:712px; height:532px;\" src=\"images/DERM/97928_Acne_keloidalis_nch_fllclts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inflammation involving a hair follicle, extruded hair shafts surrounded by inflammatory cells, and dermal fibrosis.</div><div class=\"graphic_reference\">Courtesy of Sameera Husain, MD.</div><div id=\"graphicVersion\">Graphic 97928 Version 1.0</div></div></div>"},"97929":{"type":"graphic_picture","displayName":"Acne keloidalis nuchae - microabscess","title":"Acne keloidalis nuchae","html":"<div class=\"graphic\"><div style=\"width: 747px\" class=\"figure\"><div class=\"ttl\">Acne keloidalis nuchae</div><div class=\"cntnt\"><img style=\"width:727px; height:274px;\" src=\"images/DERM/97929_Acn_kldls_nch_mcrbscss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ruptured pilosebaceous unit associated with a microabscess. Shown with 4x magnification (A) and 10x magnification (B).</div><div class=\"graphic_reference\">Courtesy of Sameera Husain, MD.</div><div id=\"graphicVersion\">Graphic 97929 Version 1.0</div></div></div>"},"97930":{"type":"graphic_picture","displayName":"Acne keloidalis nuchae - hair follicle destruction","title":"Acne keloidalis nuchae","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Acne keloidalis nuchae</div><div class=\"cntnt\"><img style=\"width:710px; height:530px;\" src=\"images/DERM/97930_Acn_kldls_nch_fllcl_dstrc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extruded hair shafts in the dermis associated with a mainly neutrophilic infiltrate, following inflammatory destruction of hair follicles.</div><div class=\"graphic_reference\">Courtesy of Sameera Husain, MD.</div><div id=\"graphicVersion\">Graphic 97930 Version 1.0</div></div></div>"},"97931":{"type":"graphic_picture","displayName":"Acne keloidalis nuchae - fibrosis","title":"Acne keloidalis nuchae","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Acne keloidalis nuchae</div><div class=\"cntnt\"><img style=\"width:710px; height:531px;\" src=\"images/DERM/97931_Acne_keloidali_nuchae_fbrss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dense dermal fibrosis.</div><div class=\"graphic_reference\">Courtesy of Sameera Husain, MD.</div><div id=\"graphicVersion\">Graphic 97931 Version 1.0</div></div></div>"},"97965":{"type":"graphic_table","displayName":"Vancomycin dose in patients with high-flux HD","title":"Approach to vancomycin dose adjustments for patients receiving intermittent high-flux hemodialysis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to vancomycin dose adjustments for patients receiving intermittent high-flux hemodialysis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"2\"> <ol class=\"numbers_to_nine\"> <li>Administer an IV loading dose* of 25 mg/kg (estimated dry weight).<sup>&#182;</sup> </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"> <ol class=\"numbers_to_nine\" start=\"2\"> <li>A maintenance IV dose of 10 mg/kg (estimated dry weight), usually 500 or 750 mg, is given in the last 1 to 2 hours of each high-flux dialysis session. </li> </ol> </td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_to_nine\" start=\"3\"> <li>A \"spot\" serum concentration should be obtained <strong>prior</strong> to the third dialysis session following initiation of therapy and the dose adjusted as follows:<sup>&#916;</sup> </li> </ol> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li><strong>Estimated vancomycin trough concentration: Extrapolate by reducing predialysis level by 40% to account for drug removal during a 4-hour dialysis session</strong></li> </ul> </td> <td> <ul> <li><strong>Maintenance dose adjustment (dose given in the last 1 to 2 hours of each dialysis session)</strong></li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>&#60;15 mcg/mL </li> </ul> </td> <td class=\"indent1\"> <ul style=\"list-style-type: disc;\"> <li>Increase dose by 250 to 500 mg </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>15 to 25 mcg/mL </li> </ul> </td> <td class=\"indent1\"> <ul style=\"list-style-type: disc;\"> <li>No change in therapy </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>26 to 35 mcg/mL </li> </ul> </td> <td class=\"indent1\"> <ul style=\"list-style-type: disc;\"> <li>Decrease dose by 250 to 500 mg </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul style=\"list-style-type: disc;\"> <li>&#62;35 mcg/mL </li> </ul> </td> <td class=\"indent1\"> <ul style=\"list-style-type: disc;\"> <li>Hold vancomycin dose<sup>&#9674;</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"> <ol class=\"numbers_to_nine\" start=\"4\"> <li>Following dose adjustment, a repeat vancomycin serum concentration should be measured prior to the third dialysis session, with subsequent adjustment (if necessary) according to the principles above. </li> </ol> </td> </tr> <tr> <td colspan=\"2\"> <ol class=\"numbers_to_nine\" start=\"5\"> <li>Once the predialysis vancomycin concentration is within the target range, it should be rechecked weekly. </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The approach described is for patients receiving intermittent hemodialysis via high-flux membranes three times per week. Vancomycin is significantly cleared by high-flux dialysis membranes (ie, approximately 40% cleared in a 4-hour session). Refer to the UpToDate topic on vancomycin dosing for discussion of approach to patients receiving intermittent hemodialysis via older, less permeable low-flux membranes.</div><div class=\"graphic_footnotes\">IV: intravenous.<br />* A maximum loading dose of 3 grams may be given; however, many use a loading dose of no more than 2 grams (especially in older patients and in patients with nonsevere infection).<br />¶ In obese patients, use actual body weight (estimated dry weight). If morbidly obese, an adjusted dosing weight is suggested. A calculator to determine adjusted dosing weight is available in UpToDate.<br />Δ In critically ill patients or other concern for altered pharmacokinetics (eg, residual renal function, acutely post-transplant), a pre-dialysis vancomycin concentration should be assessed prior to each dialysis session until stable dosing has been established.<br /><FONT class=lozenge>◊</FONT> The vancomycin serum concentration should be repeated prior to each subsequent dialysis session until it falls below 35 mcg/mL, at which time vancomycin administration during the last 2 hours of hemodialysis should be resumed with dose reduction of 500 to 1000 mg. Following dose adjustment, repeat vancomycin serum concentration should be measured prior to the following dialysis session, with subsequent adjustment (if necessary) as summarized above.</div><div class=\"graphic_reference\">Adapted from: Duke University Hospital Adult Pharmacokinetics Policy, Department of Pharmacy (June 2014). Courtesy of Richard H Drew, PharmD.</div><div id=\"graphicVersion\">Graphic 97965 Version 3.0</div></div></div>"},"97966":{"type":"graphic_table","displayName":"Rates of adverse cardiac outcomes from noncardiac surgery","title":"Rates of adverse cardiac outcomes from noncardiac surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rates of adverse cardiac outcomes from noncardiac surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Number of risk factors</td> <td class=\"subtitle1\">Lee derivation</td> <td class=\"subtitle1\">Lee validation</td> <td class=\"subtitle1\">Devereaux*</td> <td class=\"subtitle1\">Lindenauer<sup>&#182;</sup></td> <td class=\"subtitle1\">Davis 6 factor RCRI</td> <td class=\"subtitle1\">Davis 5 factor RCRI</td> </tr> <tr> <td class=\"centered\">0</td> <td class=\"centered\">0.5%</td> <td class=\"centered\">0.4%</td> <td class=\"centered\">0.4%</td> <td class=\"centered\">1.4%</td> <td class=\"centered\">0.5%</td> <td class=\"centered\">0.5%</td> </tr> <tr> <td class=\"centered\">1</td> <td class=\"centered\">1.3%</td> <td class=\"centered\">0.9%</td> <td class=\"centered\">1%</td> <td class=\"centered\">2.2%</td> <td class=\"centered\">2.6%</td> <td class=\"centered\">2.9%</td> </tr> <tr> <td class=\"centered\">2</td> <td class=\"centered\">3.6%</td> <td class=\"centered\">6.6%</td> <td class=\"centered\">2.4%</td> <td class=\"centered\">3.9%</td> <td class=\"centered\">7.2%</td> <td class=\"centered\">7.4%</td> </tr> <tr> <td class=\"centered\">3 or more</td> <td class=\"centered\">9.1%</td> <td class=\"centered\">11%</td> <td class=\"centered\">5.4%</td> <td class=\"centered\">5.8 to 7.4%</td> <td class=\"centered\">14.4%</td> <td class=\"centered\">17%</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RCRI: Revised cardiac risk index.<br />* Excluded pulmonary edema and complete heart block.<br />&para; Hospital mortality only.</div><div class=\"graphic_reference\"><ol>&#xD;&#xA;    <li>1. Devereaux PJ, Goldman L, Cook DJ, et al. Perioperative cardiac events in patients undergoing noncardiac surgery: a review of the magnitude of the problem, the pathophysiology of the events and methods to estimate and communicate risk. CMAJ 2005; 173:627.</li>&#xD;&#xA;    <li>2. Lindenauer PK, Pekow P, Wang K, et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med 2005; 353:349.</li>&#xD;&#xA;    <li>3. Davis C, Tait G, Carroll J, et al. The Revised Cardiac Risk Index in the new millennium: a single-centre prospective cohort re-evaluation of the original variables in 9,519 consecutive elective surgical patients. Can J Anaesth 2013; 60:855.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 97966 Version 2.0</div></div></div>"},"97986":{"type":"graphic_picture","displayName":"Bullous myringitis","title":"Bullous myringitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bullous myringitis</div><div class=\"cntnt\"><img style=\"width:404px; height:405px;\" src=\"images/PEDS/97986_Bullous_myringitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bullous myringitis is characterized by painful vesicles that appear on the tympanic membrane.</div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 97986 Version 3.0</div></div></div>"},"97987":{"type":"graphic_picture","displayName":"Acute perforation with otorrhea","title":"Acute tympanic membrane perforation with otorrhea","html":"<div class=\"graphic\"><div style=\"width: 471px\" class=\"figure\"><div class=\"ttl\">Acute tympanic membrane perforation with otorrhea</div><div class=\"cntnt\"><img style=\"width:451px; height:446px;\" src=\"images/PEDS/97987_Acute_perforation_otorrhea.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Glenn C Isaacson, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 97987 Version 3.0</div></div></div>"},"97988":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph and CT of Hampton's hump","title":"Hampton's hump on radiograph and CT scan","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Hampton's hump on radiograph and CT scan</div><div class=\"cntnt\"><img style=\"width:725px; height:350px;\" src=\"images/RADIOL/97988_Imaging_hamptons_hump.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hampton's hump in a patient with suspected pulmonary embolus. An anterior-posterior chest radiograph&nbsp;(A) shows a wedge-shaped&nbsp;opacity in the lateral segment of the middle lobe (arrow). CT&nbsp;image through the mid-chest shows the corresponding wedge-shaped&nbsp;opacity (arrowhead) and thrombus in the pulmonary arteries (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 97988 Version 2.0</div></div></div>"},"97989":{"type":"graphic_diagnosticimage","displayName":"Radiograph of calcinosis cutis in scleroderma","title":"Calcinosis cutis in scleroderma on radiograph","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\">Calcinosis cutis in scleroderma on radiograph</div><div class=\"cntnt\"><img style=\"width:711px; height:536px;\" src=\"images/RADIOL/97989_Rdgrph_clcnss_cts_sclrdrm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A-P view of the hands in a patient with scleroderma shows extensive calcification involving the soft tissues of the distal phalanges of both hands.</div><div class=\"graphic_footnotes\">A-P: anteroposterior.</div><div id=\"graphicVersion\">Graphic 97989 Version 1.0</div></div></div>"},"97991":{"type":"graphic_diagnosticimage","displayName":"Radiography of lunate dislocation","title":"Lunate dislocation on radiography","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Lunate dislocation on radiography</div><div class=\"cntnt\"><img style=\"width:510px; height:526px;\" src=\"images/RADIOL/97991_Rdgrphy_lunate_dislocation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A radiograph of the right wrist in A-P projection (A) shows a lunate dislocation (arrow), distal radial fracture (arrowhead), and ulnar styloid fracture (dashed arrow). Image B is a normal wrist in A-P projection and shows the normal appearance of the lunate (asterisk). Image C is a lateral projection and shows a dislocated lunate (asterisk). Image D is a normal lateral projection of the wrist and shows the position of the lunate (asterisk).</div><div class=\"graphic_footnotes\">A-P: anteroposterior.</div><div id=\"graphicVersion\">Graphic 97991 Version 1.0</div></div></div>"},"97993":{"type":"graphic_picture","displayName":"Acne keloidalis nuchae - mild","title":"Acne keloidalis nuchae","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Acne keloidalis nuchae</div><div class=\"cntnt\"><img style=\"width:712px; height:412px;\" src=\"images/DERM/97993_Acne_keloidalis_nuchae_mild.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Follicular keloidal papules on the lower posterior scalp and nape of the neck. Mildly inflamed follicular papules and dried pustules are present in the upper portion of the photograph.</div><div class=\"graphic_reference\">Courtesy of Julian M Mackay-Wiggan, MD, MS.</div><div id=\"graphicVersion\">Graphic 97993 Version 1.0</div></div></div>"},"97994":{"type":"graphic_picture","displayName":"Acne keloidalis nuchae - scarring and inflammation","title":"Acne keloidalis nuchae","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Acne keloidalis nuchae</div><div class=\"cntnt\"><img style=\"width:538px; height:722px;\" src=\"images/DERM/97994_Acne_kldls_nch_scr_inflmmtn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scarring and&nbsp;inflamed follicular papules and pustules on the lower portion of the posterior scalp.</div><div class=\"graphic_reference\">Julian M Mackay-Wiggan, MD, MS.</div><div id=\"graphicVersion\">Graphic 97994 Version 1.0</div></div></div>"},"97995":{"type":"graphic_table","displayName":"Quadriceps contusion rehabilitation scheme","title":"Quadriceps contusion rehabilitation scheme","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Quadriceps contusion rehabilitation scheme</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Phase 1</td> <td class=\"subtitle1\">Phase 2</td> <td class=\"subtitle1\">Phase 3</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Purpose</strong></td> <td> <ul> <li>Limit hemorrhage </li> </ul> </td> <td> <ul> <li>Restore pain-free motion </li> </ul> </td> <td> <ul> <li>Functional rehabilitation </li> <li>Regain strength and endurance </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Treatments</strong></td> <td> <ul> <li>Weight bearing as tolerated with crutches </li> <li>Leg elevation </li> <li>Ice massage 10 to 15 minutes 3 to 10 times per day </li> <li>Cold pack or cold whirlpool 20 minutes </li> <li>Full thigh compression wrap </li> <li>Isometric contractions of 8 to 10 reps 3 to 5 times per day as tolerated </li> </ul> </td> <td> <ul> <li>Ice or cold therapy 15 to 20 minutes 3 to 5 times per day </li> <li>Active flexion while supine and prone </li> <li>Low resistance cycling </li> <li>Restoration of normal weight bearing gait </li> <li>Discard crutches when &#62;90 degrees knee flexion, no limp, pain free weight bearing gait </li> </ul> </td> <td> <ul> <li>Cycling </li> <li>Running </li> <li>Swimming </li> <li>Functional exercises </li> <li>Increase in activity intensity OR volume no more than 10% per week </li> </ul> </td> </tr> <tr> <td><strong>Indications for advancing to next phase</strong></td> <td> <ul> <li>Pain free at rest </li> <li>Thigh girth no longer increasing </li> </ul> </td> <td> <ul> <li>&#62;120 degrees pain free active knee flexion </li> <li>Equal thigh girth </li> </ul> </td> <td> <ul> <li>Full active range of motion </li> <li>Perform all activities pain-free </li> <li>Thigh pad with contact sports for next 3 to 6 months </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Ryan JB, Wheeler JH, Hopkinson WJ, et al. Quadriceps contusions. West Point update. Am J Sports Med 1991; 19:299.</div><div id=\"graphicVersion\">Graphic 97995 Version 1.0</div></div></div>"},"97997":{"type":"graphic_picture","displayName":"Chikungunya virus infection skin eruption","title":"Chikungunya virus infection","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Chikungunya virus infection</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/ID/97997_Chkngny_vrs_infct_skn_erptn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse maculopapular skin eruption in a patient with chikungunya virus infection.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 97997 Version 2.0</div></div></div>"},"97998":{"type":"graphic_picture","displayName":"Scrub typhus eschar","title":"Scrub typhus","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Scrub typhus</div><div class=\"cntnt\"><img style=\"width:600px; height:450px;\" src=\"images/DERM/97998_Scrub_typhus_eschar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eschar in scrub typhus.</div><div class=\"graphic_reference\">Reproduced from: Faa AG, McBride WJ, Garstone G, et al. Scrub typhus in the Torres Strait islands of north Queensland, Australia. Emerg Infect Dis 2003; 9:480.</div><div id=\"graphicVersion\">Graphic 97998 Version 1.0</div></div></div>"},"97999":{"type":"graphic_picture","displayName":"African tick bite fever eschar","title":"African tick bite fever","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">African tick bite fever</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/ID/97999_Afrcn_tck_bite_fever_eschar.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eschar with surrounding erythema in a patient with African tick bite fever.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 97999 Version 1.0</div></div></div>"}};